

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|---|--|
| (51) International Patent Classification 5 : <u>C07K 5/06, 5/02, A61K 38/55, C07C 257/18, 257/16, C07D 239/14, 211/26, 205/04, 207/09</u> | | A1 | (11) International Publication Number: WO 94/29336 |
| | | | (43) International Publication Date: 22 December 1994 (22.12.94) |
| (21) International Application Number: PCT/SE94/00535 | | (31) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, LZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). | |
| (22) International Filing Date: 2 June 1994 (02.06.94) | | | |
| (30) Priority Data: 9301916-4 3 June 1993 (03.06.93) SE | | | |
| (71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE). | | Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. | |
| (72) Inventors; and | | | |
| (75) Inventors/Applicants (for US only): ANTONSSON, Karl, Thomas [SE/SE]; Torkels väg, Pl 3503, S-437 34 Lindome (SE). BYLUND, Ruth, Elvy [SE/SE]; Forellgatan 60, S-426 58 Västra Frölunda (SE). GUSTAFSSON, Nils, David [SE/SE]; Ånglagången, Pl 3758, S-430 41 Kullavik (SE). NILSSON, Nils, Olov, Ingemar [SE/SE]; Rågvägen 50, S-430 33 Fjärås (SE). | | | |
| (74) Agent: SAMUELSSON, Britta; Astra Aktiebolag, Patent Dept., S-151 85 Södertälje (SE). | | | |

(54) Title: NEW PEPTIDE DERIVATIVES

(57) Abstract

The invention relates to new competitive inhibitors of trypsin-like serine proteases, their synthesis, pharmaceutical compositions containing the compounds as active ingredients, and the use of the compounds as thrombin inhibitors, anticoagulants and anti-inflammatory inhibitors for prophylaxis and treatment of related diseases, according to the formulas (I): $A^1-A^2-NH-(CH_2)_n-B$ and (V): $A^1-A^2-NH-(CH_2)_n-B-D$ wherein A^1 represents a structural fragment of formulas (IIa), (IIb), (IIc), (IId), (IIIe), A^2 represents a structural fragment of formulas (IIIa), (IIIb), (IIIc), B represents a structural fragment of formulas (IVa), (IVb), (IVc), (IVd). Further described are novel compounds, the new use of compounds and especially new structural fragment in synthesis of pharmaceutical compounds.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

New peptide derivatives

This invention relates to new competitive inhibitors of trypsin-like serine proteases, especially thrombin and kininogenases such as kallikrein, their synthesis, pharmaceutical compositions containing the compounds as active ingredients, and the use of the compounds as thrombin inhibitors and anticoagulants and as antiinflammatory inhibitors, respectively.

The invention also relates to novel use of compounds as starting materials in synthesis of a serine protease inhibitor. Furthermore the invention relates to a novel structural fragments in serine protease inhibitors.

15

BACKGROUND

Blood coagulation is the key process involved in both haemostasis (i.e. prevention of blood loss from a damaged vessel) and thrombosis (i.e. the pathological occlusion of a blood vessel by a blood clot).

Coagulation is the result of a complex series of enzymatic reactions, where one of the final steps is conversion of the proenzyme prothrombin to the active enzyme thrombin.

20

Thrombin plays a central role in coagulation. It activates platelets, it converts fibrinogen into fibrin monomers, which polymerise spontaneously into filaments, and it activates factor XIII, which in turn crosslinks the polymer to insoluble fibrin. Thrombin further activates factor V and factor VIII in a positive feedback reaction. Inhibitors of thrombin are therefore expected to be effective anticoagulants by inhibition of platelets, fibrin formation and fibrin stabilization. By inhibiting the positive feedback

25

30

35

mechanism they are expected to exert inhibition early in the chain of events leading to coagulation and thrombosis.

5 Kininogenases are serine proteases that act on kininogens to produce kinins (bradykinin, kallidin, and Met-Lys-bradykinin). Plasma kallikrein, tissue kallikrein, and mast cell tryptase represent important kininogenases.

10 Kinins (bradykinin, kallidin) are generally involved in inflammation. For example, the active inflammation process is associated with increased permeability of the blood vessels resulting in extravasation of plasma
15 into the tissue. The ensuing plasma exudate contains all the protein systems of circulating blood. The plasma-derived kininogens inevitably will be interacting with different kallikreins, forming kinins continually as long as the active plasma exudation
20 process is ongoing. Plasma exudation occurs independent of the mechanisms that are involved in the inflammation, whether it is allergy, infection or other factors (Persson et al., Editorial, Thorax, 1992, 47:993-1000). Plasma exudation is thus a feature of
25 many diseases including asthma, rhinitis, common cold, and inflammatory bowel diseases. Particularly in allergy mast cell tryptase will be released (Salomonsson et al., Am. Rev. Respir. Dis., 1992, 146:1535-1542) to contribute to kinin formation and other pathogenic events in asthma, rhinitis, and intestinal diseases.

30 The kinins are biologically highly active substances with smooth muscle effects, secretory effects, neurogenic effects, and actions that may perpetuate inflammatory processes including activation of phospholipase A₂ and increasing vascular permeability. The latter action potentially induces a vicious circle
35

with kinins providing for the generation of more kinins etc.

5 Tissue kallikrein cleaves primarily low molecular weight kininogen to produce kallidin and plasma kallikrein preferably releases bradykinin from high molecular weight kininogen.

PRIOR ART

10 Inhibitors of thrombin based on the amino acid sequence around the cleavage site for the fibrinogen A α chain were first reported by Blombäck et al. in J. Clin. Lab. Invest. 24, suppl 107, 59, (1969), who suggested the 15 sequence Phe-Val-Arg (P9-P2-P1, herein referred to as the P3-P2-P1 sequence) to be the best inhibitor.

In US 4,346,078 has S. Bajusz et al. described the 20 thrombin inhibitor H-DPhe-Pro-Agm, a dipeptidyl derivative with an aminoalkyl guanidine in the P1-position.

Inhibitors of thrombin based on peptide derivatives 25 with a cyclic aminoalkyl guanidine, e.g. 3-aminomethyl-1-amidinopiperidine, in the P1-position have been disclosed in EP-A2-0,468,231.

In EP-A2-0,185,390 has S. Bajusz et. al. disclosed 30 that replacing the agmatine with an arginine aldehyde gave a thrombin inhibitor which had much higher potency.

Inhibitors of kallikrein based on the amino acid 35 sequence around the cleavage site Arg-Ser have been reported earlier.

The arginine chloromethyl ketones H-DPro-Phe-Arg-CH₂Cl

and H-D Phe-Phe-Arg-CH₂Cl were reported as plasma kallikrein inhibitors by Kettner and Shaw in Biochemistry 1978, 17:4778-4784 and Meth. Enzym. 1981, 80:826-842.

5

Likewise, esters and amides containing the H-DPro-Phe-Arg sequence were reported by Fareed et al. in Ann. N.Y. Acad. Sci. 1981, 370:765-784 to be plasma kallikrein inhibitors.

10

Inhibitors of serine proteases that are based on electrophilic ketones instead of aldehydes in the P1-position are described in the following patent documents:

15

EP-A2-0,195,212 describing peptidyl α -keto esters and amides, EP-A1-0,362,002 describing fluoroalkylamide ketones and EP-A2-0,364,344 describing α,β,δ - triketo compounds possessing different peptidase inhibiting properties.

20

Inhibitors of trypsin-like serine proteases, such as thrombin and kallikrein, based on C-terminal boronic acid derivatives of arginine and isothiocuronium analogues thereof have been revealed in EP-A2-0,293,881.

25

WO 92/04371 describing kininogenase inhibitors, e.g. kallikrein inhibitors based on derivatives of arginine.

30

EP-A1-0,530,167 describing α -alkoxy ketone derivatives of arginine as thrombin inhibitors.

35


DISCLOSURE OF THE INVENTION

An object of the present invention is to provide novel

and potent trypsin-like serine protease inhibitors, especially anticoagulantia and antiinflammatory compounds with competitive inhibitory activity towards their enzyme i.e. causing reversible inhibition. More specifically anticoagulants for prophylaxis and treatment of thromboembolic diseases such as venous thrombosis, pulmonary embolism, arterial thrombosis, in particular myocardial infarction and cerebral thrombosis, general hypercoagulable states and local hypercoagulable states, e.g. following angioplasty and coronary bypass operations, and other situations where thrombin is believed to play a role, e.g. Alzheimers disease, as well as inhibition of kininogenases for treatment of inflammatory disorders e.g. asthma, rhinitis, urticaria, inflammatory bowel disease, and arthritis. A further object is to obtain thrombin inhibitors which are orally bioavailable and selective in inhibiting thrombin over other serine proteases. A further object of the invention is to obtain kininogenase inhibitors which can be given orally, rectally, topically e.g. dermally, or via the inhalation route.

Compounds

According to the invention it has been found that compounds of the general Formula I, either as such or in the form of physiologically acceptable salts, and including stereoisomers, are potent inhibitors of serine proteases, especially thrombin and kininogenases such as kallikrein:




wherein:


A^1 represents a structural fragment of Formula
IIa, IIb, IIc, IId or IIe;

5


10



IIa




IIb




IIc

15

20



IId



IIe

25

wherein:

k is an integer 0, 1, 2, 3 or 4;

m is an integer 1, 2, 3 or 4;

30

q is an integer 0, 1, 2 or 3;

35

R^1 represents H, an alkyl group having 1 to 4 carbon atoms, or $R^{11}OOC\text{-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted in the position which is alpha to the carbonyl group, and the alpha substituent is a group $R^{17}\text{-(CH}_2\text{)}_p\text{-}$, wherein p is

0, 1 or 2 and R¹⁷ is methyl, phenyl, OH, COOR¹², CONHR¹², where R¹² is H or an alkyl group having 1 to 4 carbon atoms, and R¹¹ is H or an alkyl group having 1 to 6 carbon atoms, or

5

R¹ represents Ph(4-COOR¹²)-CH₂-, where R¹² is as defined above, or

10

R¹ represents R¹³-NH-CO-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R¹³ is H or an alkyl group having 1 to 4 carbon atoms or -CH₂COOR¹², where R¹² is as defined above, or

15

R¹ represents R¹²OOC-CH₂-OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R¹² is as defined above, or

20

R¹ represents R¹⁴SO₂-, Ph(4-COOR¹²)-SO₂-, Ph(3-COOR¹²)-SO₂-, Ph(2-COOR¹²)-SO₂-, where R¹² is as defined above and R¹⁴ is an alkyl group having 1-4 carbon atoms, or

25

R¹ represents -CO-R¹⁵, wherein R¹⁵ is an alkyl group having 1-4 carbon atoms, or

30

R¹ represents -CO-OR¹⁵, where R¹⁵ is as defined above, or

R¹ represents -CO-(CH₂)_p-COOR¹², where R¹² is as defined above and p is an integer 0, 1 or 2, or

35

R¹ represents -CH₂PO(OR¹⁶)₂, -CH₂SO₃H or -CH₂-(5-(1H)-tetrazolyl), where R¹⁶ is, individually at each occurrence, H, methyl or ethyl;

R² represents H or an alkyl group having 1 to 4 carbon atoms or R²¹OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and, where R²¹ is H or an alkyl group having 1 to 4 carbon atoms;

5

R³ represents an alkyl group having 1-4 carbon atoms, and the alkyl group may or may not carry one or more fluorine atoms, or

10 R³ represents a cyclopentyl, cyclohexyl- or a phenyl group which may or may not be substituted with an alkyl group having 1 to 4 carbon atoms, or

15 R³ represents a phenyl group substituted with a OR³¹ group, where R³¹ is H or an alkyl group having 1 to 4 carbon atoms and k is 0, 1, or

R³ represents a 1-naphthyl or 2-naphthyl group and k is 0, 1, or

20

R³ represent a cis- or trans-decalin group and k is 0, 1, or




25 R³ represents 4-pyridyl, 3-pyrrolidyl or 3-indolyl which may or may not be substituted with a OR³¹ group, where R³¹ is as defined above and k is 0, 1, or

R³ represents Si(Me)₃ or CH(R³²)₂, wherein R³² is a cyclohexyl- or a phenyl group;

30

R⁴ represents H, an alkyl group having 1 to 4 carbon atoms, a cyclohexyl- or a phenyl group;

35 A² represents a structural fragment of Formula IIIa, IIIb or IIIc



10 wherein:

p is an integer 0, 1 or 2;

m is an integer 1, 2, 3 or 4;

15

Y represents a methylene group, or

20

Y represents an ethylene group and the resulting 5-membered ring may or may not carry one or two fluorine atoms, a hydroxy group or an oxo group in position 4, or may or may not be unsaturated, or

25 Y represents -CH₂-O-, -CH₂-S-, -CH₂-SO-, with the heteroatom functionality in position 4, or

30

Y represents a n-propylene group and the resulting 6-membered ring may or may not carry in position 5 one fluorine atom, a hydroxy group or an oxo group, carry two fluorine atoms in one of positions 4 or 5 or be unsaturated in position 4 and 5, or carry in position 4 an alkyl group with 1 to 4 carbon atoms, or

35 Y represents -CH₂-O-CH₂-, -CH₂-S-CH₂-, -CH₂-SO-CH₂-, or

Y represent -CH₂-CH₂-CH₂-CH₂-;

R³ is as defined above;





R^5 represents H or an alkyl group having 1 to 4 carbon atoms, r

5 R^5 represents $-(CH_2)_p-COOR^{51}$, where p is 0, 1 or 2 and R^{51} is H or an alkyl group having 1 to 4 carbon atoms;

n is an integer 0, 1, 2, 3 or 4;

10 B represents a structural fragment of Formula IVa, IVb,
IVc or IVd

15



20

wherein:

r is an interger 0 or 1;

25 X^1 represent CH_2 , NH or is absent;

X^2 represents CH_2 , NH or $C=NH$;

30 X^3 represents NH, $C=NH$, $N-C(NH)-NH_2$, $CH-C(NH)-NH_2$, $CH-NH-C(NH)-NH_2$ or $CH-CH_2-C(NH)-NH_2$;

X^4 represents CH_2 or NH;

Preferred combinations of X^1 , X^2 , X^3 , X^4 and r are

35 X^1 , X^2 and X^4 are CH_2 , X^3 is $CH-C(NH)-NH_2$ and r is 0, 1, r,

x^1 , x^2 and x^4 are CH_2 , x^3 is $\text{N}-\text{C}(\text{NH})-\text{NH}_2$ and r is 0, 1,

or

x^1 and x^3 are NH, x^2 is $\text{C}=\text{NH}$, x^4 is CH_2 and r is 0, 1,

or

5 x^1 and x^4 are CH_2 , x^2 is $\text{C}=\text{NH}$, x^3 is NH and r is 0, 1,

or

x^1 is CH_2 , x^2 and x^4 are NH, x^3 is $\text{C}=\text{NH}$ and r is 1, or

x^1 , x^2 and x^4 are CH_2 , x^3 is $\text{CH}-\text{NH}-\text{C}(\text{NH})-\text{NH}_2$

and r is 0, 1, or

10 x^1 is absent, x^2 and x^4 are CH_2 , x^3 is $\text{CH}-\text{C}(\text{NH})-\text{NH}_2$ and

r is 0, or

x^1 is absent, x^2 and x^4 are CH_2 , x^3 is $\text{N}-\text{C}(\text{NH})-\text{NH}_2$ and r is 0;

15 Particularly preferred combinations of x^1 , x^2 , x^3 , x^4 and r are

x^1 , x^2 and x^4 are CH_2 , x^3 is $\text{CH}-\text{C}(\text{NH})-\text{NH}_2$ and r is 1;

x^1 , x^2 and x^4 are CH_2 , x^3 is $\text{N}-\text{C}(\text{NH})-\text{NH}_2$ and r is 0 or

1;

20 x^1 is absent, x^2 and x^4 are CH_2 , x^3 is $\text{N}-\text{C}(\text{NH})-\text{NH}_2$ and r is 0;

x^1 and x^3 are NH, x^2 is $\text{C}=\text{NH}$, x^4 is CH_2 and r is 1;

25 x^5 represents $\text{C}(\text{NH})-\text{NH}_2$ or $\text{NH}-\text{C}(\text{NH})-\text{NH}_2$;

25 R^6 is H or an alkyl group having 1-4 carbon atoms;

x^6 represents CH or N;

30 Compounds of Formula I having S-configuration on the A^2 amino acid are preferred ones, of those compounds also having R-configuration on the A^1 amino acid are particularly preferred ones.

35 In the present context the term "an alkyl group having 1 to 4 carbon atoms" may be straight or branched unless specified otherwise. An alkyl group having 1 to


4 carbon atoms may be methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl.

In the present context the term "an alkyl group having 5 1 to 6 carbon atoms" may be straight or branched unless specified otherwise. An alkyl group having 1 to 6 carbon atoms may be methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, n-hexyl or i-hexyl. When 10 unsaturation is referred to, a carbon-carbon double bond is intended.

The wavy lines on the carbon atom in the carbonyl group 15 in formulas IIa, IIb, IIc, IID, IIe, IIIa, IIIb, IIIc, on the nitrogen atom in formulas IIIa, IIIb, IIIc and on the carbon atom in the ring system in formulas IVa, IVb, IVc, IVd signify the bond position of the fragment.

Abbreviations are listed at the end of this 20 specification.

According to the invention it has been found that compounds of the general Formula Ia, either as such or in the form of physiologically acceptable salts, and 25 including stereoisomers, are potent inhibitors of thrombin:



Ia

30

wherein:

35 A^1 represents a structural fragment of Formula IIa, IIb, IIc or IID, preferably IIa or IIb;

wherein:

k is an integer 0, 1, 2, 3 or 4, preferably 0, 1;

5 q is an integer 0, 1, 2 or 3, preferably 1;

R¹ represents H, an alkyl group having 1 to 4 carbon atoms, R¹¹OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted in the

10 position which is alpha to the carbonyl group, and the alpha substituent is a group R¹⁷-(CH₂)_p-, wherein p is 0, 1 or 2 and R¹⁷ is methyl, phenyl, OH, COOR¹², CONHR¹², where R¹² is H or an alkyl group having 1 to 4 carbon atoms, and R¹¹ is H or an alkyl group having 1 to 6

15 carbon atoms, or

R¹ represents Ph(4-COOR¹²)-CH₂-, where R¹² is as defined above, or

20 R¹ represents R¹³-NH-CO-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R¹³ is H or an alkyl group having 1 to 4 carbon atoms or -CH₂COOR¹² where R¹² is as

25 defined above, or

30 R¹ represents R¹²OOC-CH₂-OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R¹² is as defined above,

above, or

35 R¹ represents R¹⁴SO₂-, Ph(4-COOR¹²)-SO₂-, Ph(3-COOR¹²)-SO₂-, Ph(2-COOR¹²)-SO₂- where R¹² is as defined above and R¹⁴ is an alkyl group having 1-4 carbon atoms, or

R¹ represents -CO-R¹⁵, wherein R¹⁵ is an alkyl group

having 1-4 carbon atoms, or

R¹ represents -CO-OR¹⁵, where R¹⁵ is as defined above,
or

5 R¹ represent -CO-(CH₂)_p-COOR¹², where R¹² is as defined
above and p is an interger 0, 1 or 2, or

10 R¹ represents -CH₂PO(OR¹⁶)₂, -CH₂SO₃H or
-CH₂-(5-(1H)-tetrazolyl), where R¹⁶ is, individually at
each occurrence, H, methyl or ethyl;

Preferably R¹ represents R¹¹OOC-alkyl-, where the alkyl
group has 1 to 4 carbon atoms and R¹¹ is H.

15 R² represents H or an alkyl group having 1 to 4 carbon
atoms, or R²¹OOC-alkyl-, where the alkyl group has 1 to
4 carbon atoms and R²¹ is H or an alkyl group having 1
to 4 carbon atoms;

20 R³ represents an alkyl group having 1-4 carbon atoms,
and the alkyl group may or may not carry one or more
fluorine atoms, or

25 R³ represents a cyclopentyl, cyclohexyl- or a phenyl
group which may or may not be substituted with an alkyl
group having 1 to 4 carbon atoms, or

30 R³ represents a 1- naphthyl or 2-naphthyl group and k
is 0, 1, or

R³ represent a cis- or trans-decalin group and k is 0,
1, or

35 R³ represents Si(Me)₃ or CH(R³²)₂, wherein R³² is a
cyclohexyl- or phenyl group;

R⁴ represents an alkyl group having 1 to 4 carbon atoms, a cyclohexyl or a phenyl group, preferably a cyclohexyl or a phenyl group;

5 A² represents a structural fragment of Formula IIIa, IIIb or IIIc, preferably IIIa;

wherein:

10 p is an integer 0, 1 or 2;

m is an integer 1, 2, 3 or 4, preferably 2, 3;

15 Y represents a methylene group, or

Y represents an ethylene group and the resulting 5-membered ring may or may not carry one or two fluorine atoms, a hydroxy group or an oxo group in position 4, or may or may not be unsaturated, or

20 Y represents -CH₂-O-, -CH₂-S-, -CH₂-SO-, with the heteroatom functionality in position 4, or

25 Y represents a n-propylene group and the resulting 6-membered ring may or may not carry in position 5 one fluorine atom, a hydroxy group or an oxo group, carry two fluorine atoms in one of positions 4 or 5 or be unsaturated in position 4 and 5, or carry in position 4 an alkyl group with 1 to 4 carbon atoms, or

30 Y represents -CH₂-O-CH₂-, -CH₂-S-CH₂-, -CH₂-SO-CH₂-, or

Y represent -CH₂-CH₂-CH₂-CH₂-;

35 R³ represents an alkyl group having 1-4 carbon atoms, or

R³ represents a Si(Me)₃ gr up;

R⁵ represents H or an alkyl gr up having 1 to 4 carbon atoms, preferably H or a methylgroup, or

5

R⁵ represents -(CH₂)_p-COOR⁵¹, where p is 0, 1 or 2 and R⁵¹ is H or an alkyl group having 1 to 4 carbon atoms, preferably p is 0 and R⁵¹ is H;

10 n is an integer 0, 1, 2, 3 or 4, preferably 1, 2, 3;

B represents a structural fragment of Formula IVa, IVb, IVc or IVd, preferably IVa or IVb

15 wherein:

x¹, x², x³, x⁴, x⁵ and x⁶ are as defined above;

r is an integer 0 or 1;

20

R⁶ is H or an alkyl group having 1-4 carbon atoms, preferably H;

25

preferred combinations of x¹, x², x³, x⁴ and r are

x¹, x² and x⁴ are CH₂, x³ is CH-C(NH)-NH₂ and r is 0 or 1, or

30

x¹, x² and x⁴ are CH₂, x³ is N-C(NH)-NH₂ and r is 0 or 1, or

x¹ and x³ are NH, x² is C=NH, x⁴ is CH₂ and r is 0 or 1, or

35

x¹ and x⁴ are CH₂, x² is C=NH, x³ is NH and r is 0 or 1, or

x¹ is CH₂, x² and x⁴ are NH, x³ is C=NH and r is 1, or

x¹, x² and x⁴ are CH₂, x³ is CH-NH-C(NH)-NH₂ and r = 0
or 1, or

5 or x¹ is absent, x² and x⁴ are CH₂, x³ is CH-C(NH)-NH₂
and r is 0,

or x¹ is absent, x² and x⁴ are CH₂, x³ is N-C(NH)-NH₂
10 and r is 0;

Particularly preferred combinations of x¹, x², x³, x⁴
and r are

15 x¹ is absent, x² and x⁴ are CH₂, x³ is N-C(NH)-NH₂ and r
is 0, or

x¹, x² and x⁴ are CH₂, x³ is CH-C(NH)-NH₂ and r = 1, or

20 x¹, x² and x⁴ are CH₂, x³ is N-C(NH)-NH₂ and r = 0 or 1,
or

x¹ and x³ are NH, x² is C=NH, x⁴ is CH₂ r is 1;

25 x⁵ represents C(NH)-NH₂ or NH-C(NH)-NH₂, preferably
C(NH)-NH₂;

x⁶ represents CH or N;

30 According to a preferred embodiment the invention
relates to compounds of Formula Ia,

wherein:

35 A¹ represents a structural fragment of Formula IIa,

wherein:

k is 0 or 1;

5 R¹ represents R¹¹OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms, particularly methylene, ethylene and R¹¹ is H;

R² represents H;

10 R³ represents a cyclohexyl group;

A² represents a structural fragment of Formula IIIa,
wherein:

15 Y represents a methylene group, an ethylene group, or a n-propylene group and the resulting 6-membered ring may or may not carry in position 4 an alkyl group with 1-to 4 carbon atoms, preferably Y represents methylene, ethylene;

R⁵ represents H;

B represents a structural fragment of formula IVa

25 wherein:

x¹ is absent, x² and x⁴ are CH₂, x³ is N-C(NH)-NH₂, r is 0 and n is 1 or 2;

30 x¹, and x³ are NH, x² is C=NH, x⁴ is CH₂, r is 1 and n is 2, or

35 x¹, x² and x⁴ are CH₂, x³ is CH-C(NH)-NH₂, r is 1 and n is 1, or

x¹, x² and x⁴ are CH₂, x³ is N-C(NH)-NH₂, r is 0 or 1

and n is 1 or 2, or

More particularly preferred are compounds wherein B
represents a structural fragment fo formula IVb
5 wherein:

x⁵ represents C(NH)-NH₂, R⁶ is H, and n = 1

Preferred compounds of the invention are:

10

HOOC-CH₂-(R)Cgl-Aze-Pab

HOOC-CH₂-CH₂-(R)Cgl-Aze-Pab

HOOC-CH₂-(R)Cgl-Pro-Pab

HOOC-CH₂-CH₂-(R)Cgl-Pro-Pab

15

(HOOC-CH₂)₂-(R)Cgl-Pro-Pab

H-(R)Cgl-Pic-Pab

HOOC-CH₂-(R,S)CH(COOH)-(R)Cgl-Pic-Pab

H-(R)Cha-Aze-Pab

HOOC-CH₂-(R)Cha-Aze-Pab

20

HOOC-CH₂-(R,S)CH(COOH)-(R)Cha-Aze-Pab

HOOC-CH₂-(RorS)CH(COOH)-(R)Cha-Aze-Pab/a

HOOC-CH₂-(RorS)CH(COOH)-(R)Cha-Aze-Pab/b

HOOC-CH₂-CH₂-(R)Cha-Aze-Pab

HOOC-CH₂-NH-CO-CH₂-(R)Cha-Aze-Pab

25

H-(R)Cha-Pro-Pab

HOOC-CH₂-(R)Cha-Pro-Pab

HOOC-CH₂-(Me)(R)Cha-Pro-Pab

HOOC-CH₂-CH₂-(R)Cha-Pro-Pab

HOOC-CH₂-CH₂-(Me)(R)Cha-Pro-Pab

30

HOOC-CH₂-(RorS)CH(COOH)-(R)Cha-Pro-Pab/a

HOOC-CH₂-(RorS)CH(COOH)-(R)Cha-Pro-Pab/b

HOOC-CH₂-NH-CO-CH₂-(R)Cha-Pro-Pab

EtoOC-CH₂-CH₂-CH₂-(R)Cha-Pro-Pab

Ph(4-COOH)-SO₂-(R)Cha-Pro-Pab

35

H-(R)Cha-Pic-Pab

HOOC-CH₂-(R)Cha-Pic-Pab

HOOC-CH₂-(RorS)CH(COOH)-(R)Cha-Pic-Pab/a

HOOC-CH₂-(R or S)CH(COOH)-(R)Cha-Pic-Pab/b
HOOC-CH₂-CH₂-(R)Cha-Pic-Pab
HOOC-CO-(R)Cha-Pic-Pab
HOOC-CH₂-CO-(R)Cha-Pic-Pab
5 Me-OOC-CH₂-CO-(R)Cha-Pic-Pab
H₂N-CO-CH₂-(R)Cha-Pic-Pab
Boc-(R)Cha-Pic-Pab
Ac-(R)Cha-Pic-Pab
Me-SO₂-(R)Cha-Pic-Pab
10 H-(R)Cha-(R,S)betaPic-Pab
HOOC-CH₂-CH₂-(R)Cha-(R,S)betaPic-Pab
HOOC-CH₂-(R)Cha-Val-Pab
HOOC-CH₂-CH₂-(R)Cha-Val-Pab
H-(R)Hoc-Aze-Pab
15 HOOC-CH₂-CH₂-(R)Hoc-Aze-Pab
HOOC-CH₂-(R,S)CH(COOH)-(R)Hoc-Pro-Pab
HOOC-CH₂-(R)Hoc-Pic-Pab
(HOOC-CH₂)₂-(R)Hoc-Pic-Pab
HOOC-CH₂-(R)Pro(3-(S)Ph)-Pro-Pab
20 HOOC-CH₂-CH₂-(R)Pro(3-(S)Ph)-Pro-Pab
HOOC-CH₂-CH₂-(R)Tic-Pro-Pab
HOOC-CH₂-CH₂-(R)Cgl-Aze-Pig
HOOC-CH₂-(R)Cgl-Pro-Pig
H-(R)Cha-Aze-Pig
25 HOOC-CH₂-(R)Cgl-Aze-Pac
H-(R)Cha-Pro-Pac
H-(R)Cgl-Ile-Pab
H-(R)Cgl-Aze-Pab
HOOC-(R,S)CH(Me)-(R)Cha-Pro-Pab
30 MeOOC-CH₂-(R)Cgl-Aze-Pab
EtOOC-CH₂-(R)Cgl-Aze-Pab
nBuOOC-CH₂-(R)Cgl-Aze-Pab
nHexOOC-CH₂-(R)Cgl-Aze-Pab
H-(R)Cgl-Pro-Pac
35 HOOC-CH₂-(R)Cha-Pro-Pac
HOOC-CH₂-CH₂-(R)Cgl-Pro-Pac
HOOC-CH₂-CH₂-(R)Cha-Aze-Pac

HOOC-CH₂-(R) Cha-Aze-Pig
 HOOC-CH₂-(R) Cha-Pro-Pig
 HOOC-CH₂-CH₂-(R) Cha-Pro-Pig
 (HOOC-CH₂)₂-(R) Cgl-Pro-Pig
 5 HOOC-CH₂-CH₂(HOOC-CH₂)-(R) Cha-Pro-Pig
 HOOC-CH₂-(R) Cgl-Aze-(R,S) Itp
 HOOC-CH₂-(R) Cha-Aze-(R,S) Itp
 H-(R) Cha-Pic-(R,S) Itp
 HOOC-CH₂-(R) Cha-Pic-(R,S) Itp
 10 H-(R) Cgl-Pro-(R,S) Hig
 HOOC-CH₂-(R) Cgl-Pro-(R,S) Hig
 H-(R) Cha-Pro-(R,S) Hig
 H-(R) Cgl-Aze-Rig
 HOOC-CH₂-(R) Cgl-Aze-Rig
 15 HOOC-CH₂-(R) Cha-Pro-Rig
 HOOC-CH₂-CH₂-(R) Cha-Aze-Rig
 HOOC-CH₂-(R) Cha-Pro-(S) Itp
 H-(R) Cha-Pro-(R,S) Nig
 H-(R) Cha-Pro-Mig
 20 H-(R) Cha-Pro-Dig
 H-(R) Cha-Aze-Dig

At present the particularly preferred compounds of formula Ia is

25 HOOC-CH₂-(R) Cgl-Aze-Pab
 HOOC-CH₂-CH₂-(R) Cha-Aze-Pab
 HOOC-CH₂-(R) Cha-Pro-Pab
 HOOC-CH₂-CH₂-(R) Cha-Pro-Pab
 30 HOOC-CH₂-(R) Cha-Pic-Pab
 HOOC-CH₂-(R) Cgl-Pro-Pig
 EtoOC-CH₂-(R) Cgl-Aze-Pab
 HOOC-CH₂-(R) Cha-Pro-Pac
 HOOC-CH₂-(R) Cha-Pro-Pig


35 In the above tables f compounds, the letters /a and /b refer to a substantially pure stereoisomer at the

carbon at α noted "R₁S". The stereoisomer can be identified for each compound with reference to the experimental part herein. "R,S" refers to a mixture of stereoisomers.

5

According to the invention it has been found that compounds of the general Formula Ib, either as such or in the form of physiologically acceptable salts, and including stereoisomers, are potent inhibitors of kininogenases:

10



15

wherein:

A^1 represents a structural fragment of formula IIa, IIb or IIc, preferably IIa or IIb;

wherein:

20

k is an integer 0, 1, 2, 3 or 4, preferably 0, 1;

q is an integer 0, 1, 2, or 3, preferably 1;

25 R^1 represents H, an alkyl group having 1 to 4 carbon atoms, or $\text{R}^{11}\text{OOC-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted in the position which is alpha to the carbonyl group, and the alpha substituent is a group $\text{R}^{17}-(\text{CH}_2)_p-$, wherein p is 0, 1 or 2 and R^{17} is methyl, phenyl, OH, COOR^{12} ,

30 CONHR^{12} , where R^{12} is H or an alkyl group having 1 to 4 carbon atoms, and R^{11} is H or an alkyl group having 1 to 6 carbon atoms, or

35 R^1 represents $\text{Ph}(4-\text{COOR}^{12})-\text{CH}_2-$, where R^{12} is H or an alkyl group having 1 to 4 carbon atoms, or

R¹ represents R¹³-NH-CO-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R¹³ is H or an alkyl group having 1 to 4 carbon atoms or -CH₂COOR¹² where R¹² is as defined above, or

R¹ represents R¹²OOC-CH₂-OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R¹² is as defined above, or

R¹ represents R¹⁴SO₂-, Ph(4-COOR¹²)-SO₂-, Ph(3-COOR¹²)-SO₂, Ph(2-COOR¹²)-SO₂-, where R¹² is as defined above and R¹⁴ is an alkyl group having 1-4 carbon atoms, or

R¹ represents -CO-R¹⁵, wherein R¹⁵ is an alkyl group having 1-4 carbon atoms, or

R¹ represents -CO-OR¹⁵, where R¹⁵ is as defined above, or

R¹ represents -CO-(CH₂)_p-COOR¹², where R¹² is as defined above and p is 0, 1 or 2, or

R¹ represents -CH₂PO(OR¹⁶)₂, -CH₂SO₃H or -CH₂-(5-(1H)-tetrazolyl), where R¹⁶ is, individually at each occurrence, H, methyl or ethyl;

R² represents H or an alkyl group having 1 to 4 carbon atoms or R²¹OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and R²¹ is H or an alkyl group having 1 to 4 carbon atoms;

R³ represents an alkyl group having 1-4 carbon atoms, and the alkyl group may or may not carry one or more

fluorine atoms, or

R³ represents a cyclopentyl, cyclohexyl- or a phenyl group which may or may not be substituted with an alkyl group having 1 to 4 carbon atoms, or

R³ represents a phenyl group substituted with a OR³¹ group, where R³¹ is H or an alkyl group having 1 to 4 carbon atoms and k is 0, 1, or

10

R³ represents a 1-naphthyl or 1-naphthyl group and k is 0, 1, or

15

R³ represent a cis- or trans-decalin group and k is 0, 1, or

R³ represents 4-pyridyl, 3-pyrrolidyl or 3-indolyl which may or may not be substituted with a OR³¹ group, where R³¹ is as defined above and k is 0, 1, or

20

R³ represents Si(Me)₃ or CH(R³²)₂, wherein R³² is a cyclohexyl- or phenyl group;

25

R⁴ represents H, an alkyl group having 1 to carbon atoms, a cyclohexyl or a phenyl group, preferably H;

A² represents a structural fragment of formula IIIb or IIIc, preferably IIIb

30

wherein:

p is an integer 0, 1 or 2;

m is an integer 1, 2, 3, or 4, preferably 2, 3;

R³ is as defined above;

35

n is an integer 0, 1, 2, 3 or 4, preferably 1,2,3;

B represents a structural fragment of Formula IVa, IVb, IVc or IVd, preferably IVa or IVb;

wherein:

5

x^1 , x^2 , x^3 , x^4 are as defined above;

R^6 is H or an alkyl group having 1-4 carbon atoms, preferably H or a methyl group;

10

r is an integer 0 or 1;

preferred combinations of x^1 , x^2 , x^3 and x^4 are

15

x^1 , x^2 and x^4 are CH_2 , x^3 is $CH-C(NH)-NH_2$ and r is 0 or 1, or

x^1 , x^2 and x^4 are CH_2 , x^3 is $N-C(NH)-NH_2$ and r is 0 or 1, or

20

x^1 and x^3 are NH, x^2 is C=NH, x^4 is CH_2 and r is 0 or 1, or

x^1 and x^4 are CH_2 , x^2 is C=NH, x^3 is NH and r is 0 or 1,

25

or

x^1 is CH_2 , x^2 and x^4 are NH, x^3 is C=NH and r is 1, or

x^1 , x^2 and x^4 are CH_2 , x^3 is $CH-NH-C(NH)-NH_2$ and r is 0

30

or 1,

or x^1 is absent, x^2 and x^4 are CH_2 , x^3 is $CH-C(NH)-NH_2$ and r is 0, or

35

x^1 is absent, x^2 and x^4 are CH_2 , x^3 is $N-C(NH)-NH_2$ and r is 0;

particularly preferred combinations of X^1 , X^2 , X^3 and X^4 are

5 X^1 , X^2 and X^4 are CH_2 , X^3 is $CH-C(NH)-NH_2$ and r is 1 or,

X^1 , X^2 and X^4 are CH_2 , X^3 is $N-C(NH)-NH_2$ and r is 1;

10 X^5 represents $C(NH)-NH_2$ or $NH-C(NH)-NH_2$, preferably $C(NH)-NH_2$;

X^6 represents CH or N.

Preferred compound of the invention are:

15 H-(R)Pro-Phe-Pab
HOOC-CH₂-(R)Pro-Phe-Pab

H-(R)Phe-Phe-Pab

HOOC-CO-(R)Phe-Phe-Pab

20 HOOC-CH₂-(R)Phe-Phe-Pab

H-(R)Cha-Phe-Pab

HOOC-CH₂-(R)Cha-Phe-Pab

H-(R)Phe-Cha-Pab

HOOC-CH₂-(R)Phe-Cha-Pab

25 H-(R)Cha-Cha-Pab

HOOC-CH₂-(R)Cha-Cha-Pab

Furthermore, it has been found that compounds of the general Formula V, either as such or in the form of physiologically acceptable salts, and including 30 stereoisomers, are potent inhibitors of serine proteases, especially thrombin and kininogenases such as kallikrein after oral or parenteral administration:




35 A¹ - A² - NH - (CH₂)_n - B - D
Formula V

wherein:



A¹ represents a structural fragment of Formula
IIa, **IIb**, **IIc**, **IID** or **IIe**;

5

10

**IIa****IIb****IIc**

15

**IID****IIe**

20

wherein:

k is an integer 0, 1, 2, 3 or 4;

25

m is an integer 1, 2, 3 or 4;

q is an integer 0, 1, 2 or 3;

30

R¹ represents R¹¹OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted in the position which is alpha to the carbonyl group, and the alpha substituent is a group R¹⁷-(CH₂)_p- , wherein p is 0, 1 or 2 and R¹⁷ is COOR¹², CONHR¹², where R¹² is H or an alkyl group having 1 to 4 carbon atoms or a benzyl group, and R¹¹ is H or an alkyl group having 1 to 6 carbon atoms, or a benzyl group, or

35

R¹ represents Ph(4-COOR¹²)-CH₂-, where R¹² is as defined above, or

5 R¹ represents R¹³-NH-CO-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R¹³ is H or an alkyl group having 1 to 4 carbon atoms or -CH₂COOR¹², where R¹² is as defined above, or

10 R¹ represents R¹²OOC-CH₂-OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R¹² is as defined above, or

15 R¹ represents R¹⁴SO₂-, Ph(4-COOR¹²)-SO₂-, Ph(3-COOR¹²)-SO₂-, Ph(2-COOR¹²)-SO₂-, where R¹² is as defined above and R¹⁴ is an alkyl group having 1-4 carbon atoms, or

20 R¹ represents -CO-R¹⁵, wherein R¹⁵ is an alkyl group having 1-4 carbon atoms, or

25 R¹ represents -CO-OR¹⁵, where R¹⁵ is as defined above, or

R¹ represent -CO-(CH₂)_p-COOR¹², where R¹² is as defined above and p is an interger 0, 1 or 2, or

30 R² represents H or an alkyl group having 1 to 4 carbon atoms or R²¹OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and, where R²¹ is H, an alkyl group having 1 to 4 carbon atoms or a benzyl group;

35 R³ represents an alkyl group having 1-4 carbon atoms, and the alkyl group may or may not carry one or more flourine atoms, or

R³ represents a cyclopentyl, cyclohexyl- or a phenyl group which may or may not be substituted with an alkyl group having 1 to 4 carbon atoms, or

5 R³ represents a phenyl group substituted with a OR³¹ group, where R³¹ is H or an alkyl group having 1 to 4 carbon atoms and k is 0, 1, or

10 R³ represents a 1-naphthyl or 2-naphthyl group and k is 0, 1, or

R³ represent a cis- or trans-decalin group and k is 0, 1, or

15 R³ represents 4-pyridyl, 3-pyrrolidyl or 3-indolyl which may or may not be substituted with a OR³¹ group, where R³¹ is as defined above and k is 0, 1, or

20 R³ represents Si(Me)₃ or CH(R³²)₂, wherein R³² is a cyclohexyl- or a phenyl group;

R⁴ represents H, an alkyl group having 1 to 4 carbon atoms, a cyclohexyl- or a phenyl group;

25 A², B and n are defined as described under Formula I above;

D is Z or (Z)₂, wherein Z represents a benzyloxycarbonyl group.


30 The benzyloxycarbonyl group (Z or (Z)₂) will bind to the amidino- or guanidino nitrogens present in B.

35 Preferred and particularly preferred combinations are the same as described for Formula I above.

Furthermore, it has been found that compounds of the

general Formula Va, either as such or in the form of physiologically acceptable salts, and including stereoisomers, are potent inhibitors of thrombin after oral or parenteral administration:

5



Formula Va

10

wherein:

A^1 represents a structural fragment of Formula IIIa, IIIb, IIIc or IIId, preferably IIIa or IIIb;

15

wherein:

k is an integer 0, 1, 2, 3 or 4, preferably 0, 1;

20

q is an integer 0, 1, 2 or 3, preferably 1;

25

R^1 represents $R^{11}OOC$ -alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted in the position which is alpha to the carbonyl group, and the alpha substituent is a group $R^{17}-(CH_2)_p-$, wherein p is 0, 1 or 2 and R^{17} is $COOR^{12}$, $CONHR^{12}$, where R^{12} is H, an alkyl group having 1 to 4 carbon atoms or a benzyl group, and R^{11} is H or an alkyl group having 1 to 6 carbon atoms, or a benzyl group, or

30

R^1 represents $Ph(4-COOR^{12})-CH_2-$, where R^{12} is as defined above, or

35

R^1 represents $R^{13}-NH-CO$ -alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R^{13} is H or an alkyl group having

1 to 4 carbon atoms or $\text{CH}_2\text{COOR}^{12}$ where R^{12} is as defined above, or

5 R^1 represents $\text{R}^{12}\text{OOC-CH}_2\text{-OOC-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R^{12} is as defined above, or

10 R^1 represents $\text{R}^{14}\text{SO}_2-$, $\text{Ph}(4-\text{COOR}^{12})\text{-SO}_2-$, $\text{Ph}(3-\text{COOR}^{12})\text{-SO}_2-$, $\text{Ph}(2-\text{COOR}^{12})\text{-SO}_2-$ where R^{12} is as defined above and R^{14} is an alkyl group having 1-4 carbon atoms, or

15 R^1 represents $-\text{CO-R}^{15}$, wherein R^{15} is an alkyl group having 1-4 carbon atoms, or

R^1 represents $-\text{CO-OR}^{15}$, where R^{15} is as defined above, or

20 R^1 represents $-\text{CO-(CH}_2)_p\text{-COOR}^{12}$, where R^{12} is as defined above and p is an integer 0, 1 or 2, or

25 Preferably R^1 represents $\text{R}^{11}\text{OOC-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and R^{11} is as defined above.

30 R^2 represents H or an alkyl group having 1 to 4 carbon atoms, or $\text{R}^{21}\text{OOC-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms and R^{21} is H or an alkyl group having 1 to 4 carbon atoms or a benzyl group;

35 R^3 represents an alkyl group having 1-4 carbon atoms, and the alkyl group may or may not carry one or more fluorine atoms, or

R^3 represents a cyclopentyl, cyclohexyl- or a phenyl group which may or may not be substituted with an alkyl

group having 1 to 4 carbon atoms, or

R³ represents a 1-naphthyl or 2-naphthyl group and k is 0, 1, or

5 R³ represent a cis- or trans-decalin group and k is 0, 1, or

10 R³ represents Si(Me)₃ or CH(R³²)₂, wherein R³² is a cyclohexyl- or phenyl group;

15 R⁴ represents an alkyl group having 1 to 4 carbon atoms, a cyclohexyl or a phenyl group, preferably a cyclohexyl or a phenyl group;

20 A², B and n are defined as described under Formula Ia above;

D is Z or (Z)₂;

25 Z represents a benzyloxycarbonyl group.

Preferred integers, groups or combinations and particularly preferred combinations are the same as described for Formula Ia above but R¹¹ is H, an alkyl group having 1 to 6 carbon atoms or a benzyl group.

Preferred compounds having Formula Va are:

30 BnOOC-CH₂-(R)Cgl-Aze-Pab(Z)

BnOOC-CH₂-CH₂-(R)Cgl-Aze-Pab(Z)

BnOOC-CH₂-(R)Cgl-Pro-Pab(Z)

BnOOC-CH₂-CH₂-(R)Cgl-Pro-Pab(Z)

35 (BnOOC-CH₂)₂-(R)Cgl-Pro-Pab(Z)

BnOOC-CH₂-(R,S)CH(COOBn)-(R)Cgl-Pic-Pab(Z)

BnOOC-CH₂-(R)Cha-Aze-Pab(Z)


BnOOC-CH₂-(R,S)CH(COOBn)-(R)Cha-Aze-Pab(Z)
BnOOC-CH₂-(RorS)CH(COOBn)-(R)Cha-Aze-Pab(Z)/a
BnOOC-CH₂-(RorS)CH(COOBn)-(R)Cha-Aze-Pab(Z)/b
BnOOC-CH₂-CH₂-(R)Cha-Aze-Pab(Z)
5 BnOOC-CH₂-NH-CO-CH₂-(R)Cha-Aze-Pab(Z)
BnOOC-CH₂-(R)Cha-Pro-Pab(Z)
BnOOC-CH₂-(Me)(R)Cha-Pro-Pab(Z)
BnOOC-CH₂-CH₂-(R)Cha-Pro-Pab(Z)
BnOOC-CH₂-CH₂-(Me)(R)Cha-Pro-Pab(Z)
10 BnOOC-CH₂-(R,S)CH(COOBn)-(R)Cha-Pro-Pab(Z)
BnOOC-CH₂-NH-CO-CH₂-(R)Cha-Pro-Pab(Z)
Ph(4-COOH)-SO₂-(R)Cha-Pro-Pab(Z)
Boc-(R)Cha-Pic-Pab(Z)
BnOOC-CH₂-(R)Cha-Pic-Pab(Z)
15 BnOOC-CH₂-(R,S)CH(COOBn)-(R)Cha-Pic-Pab(Z)
BnOOC-CH₂-CH₂-(R)Cha-Pic-Pab(Z)
EtOOC-CO-(R)Cha-Pic-Pab(Z)
MeOOC-CH₂-CO-(R)Cha-Pic-Pab(Z)
H₂N-CO-CH₂-(R)Cha-Pic-Pab(Z)
20 Ac-(R)Cha-Pic-Pab(Z)
Me-SO₂-(R)Cha-Pic-Pab(Z)
BnOOC-CH₂-(R)Cha-Val-Pab(Z)
BnOOC-CH₂-CH₂-(R)Cha-(R,S)Val-Pab(Z)
BnOOC-CH₂-CH₂-(R)Hoc-Aze-Pab(Z)
25 BnOOC-CH₂-(R,S)CH(COOBn)-(R)Hoc-Pro-Pab(Z)
BnOOC-CH₂-(R)Hoc-Pic-Pab(Z)
(BnOOC-CH₂)₂-(R)Hoc-Pic-Pab(Z)
BnOOC-CH₂-CH₂-(R)Pro(3-(S)Ph)-Pro-Pab(Z)
BnOOC-CH₂-CH₂-(R)Pro(3-(S)Ph)-Pro-Pab(Z)
30 BnOOC-CH₂-CH₂-(R)Tic-Pro-Pab(Z)
BnOOC-CH₂-CH₂-(R)Cgl-Aze-Pig(Z)₂
BnOOC-CH₂-(R)Cgl-Pro-Pig(Z)₂
BnOOC-CH₂-(R)Cgl-Aze-Pac(Z)
BnOOC-(R,S)CH(Me)-(R)Cha-Pro-Pab(Z)
35 MeOOC-CH₂-(R)Cgl-Aze-Pab(Z)
EtOOC-CH₂-(R)Cgl-Aze-Pab(Z)
ⁿBuOOC-CH₂-(R)Cgl-Aze-Pab(Z)

nHexOOC-CH₂-(R)Cgl-Aze-Pab(Z)
BnOOC-CH₂-(R)Cha-Pro-Pac(Z)
BnOOC-CH₂-CH₂-(R)Cgl-Pro-Pac(Z)
BnOOC-CH₂-CH₂-(R)Cha-Aze-Pac(Z)
5 BnOOC-CH₂-(R)Cha-Aze-Pig(Z)
BnOOC-CH₂-(R)Cha-Pro-Pig(Z)
BnOOC-CH₂-CH₂-(R)Cha-Pro-Pig(Z)
(BnOOC-CH₂)₂-(R)Cgl-Pro-Pig(Z)
BnOOC-CH₂-CH₂(BnOOC-CH₂)-(R)Cha-Pro-Pig(Z)
10 BnOOC-CH₂-(R)Cha-Pic-(R,S)Itp(Z)
BnOOC-CH₂-(R)Cgl-Pro-(R,S)Hig(Z)
BnOOC-CH₂-(R)Cgl-Aze-Rig(Z)
BnOOC-CH₂-(R)Cha-Pro-Rig(Z)
BnOOC-CH₂-CH₂-(R)Cha-Aze-Rig(Z)

15 Particularly preferred compounds are:

BnOOC-CH₂-(R)Cgl-Aze-Pab(Z)
BnOOC-CH₂-(R)Cha-Pro-Pab(Z)
20 BnOOC-CH₂-(R)Cha-Pic-Pab(Z)
BnOOC-CH₂-(R)Cgl-Pro-Pig(Z)
EtoOC-CH₂-(R)Cgl-Aze-Pab(Z)
BnOOC-CH₂-(R)Cha-Pro-Pac(Z)
BnOOC-CH₂-(R)Cha-Pro-Pig(Z)

25 Furthermore, it has been found that compounds of the general Formula Vb, either as such or in the form of physiologically acceptable salts, and including stereoisomers, are potent inhibitors of kallikrein after oral or parenteral administration:



wherein:

A¹ represents a structural fragment of formula IIa, IIb or IIe, preferably IIa or IIb;

5 wherein:

k is an integer 0, 1, 2, 3 or 4, preferably 0, 1;

10 q is an integer 0, 1, 2, or 3, preferably 1;

R¹ represents R¹¹OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted in the position which is alpha to the carbonyl group, and the alpha substituent is a group R¹⁷-(CH₂)_p-, wherein p is 15 0, 1 or 2 and R¹⁷ is COOR¹², CONHR¹², where R¹¹ is H or an alkyl group having 1 to 4 carbon atoms, and R¹¹ is H or an alkyl group having 1 to 6 carbon atoms, or a benzyl group, or

20 R¹ represents Ph(4-COOR¹²)-CH₂-, where R¹² is as defined above, or

25 R¹ represents R¹³-NH-CO-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R¹³ is H or an alkyl group having 1 to 4 carbon atoms or -CH₂COOR¹² where R¹² is as defined above, or

30 R¹ represents R¹²OOC-CH₂-OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R¹² is as defined above, or

35

R¹ represents R¹⁴SO₂-, Ph(4-COOR¹²)-SO₂-, Ph(3-COOR¹²)-SO₂, Ph(2-COOR¹²)-SO₂-, where R¹² is as defined above

and R¹⁴ is an alkyl group having 1-4 carbon atoms, or

R¹ represents -CO-R¹⁵, wherein R¹⁵ is an alkyl group having 1-4 carbon atoms, or

5 R¹ represents -CO-OR¹⁵, where R¹⁵ is as defined above, or

10 R¹ represent -CO-(CH₂)_p-COOR¹², where R¹² is as defined above and p is 0, 1 or 2, or

15 R² represents H or an alkyl group having 1 to 4 carbon atoms or R²¹OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and R²¹ is H, an alkyl group having 1 to 4 carbon atoms or a benzyl group;

20 R³ represents an alkyl group having 1-4 carbon atoms, and the alkyl group may or may not carry one or more fluorine atoms, or

25 R³ represents a cyclopentyl, cyclohexyl- or a phenyl group which may or may not be substituted with an alkyl group having 1 to 4 carbon atoms, or

30 R³ represents a phenyl group substituted with a OR³¹ group, where R³¹ is H or an alkyl group having 1 to 4 carbon atoms and k is 0, 1, or

R³ represents a 1-naphthyl or 1-naphthyl group and k is 0, 1, or

35 R³ represent a cis- or trans-decalin group and k is 0, 1, or

R³ represents 4-pyridyl, 3-pyrrolidyl or 3-indolyl which may or may not be substituted with a OR³¹ group, where R³¹ is as defined above and k is 0, 1, or

R^3 represents $\text{Si}(\text{Me})_3$ or $\text{CH}(\text{R}^{32})_2$, wherein R^{32} is a cyclohexyl- or phenyl group;

5 R^4 represents H, an alkyl group having 1 to carbon atoms, a cyclohexyl or a phenyl group, preferably H;

A², B and n are defined as described under Formula Ib above;

10 D represents Z or (Z)₂.

Preferred integers, groups or combinations and particularly preferred combinations are the same as described in Formula Ib above but R^{11} is H, an alkyl group having 1 to 6 carbon atoms or a benzyl group.

15 Preferred compounds having Formula Vb are:

Boc-(R)Pro-Phe-Pab(Z)

20 BnOOC-CH₂-(R)Pro-Phe-Pab(Z)

Boc-(R)Phe-Phe-Pab(Z)

MeOOC-CO-(R)Phe-Phe-Pab(Z)

BnOOC-CH₂-(R)Phe-Phe-Pab(Z)

25

In a further embodiment the invention relates to novel use of a compound of the formula:

30




35

as a starting material in synthesis of a peptidic serine protease inhibitor, and in particular in synthesis of peptidic thrombin inhibitors or kininogenases inhibitors. It can be used as such or

has however not been previously disclosed as a structural element in a pharmaceutically active compound, especially a peptic compound. The fragment renders a serine protease inhibitor, and in particular a thrombin inhibitor or kininogenases inhibitor valuable.

In a further embodiment the invention relates to a novel compound of the formula:

10




15

and the use of said compound as a starting material in synthesis of a serine protease inhibitor especially a thrombin inhibitor or kininogenase inhibitor. The compound may have the amidino group either mono- or diprotected at the nitrogens with a protective group such as benzyloxy carbonyl. Protection of the amidino derivatives is carried out by methods known in the art for amidino compounds. This compound is named "1,3-diaza-2-imino-4-aminoethyl cyclohexane" or "H-Itp" herein.

The structural fragment of the formula

30



35

has however not been previously disclosed as a structural element in a pharmaceutically active

is named "1-amidino-4-aminomethyl cyclohexane" or "H-Pac" herein.

The compound has been previously disclosed in DE 2748295.

5

The structural fragment of the formula

10



has however not been previously disclosed as a structural element in a thrombin inhibitor valuable.

15

In a further embodiment the invention relates to a novel compound of the formula:


20




and the use of said compound as a starting material in synthesis of a serine protease inhibitor, especially a thrombin inhibitor or kininogenase inhibitor. The compound may have the amidino group either mono- or diprotected at the nitrogens with a protective group such as benzyloxy carbonyl. Protection of the amidino derivatives is carried out by methods known in the art for amino compounds. This compound is named "4-aminoethyl-1-amidino piperidine" or "H-Rig" herein.

The structural fragment of the formula

35



The structural fragment of the formula



has however not been previously disclosed as a structural element in a pharmaceutically active compound, especially a peptic compound. The fragment
15 renders a serine protease inhibitor, and in particular a thrombin inhibitor or kininogenases inhibitor valuable.

A further embodiment of the invention are the novel
20 compounds having the amidino group mono- or di-protected at the nitrogens with a benzyloxycarbonyl group, examples of such compounds are


25 4-aminomethyl-1-(N-benzyloxycarbonylamidino) benzene (H-Pab(Z)),
4-aminomethyl-1-(N,N'-di(benzyloxycarbonyl)amidino)
benzene (H-Pab(Z)₂),
4-aminomethyl-1-(N-benzyloxycarbonylamidino)
cyclohexane (H-Pac(Z)),
30 4-aminomethyl-1-(N,N'-di(benzyloxycarbonyl)amidino)
cyclohexane (H-Pac(Z)₂),
4-aminoethyl-1-(N-benzyloxy-carbonylamidino piperidine
(H-Rig(Z)),
4-aminoethyl-1-N,N'-di(benzyloxycarbonyl)amidino
35 piperidine (H-Rig(Z)₂),
(3RS)-1-(N-benzyloxycarbonylamidino)-3-aminomethyl
pyrrolidine (H-Nig(Z)),

comp und, especially a peptic compound. The fragment renders a serine protease inhibitor, and in particular a thrombin inhibitor or kininogenases inhibitor varuable.

5

In a further embodiment the invention relates to novel compounds of the formula:

10



15

where n is 1 or 2

s is 0 to 1,

20

and the use of said compounds as a starting material in synthesis of serine protease inhibitors, especially thrombin inhibitors or kininogenases inhibitors. The compound may have the amidino group either mono- or diprotected at the nitrogens with a protective group such as benzyloxy carbonyl. Protection of the amidino derivatives is carried out by methods known in the art for amidino compounds. These compounds are named:

25

1-amidino-3-aminomethyl pyrrolidine or "H-Nig" when n is 1 and s is 1

30

1-amidino-3-aminoethyl pyrrolidine or "H-Hig" when n is 2 and s is 1

3-aminomethyl-1-amidino azetidine or "H-Mig" when n is 1 and s is 0

35

3-aminoethyl-1-amidino azetidine or "H-Dig" when n is 2 and s is 0

and pulmonary embolism, arterial thrombosis, such as in myocardial infarction, unstable angina, thrombosis-based stroke and peripheral arterial thrombosis and systemic embolism usually from the atrium during 5 arterial fibrillation or from the left ventricle after transmural myocardial infarction. Further, these compounds have expected utility in prophylaxis of atherosclerotic diseases such as coronary arterial disease, cerebral arterial disease and peripheral 10 arterial disease. Further, these compounds are expected to have synergistic antithrombotic effects when combined with any antithrombotic agent with a different mechanism of action, such as the antiplatelet agent acetylsalicylic acid. Further, these compounds are 15 expected to be useful together with thrombolytics in thrombotic diseases, in particular myocardial infarction. Further, these compounds have expected utility in prophylaxis for re-occlusion after thrombolysis, percutaneous trans-luminal angioplasty 20 (PTCA) and coronary bypass operations. Further, these compounds have expected utility in prevention of re-thrombosis after microsurgery and vascular surgery in general. Further, these compounds have expected utility 25 in treatment and prophylaxis of disseminated intravascular coagulation caused by bacteria, multiple trauma, intoxication or any other mechanism. Further, these compounds are expected to be useful in anticoagulant treatment when blood is in contact with foreign surfaces in the body such as vascular grafts, 30 vascular stents, vascular catheters, mechanical and biological prosthetic or any other medical device. Further, these compounds have expected utility in anticoagulant treatment when blood is in contact with medical devices outside the body such as during 35 cardiovascular surgery using or heart-lung machine or in haemodialysis.

(3RS)-1-(N,N'-di(benzyloxycarbonyl)amidino)-3-aminomethyl pyrrolidine (H-Mig(Z)₂),
(3RS)-1-(N-benzyloxycarbonylamidino)-3-aminoethyl pyrrolidine (H-Hig(Z)),
5 (3RS)-1-(N,N'-di(benzyloxycarbonyl)amidino)-3-aminoethyl pyrrolidine (H-Hig(Z)₂),
3-aminomethyl-1-(N-benzyloxycarbonylamidino) azetidine (H-Mig(Z)),
3-aminomethyl-1-(N,N'-di(benzyloxycarbonyl)amidino)
10 azetidine (H-Mig(Z)₂),
3-aminoethyl-1-(N-benzyloxycarbonylamidino) azetidine (H-Dig(Z)),
3-aminoethyl-1-(N,N'-di(benzyloxycarbonyl)amidino)
azetidine (H-Dig(Z)₂),

15 Said compounds are used as starting materials in the preparation of the claimed peptide derivatives of formulas I, Ia, Ib, V, Va and Vb.

20 Medical and pharmaceutical use

The invention also provides compositions and methods for the treatment, in a human or animal organism, of conditions where inhibition of thrombin is required and 25 of physiologically disorders especially inflammatory diseases.

The thrombin inhibiting compounds of the invention are expected to be useful in particular in animals including man in treatment or prophylaxis of thrombosis and hypercoagulability in blood and tissues. They are furthermore expected to be useful in situations where there is an undesirable excess of the thrombin without signs of hypercoagulability, for example as in 30 Alzheimers disease and pancreatitis. Disease states in which these compounds have a potential utility, in 35 treatment and/or prophylaxis, include venous thrombosis

the disorder and patient to be treated and the route of administration, the compositions may be administered at varying doses.

5 The dosage form may be a solid, semisolid or liquid preparation prepared by per se known techniques. Usually the active substance will constitute between 0.1 and 99 % by weight of the preparation, more specifically between 0.1 and 50 % by weight for
10 preparations intended for parenteral administration and between 0.2 and 75 % by weight for preparations suitable for oral administration.

15 Suitable daily doses of the compounds of the invention in therapeutical treatment of humans are about 0.001-100 mg/kg body weight at peroral administration and 0.001-50 mg/kg body weight at parenteral administration.

20

Preparation

25 A further objective of the invention is the mode of preparation of the compounds. The compounds of Formula I and V may be prepared by processes comprise coupling of an N-terminally protected dipeptide or aminoacid, when a N-terminally amino acid is used a second aminoacid is added afterwards using standard methods to a compound

30



35 wherein n is an integer 0, 1, 2, 3 or 4, X is B or B-D where B is as defined in formula I and D is as defined in formula V as such or having the guanidino or amidino

A further expected utility of the anticoagulant compounds of the invention are in rinsing of catheters and mechanical devices used in patients in vivo, and as anticoagulants for preservation of blood, plasma and other blood products in vitro.

The antiinflammatory inhibiting compounds of the invention are expected to be useful in particular in animals including man in treatment or prophylaxis of inflammatory diseases such as asthma, rhinitis, 10 pancreatitis, uticaria, inflammatory bowel diseases, and arthritis. An effective amount of kininogenase inhibiting compounds with or without a physiologically acceptable carrier or diluent can be used solely or in 15 combination with other therapeutic agents.

The compounds inhibit the activity of kallikreins assessed with chromogenic substrates according to known procedures. The anti-inflammatory actions of the 20 present compounds can for example be studied by their inhibition of allergen-induced exudative inflammatory processes in airway mucosa or gut mucosa.

25 Pharmaceutical preparations

The compounds of the invention will normally be administered orally, rectally, dermally, nasally, tracheally, bronchially, parenterally or via inhalation route, in the form of pharmaceutical preparations 30 comprising the active ingredient either as a free base or a pharmaceutical acceptable non-toxic organic or inorganic acid addition salt, e.g. the hydrochloride, hydrobromide, sulphate, hydrosulphate, nitrate, lactate, acetate, citrate, benzoate, succinate, tartrate, trifluoroacetate and the like in a 35 pharmaceutically acceptable dosage form. Depending upon

wherein n is as defined in Formula I W^1 is an N-terminal amino protecting group such as tert-butyloxyl carbonyl and benzyloxyl carbonyl and and Q^1 is $-C(NH)-NH_2$, $-C(NW^2)-NH-W^2$, $-C(NH)-NH-W^2$, $-NH-C(NH)-NH_2$, $-NH-C(NH)-NH-W^2$, $-N(W^2)-C(NH)-NH-W^2$ or $-NH-C(NW^2)-NH-W^2$, where W^2 is an amine protecting group such as tert-butyloxyl carbonyl or benzyloxyl carbonyl, or Q^1 is $-CN$, $-CO-NH_2$ or $-CS-NH_2$, where the group is subsequently transferred into a amidino group (e.g giving $Q^1 = -C(NH)-NH_2$) by methods known in the art or Q^1 is NH_2 or $NH-W^2$, where W^2 is as defined above, where the amino group is subsequently transferred into a guanidino group (giving $Q^1 = -NH-C(NH)-NH_2$), after deprotection of the W^2 -group when Q^1 is $-NH-W^2$ (W^2 in this case must be orthogonal to W^1), by methods known in the art.

The final compounds can be made in any of the following ways, depending on the nature of the Q^1 - group used:


Removal of the protecting group(s) (when $Q^1 = -C(NH)-NH_2$, $-C(NW^2)-NH-W^2$, $-C(NH)-NH-W^2$, $-NH-C(NH)-NH_2$, $-NH-C(NH)-NH-W^2$, $-N(W^2)-C(NH)-NH-W^2$ or $-NH-C(NW^2)-NH-W^2$), or a selective deprotection of the W^1 - group (e.g when $Q^1 = -C(NW^2)-NH-W^2$, $-C(NH)-NH-W^2$, $-NH-C(NH)-NH-W^2$, $-N(W^2)-C(NH)-NH-W^2$ or $-NH-C(NW^2)-NH-W^2$ (W^2 in this case must be orthogonal to W^1)) followed by alkylation of the N-terminal nitrogen by methods known in the art and if desired deprotection by known methods.

Method Ib

30

Coupling of an N-terminally protected amino acid, selected from A² in Formulas I or V and prepared by standard methods, with a compound of formula

35




nitrogens either mono or diprotected with an amine protecting group such as a benzyloxy carbonyl-, tert-butyloxycarbonyl- or p-toluenesulphonyl- group or X is a group transferable into B followed by removal of the 5 protective group(s) or deprotection of the N-terminal nitrogen followed by alkylation of the N-terminal nitrogen and if desired deprotection by known methods and if desired forming a physiologically acceptable salt, and in those cases where the reaction results in 10 a mixture of stereoisomers, these are optionally separated by standard chromatographic or re-crystallisation techniques, and if desired a single stereoisomer is isolated.



15 In more detail the compounds of Formula I or V may be prepared by either of the following methods:

Method Ia

20 Coupling of an N-terminally protected dipeptide, selected from A¹ and A² in Formulas I or V and prepared by standard peptide coupling, with a compound




using standard peptide coupling, shown in the formula




using standard peptide coupling, shown in the formula



5



10



15

wherein n is as defined in Formula I, W^1 is an N-terminal amino protecting group such as tertbutyloxycarbonyl and benzyloxycarbonyl and Q^1 is $-\text{C}(\text{NH})-\text{NH}_2$, $-\text{C}(\text{NW}^2)-\text{NH}-\text{W}^2$, $-\text{C}(\text{NH})-\text{NH}-\text{W}^2$, $-\text{NH}-\text{C}(\text{NH})-\text{NH}_2$, $-\text{NH}-\text{C}(\text{NH})-\text{NH}-\text{W}^2$, $-\text{N}(\text{W}^2)-\text{C}(\text{NH})-\text{NH}-\text{W}^2$ or $-\text{NH}-\text{C}(\text{NW}^2)-\text{NH}-\text{W}^2$, where W^2 is an amine protecting group such as tertbutyloxycarbonyl or benzyloxycarbonyl, or Q^1 is $-\text{CN}$, $-\text{CO}-\text{NH}_2$ or $-\text{CS}-\text{NH}_2$, where the group is subsequently transferred into a amidino group (e.g giving $Q^1 = -\text{C}(\text{NH})-\text{NH}_2$) by methods known in the art or Q^1 is NH_2 or $\text{NH}-\text{W}^2$, where W^2 is as defined above, where the amino group is subsequently transferred into a guanidino group (giving $Q^1 = -\text{NH}-\text{C}(\text{NH})-\text{NH}_2$), after deprotection of the W^2 -group when Q^1 is $-\text{NH}-\text{W}^2$ (W^2 in this case must be orthogonal to W^1), by methods known in the art.

35


The final compounds can be made in any of the following ways, depending on the nature of the Q^1 - group used:
 Removal of the protecting group(s) (when $Q^1 = -\text{C}(\text{NH})-\text{NH}_2$, $-\text{C}(\text{NW}^2)-\text{NH}-\text{W}^2$, $-\text{C}(\text{NH})-\text{NH}-\text{W}^2$, $-\text{NH}-\text{C}(\text{NH})-\text{NH}_2$, $-\text{NH}-\text{C}(\text{NH})-\text{NH}-\text{W}^2$, $-\text{N}(\text{W}^2)-\text{C}(\text{NH})-\text{NH}-\text{W}^2$ or $-\text{NH}-\text{C}(\text{NW}^2)-\text{NH}-\text{W}^2$), or a selective deprotection of the W^1 - group (e.g when $Q^1 = -$

using standard peptide coupling, shown in the formula


5



10



15



20

wherein n, W¹, and Q¹ are as defined above followed by deprotection of the W¹-group and coupling with the N-terminal amino acid, in a protected form, leading to the protected peptide described in Method Ia. The synthesis to the final peptides is then continued according to Method Ia.


25

Method IIIa

30


Coupling of an N-terminally protected dipeptide, selected from A¹ and A² in Formulas I or V and prepared by standard peptide coupling, with a compound

35



Method IIIa

Coupling of an N-terminally protected dipeptide,
selected from A¹ and A² in Formulas I or V and prepared
5 by standard peptide coupling, with a compound




10

using standard peptide coupling, shown in the formula



15



20


wherein n is as defined in Formula I and r is 0.1 when
X¹, X² and X⁴ are CH₂ or r is 0 when X² and X⁴ are CH₂
and X¹ is absent, W¹ is an N-terminal amino protecting
group such as tert-butyloxycarbonyl and benzyloxycarbonyl
30 and Q² is -C(NH)-NH₂, -C(NW²)-NH-W², or -C(NH)-NH-W², where W² is an amine protecting group such as tert-butyloxycarbonyl or benzyloxycarbonyl, or Q² is equal to W² where the amino group, after
deprotection of the W² group (W² in this case must be
35 orthogonal to W¹), is subsequently transferred into a guanidino group using an unprotected, N-protected or N,N'-diprotected guanidation reagent by methods known

C(NW²) - NH - W², - C(NH) - NH - W², - NH - C(NH) - NH - W², - N(W²) - C(NH) - NH - W² or - NH - C(NW²) - NH - W² (W² in this case must be orthogonal to W¹) followed by alkylation of the N-terminal nitrogen by methods known in the art and if desired deprotection by known methods.



5.

Method IIb

10 Coupling of an N-terminally protected amino acid, selected from A² in Formulas I or V and prepared by standard methods, with a compound of formula



using standard peptide coupling, shown in the formula




wherein n, W¹ and Q¹ are as defined above followed by deprotection of the W¹-group and coupling with the N-terminal amino acid, in a protected form, leading to the protected peptide described in Method IIa. The synthesis to the final peptides is then continued according to Method IIa.

35



above foll wed by deprotection of the W^1 -group and coupling with the N-terminal amino acid, in a protected form, leading to the pr tected peptide described in Method IIIa. The synthesis to the final peptides is
 5 then continued according to Method IIIa.

Method IVa

10 Coupling of an N-terminally protected dipeptide, selected from A^1 and A^2 in Formulas I or V and prepared by standard peptide coupling, with a compound



using standard peptide coupling, shown in the formula



wherein n is as defined in Formula I, W^1 is an N-terminal amino protecting group such as tert-butyloxyl carbonyl or benzyloxyl carbonyl and W^3 is H or an amino protecting group such as aryl sulfonyl, benzyloxyl carbonyl or tert-butyloxyl carbonyl. The final compounds
 35

in the art (giving $Q^2 = -C(NH)-NH_2$, $-C(NW^2)-NH-W^2$ or $-C(NH)-NH-W^2$).


The final compounds can be made in any of the following ways, depending on the nature of the Q^2 - group used:
 5 Removal of the protecting group(s) (when $Q^2 = -C(NH)-NH_2$,
 $-C(NW^2)-NH-W^2$ or $-C(NH)-NH-W^2$), or a selective
 deprotection of the W^1 - group (e.g when $Q^2 = -C(NW^2)-NH-$
 10 W^2 , $-C(NH)-NH-W^2$, W^2 in this case must be orthogonal to
 W^1) followed by alkylation of the N-terminal nitrogen
 by methods known in the art and if desired deprotection
 known methods.

Method IIIb

15

Coupling of an N-terminally protected amino acid, selected from A^2 in Formulas I or V and prepared by standard methods, with a compound of formula

20




using standard peptide coupling, shown in the formula

25



30



35

wherein n , r , X^1 , X^2 and X^4 , W^1 , and Q^2 are as defined

DETAILED DESCRIPTION OF THE INVENTION

The following description is illustrative of aspects of the invention.

5

EXPERIMENTAL PART**General experimental Procedures.**

10 Mass spectra were recorded on a Finnigan MAT TSQ 700 triple quadropole mass spectrometer equipped with an electrospray interface.

15 The ^1H NMR and ^{13}C NMR measurements were performed on BRUKER AC-P 300 and BRUKER AM 500 spectrometers, the former operating at a ^1H frequency of 500.14 MHz and a ^{13}C frequency of 125.76 MHz and the latter at ^1H and ^{13}C frequency of 300.13 MHz and 75.46 MHz respectively.

20 The samples were about 10-50 mg dissolved in 0.6 ml of either of the following solvents ; CDCl_3 (isotopic purity > 99.8%), CD_3OD (isotopic purity > 99.95%), D_2O (isotopic purity > 99.98%) or DMSO-d_6 (isotopic purity > 99.8%). All solvents where purchased from Dr. Glaser AG, Basel.

25 The ^1H and ^{13}C chemical shift values in CDCl_3 and CD_3OD are relative to tetramethylsilane as an external standard. The ^1H chemical shifts in D_2O are relative to the sodium salt of 3-(trimethylsilyl)- d_4 -propanoic acid and the ^{13}C chemical shifts in D_2O are referenced relative to 1,4-dioxane (67.3 ppm), both as external standard. Calibrating with an external standard may in some cases cause minor shift differences compared to an internal standard, however, the difference in ^1H chemical shift is less than 0.02 ppm and in ^{13}C less than 0.1 ppm.


can be made in any of the following ways: Removal of the protecting group(s), or a selective deprotection of the W^1 -group (W^1 must be orthogonal to W^3) followed by alkylation of the N-terminal nitrogen and if desired deprotection.

5

Method IVb

10 Coupling of an N-terminally protected amino acid, selected from A^2 in Formulas I or V and prepared by standard methods, with a compound of formula

15




using standard peptide coupling, shown in the formula


20



25



30



35

wherein n , W^1 , and W^3 are as defined above followed by deprotection of the W^1 -group (W^1 must be orthogonal to W^3) and coupling with the N-terminal amino acid, in a protected form, leading to the protected peptide described in Method IVa. The synthesis to the final peptides is then continued according to Method IVa.

different dimensions for analytical (4.6 mm x 250 mm), semipreparative (1" x 250 mm) and preparative (2" x 500 mm) chromatography detecting at 226 nm.

5 Freeze-drying was done on a Leybold-Heraeus, model Lyovac GT 2, apparatus.

Preparation of starting materials

10

Boc-(R)Pgl-OH

Prepared in the same way as described for Boc-(R)Cha-OH (vide infra) from H-(R)Pgl-OH.

15

Boc-(R)Cha-OH

To a solution of H-(R)Cha-OH, 21.55 g (125.8 mmol), in 130 ml 1 M NaOH and 65 ml THF was added 30 g (137.5 mmol) of (Boc)₂O and the mixture was stirred for 4.5 h at room temperature. The THF was evaporated and an additional 150 ml of water was added. The alkaline aqueous phase was washed twice with EtOAc, then acidified with 2 M KHSO₄ and extracted with 3 x 150 ml of EtOAc. The combined organic phase was washed with water, brine and dried (Na₂SO₄). Evaporation of the solvent afforded 30.9 g (90.5 %) of the title compound as a white solid.

30

Boc-(R)Hop-OH

Prepared by the same procedure as described for Boc-(R)Cha-OH starting from H-(R)Hop-OH.

35 ¹H-NMR (300 MHz, CDCl₃): δ 1.45 (s, 9H), 2.00 (m, 1H), 2.22 (m, 1H), 2.75 (bt, 2H), 4.36 (bs, 1H), 5.05 (bs, 1H), 7.15-7.33 (m, 5H).

The ^1H NMR spectrum of peptide sequences containing a proline or a "proline like" residue frequently exhibits two sets of resonances. This corresponds to the existence of two contributing conformers with respect to the rotation around the amide bond, where proline is the N-part of the amide bond. The conformers are named cis and trans. In our compounds the sequences (R)Cha-Aze-, (R)Cha-Pro- and (R)Cha-Pic- often give rise to a cis-trans equilibrium with one conformer as the preponderant conformer (>90%). In those cases only the chemical shifts of the major rotamer is reported. Only in the cases where the signals of the minor rotamer are clearly resolved they are reported in the NMR documentation. The same criterium is valid for the NH-signals in CDCl_3 , only in the cases where the signals are clearly resolved they are reported in the NMR-documentation. This implies that the number of protons reported for some of the intermediates are less than the number of protons expected from the chemical formula.

Thin-Layer Chromatography was carried out on commercial Merck Silicagel 60F₂₅₄ coated glass or aluminium plates. Visualisation was by a combination of UV-light, followed by spraying with a solution prepared by mixing 372 ml of EtOH(95%), 13.8 ml of concentrated H_2SO_4 , 4.2 ml of concentrated acetic acid and 10.2 ml of p-methoxy benzaldehyde or phosphomolybdic acid reagent (5-10 w.t % in EtOH(95%)) and heating.

Flash chromatography was carried out on Merck Silica gel 60 (40-63 mm, 230-400 mesh) under pressure of air.

Reversed phase high-performance liquid chromatography (in the Examples referred to as RPLC) was performed on a Waters M-590 instrument equipped with three reverse phase Kromasil 100,C8 columns (Eka-Nobel) having

(d, 2H).

(ii) 4-amidino benzyl azide

5 Hydrogen chloride was bubbled into a mixture of 250 ml absolute ethanol and the solution from step (i) (approximately 200 ml) above at - 5°C until saturation. Storage at 8°C for 24 h and evaporation of most of the solvent followed by precipitation by addition of
10 anhydrous ether gave white crystals which were isolated by filtration and dissolved in 1.8 l of alcoholic ammonia. After 48 h most of the solvent was removed and 200 ml 3.75 M NaOH solution was added whereupon 4-amidino benzyl azide precipitated as colourless
15 crystals. The crystals were isolated by filtration. At this point the yield of 4-amidino benzyl azide was 22.5 g (total 51%).

Ethylimidatobenzyl azide hydrochloride:

20 $^1\text{H-NMR}$ (500 MHz, CD_3OD); δ 1.6 (t, 3H), 4.5 (s, 2H), 4.65 (q, 2H), 4.8 (br s, 2H), 7.6 (d, 2H), 8.1 (d, 2H)

4-amidino benzyl azide:

25 $^1\text{H-NMR}$ (500 MHz, CDCl_3); δ 4.3 (s, 2H), 5.7 (br s, 3H), 7.3 (d, 2H), 7.6 (d, 2H).

30 $^{13}\text{C-NMR}$ (125 MHz, CDCl_3): amidine carbon: δ 165.5.

(iii) 4-(benzyloxycarbonylamidino) benzyl azide

The crystals from (ii) above were dissolved in 500 ml methylene chloride and the resulting solution was dried
35 (K_2CO_3), filtered and 27 ml (194 mmol) triethyl amine was added. 25 ml Benzyl chloroformate was slowly added to the stirred solution while the reaction mixture was

4-(tert-butyloxycarbonylamino methyl) pyridine

To a solution of 10.81 g (100 mmol) 4-aminomethyl pyridine in 100 ml THF was added 24 g (110 mmol) Boc_2O dissolved in 70 ml THF at 10°C for 20 minutes. The solution was allowed to reach room temperature and stirred for 4 h (a precipitate was formed during the reaction and the slurry became red). The solvent was removed and the residue was dissolved in EtOAc and filtered through silica gel. Evaporation of the solvent gave the title compound as a red oil which crystallized on standing. The crude product was used without further purification.

¹⁵ $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 1.45 (s, 9H), 4.32 (d, 2H), 5.05 (bs, 1H (NH)), 7.2 (d, 2H), 8.55 (d, 2H).

**4-aminomethyl-1-(N-benzyloxycarbonylamidino)-benzene
(E-Pab(Z))**

²⁰ (i) 4-cyanobenzyl azide

A solution of 20.23 g (0.31 mol) sodium azide in 50 ml water was added to 49.15 g (251 mmol) 4-cyanobenzyl bromide in 200 ml DMF at ambient temperature. An exothermic reaction took place and after 1.5 h the reaction mixture was diluted with 200 ml toluene (caution: In order to avoid separation of potentially explosive azide compounds it is advisable to add the toluene to the reaction mixture before addition of the water) and 500 ml water. The aqueous phase was extracted with an additional 2x50 ml toluene. The combined organic extracts were washed with 2x50 ml water and brine and finally dried (MgSO_4) and filtered. The solution was used as such in the next step.

³⁵ $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 4.4 (s, 2H), 7.4 (d, 2H), 7.7

(d, 2H), 9.1-9.6 (br s, 1H).

¹³C-NMR (125 MHz, CDCl₃): amidine and carbonyl carb ns:
δ 164.6 and 168.17.

5

H-Pig(Z)₂

(i) 4-(tert-butyloxycarbonyl-aminomethyl) piperidine

10 To a solution of 17.7 g 4-tert-
butyloxycarbonylaminomethyl pyridine in 125 ml MeOH was
added 2 g of 5 % Rh/Al₂O₃ and the mixture was
hydrogenated at 0.34 MPa over night. ¹H-NMR showed that
the hydrogenation was incomplete. Therefore, the
15 catalyst was filtered off and the solvent removed in
vaccum and the residue was dissolved in 100 ml acetic
acid, 2 g of 5 % Rh/Al₂O₃ was added and the mixture was
hydrogenated for 4 days at 0.34 MPa. The catalyst was
filtered off and most of the acetic acid was removed in
20 vacuum. After addition of 50 ml water to the residue
the mixture was made alkaline with 5 M NaOH and the
water phase was extracted with 1 x 200 + 1 x 100 ml
CH₂Cl₂. The combined organic phase was washed with 25 ml
water and dried (MgSO₄). Evaporation of the solvent
25 gave a 17.2 g of a brownish oil which was dissolved in
50 ml of diethyl ether. Addition of 200 ml pentane gave
a precipitate which was filtered off to give 7.7 g of a
brown powder. Evaporation of the mother liquor gave 7 g
of a white oil. The brown powder was dissolved in 100
30 ml EtOAc and the organic phase was washed with 1 x 50
ml + 1 x 25 ml 1 M KHSO₄. The combined acidic phase was
made alkaline with 2 M NaOH and extracted with 1 x 200
+ 1 x 75 ml EtOAc. The combined organic phase was dried
and evaporated to give 5.2 g of the title compound as a
white powder.
35

Treatment of the white oil obtained from the mother

cooled in an ice bath. After 30 minutes an additional 2 ml benzyl chloroformate was added and stirring was continued for another 30 minutes. Subsequently, water was added and the aqueous phase was adjusted to pH 7 with 2M HCl. The organic phase was dried ($MgSO_4$) and the solvent was removed in vacuo. 4-(benzyloxycarbonylamidino) benzyl azide was finally isolated as colorless crystals from ether/methylene chloride/hexane.

¹⁰ 1H -NMR (500 MHz, $CDCl_3$): δ 4.4 (s, 2H), 5.3 (s, 2H), 6.3-7.0 (br s, 1H), 7.3-7.4 (m, 5H), 7.5 (d, 2H), 7.9 (d, 2H), 9.3-9.6 (br s, 1H).

¹⁵ ^{13}C -NMR (125 MHz, $CDCl_3$): amidine carbon: δ 167.5.

(iv) 4-aminomethyl-1-(N-benzyloxycarbonylamidino)-
benzene (H-Pab(Z))

²⁰ 26.3 g (100 mmol) triphenylphosphine was added at room temperature to the 4-(benzyloxycarbonylamidino) benzyl azide from (iii) above dissolved in 160 ml THF. After 16 h an additional 6.6 g (25 mmol) triphenylphosphine
²⁵ was added and the solution was allowed to stand for 4 h before removal of the solvent in vacuo. The residue was dissolved in methylene chloride and extracted with 2M HCl. The aqueous phase was washed with methylene chloride and ether and was subsequently made alkaline with 3.75M sodium hydroxide solution. Extraction with methylene chloride followed by drying (K_2CO_3) and removal of the solvent in vacuo gave 20 g (The total yield starting from cyanobenzyl bromide is 28%) of a yellow oil which solidified on standing.

³⁵ 1H -NMR (500 MHz, $CDCl_3$): δ 1.2-2.2 (br s, 2H), 3.8 (s, 2H), 5.2 (s, 2H), 7.2-7.35 (m, 5H), 7.4 (d, 2H), 7.8

A solution of 163 mg (0.31 mm l) Boc-Pig(Z)₂ in 5 ml EtOAc saturated with HCl(g) was stirred at ambient temperatur for 3 h and 20 minutes. The solvent was evaporated and the residue was dissolved in 30 ml CH₂Cl₂. The organic phase was washed with 5 ml 2 M NaOH, 1 x 5 ml water, 1 x 5 ml brine and dried(MgSO₄). Evaporation of the solvent afforded 100 mg (76 %) of the title compound.

¹⁰ ¹H-NMR (500 MHz, CDCl₃): Some signals, especially in the piperidin ring, are selectively broadend due to an intramolecular exchange process. This is especially pronounced for the 2- and 6-CH₂ groups of the piperidine ring, which exhibit a broad peak ranging
¹⁵ from 3.7 to 4.5 ppm.
δ 1.18-1.37 (m, 2H), 1.46-1.63 (m, 1H), 1.68-1.83 (m, 2H), 2.57 (d, 2H), 2.86-3.03 (m, 2H), 3.7-4.5 (bs, 2H), 5.13 (s, 4H), 7.2-7.4 (m, 10H).

²⁰ 4-aminomethyl-1-(N-benzyloxy carbonylamidino)-cyclohexane (H-Pac(Z) x 2HCl).

(i) N-[N-4-(benzyloxycarbonyl)amidino benzyl] tert-butyl carbamate

²⁵ 1.466 g (6.7 mmol) (Boc)₂O was added to a stirred ice cold solution of 1.81 g (6.4 mmol) 4-(benzyloxycarbonyl)amidino benzyl amine and 1 ml (7.1 mmol) triethyl amine in 25 ml methylene chloride. After
³⁰ 20 minutes more methylene chloride was added and the mixture was washed with 5% acetic acid and 10% sodium carbonate solution. Drying (magnesium sulphate) and removal of the solvent in vauo left a residue which could be crystallised from methylene chloride/hexane.
³⁵ The yield was 1.66 g (68%).

(ii) N-[N-4-amidino benzyl]tert-butyl carbamate

liqour above in the same way afforded an additional 3.4 g of the product. Total yield 40 %.

5 ¹H-NMR (500 MHz, CDCl₃, mixture of two rotamers, 3:1):
major rotamer: δ 1.11 (dq, 2H), 1.44 (s, 9H), 1.49-1.60
(m, 1H), 1.63-1.70 (m, 2H), 2.58 (dt, 2H), 2.93-3.03
(m, 2H), 3.07 (m, 2H), 4.75 (bs, 1H (NH)).

10 Resolved signals arising from the minor rotamer appear
at δ 1.21 (dq) and 1.91 (dt).

(ii) Boc-Pig(Z)₂

15 To a solution of 2 g (9.33 mmol) 4-(tert-
butylcarbonyl-aminomethyl) piperidine in 60 ml CH₃CN
was added 3.34 g (9.33 mmol) of N,N'-(dibenzylxy-
carbonyl)methylisothiourea and the mixture was stirred
at 60°C for 22 h. The solvent was evaporated and the
residue was dissolved in EtOAc. The organic phase was
20 washed with 2 x 20 ml 1 M KHSO₄, 1 x 20 ml water, 1 x
20 ml brine and dried(MgSO₄). Evaporation of the
solvent followed by flash chromatography using
petroleum ether/EtOAc (1/1) as eluent afforded 2.43 g
(50%) of the desired product.

25 ¹H-NMR (500 MHz, CDCl₃): Some signals, especially in the
piperidine ring, are selectively broadend due to an
intramolecular exchange process. This is especially
pronounced for the 2- and 6-CH₂ groups of the
30 piperidine ring, which exhibit a broad peak ranging
from 3.7 to 4.5 ppm.
δ 1.19-1.31 (m, 2H), 1.43 (s, 9H), 1.63-1.80 (m, 3H),
2.66-3.05 (m, 4H), 3.7-4.5 (bs, 2H), 4.65 (bt, 1H(NH)),
5.13 (s, 4H), 7.2-7.4 (m, 10H), 10.5 (bs, 1H(NH)).

35 (iii) H-Pig(Z)₂

c mp und.

(v) 4-aminomethyl-1-(N-benzyloxy carbonylamidino)-cyclohexane (H-Pig(Z) x 2HCl).

5

Hydrogen chloride was passed through a solution of 2 g (5.1 mmol) N-[4-(benzyloxycarbonyl)amidino cyclohexyl methyl]tert-butyl carbamate in 40 ml ethyl acetate.

10 After 10 minutes methanol was added and upon removal of some of the solvent in vacuo the dihydrochloride of title compound crystallised.

4-aminomethyl-1-(N-benzyloxy carbonylamidino)piperidine (H-Pig(Z) x HCl)

15

(i) 4-(N-tert-butyloxycarbonylaminomethyl)-1-(N-benzyloxycarbonylamidino) piperidine (Boc-Pig(Z))

20 7.8 g (36.4 mmole) of 4-(N-tert-butyloxycarbonylaminomethyl) piperidine and 8.98 g (40 mmole) of N-benzyloxycarbonyl-S-methylisothiourea was mixed in 25 mL ethanol. The mixture was heated at 60-70°C for six hours and left at roomtemperature for two days. The solvent was evaporated and the residue 25 was dissolved in CH₂Cl₂. The organic layer was washed twice with 0.3 M KHSO₄ and once with brine. The combined organic layer was dried (Na₂SO₄), filtered and evaporated. The crude product was purified by flash chromatography using a stepwise gradient of CH₂Cl₂/MeOH (100/0, 97/3, 95/5, 90/10) as eluent to yield 5.22 g 30 (37%) of the title product.

(ii) H-Pig(Z) x HCl (4-aminomethyl-1-(N-benzyloxy carbonylamidino) piperidine

35

5.22 g (13.5 mmole) of Boc-Pig(Z) was dissolved in 100 mL ethyl acetate saturated with HCl(g). The mixture was

A mixture of 1.60 g (4.2 mmol) N-[4-(benzyloxycarbonyl)amidino benzyl] tert-butyl carbamate, 5 ml acetic acid, and 160 mg 10% palladium on charcoal in 50 ml ethanol was stirred in an atmosphere of hydrogen for 2 h. The catalyst was removed by filtration through celite and the solvent was removed in vacuo to give the acetate of the title compound in quantitative yield.

10 (iii) N-[4-amidino cyclohexyl methyl]tert-butyl carbamate

17 mmol of the acetate of N-[4-amidino benzyl]tert-butyl carbamate was hydrogenated in 100 ml metanol in the presence of 863 mg 5% rhodium on alumina at 3.4 MPa for 20 h. The catalyst was removed by filtration and the solvent was removed in vacuo. The residue was dissolved in water and the solution was made basic with sodium hydroxide. Subsequent extraction with methylene chloride, drying of the combined organic phases (potassium carbonate) and removal of the solvent in vacuo gave 3.8 g (87%) of the title compound.

25 (iv) N-[N-4-(benzyloxycarbonyl)amidino cyclohexyl methyl] tert-butyl carbamate

1.25 ml (8.8 mmol) benzyl chloroformate was added at 0°C to a stirred solution of 2.04 g (8 mmol) N-[4-amidino cyclohexyl]tert-butyl carbamate, 1.23 ml (8.8 mmol) triethyl amine, and 197 mg DMAP in 40 ml methylene chloride. After 10 minutes the reaction mixture was diluted with methylene chloride and extracted with water, dilute acetic acid, and sodium hydrogen carbonate solution. The organic phase was applied on a column of silica and subsequent elution with methylene chloride containing increasing amounts of ethyl acetate yielded 2.49 g (80%) of the title

The reaction mixture was allowed to stir for 1 h. The mixture was poured into water and the organic layer was kept. The aqueous layer was extracted with methylene chloride and the combined organic layers were washed
5 with water, dried (Na_2SO_4) and evaporated. The product was used without further purification in the next step. Yield: 4.4 g (100%).

10 ^1H NMR (500 MHz, CDCl_3) δ 1.15-1.3 (m, 2 H), 1.65-1.8 (m, 5 H), 2.84 (bt, 2 H), 3.01 (s, 3 H), 4.20 (bd, 2 H), 4.27 (t, 2 H), 5.12 (s, 2 H), 7.1-7.5 (m, 7 H).

15 (iii) 4-Azidoethyl-1-benzyloxycarbonylamidino piperidine

20 In 100 ml of dimethylformamide was dissolved 4.4 g (0.0115 mol) of crude 1-benzyloxycarbonylamidino-4-mesyloxyethyl piperidine and 4.5 g (0.069 mol) of sodium azide was added. The mixture was heated at 100°C for 2.5 h. It was then poured into water and extracted with ethyl acetate three times. The combined organic phase was washed with water, dried (Na_2SO_4) and evaporated. The residue was flash chromatographed on silica gel using ethyl acetate/heptane 1/1 as eluent.
25 Yield: 3.0 g (79%).

30 $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ 1.20 (dq, 2H), 1.5-1.8 (m, 5 H), 2.85 (dt, 2 H), 3.35 (t, 2 H), 4.22 (bd, 2 H), 5.13 (s, 2 H), 6.9-7.2 (b, 2 H), 7.2-7.45 (m, 5 H).

(iv) 4-Aminoethyl-1-benzyloxycarbonylamidino piperidine (H-Rig(Z))

35 To 30 ml of water was added 0.40 g of 10% Pd/C. Sodium borohydride, 1.0 g (0.031 mol), was dissolved in 30 ml of water and was added carefully to the stirred and ice-cooled slurry of Pd/C and water. 4-Azidoethyl-1-

allowed to stand for one hour and then evaporated. The residue was dissolved in water and washed with a mixture of diethylether and ethyl acetate. The water layer was freeze-dried to yield 4.0 g (91%) of the title compound.

¹H-NMR (D₂O, 300 MHz): δ 1.40-1.60 (m, 2H), 2.05 (bd, 2H), 2.19 (m, 1H), 3.07(d, 2H), 3.34(bt, 2H), 4.08 (bd, 2H), 5.40 (s, 2H), 7.5-7.63 (m, 5H)

MS m/z 291 (M⁺+1)

4-Aminoethyl-1-benzyloxycarbonylamidino piperidine (E-Rig(Z))

(i) 1-Benzylloxycarbonylamidino-4-hydroxyethyl piperidine

A mixture of 6.2 g (0.028 mol) of 4-hydroxyethyl piperidine and 3.6 g (0.028 mol) of N-benzyloxycarbonyl-S-methyl isothiourea in 50 ml of acetonitrile was refluxed overnight. Evaporation and flash chromatography on silica gel with ethyl acetate gave 3.5 g (41%) of the title compound.

¹H-NMR (300 MHz, CDCl₃): δ 1.1-1.85 (m, 7 H), 2.83 (bt, 2 H), 4.70 (bt, 2 H), 4.18 (bd, 2 H), 5.12 (s, 2 H), 6.9- 7.2 (m, 2 H), 7.2-7.5 (m, 5 H).

(ii) 1-Benzylloxycarbonylamidino-4-mesyloxyethyl piperidine

To an ice cooled solution of 3.50 g (0.0115 mol) of 1-benzyloxycarbonylamidino-4-hydroxyethyl piperidine, 1.15 g (0.0115 mol) of triethyl amine in 40 ml of methylene chloride and 10 ml of tetrahydrofuran was added dropwise 1.30 g (0.115 mol) of mesyl chloride.

(ii) (3RS)-1-(N-benzyloxycarbonylamidino)-3-hydroxymethyl pyrrolidine

1.01 g (0.01 mole) (3RS)-3-hydroxymethyl pyrrolidine
5 and 2.29 g (0.011 mole) N-benzyloxycarbonyl-O-methylisourea was dissolved (the amine not very soluble) in toluene and heated to 60°C for three hours followed by stirring at room temperature over night. The mixture was evaporated and the ¹H-NMR showed that
10 the reaction was not completed. The mixture was therefore dissolved in 15 ml acetonitrile and heated to 60°C for three hours followed by stirring at room temperature over night. The solvent was evaporated and the mixture was dissolved in CH₂Cl₂, washed once with
15 water, dried (Na₂SO₄), filtered and evaporated. The crude product was purified by flash chromatography using CH₂Cl₂/MeOH 95/5 as eluent to yield 0.70 g (25%) of the product.

20 MS m/z 278 (M⁺+1)

(iii) (3RS)-1-(N-benzyloxycarbonylamidino)-3-mesyloxymethyl pyrrolidine

25 0.7 g (2.53 mmole) (3RS)-1-(N-benzyloxycarbonylamidino)-3-hydroxymethyl pyrrolidine and 0.70 ml (5.05 mmole) triethylamine was dissolved in 15 ml diethyl ether/CH₂Cl₂ 1/1 and the mixture was cooled to 0°C. 0.25 ml (3.29 mmole) methanesulphonyl
30 chloride in 3 ml diethyl ether was slowly added and the reaction mixture was stirred at 0°C for three hours. The solvent was evaporated and the residue was dissolved in ethyl acetate and extracted with a 0.3 M KHSO₄-solution. The water layer was washed once with CH₂Cl₂.
35 The water layer was made neutral with 10 M NaOH-solution and extracted twice with CH₂Cl₂. The combined organic layer was dried (Na₂SO₄), filtered and

benzyloxycarbonylamidino piperidine, 2.9 g (8.8 mmol), was dissolved in 80 ml of tetrahydrofuran and this solution was added dropwise to the ice-cooled aqueous slurry above. After 4 h of stirring at room temperature 5 the mixture was ice-cooled again and 30 ml of 2 M HCl was added. The mixture was filtered through celite and the celite was rinsed with additional water. The tetrahydrofuran was evaporated and the aqueous phase was washed with ethyl acetate. The aqueous phase was 10 made alkaline with 2 M NaOH and extracted with methylene chloride three times. The combined organic phase was washed with water, dried (Na_2SO_4) and evaporated. The product was used in the following step without further purification.

15 $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ 1.1-1.5 (m, 6 H), 1.55-1.65 (m, 1H), 1.73 (bd, 2 H), 2.72 (b, 2 H), 2.81 (dt, 2 H), 4.20 (bd, 2 H), 5.12 (s, 2 H), 6.9-7.2 (b, 2 H), 7.2-7.5 (m, 5 H).

20 (3RS)-1-(N-benzyloxycarbonylamidino)-3-aminomethyl pyrrolidine (H-(R,S)Nig(Z))

(i) (3RS)-3-hydroxymethyl pyrrolidine

25 16.4 g (0.0857 mole) (3RS)-1-benzyl-3-hydroxymethyl pyrrolidine (See H-(R,S)Nig(Z) (i) vide supra) was mixed with 1.6 g Pd/C (10%), 5 ml water and 150 ml ethanol and the mixture was hydrogenated at 0.26 MPa over night. After filtration through hyflo and evaporation of the solvent the $^1\text{H-NMR}$ showed that the reaction was not completed. Continued hydrogenation at 30 0.26 MPa over 1.6 g Pd/C (10%) in 5 ml water/150 ml ethanol for three days completed the reduction.

35 Filtration through hyflo and evaporation of the solvent gave the product in a quantitative yield.

(3RS)-1-(N-benzyloxycarb nylamidin)-3-amin ethyl
pyrr lidine (H-(R,S)Hig(Z))

5 (i) (3RS)-1-benzyl-3-hydroxymethyl pyrrolidine

25.2 g (0.1063 mole) (3RS)-1-bensyl-2-oxo-4-methoxycarbonyl pyrrolidine was slowly added to a slurry of 6.22 g lithium aluminium hydride in 160 ml diethyl ether under an argon-atmosphere. The mixture was stirred over night and then heated to reflux for one hour. The reaction mixture was cooled to room temperature and 0.2 g of $\text{Na}_2\text{SO}_4 \times 10 \text{ H}_2\text{O}$ was added followed by a slow addition of, in that order, 6 ml water, 18 ml 3.75 M NaOH-solution and 6 ml water. The slurry was dried from excess of water with Na_2SO_4 /cellite, filtered and evaporated to give (20.3 g) of the product.

20 $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): δ 1.64-1.77 (m, 1H), 1.93-2.07 (m, 1H), 2.27-2.40 (m, 2H), 2.51 (dd, 1H), 2.62 (dd, 1H), 2.82 (m, 1H), 3.52 (dd, 1H), 3.59 (s, 2H), 3.67 (dd, 1H), 7.15-7.40 (m, 5H)

25 (ii) (3RS)-1-benzyl-3-chloromethyl pyrrolidine

To a refluxing solution of 15.3 g (0.08 mole) (3RS)-1-benzyl-3-hydroxymethyl pyrrolidine in 220 ml CHCl_3 was slowly added a solution of 330 ml thionyl chloride in 60 ml CHCl_3 , and the reflux was continued for one hour. The mixture was evaporated and the residue was dissolved in water.

The water layer was washed with ethyl acetate and then made alkaline with 0.2 M NaOH-solution. The water layer was extracted three times with ethyl acetate and the combined organic layer was dried (Na_2SO_4), filtered and evaporated to give the product in a quantitative yield

evaporated to yield 0.450 g (50%) of the title compound.

5 (iv) (3RS)-1-(N-benzyloxycarbonylamidino)-3-azidomethyl pyrrolidine

0.450 g (1.27 mmole) (3RS)-1-(N-benzyloxycarbonylamidino)-3-mesyloxymethyl pyrrolidine and 0.124 g (1.9 mmole) of sodium azide were dissolved 10 in 10 ml dimethylformamide and heated to 60°C for four hours followed by stirring at room temperature over night. Water was added and the mixture was extracted twice with toluene/ethyl acetate 2/1. The combined organic layer was dried (Na_2SO_4), filtered and 15 evaporated. The crude product was purified by flash chromatography using $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 95/5 as eluent to yield 0.262 g (68%) of the product.

MS m/z 303 (M^++1)

20 (v) (3RS)-1-(N-benzyloxycarbonylamidino)-3-aminomethyl pyrrolidine ($\text{H}-\text{(R,S)Nig(Z)}$)

32 mg Pd/C (10%) and 2.6 ml H_2O was mixed and a gentle stream of nitrogen was passed. 98 mg NaBH_4 in 2.6 ml H_2O was added followed by a slow addition of 262 mg (0.87 mmole) (3RS)-1-(N-benzyloxycarbonylamidino)-3-mesyloxymethyl pyrrolidine dissolved in 7 ml MeOH. The mixture was allowed to stand for one hour. 5 ml 1M HCl 25 was added and the mixture was filtered through hyflo. The organic solvent was evaporated under reduced pressure and the remaining water layer was washed once with ethyl acetate, made alkaline with NaOH-solution and extracted several times with CH_2Cl_2 . The combined 30 organic layer was dried (Na_2SO_4), filtered and evaporated to yield 130 mg (54%) of the product.

MS m/z 277 (M^++1)

1H), 2.43 (m, 1H), 2.55-2.73 (m, 3H), 2.80 (apparent t, 1H), 3.58 (apparent d, 2H), 7.15-7.4 (m, 5H)

(v) (3RS)-1-benzyl-3-(N-tert-

5 butyloxycarbonylaminoethyl) pyrrolidine

To a mixture of 14.84 g (0.0726 mole) (3RS)-1-benzyl-3-aminoethyl pyrrolidine, 72.6 ml 1M NaOH-solution, 76 ml water and 145 ml THF was added 17.44 g (0.08 mole) di-
10 tert-butyl dicarbonate and the mixture was stirred over night. The solution was concentrated and extracted three times with ethyl acetate. The combined organic layer was washed with brine, dried (Na_2SO_4), filtered and evaporated. The crude product was purified by flash
15 chromatography using a stepwise gradient of $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (95/5, 90/10) as eluent to yield 14.69 g (80%) of the product.

20 $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): δ 1.25-1.65 (m, 12H; thereof 1.40 (s, 9H)), 1.90-2.25 (m, 3H), 2.46 (m, 1H), 2.67 (m, 1H), 2.80 (apparent t, 1H), 3.09 (m, 2H), 3.59 (s, 2H), 4.60 (bs, NH), 7.15-7.35 (m, 5H)

25 (vi) (3RS)-3-(N-tert-butyloxycarbonylaminoethyl) pyrrolidine

30 3.1 g (0.01 mol) (3RS)-1-benzyl-3-(N-tert-butyloxycarbonylaminoethyl) pyrrolidine was hydrogenated at 0.28 MPa over 0.6 g of Pearlman's catalyst ($\text{Pd}(\text{OH})_2$) in 40 ml ethanol (95%) over night. After filtration of the catalyst through cellite and evaporation of the solvent $^1\text{H-NMR}$ showed that the reaction was not completed. Therefore 0.6 g of Pearlman's catalyst was added in 40 ml ethanol (95%) once more and the mixture was treated under H_2 -atmosphere at 0.28 MPa over night. Filtration through cellite and evaporation of the solvent gave the product

(16.8 g).

5 $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): δ 1.55 (m, 1H), 2.05 (m, 1H),
2.38 (dd, 1H), 2.48-2.64 (m, 3H; thereof 2.58 (t,
2H)), 2.73 (dd, 1H), 3.51 (d, 2 H), 3.60 (s, 2H), 7.2-
7.4 (m, 5H)

(iii) (3RS)-1-benzyl-3-cyanomethyl pyrrolidine

10 16.8 g (0.08 mole) (3RS)-1-benzyl-3-chloromethyl
pyrrolidine and 5.88 g (0.12 mole) of sodium cyanide
was dissolved in 250 ml dimethyl sulfoxide. The
mixture was stirred at 60°C for two days and at room
temperature for one week. Water was added and the
15 mixture was extracted three times with ethyl acetate.
The combined organic layer was washed with brine, dried
(Na_2SO_4), filtered and evaporated to yield 14.7 g (92%)
of the product.

20 $^1\text{H-NMR}$ (CDCl_3 , 500 MHz): δ 1.55 (m, 1H), 2.13 (m, 1H),
2.35 (dd, 1H), 2.42 (t, 2H), 2.44-2.59 (m, 2H), 2.65
(m, 1H), 2.73 (dd, 1H), 3.61 (s, 2H), 7.2-7.4 (m, 5H)

(iv) (3RS)-1-benzyl-3-aminoethyl pyrrolidine

25 14.7 g (0.0734 mole) (3RS)-1-benzyl-3-cyanomethyl
pyrrolidine dissolved in 220 ml diethyl ether was
slowly added to a slurry of 2.94 g of lithium aluminium
hydride in 74 ml diethyl ether under an argon
30 atmosphere. The mixture was stirred over night, and 6 ml
water, 18 ml 3.75 M NaOH-solution and 6 ml water was
added to the mixture. The slurry was dried from excess
of water with Na_2SO_4 /cellite, filtered by suction and
evaporated to yield 14.84 g (99%) of the product.

35 $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): δ 1.41 (m, 1H), 1.51 (q, 2H),
1.90-2.10 (m, 2H; thereof 2.05 (dd, 1H))), 2.18 (m,

12.9 g (345 mmol) LiAlH₄ was carefully added to a cold slurry (ice bath temperature) of 9.9 g (33 mmol) of (4RS)-1,3-diaza-2-tosylimino-4-carboxy cyclohexane in 330 mL dry THF. The reaction was stirred at room 5 temperature over night. The reaction mixture was worked up according to Fieser & Fieser, e.g by adding 12.9 g water, 38.7 g 3.75 M NaOH, 12.9 g water, Na₂SO₄, CH₂Cl₂ and celite to the mixture, and filtered. Evaporation of the solvent gave 7.0 g (75%) of the desired product.

10

MS m/z 284 (M⁺ + 1)

(iii) (4RS)-1,3-diaza-2-tosylimino-4-mesyloxymethyl cyclohexane

15

2.9 mL MsCl (37.1 mmol) was added carefully to a cold (ice bath temperature) slurry of 7.0 g (24.7 mmol) of (4RS)-1,3-diaza-2-tosylimino-4-hydroxymethyl cyclohexane in 6.9 mL (49.4 mmol) triethylamine and 125 20 mL CH₂Cl₂. Water was added after 1h 15 min and the organic phase was separated, dried(Na₂SO₄), filtered and evaporated to give the title compound in quantitative yield.

25

MS m/z 362 (M⁺ +1))

(iv) (4RS)-1,3-diaza-2-tosylimino-4-cyanomethyl cyclohexane

30

8.9 g (24.7 mmol) of (4RS)-1,3-diaza-2-tosylimino-4-mesyloxymethyl cyclohexane and 1.3 g (27.2 mmol) NaCN was dissolved in 75 mL DMSO. After stirring at 40°C for 60 hours an additional amount of 0.31 g (6 mmol) NaCN was added and the solution was stirred at 65°C for 35 three hours. 150 mL water was added and crystals precipitated out of the solution. They where filtered off and dried to give 5.4 g (75%) of the desired

in a quantitative yield (2.18 g).

MS m/z 214 (M⁺)

5 (vii) (3RS)-1-(N-benzyloxycarbonylamidino)-3-aminoethyl
pyrrolidine (H-(R,S)Hig(Z))

2.18 g (0.0102 mmole) (3RS)-3-(N-tert-
butyloxycarbonylaminoethyl) pyrrolidine and 2.81 g
10 (0.0125 mole) N-benzyloxycarbonyl-S-methylisothiourea
was dissolved in 30 ml toluene and heated to 60-70°C
for eight hours followed by stirring at room
temperature for one day. 0.3 M KHSO₄-solution was added
and the water layer was washed with a mixture of the
15 toluene and ethyl acetate and left for 2 days under
which time the Boc group was removed. The acidic water
phase was made alkaline and extracted four times with
CH₂Cl₂. The combined organic layer was dried (Na₂SO₄),
filtered and evaporated to yield 2.0 g (51%) of the
20 title compound.

25 ¹H-NMR (CDCl₃, 330 K, 300 MHz): δ 1.45-1.7 (m, 3H), 2.07
(m, 1H), 2.26 (m, 1H), 2.74 (t, 2H), 3.00 (apparent t,
1H), 3.33 (apparent q, 1H), 3.45-3.80 (m, 2H), 5.12 (s,
2H), 6.72 (bs, 2 NH), 7.15-7.45 (m, 5H)

(4RS)-1,3-diaza-2-tosylimino-4-aminoethyl cyclohexane
(H-(R,S)It_p(Ts))

30 (i) (4RS)-1,3-diaza-2-tosylimino-4-carboxy cyclohexane

Prepared using the same method as described in Journal
of Org. Chem., p. 46, 1971.

35 (ii) (4RS)-1,3-diaza-2-tosylimino-4-hydroxymethyl
cyclohexane

HCl from H-Aze-OH (vide infra).

H-Aze-OMe x HCl

5 Prepared according to the procedure described by
Seebach D. et. al. in Liebigs Ann. Chem., p. 687, 1990.

H-Pab(Z) x HCl

10 Prepared by adding 1 mole equivalent of 5 M HCl in iso-
propanol to a solution of crude H-Pab(Z) in EtOH (about
1 g/10 ml) where upon H-Pab(Z) x HCl immedeately
precipitates out of the solution. After filtration the
precipitate was washed 2 times with cold EtOH and dried
15 to give the title compound in almost quantitative
yield.

H-Pic-OEt x HCl

20 L-Pipecolinic acid, 4.0 g (0.031 mol), was slurried in
100 ml of abs. ethanol and HCl (g) was carefully
bubbled through until a clear solution was obtained. It
was cooled in an ice bath and 17 ml of thionyl chloride
was added dropwise over 15 min. The ice bath was
25 removed and the mixture was refluxed for 2.5 h. The
solvent was evaporated and the product was obtained as
its hydrochloride salt in a quantitative yield.

30 $^1\text{H-NMR}$ (300 MHz, D_2O): δ 1.33 (t, 3H), 1.8-2.1 (m, 5H),
2.3-2.5 (m, 1H), 3.1-3.3 (m, 1H), 3.5-3.7 (m, 1H), 4.14
(dd, 1H), 4.44 (q, 2H).

H-(R,S)betaPic-OMe x HCl

35 A mixture of 2.0 g (15.5 mmol) nipecotic acid in 8 ml
methanol was cooled in an ice-bath and 2.76 g (23.2

product.

MS m/z 293 ($M^+ + 1$)

5 (4RS)-1,3-diaza-2-tosylimino-4-aminoethyl cyclohexane
(H-(R,S)It_p(Ts))

10 935 mg LiAlH₄ was added carefully to a cooled (ice bath temperature) slurry of 2.4 g (8.2 mmol) of (4RS)-1,3-diaza-2-tosylimino-4-cyanomethyl cyclohexane in 90 mL THF. After stirring for 2 hours 1 g H₂O, 3 g 3.75M NaOH, 1 g H₂O, Na₂SO₄, celite and CH₂Cl₂ was added. The mixture was filtered and the solvent removed in vacuo to give 2.2 g (90%) of the desired product.

15 ¹H NMR (500 MHz, MeOD); δ 1.52-1.71 (m, 3H), 1.88-1.96 (m, 1H), 2.37 (s, 3H), 2.64-2.73 (m, 2H), 3.2-3.4 (m, 2H, partially overlapping with the solventsignal), 3.44-3.53 (m, 1H), 7.28 (d, 2H), 7.71 (d, 2H)

20 (4S)-1,3-diaza-2-tosylimino-4-aminoethyl cyclohexane
(H-(S)It_p(Ts))

25 Prepared in the same way as described for H-(R,S)It_p(Ts) starting from optically pure 2,4-diaminobutyric acid.

30 ¹H NMR (300.13 MHz, CDCl₃); δ 0.97-1.15 (s broad, 1H), 1.48-1.69 (m, 3H), 1.84-1.95 (m, 1H), 2.37 (s, 3H), 2.68-2.82 (m, 1H), 2.86-2.98 (m, 1H), 3.22-3.44 (m, 2H), 3.45-3.58 (m, 1H), 7.19 (d, 2H), 7.72 (d, 2H)

¹³C NMR (300.13 MHz, CDCl₃); δ guanidinecarbon 154.05

35 H-Aze-OEt × HCl

Prepared in the same way as described for H-Pic-OEt ×

quantitative yield.

Boc-(R)Cha-OSu

5 Boc-(R)Cha-OH (1 eq.), HOSu (1.1 eq) and DCC or CME-CDI (1.1 eq) were dissolved in acetonitrile (about 2.5 ml/mmol acid) and stirred at room temperature over night. The precipitate formed during the reaction was filtered off, the solvent evaporated and the product dried in vacuo. (When CME-CDI was used in the reaction the residue, after evaporation of the CH₃CN, was dissolved in EtOAc and the organic phase washed with water and dried). Evaporation of the solvent gave the title compound.

15

¹H-NMR (500 MHz, CDCl₃, 2 rotamers ca: 1:1 ratio) — 0.85-1.1 (m, 2H), 1.1-1.48 (m, 4H), 1.5-1.98 (m, 16H; thereof 1.55 (bs, 9H)), 2.82 (bs, 4H), 4.72 (bs, 1H, major rotamer), 4.85 (bs, 1H, minor).

20

Boc-(R)Hoc-OH

25 Boc-(R)Hoc-OH (See above), 3.2 g (11.46 mmol) was dissolved in methanol (75 ml). Rhodium on activated aluminium oxide (Rh/Al₂O₃), 0,5 g was added and the mixture was stirred under a hydrogen atmosphere at 0.41 MPa for 18 h. The catalyst was filtered off through hyflo and the solvent evaporated giving the product in almost quantitative yield.

30

¹H-NMR (500 MHz, CDCl₃): δ 0.90 (m, 2H), 1.08-1.33 (m, 6H), 1.43 (s, 9H), 1.60-1.74 (m, 6H), 1.88 (bs, 1H), 4.27 (bs, 1H).

35 **Boc-(R)Hoc-OSu**

Prepared in the same way as described for Boc-(R)Cha-

mmol) thionyl chl ride was added. The mixture was stirred at room temperature for 20 hours. The solvent was evaporated and the residue was dissolved in a small amount of methanol, diethylether was added and H-
5 (R,S)betaPic-OMe x HCl precipitated as white crystals. The crystals 2.57 g (92%) were isolated by filtration.

Boc-(R)Cgl-OH

10 Boc-(R)-Pgl-OH, 32.6 g (0.13 mol), was dissolved in 300 ml of methanol and 5 g of Rh/Al₂O₃ was added. The solution was hydrogenated at 5.2 to 2.8 MPa for 3 days. After filtration and evaporation of the solvent NMR
15 showed the presence of about 25 % of the methyl ester of the title compound. The crude material was dissolved in 500 ml of THF and 300 ml of water and 20 g of LiOH were added. The mixture was stirred overnight and the THF was evaporated. The remaining water phase was acidified with KHSO₄ and extracted three times with ethyl acetate. The combined organic layer was washed
20 with water, dried (Na₂SO₄) and evaporated to give 28.3 g (83 %) of the desired product.

25 ¹H-NMR (300 MHz, CDCl₃): δ 0.9-1.7 (m, 20H), 4.0-4.2 (m, 1H), 5.2 (d, 1H).

Boc-(R)Cgl-OSu

30 To an ice-cold solution of 2.01 g (7.81 mmol) of Boc-(R)Cgl-OH and 1.83 g (15.6 mmol) of HOSu in 25 ml of CH₃CN was added 1.69 g (8.2 mmol) of DCC and the reaction was allowed to reach room temperature. After stirring for 3 days the precipitated DCU was filtered off and the solvent evaporated. The residue was dissolved in EtOAc and the organic phase was washed
35 with H₂O, KHSO₄, NaHCO₃, brine and dried(Na₂SO₄). Evaporation of the solvent gave the title compound in

Pic-OEt (vide infra). The product was crystallized from EtOH/acetone/water (1/1/3.95) yield 80 %.

5 $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 0.85-1.3 (m, 5H), 1.40 (s, 9H), 1.5-1.9 (m, 6H), 1.95-2.2 (m, 2H), 3.92 (m, 1H), 4.09 (m, 1H), 4.35 (m, 1H), 4.95 (m, 1H), 5.16 (bd, 1H).

10 **Boc-(R)Cgl-Pic-OH**

(i) **Boc-(R)Cgl-Pic-OMe**

15 Pivaloyl chloride (1.0 ml, 8.1 mmol) was added to a solution of Boc-(R)Cgl-OH (2.086 g, 8.1 mmol) and triethyl amine (1.13 ml, 8.1 mmol) in toluene (25 ml) and DMF (5 ml). A mixture of H-Pic-OMe x HCl (1.46 g, 8.1 mmol) and triethyl amine (1.13 ml, 8.1 mmol) in DMF (20 ml) was subsequently added at ice bath temperature. The reaction mixture was slowly allowed to warm up to room temperature and after 24 h it was diluted with water and extracted with toluene. After washing with 0.3 M KHSO_4 , 10% Na_2CO_3 and brine the solvent was removed in vacuo to give 2.52 g (81%) of colorless oil which was used without further purification.

25 $^1\text{H-NMR}$ (500 MHz, CDCl_3 , 2 rotamers, 5:1 ratio) δ 0.8-1.8 (m, 25H), 2.25 (d, 1H), 2.75 (t, 1H, minor rotamer), 3.3 (t, 1H), 3.7 (s, 3H), 3.85 (d, 1H), 4.3 (t, 1H, minor rotamer), 4.5-4.6 (m, 1H), 5.25 (d, 1H), 5.30 (d, 1H).

30 (ii) **Boc-(R)Cgl-Pic-OH**

35 Prepared according to the procedure for hydrolysis of Boc-(R)Cha-Pic-OEt (vide infra) using the product from (i) above. The product was crystallized from di-isopropyl ether and hexane.

OSu from Boc-(R)Hoc-OH.

Boc-(R)Pro(3-(S)Ph)-OH

5 Prepared according to the method described by J.Y.L Chung et al in Journal of Organic Chemistry, No 1, pp. 270-275, 1990.

Boc-(R)Cgl-Aze-OH

10

(i) Boc-(R)Cgl-Aze-OMe

To a stirred mixture of 3.86 g (15 mmol) Boc-(R)Cgl-OH, 2.27 g (15 mmol) H-Aze-OMe x HCl and 2.75 g (22.5 mmol) DMAP in 40 mL CH₃CN at 5°C was added 3.16 g (16.5 mmol) EDC. The reaction mixture was stirred at room temperature for 48h. The solvent was evaporated and the residue was dissolved in 150 ml EtOAc and 20 ml H₂O. The separated organic layer was washed with 2 x 20 ml 0.5 M KHSO₄, 2 x 10 ml NaHCO₃ (saturated), 1 x 10 ml H₂O, 1 x 10 ml brine and dried (MgSO₄). Evaporation of the solvent gave 4.91 g (92 %) of the title compound which was used without further purification in the next step.

25 ¹H NMR (500 MHz, CDCl₃, 0.1 g/ml): major rotamer, 0.83-1.35 (m, 5H), 1.38 (s, 9H), 1.47-1.84 (m, 6H), 2.18-2.27 (m, 1H), 2.50-2.62 (m, 1H), 3.72 (s, 3H), 3.94-4.06 (m, 1H), 4.07-4.15 (m, 1H), 4.39-4.47 (m, 1H), 4.68 (dd, J=9.1, J=5.1, 1H), 5.09 (d, J=9.2, 1H).

30 Resolved peaks from minor rotamer, 2.27-2.35 (m, 1H), 3.77 (s, 3H), 3.80-3.87 (m, 1H), 3.88-3.95 (m, 1H), 4.92 (d, J=9.2, 1H), 5.21 (dd, J=9.1, J=5, 1H).

(ii) Boc-(R)Cgl-Aze-OH

35

The hydrolysis of Boc-(R)Cgl-Aze-OMe was carried out according to the procedure described for Boc-(R)Cha-

20 h. The mixture was acidified (2M KHSO₄) and extracted three times with ethyl acetate. The organic layers were combined and washed three times with water and once with brine. After drying over sodium sulphate and evaporation of the solvent, the syrupy oil was dissolved in diethyl ether, the solvent evaporated and finally the product dried in vacuo to yield Boc-(R)Cha-Pro-OH as a white powder in almost quantitative yield.

10 ¹H-NMR (500 MHz, CDCl₃, mixture of two rotamers 9:1) δ 0.8-1.05 (m, 2H), 1.05-1.55 (m, 15H; thereof 1.5 (bs, 9H)), 1.55-1.8 (m, 5H), 1.8-2.15 (m, 3H), 2.47 (m, 1H), 3.48 (m, 1H), 3.89 (m, 1H), 4.55 (m, 2H), 5.06 (m, 1H); Resolved signals from the minor rotamer appears at d 15 2.27 (m), 3.58 (m), 4.33 (m), 5.0 (m).

Boc-(Me)(R)Cha-Pro-OSu

(i) Boc-(Me)(R)Cha-Pro-OH

20 Prepared in the same way as described above for Boc-(R)Cha-Pro-OH starting from Boc-(Me)(R)Cha-OSu and H-Pro-OH.

25 (ii) Boc-(Me)(R)Cha-Pro-OSu

Prepared in the same way as described for Boc-(R)Cha-OSu starting from Boc-(Me)(R)Cha-Pro-OH.

30 Boc-(R)Cha-Pic-OH

(ia) Boc-(R)Cha-Pic-OEt

35 Boc-(R)Cha-OH, 6.3 g (0.023 mol), was dissolved in 150 ml of CH₂Cl₂. The solution was cooled in an ice bath and 6.3 g (0.047 mol) of N-hydroxybenzotriazole and 11.2 g (0.0265 mol) of CME-CDI were added. The ice bath

5 ¹H-NMR (500 MHz, CDCl₃, 2 rotamers, 5:1 ratio) δ 0.8-1.8
10 (m, 25H), 2.3 (d, 1H), 2.8 (t, 1H, minor rotamer), 3.3
15 (t, 1H), 3.9 (d, 1H), 4.4 (t, 1H, minor), 4.5-4.6 (m,
20 1H), 5.1 (s, 1H, minor rotamer), 5.3 (d, 1H), 5.40 (d,
25 1H).

Boc-(R)Cgl-Pro-OH

10 3.59 g (31.24 mmol) of L-proline was mixed with 20 ml
water and 1.18 g (29.7 mmol) of sodium hydroxide. 2.8 g
(7.8 mmol) of Boc-(R)Cgl-OSu in 10 ml DMF was added to
the mixture. Because of solubility problem an
additional 30 ml of DMF was added and the reaction
mixture was stirred for three days. The solvent was
15 evaporated and water was added. The water phase was
washed with ethyl acetate, acidified with 0.3 M KHSO₄-
solution and extracted three times with ethyl acetate.
The organic phase was washed once with water and once
with brine, dried (Na₂SO₄), filtered and evaporated to
20 yield 2.3 g (83 %) of the product.

25 ¹H-NMR (300 MHz, CDCl₃): δ 0.89-2.17 (m, 23H), 2.37 (m,
1H), 3.55 (q, 1H), 3.90 (bs, 1H), 4.28 (t, 1H), 4.52
(bs, 1H), 5.22 (bs, 1H (NH)).

Boc-(R)Cha-Aze-OH

30 Prepared in the same way as described for Boc-(R)Cha-
Pic-OH starting from Boc-(R)Cha-OH and H-Aze=OEt × HCl
(vide infra).

Boc-(R)Cha-Pro-OH

35 H-(S)Pro-OH (680 mmol) was dissolved in 0.87 M sodium
hydroxide (750 ml). Boc-(R)Cha-OSu (170 mmol) dissolved
in DMF (375 ml) was added dropwise during 20 min. The
reaction mixture was stirred at room temperature for

(ii) Boc-(R) Cha-Pic-OH

Boc-(R) Cha-Pic-OEt, 5.6 g (0.014 mol), was mixed with 100 ml of THF, 100 ml of water and 7 g of LiOH. The 5 mixture was stirred at room temperature overnight. The THF was evaporated and the aqueous solution was acidified with KHSO₄ (aq) and extracted three times with ethyl acetate. The combined organic phase was washed with water, dried (Na₂SO₄) and evaporated to give 10 4.9 g (94 %) of Boc-(R) Cha-Pic-OH which was used without further purification. The compound can be crystallized from diisopropyl ether/hexane.

15 The methyl ester formed in procedure (ib) above can be hydrolysed using the same procedure as described for the ethyl ester in (ii).

20 ¹H-NMR (500 MHz, CDCl₃, 2 rotamers, 3.5:1 ratio) δ 0.8-1.1 (m, 2H), 1.1-2.1 (m, 27H; thereof 1.43 (s, 9H, major rotamer), 1.46 (s, 9H, minor)), 2.33 (bd, 1H), 2.80 (bt, 1H, minor), 3.33 (bt, 1H, major), 3.85 (bd, 1H, major), 4.57 (bd, 1H, minor), 4.68 (m, 1H, minor), 4.77 (bg, 1H, major), 5.03 (bs, 1H, minor), 5.33 (bd, 1H, major), 5.56 (m, 1H, major).

25

Boc-(R) Cha-(R,S)betaPic-OH

(i) Boc-(R) Cha-(R,S)betaPic-OMe

30 Pivaloyl chloride 0.9 ml (7.3 mmol) was added to a solution of 2.0 g (7.3 mmol) Boc-(R) Cha-OH and 0.81 ml (7.3 mmol) 4-N-methyl morpholin in 20 ml acetonitrile. After stirring for 1 h and 30 minutes 1.3 g (7.3 mmol) H-(R,S)betaPic-OMe x HCl and 1.62 ml (14.6 mmol) 4-N-35 methyl morpholine was added and the reaction mixture was stirred for 24 h. The solvent was evaporated and the residue was dissolved in toluene and some

was removed after 15 min and the reaction mixture was stirred for 4 h at room temperature. The solvent was evaporated and the residue dissolved in 150 ml of DMF and cooled in an ice bath. H-Pic-OEt₂HCl, 4.1 g (0.021 mol) was added and the pH adjusted to approximately 9 by addition of N-methylmorpholine. The ice bath was removed after 15 min and the reaction mixture was stirred for 3 days. The solvent was evaporated and the residue was dissolved in ethyl acetate and washed with dilute KHSO₄ (aq), NaHCO₃ (aq) and water. The organic layer was dried (Na₂SO₄) and evaporated to give 7.7 g (89 %) of Boc-(R)Cha-Pic-OEt which was used without further purification.

¹⁵ ¹H-NMR (500 MHz, CDCl₃, 2 rotamers, 3:1 ratio) d 0.7-1.0 (m, 2H), 1.1-1.9 (m, 29H; thereof 1.28 (t, 3H)), 1.45 (bs, 9H), 2.01 (bd, 1H, major rotamer), 2.31 (bd, 1H), 2.88 (bt, 1H, minor), 3.30 (bt, 1H, major), 3.80 (bd, 1H, major), 4.15-4.3 (m, 2H), 4.5-4.7 (m, 2H, minor), 4.77 (bg, 1H, major), 4.90 (bd, 1H, minor), 5.28 (bd, 1H, major), 5.33 (bd, 1H, major).

(ib) Boc-(R)Cha-Pic-OMe

²⁵ 400 μ l (3.23 mmol) of pivaloyl chloride was added to a stirred mixture of 875 mg (3.22 mmol) Boc-(R)Cha-OH and 450 μ l (3.23 mmol) triethyl amine in 10 ml toluene and 2 ml DMF. A mixture of 596 mg (3.32 mmol) methyl (S)-pipecolate hydrochloride and 463 μ l (3.32 mmol) triethyl amine in 5 ml DMF was added to the resulting slurry after 45 minutes. After 2 h 100 μ l (0.72 mmol) triethyl amine was added and stirring was continued for another 18 h. Water and toluene was added to the reaction mixture and the organic phase was washed with 0.3 M KHSO₄, 10% Na₂CO₃ and brine. Drying (MgSO₄) and removal of the solvent in vacuo gave 1.16 g of the title compound.

A mixture of 8.73 g (23 mm l) Boc-(R)Cha-Val-OMe and 5.6 g (230 mmol) lithium hydroxide in 75 ml THF and 75 ml f water was stirred f r 4 hours. The THF was removed in vacuo and the remaining solution was diluted 5 with water and extracted with ether. Acidification with 2 M KHSO₄ and extraction with ethyl acetate followed by drying (MgSO₄) and removal of the solvent in vacuo gave 8.15 g (96%) of the title compound.

10 **Boc-(R)Hoc-Aze-OH**

(i) **Boc-(R)Hoc-Aze-OEt**

At room temperature 1.0 g (3.5 mmol) Boc-(R)Hoc-OH and 15 0.95 g (7.0 mmol) HOBr was dissolved in 15 ml CH₂Cl₂. The solution was cooled in an ice bath and 0.77 g (4.0 mmol) of EDC was added. The ice bath was removed and the reaction mixture was stirred for 3 h at room 20 temperature. The solvent was evaporated and the residue dissolved in 20 ml DMF. 0.58 g (3.5 mmol) H-(R)Aze-OH was added and the pH adjusted to approximately 9 by addition of N-methyl morpholin. The reaction mixture was stirred for one day. The reaction mixture was partitioned between water and toluene. The organic 25 phase was separated and washed with 0.3 M KHSO₄, diluted KHCO₃, brine, dried with Na₂SO₄ and evaporated. Flash chromatography (1% EtOH in CH₂Cl₂ and heptane: EtOAc) gave 0.35 g (25%) of the desired product.

30 (ii) **Boc-(R)Hoc-Aze-OH**

At room temperature 0.65 g (1.6 mmol) Boc-(R)Hoc-Aze-OEt was dissolved in 10 ml THF and 0.59 g of LiOH in 10 ml water was added. After stirring for 24 hours 2 M 35 KHSO₄ was added and the THF was removed in vacuo. The aqueous phase was then made acidic with more 2M KHSO₄ and extracted with ethyl acetate, dried over Na₂SO₄ and

diethyleter. After washing with 0.3 M KHSO_4 and KHCO_3^- solution, and drying with Na_2SO_4 the solvent was removed in vacuo. Flash chromatography using heptane/ethyl acetate (7/3) as eluent gave 2.4 g (83%) of the desired product.

5

(ii) $\text{Boc}-(\text{R})\text{Cha}-(\text{R},\text{S})\beta\text{etaPic-OH}$

At room temperature 2.35 g (5.9 mmol) of $\text{Boc}-(\text{R})\text{Cha}-(\text{R},\text{S})\beta\text{etaPic-OMe}$ was dissolved in 35 ml THF and 2.1 g of LiOH in 35 ml water was added. After stirring for 5 h the THF was removed in vacuo. The aqueous phase was acidified with 2M KHSO_4 and extracted with ethyl acetate, dried over Na_2SO_4 and evaporated to give 2.0 g (89%) of the product.

10

15

$\text{Boc}-(\text{R})\text{Cha-Val-OH}$

(i) $\text{Boc}-(\text{R})\text{Cha-Val-OMe}$

20

3.1 ml (25 mmol) pivaloyl chloride was added at ambient temperature to a stirred mixture of 6.75 g (25 mmol) $\text{Boc}-(\text{R})\text{Cha-OH}$ and 3.5 ml (25 mmol) triethyl amine in 50 ml DMF. After 3 hours 4.16 g (25 mmol) valine methyl ester hydrochloride in 50 ml DMF and 3.5 ml triethyl amine was added. After stirring over night , a few crystals of DMAP were added and the reaction mixture was heated to 50°C for 5 minutes. The solvent was removed in vacuo and ether and toluene was added to the residue. Washing with 0.3 M KHSO_4 and 10% Na_2CO_3 followed by drying (MgSO_4) and removal of the solvent in vacuo gave a residue which was subjected to flash chromatography using toluene/ethyl acetate as eluent. The yield of the title compound was 6.99 g (73%).

25

30

35

(ii) $\text{Boc}-(\text{R})\text{Cha-Val-OH}$

To a solution of 2.0 g (9.29 mmol) Boc-(R)Pro-OH and 0.94 g (9.29 mmol) triethyl amine in 70 ml toluene/DMF (5/2) was added 1.12 g (9.29 mmol) pival ylchloride and the reaction was stirred for 30 minutes at room 5 temperature. The reaction was cooled to 0°C and a mixture of 2.0 g (9.29 mmol) H-Phe-OMe and 0.94 g triethyl amine in 40 ml DMF was added and the reaction was stirred over night at room temperature. The reaction mixture was diluted with toluene and the 10 organic phase was washed with 3 x 50 ml 0.3 M KHSO₄, 1 x 50 ml water and dried (Na₂SO₄). Evaporation of the solvent gave the title compound in quantitative yield which was used in the next step without further purification.

15

(ii) Boc-(R)Pro-Phe-OH

A mixture of 4.0 g (10.6 mmol) Boc-(R)Pro-Phe-OMe and 8.93 g (21.3 mmol) LiOH x H₂O in 140 ml water/THF (1/1) 20 was stirred vigorously over night at room temperature. The THF was evaporated and the water phase was made acidic with 1 M KHSO₄ and extracted with 3 x 75 ml EtOAc. The combined organic phase was washed with water and dried (Na₂SO₄). Filtration and evaporation of the 25 solvent gave a residue which was purified by crystallization from diisopropyl ether to give 2.329 g (60 %) of the title compound as a white crystalline solid.

30 Boc-(R)Pro(3-(S)Ph)-Pro-OH

(i) Boc-(R)Pro(3-(S)Ph)-Pro-OBn

To a mixture of 1.61 g Boc-(R)Pro(3-(S)Ph)-OH, 1.65 g 35 H-Pro-OBn x HCl and 0.75 g HOEt in 11 mL DMF was added 0.84 mL NMM and 2.92 g CME-CDI at room temperature and the reaction mixture was stirred for three days. The

evaporated to give 0.5 g (85%) of the title compound.

Boc-(R)Hoc-Pro-OH

5 Prepared in the same way as described for Boc-(R)Cha-Pro-OH from Boc-(R)Hoc-OSu.

10 $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 0.80-0.94 (m, 2H), 1.05-1.36 (m, 7H), 1.36-1.48 (bs, 9H), 1.48-1.78 (m, 7H), 1.98-2.14 (m, 2H), 2.34 (m, 1H), 3.48 (m, 1H), 3.85 (m, 1H), 4.43 (m, 1H), 4.52 (bd, 1H), 5.26 (bd, 1H), signals of a minor rotamer appears at: δ 1.92, 2.25, 3.58, 4.20 and 4.93.

15 **Boc-(R)Hoc-Pic-OH**

(i) **Boc-(R)Hoc-Pic-OMe**

20 Prepared the same way as described for Boc-(R)Cha-Pic-OEt (vide supra) from Boc-(R)Hoc-OH and H-Pic-OMe x HCl.

(ii) **Boc-(R)Hoc-Pic-OH**

25 Prepared in the same way as described for Boc-(R)Cha-Pic-OH (vide supra) from Boc-(R)Hoc-Pic-OMe.

30 $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 0.82-0.97 (m, 2H), 1.10-1.36 (m, 7H), 1.36-1.50 (bs, 9H), 1.50-1.82 (m, 11H), 2.35 (bd, 1H) 3.28 (bt. 1H), 3.85 (bd, 1H) 4.63 (m, 1H), 5.33 (bs, 1H), 5.44 (bd, 1H), signals of a minor rotamer appear at: δ 1.88, 2.80, 4.25, 4.55 and 4.97.

Boc-(R)Pro-Phe-OH

35 (i) **Boc-(R)Pro-Phe-OMe**

Boc-(R)Cgl-Ile-OH

Prepared in the same way as described for Boc-(R)Cgl-Pro-OH using H-Ile-OH, instead of H-Pro-OH, in 91 %
5 yield.

Boc-(R)Phe-Phe-OH

(i) Boc-(R)Phe-Phe-OMe

10 Boc-(R)Phe-OH (18.8 mmol; purchased from Bachem Feinchemicalien AG), Phe-OMe (20.7 mmol) and 4-dimethylaminopyridine (37.7 mmol) were dissolved in 30 mL of acetonitrile. The solution was cooled to ice-water temperature and 1-(3-dimethylaminopropyl)-3-15 -ethylcarbodiimide hydrochloride (24.5 mmol) was added. The cooling bath was removed and the reaction mixture was stirred over night. The solvent was then removed under reduced pressure and the residue was dissolved in 20 50 mL of ethylacetate. Extraction of the organic phase with 50 mL aliquots of 0.5 M potassiumhydrogensulfate, 1 M sodiumbicarbonate and finally water followed by evaporation of the solvent yielded 7.5 g of Boc-(R)Phe-Phe-OMe (94%) which was used in the next step without 25 further purification.

(ii) Boc-(R)Phe-Phe-OH

30 Boc-(R)Phe-Phe-OMe (16.4 mmol) was dissolved in 40 mL of tetrahydrofuran and lithiumhydroxide (32.8 mmol) dissolved in 20 mL of water was added rapidly. The reaction mixture was stirred for 3.5 h after which the solvent was removed under reduced pressure. The residue was dissolved in 50 mL of ethylacetate and extracted 35 with 50 mL of 0.5 M potassiumsulfate followed by 50 mL of water. The solvent was removed under reduced pressure yielding 8.0 g of Boc-(R)Phe-Phe-OH (quant) as

solvent was evaporated and the residue was dissolved in 300 mL EtOAc. The organic phase was washed with 2 x 100 mL H₂O, 2 x 100 mL 1 M KHSO₄, 3 x 100 mL 1 M NaOH, 3 x 100 mL H₂O and dried (MgSO₄). Evaporation of the solvent gave 2.53 g of an oil which was purified by flash chromatography using CH₂Cl₂/MeOH (97/3) as eluent to give 2.11 g (88%) of the title compound.

(ii) Boc-(R)Pro(3-(S)Ph)-Pro-OH

0.94 g of Boc-(R)Pro(3-(S)Ph)-Pro-OBn was dissolved in 70 ml EtOH and hydrogenated over 0.42 g 5 % Pd/C for 3.5 hours. Filtration of the catalyst and evaporation of the solvent gave the title compound as white crystals in a quantitative yield.

Boc-(R)Tic-Pro-OH

Prepared according to the procedure described by P.D. Gesellchen and R.T. Shuman in EP-0,479,489-A2.

BnOOC-CH₂-NH-CO-CH₂-Br

To a solution of p-TsOH x H-Gly-OBn (5 mmol) and triethyl amine (5 mmol) in 10 ml of CH₂Cl₂ was added 2-bromoacetic acid (5 mmol) dissolved in 10 ml of CH₂Cl₂ and dicyclohexyl carbodiimide (5 mmol). The mixture was stirred at room temperature over night and filtered. The organic phase was washed twice with 0.2 M KHSO₄, 0.2 M NaOH, brine and dried. Evaporation and flash chromatography (CH₂Cl₂/MeOH, 95/5) gave a quantitative yield of the desired compound.

¹H-NMR (300 MHz, CDCl₃): δ 3.89 (s, 2H), 4.05-4.11 (d, 2H), 5.19 (s, 2H), 7.06 (bs, 1H), 7.3-7.4 (m, 5H).

¹H-NMR (300 MHz, CDCl₃): δ 4.79 (s, 2H), 5.13 (s, 2H), 7.2-7.4 (m, 5H), 8.10 (d, 2H), 8.30 (d, 2H).

TFO-CH₂COOMe

5

10.09 ml (60 mmol) trifluorometansulfonic anhydrid dissolved in CH₂Cl₂ was added dropwise to a mixture of 4.05 ml (50 mmol) methylglycolate and 4.04 ml (50 mmol) pyridin in CH₂Cl₂ (totally 62.5 ml) at 0°C during 25 minutes, and thereafter stirred at 0°C for 1 H. After washing with 0.3 M KHSO₄ and saturated Na₂CO₃, drying (Na₂SO₄) and filtration, evaporation of the solvent in vacuo gave 9.94 g (90 %) of the title compound.

15 **TFO-CH₂COOEt**

Prepared in the same way as described for TFO-CH₂COOMe starting with ethylglycolate.

20 **TFO-CH₂COOBu**

Prepared in the same way as described for TFO-CH₂COOMe starting with butylglycolate.

25

TFO-CH₂COOBn

Prepared in the same way as described for TFO-CH₂COOMe starting with HO-CH₂COOBn


30

TFO-CH₂COOⁿHex

(i) HO-CH₂COOⁿHex

35 To 215 mg (2.82 mmol) glycolic acid in 12.8 ml CH₃CN was added 719 mg (3.39 mmol) 1-hexyl iodide and 429 mg (2.82 mmol) DBU. After stirring over night and reflux

an amorphous solid. ^1H NMR (200 MHz, d-CHCl₃); δ 7.4-6.7 (m, 10H), 5.7-4.2 (m, 6H), 1.34 (s, 9H).



5

Prepared according to the procedure described by Lattes A. et al in Bull. Soc. Chim. France., No 11, pp 4018-23, 1971.

10 **Benzyl-2-(ortho-nitrobenzenesulfonyloxy)acetate (2-**
NO₂)Ph-SO₂-OCH₂-COOBn

15 1.66 g (10 mmol) benzylglycolate was dissolved in 25 ml CH₂Cl₂ and 25 ml diethylether. The mixture was cooled to 0°C and 2.8 ml (20 mmol) triethylamin was added. While keeping the temperature at 0°C 2.44 g (11 mmol) ortho-nitrobenzenesulfonylchloride was added in small portions during 15 minutes. The slurry was stirred at 0°C for 50 minutes and then 20 ml water and 30 ml CH₂Cl₂ were added. The phases were separated and the organic phase was washed with 20 ml 1 M HCl and 20 ml H₂O, dried (Na₂SO₄), filtered and evaporated in vacuo to give 3.34 g of a residue that was subjected to flash chromatography, using heptan:EtOAc 2:1 as eluent to give 1.18 g (34 %) of the title compound.

20 $^1\text{H-NMR}$ (300MHz, CDCl₃): δ 4.92 (s, 2H), 5.17 (s, 2H), 7.83 (m, 5H), 7.76 (m, 3H), 8.16(dd, 1H).

30 **Benzyl-2-(para-nitrobenzenesulfonyloxy)acetate (4-**
NO₂)Ph-SO₂-OCH₂-COOBn

35 Prepared according to the same procedure as described for Benzyl-2-(ortho-nitrobenzenesulfonyloxy)acetate above. The final compound was obtained in a crystalline form after evaporation of the solvent and pure enough to use without further purification (64 % yield).

butyloxycarbonylaminomethyl)-1-benzhydryl azetidine was dissolved in 170 mL MeOH and hydrogenated over 0.30 g Pd(OH)₂ at 5 MPa over night. The catalyst was filtered off and the solvent evaporated. The crude product was purified by flash chromatography using MeOH/CH₂Cl₂, 1/9, followed by MeOH (saturated with NH₃(g))/CH₂Cl₂, 1/9, as eluent to yield 1.2 g (67 %) of the title compound.

10 (iv) 3-(N-tert-butyloxycarbonylaminomethyl)-1-(N-benzyloxycarbonylamidino) azetidine (Boc-Mig(Z))

15 0.9 g (4.8 mmol) of 3-(N-tert-butyloxycarbonylaminomethyl) azetidine and 1.3 g (6.3 mmol) of N-benzyloxycarbonyl-O-methylisourea was mixed in 6.5 mL toluene and heated to 70°C for 72 h and then left at roomtemperature for another 72 h. Evaporation followed by flash chromatography using EtOAc followed by MeOH (saturated with NH₃(g))/CH₂Cl₂, 1/9, as eluent gave 0.67 g (38 %) of the title compound as a white powder.

20 (v) 3-aminomethyl-1-(N-benzyloxycarbonylamidino) azetidine (H-Mig(Z))

25 0.67 g (1.85 mmol) of Boc-Mig(Z) was dissolved in 10 mL of EtOAc saturated with HCl(g) and stirred for 10 min. at roomtemperature. 10 mL of a saturated solution of KOH(aq) was added dropwise. The layers were separated and the aqueous phase was extracted with 3x8 mL EtOAc. The organic layers were combined, washed with brine, dried with Na₂SO₄ and evaporated to yield 0.43 g (89 %) of the title compound.

30 ¹H-NMR (300 MHz, CDCl₃): δ 2.55-2.65 (m, 1H), 2.84 (d, 2H), 3.66 (dd, 2H) 4.03 (dd, 2H) 5.07 (s, 2H), 7.2-7.4 (m, 5H).

for 4 h, the solvent was evaporated, ethylacetat and 1 M KHSO₄ was added and the phases were separated. The organic layer was washed with brine, dried (MgSO₄), filtered and evaporated in vacuo to give 333 mg (74 %) of the product.

5

(ii) TfO-CH₂COOⁿHex

Prepared in the same way as described for TfO-CH₂COOME starting with HO-CH₂COOⁿHex.

10

H-Mig(Z) (3-aminomethyl-1-(N-benzyloxycarbonylamidino)azetidine

15

(i) 3-aminomethyl-1-benzhydryl azetidine was prepared according to the literature, see A.G. Anderson, Jr., and R. Lok, J.Org.Chem., 37, 3953, 1972.

20

(ii) 3-(N-tert-butyloxycarbonylaminomethyl)-1-benzhydryl azetidine

25

To 3.50 g (13.9 mmol) of 3-aminomethyl-1-benzhydryl azetidine dissolved in 45 mL THF was added a solution of 0.56 g (13.9 mmol) NaOH in 45 mL H₂O. The reaction mixture was cooled to 0°C and 3.03 g (13.9 mmol) of di-tert-butyl dicarbonate was added. The cooling bath was removed after a few minutes and the mixture was stirred at roomtemperature over night. The THF was evaporated and the residue was extracted with 3x45 mL of diethyl ether. The combined organic layer was washed with brine, dried with Na₂SO₄ and filtered. Evaporation of the solvent gave 4.6 g (94 %) of the title compound.

30

35

(iii) 3-(N-tert-butyloxycarbonylaminomethyl) azetidine

3.4 g (9.6 mmol) of 3-(N-tert-

methanesulfonatomethyl-1-benzhydryl azetidine in 50 mL DMF was added a s luti n f 3.44 g (70.0 mmol) NaCN in 10 mL H₂O. The mixture was heated at 65°C for 20 h, cooled, and poured int a mixture of ice and H₂O. The 5 precipitate was collected, washed with H₂O and dried in vacuo to yield 5.7 g (93 %) of the title compound.

(v) 3-aminoethyl-1-benzhydryl azetidine

10 5.7 g (21.7 mmol) of 3-cyanomethyl-1-benzhydryl azetidine was added slowly to a suspension of 2.9 g (76.0 mmol) of LiAlH₄ in 80 mL of dry THF at roomtemperature. The reaction mixture was refluxed for 4 h. Excess hydride reagent was hydrolyzed by careful 15 addition, with cooling, of NH₄Cl(aq), the gelatinous mixture was filtered and the filter cake was washed repeatedly with THF. The solvent was evaporated, the residue was dissolved in diethyl ether, washed with brine and dried with Na₂SO₄. Evaporation of the solvent 20 gave 5.0 g (87 %) of the title compound.

(vi) 3-(N-tert-butyloxycarbonylaminoethyl)-1-benzhydryl azetidine

25 The title compound was prepared from 3-aminoethyl-1-benzhydryl azetidine according the procedure for 3-(N-tert-butyloxycarbonylaminomethyl)-1-benzhydryl azetidine, in a yield of 6.5 g (95 %).

30 (vii) 3-(N-tert-butyloxycarbonylaminoethyl) azetidine

The title compound was prepared from 3-(N-tert-butyloxycarbonylaminoethyl)-1-benzhydryl azetidine according the procedure for 3-(N-tert-butyloxycarbonylaminomethyl) azetidine, in a yield of 1.2 g (70 %).

MS m/z 263 ($M^+ + 1$)

3-aminoethyl-1-(N-benzyloxycarbonylamidin) azetidine
(H-Dig(Z))

5

(i) 3-carboxylic acid-1-benzhydryl azetidine was prepared according to the literature, see A.G. Anderson, Jr., and R. Lok, J.Org.Chem., 37, 3953, 1972.

10 (ii) 3-hydroxymethyl-1-benzhydryl azetidine

A solution of 8.7 g (32.5 mmol) 3-carboxylic acid-1-benzhydryl azetidine in 80 mL of dry THF was added slowly to a suspension of 4.9 g (130.2 mmol) of LiAlH₄ in 30 mL THF at roomtemperature. The reaction mixture was refluxed for 3.5 h. Excess hydride reagent was hydrolyzed by careful addition, with cooling, of NH₄Cl(aq), the gelatinous mixture was filtered and the filter cake was washed repeatedly with THF. Evaporation of the solvent gave 7.1 g (86 %) of the title compound as pale yellow crystals.

(iii) 3-methanesulfonatomethyl-1-benzhydryl azetidine

25 To a solution of 6.62 g (26.1 mmol) 3-hydroxymethyl-1-benzhydryl azetidine in 50 mL of dry pyridine was added 4.50 g (39.2 mmol) of methanesulfonyl chloride at 0°C. The reaction mixture was stirred for 1 h. and then allowed to stand in a refrigerator over night. The 30 reaction mixture was poured into a mixture of ice and H₂O. The precipitate was collected, washed with H₂O and dried in vacuo to yield 7.75 g (89.5 %) of the title compound.

35 (iv) 3-cyanomethyl-1-benzhydryl azetidine

To a solution of 7.75 g (23.4 mmol) 3-

After stirring for 2 hours at room temperature the mixture was cooled to -8°C and 2.01 g (10.5 mmol) EDC was added. The reaction was allowed to reach room temperature and the stirring was continued for an additional 47 hours. The solvent was evaporated and the residue was dissolved in 200 ml EtOAc. The organic phase was washed with 1 x 50 ml water, 1 x 50 + 2 x 25 ml 0.5 M KHSO₄, 2 x 25 ml NaHCO₃ (saturated), 1 x 50 ml water and dried. Evaporation of the solvent gave 5.21 g (86%) of the title compound.

¹H-NMR (500 MHz, CDCl₃): δ 0.8-1.9 (m, 20H; thereof 1.30 (s, 9H)), 2.35-2.6 (m, 2H), 3.74 (bt, 1H), 4.10 (m, 1H), 4.25-4.4 (m, 2H), 4.45-4.6 (m, 1H, rotamers), 4.75-5.0 (m, 1H, rotamers), 5.08 (bd, 2H), 5.15 (s, 2H), 7.15-7.35 (m, 5H), 7.41 (d, 2H), 7.77 (d, 2H), 8.21 (m, 1H).

(ii) H-(R)Cgl-Aze-Pab(Z)

To a cold (ice bath temperature) solution of 18.8 g HCl_(g) in 195 ml EtOAc was added 4.69 g (7.743 mmol) of Boc-(R)Cgl-Aze-Pab(Z) together with 40 ml EtOAc. The reaction mixture was allowed to reach room temperature and stirred for 30 min. 140 ml Et₂O was added to the clear solution where upon a precipitate was formed. The reaction was left at room temperature for an additional 1 h and 40 minutes. The precipitate was filtered off, washed quickly with 150 ml Et₂O and dried in vacuo. The precipitate was dissolved in 50 ml of water and made alkaline with 15 ml 2 M NaOH. The alkaline waterphase was extracted with 1 x 100 + 1 x 50 ml CH₂Cl₂. The combined organic phase was washed with 1 x 20 ml water, 1 x 20 ml Brine and dried (MgSO₄). Evaporation of the solvent gave 3.44 g (88%) of the title compound.

(viii) 3-(N-tert-butyloxycarb nylaminoethyl)-1-(N-benzyl xycarbony lamidino) azetidine (Boc-Dig(Z))

The title compound was prepared from 3-(N-tert-butylloxycarbonylaminoethyl) azetidine according the procedure for 3-(N-tert-butyloxycarbonylaminomethyl)-1-(N-benzyloxycarbon ylamidino) azetidine, in a yield of 0.090 g (34 %).

(ix) 3-aminoethyl-1-(N-benzyloxycarbonylamidino) azetidine (H-Dig(Z))

0.589 g (1.56 mmol) of Boc-Dig(Z) was dissolved in 10 mL of EtOAc saturated with HCl(g) and stirred for 10 min. at roomtemperature. 10 mL of a saturated solution of KOH(aq) was added dropwise. The layers were separated and the aqueous phase was extracted with 3x8 mL EtOAc. The organic layers were combined, washed with brine, dried with Na₂SO₄ and evaporated to yield 0.415 g (96 %) of the title compound.

¹H-NMR (500 MHz, CDCl₃): δ 1.60 (dt, 2H), 2.52-2.54 (m, 3H), 3.53 (bs, 2H), 4.0 (bt, 2H), 5.00 (s, 2H), 7.17-7.31 (m, 5H).

25

Working Examples

Example 1

30 HOOC-CH₂-(R)Cgl-Aze-Pab

(i) Boc-(R)Cgl-Aze-Pab(Z)

To a stirred mixture of 3.40 g (10 mmol) Boc-(R)Cgl-Aze-OH (See Preparation of starting materials) and 5.13 g DMAP (42 mmol) in 120 ml CH₃CN was added 3.18 g H-Pab(Z) × HCl (See Preparation of starting materials).

BnOOC-CH₂-(R)Cgl-Aze-Pab(Z), 20 mg (0.031 mmol), was dissolved in 5 ml of methanol. A few drops of chl r form and 5 % Pd/C were added and the mixture was hydrogenated at atmospheric pressure for 1 h. After 5 filtration and evaporation the product was lyophilized from water to give 11 mg (72%) of the title compound.

10 ¹H-NMR (500 MHz, D₂O): δ 1.0-2.0 (m, 11H), 2.10 (m, 1H), 2.44 (m, 1H), 2.82 (m, 1H), 3.90 (s, 2H), 4.09 (d, 1H), 4.4-4.55 (m, 2H), 4.66 (s, 2H), 5.08 (m, 1H), 7.65 (d, 2H), 7.89 (d, 2H).

15 ¹³C-NMR (75.5 MHz, D₂O): amidine and carbonyl carbons: δ 167.3, 167.9, 169.9 and 172.4.

15 (ivb) HOOC-CH₂-(R)Cgl-Aze-Pab

20 BnOOC-CH₂-(R)Cgl-Aze-Pab(Z) was dissolved in ETOH (99%) and hydrogenated over 5 % Pd/C at atmospheric pressure for 5 hours. Filtration of the catalyst through cellite and evaporation of the solvent gave the title compound in 97 % yield.

25 ¹H-NMR (500 MHz, CD₃OD, mixture of two rotamers): major rotamer: δ 1.00-1.12 (m, 1H), 1.13-1.34 (m, 4H), 1.55-1.70 (m, 3H), 1.73-1.85 (m, 2H), 1.94-2.02 (bd, 1H), 2.32-2.42 (m, 1H), 2.54-2.64 (m, 1H), 2.95-3.10 (AB-system plus d, 3H), 4.18-4.25 (bq, 1H), 4.28-4.32 (bq, 1H), 4.43-4.60 (AB-system, 2H), 4.80-4.85 (dd, 1H), 7.48-7.54 (d, 2H), 7.66-7.71 (d, 2H).

30 Resolved signals from the minor rotamer appears at δ 0.95 (m), 1.43 (m), 2.24 (m), 2.84 (d), 3.96 (m), 4.03 (m), 7.57 (bd), 7.78 (bd).

35 ¹³C-NMR (125 MHz, CD₃OD): amidine and carbonyl carbons: δ 168.0, 173.0, 176.3 and 179.0

¹H-NMR (500 MHz, CDCl₃): δ 0.8-2.0 (m, 11H), 2.51 (m, 1H), 2.67 (m, 1H), 3.07 (d, 1H), 4.11 (m, 1H), 4.18 (m, 1H), 4.43 (dd, 1H), 4.53 (dd, 1H), 4.91 (m, 1H), 5.22 (s, 2H), 7.2-7.4 (m, 7H), 7.45 (d, 2H), 8.51 (d, 2H).

5

(iii) BnOOC-CH₂-(R)Cgl-Aze-Pab(Z)

1.13 g (2.2 mmol) H-(R)Cgl-Aze-Pab(Z), 0.9 g (2.6 mmol) benzyl-2-(ortho-nitrobenzenesulfonyloxy)acetate ((2-NO₂)Ph-SO₂-OCH₂-COOBn) (See Preparation of starting materials), 0.99 g (5.6 mmol) K₂CO₃ and 113 ml CH₃CN were mixed and heated in a 60°C oilbath for 3 h. The solvent was evaporated in vacuo. EtOAc was added and the mixture was washed with water, the organic phase was extracted with 1 M KHSO₄ and this waterphase was washed with EtOAc. The acidic waterphase was made alcaline with 1 N NaOH to pH>8 and extracted with EtOAc. The organic phase was washed with water, dried (Na₂SO₄), filtered and evaporated in vacuo to give 1.17 g of a residue that was twice subjected to flash chromatography using first CH₂Cl₂/MeOH(NH₃-saturated) 95/5 and then diethylether/MeOH(NH₃-saturated) 9/1 as eluents to give 0.525 g (36 %) of the title compound.

25 The alkylation was also carried out using Benzyl-2-(para-nitrobenzenesulfonyloxy)acetate ((4-NO₂)Ph-SO₂-OCH₂-COOBn) (See Preparation of starting materials) using the same procedure as above to give the title compound in 52 % yield.

30


¹H-NMR (300 MHz, CDCl₃): δ 0.85-2.15 (m, 11H), 2.48 (m, 1H), 2.63 (m, 1H), 2.88 (d, 1H), 3.24 (d, 1H), 3.27 (d, 1H), 3.95 (m, 1H), 4.05 (m, 1H), 4.44 (m, 1H), 4.55 (m, 1H), 4.91 (m, 1H), 5.07 (s, 2H), 5.22 (s, 2H), 7.2-7.4 (m, 10H), 7.45 (d, 2H), 7.79 (d, 2H), 8.42 (m, 1H).

35 (iva) HOOC-CH₂-(R)Cgl-Aze-Pab x 2 HCl

4.55 (m, 2 H), 4.60 (s, 2 H), 5.04 (dd, 1 H), 7.59 (d, 2 H), 7.83 (d, 2 H).

5 ¹³C NMR (75 MHz, D₂O): amidine and carbonyl carbons: δ 167.2, 167.8, 172.3 and 175.5.

Example 3



10

(i) Boc-(R)Cgl-Pro-Pab(Z)

15 Boc-(R)Cgl-Pro-OH (See preparation of starting materials), 2.3 g (6.49 mmol), DMAP, 2.38 g (19.47 mmol), and H-Pab(Z) (See preparation of starting materials), 1.84 g (6.49 mmol) was mixed in 30 ml acetonitrile. The mixture was cooled to -15°C and EDC, 1.31 g (6.81 mmole) was added. The temperature was allowed to reach room temperature and the mixture was 20 stirred over night. After evaporation, the residue was dissolved in ethyl acetate and 0.3 M KHSO₄-solution. The acidic water phase was extracted three times with ethyl acetate. The organic phase was washed twice with a 0.3 M KHSO₄-solution, twice with a NaHCO₃-solution and once with 25 brine, dried (Na₂SO₄), filtered and evaporated. The crude product was purified by flash chromatography on silica gel using ethyl acetate as eluent to yield 1.77 g (44%) of the product.

30 ¹H-NMR (500 MHz, CDCl₃): δ 0.9-1.49 (m, 14H), 1.5-2.1 (m, 9H), 2.37 (bs, 1H), 3.53 (q, 1H), 3.94 (bs, 1H), 4.02 (m, 1H), 4.43 (bs, 2H), 4.65 (d, 1H), 5.09 (bs, 1H), 5.20 (s, 2H), 7.18-7.4 (m, 5H), 7.45 (d, 2H), 7.62 (bs, 1H), 7.81 (m, 2H),

35

(ii) H-(R)Cgl-Pro-Pab(Z)

Example 25 (i) $\text{H-(R)Cgl-Aze-Pab(Z)}$

Prepared in the same way as described in Example 1 (ii) by treating the formed hydrochloride salt with base to afford the free base.

10

(ii) $\text{BnOOC-CH}_2\text{-CH}_2\text{-(R)Cgl-Aze-Pab(Z)}$

15 $\text{H-(R)Cgl-Aze-Pab(Z)}$, 0.19 g (0.38 mmol), and 70 mg (0.43 mmol) of benzyl acrylate were dissolved in 2 ml of isopropanol. The mixture was left standing for 6 days. Flash chromatography using $\text{CH}_2\text{Cl}_2/\text{THF} = 8/2$ as eluent afforded 0.12 g (48%) of the title compound.

20 $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 0.8-1.9 (m, 10 H), 1.95 (bd, 1 H), 2.4-2.6 (m, 4 H), 2.7-2.8 (m, 3 H; thereof 2.79 (d, 1 H)), 4.13 (m, 1 H), 4.37 (dd, 1 H), 4.60 (dd, 1 H), 4.97 (dd, 1 H), 5.09 (dd, 2 H), 5.22 (s, 2 H), 7.25-7.4 (m, 10 H), 7.47 (d, 2 H), 7.83 (d, 2 H), 8.61 (bt, 1 H).

25 (iii) $\text{HOOC-CH}_2\text{-CH}_2\text{-(R)Cgl-Aze-Pab} \times 2 \text{ HCl}$

BnOOC-CH₂-CH₂-(R)Cgl-Aze-Pab(Z), 0.10 g (0.15 mmol), was dissolved in 10 ml of ethanol and hydrogenated over 5% Pd/C at atmospheric pressure for 1 h.

30 The solution was filtered, evaporated and the crude product was purified on RPLC using $\text{CH}_3\text{CN}/0.1 \text{ M NH}_4\text{OAc}$ (1/4). The resulting product was freeze dried, treated with an excess of conc. HCl and freeze dried again to give 31 mg of the dihydrochloride salt.

35

$^1\text{H NMR}$ (300 MHz, D_2O) δ 0.8-2.1 (m, 11 H), 2.38 (m, 1 H), 2.7-2.9 (m, 3 H), 3.2-3.4 (m, 2 H), 3.98 (d, 1 H), 4.35-

5 $^1\text{H-NMR}$ (300 MHz, CDCl_3): $\text{BnOOCH}_2-(\text{R})\text{Cgl-Pro-Pab(Z)}$: δ 0.9-1.3 (m, 5H), 1.4-2.1 (m, 9H), 2.3-2.4 (m, 1H), 3.05 (d, 1H), 3.20-3.37 (AB-system centered at δ 3.29, 2 H), 3.5-3.6 (m, 2H), 4.29-4.57 (ABX-system centered at d 4.43, 2 H), 4.62 (d, 1H), 4.91 (apparent singlet, 2H), 5.19 (s, 2H), 6.75 (bs, NH), 7.1-7.5 (m, 12H), 8.7-8.8 (m, 2H+NH), 9.45 (bs, NH)

10 $^1\text{H-NMR}$ (300 MHz, CDCl_3): $(\text{BnOOCH}_2)_2-(\text{R})\text{Cgl-Pro-Pab(Z)}$: δ 0.68-0.9 (m, 2H), 1.0-1.3 (m, 3H), 1.43 (bd, 1H), 1.55-2.0 (m, 7H), 2.05 (bd, 1H), 2.3-2.4 (m, 1H), 3.15 (d, 1H), 3.25-3.48 (m, 2H), 3.55-3.79 (AB-system centered at d 3.67, 4 H), 4.38-4.58 (ABX-system centered at d 4.48, 2 H), 4.68 (d, 1H), 4.82-4.98 (AB-system centered at d 4.91, 4 H), 5.19 (s, 2H), 6.66 (bs, NH), 7.1-7.5 (m, 17H), 7.75 (d, 2H), 7.80 (t, NH), 9.37 (bs, NH)

15 $^{13}\text{C-NMR}$ (75 MHz, CDCl_3): amidine and carbonyl carbons: δ 164.7, 168.1, 171.5, 172.3 and 172.6

20 (iv) $\text{HOOC-CH}_2-(\text{R})\text{Cgl-Pro-Pab} \times 2 \text{ HCl}$

25 0.133 g (0.20 mmole) of $\text{BnOOCH}_2-(\text{R})\text{Cgl-Pro-Pab(Z)}$ was mixed with 0.060 g 5 % Pd/C, 1ml 1M HCl-solution and 10 ml ethanol. The mixture was treated under H_2 -atmosphere for one hour. After filtration through hyflo and evaporation of the solvent the product in 90% yield, 93 mg, was obtained by freeze drying twice from water.

30 $^1\text{H-NMR}$ (300 MHz, D_2O): δ 1.0-1.45 (m, 5H), 1.5-2.1 (m, 9H), 2.2-2.4 (m, 1H), 3.55-3.85 (m, 4H; thereof 3.79 (s, 2H)), 4.23 (d, 1H), 4.33-4.57 (m, 3H), 7.44 (d, 2H), 7.69 (d, 2H)

35 $^{13}\text{C-NMR}$ (75 MHz, D_2O): amidine and carbonyl carbons: δ 166.9, 167.2, 169.1, 174.5

1.45 g (2.34 mmol) of Boc-(R)Cgl-Pro-Pab(Z) was dissolved in 75 ml HCl saturated ethyl acetate. The mixture was allowed to stand for 10 min at room temperature. The solvent was evaporated to yield 1.3 g of the dihydrochloride salt of the product.

10 ¹H-NMR (300 MHz, D₂O): δ 1.0-1.45 (m, 5H), 1.58-2.2 (m, 9H), 2.3-2.5 (m, 1H), 3.75-3.90 (m, 2H), 4.25 (d, 2H), 4.5-4.66 (m, 3H), 5.49 (s, 2H), 7.45-7.7 (m, 7H), 7.87 (d, 2H)

15 The amine was obtained by dissolving the dihydrochloride salt in 0.1 M NaOH-solution and extracting the water phase three times with ethyl acetate. The organic phase was washed once with brine, dried (Na₂SO₄), filtered and evaporated to yield 1.19 g (97%) of the title compound.

(iii) BnOOC-CH₂-(R)Cgl-Pro-Pab(Z)

20 0.340 g (0.65 mmole) H-(R)Cgl-Pro-Pab(Z) was mixed with 0.215 g (0.65 mmole) BnOOC-CH₂-OTf (see preparation of starting materials), 0.299 g (2.17 mmole) K₂CO₃ in 4 ml dichloromethane and refluxed for half an hour. The reaction mixture was then stirred over night at room temperature. The reaction mixture was diluted with CH₂Cl₂ and the organic layer was washed once with water and brine, dried (Na₂SO₄), filtered and evaporated. The crude product was purified by flash chromatography using a stepwise gradient of CH₂Cl₂/MeOH (97/3 followed by 95/5) to give 299 mg of a mixture of two products according to TLC. The mixture was therefore purified further by flash chromatography using a stepwise gradient of ethyl acetate/toluene (9/1, 93/7, 95/5, 100/0) to give 46 mg (9%) of (BnOOC-CH₂)₂-(R)Cgl-Pro-Pab(Z) which eluated first from the column followed by 133 mg (31%) of the desired product BnOOC-CH₂-(R)Cgl-Pro-Pab(Z).

3.11-3.36 (ABX₂-system centered at δ 3.24, 2H), 3.63-3.90 (m, 2H), 4.25 (d, 1H), 4.42-4.63 (m, 3H), 7.54 (d, 2H), 7.78 (d, 2H)

5 ¹³C-NMR (75 MHz, D₂O): amidine and carbonyl carbons: δ 167.0, 167.30, 174.6 and 174.7.

Example 5

10 (HOOC-CH₂)₂-(R)Cgl-Pro-Pab × 2 HCl

46 mg (0.056 mmole) of (BnOOC-CH₂)₂-(R)Cgl-Pro-Pab(Z) (See Example 3) was mixed with 25 mg 5 % Pd/C, 0.7 ml 1M HCl-solution and 7 ml ethanol. The mixture was hydrogenated at atmospheric pressure for one hour. The catalyst was filtered off through hyflo and the solvent evaporated. The final product 25 mg (77 %) was obtained by freeze drying twice from water.

20 ¹H-NMR (300 MHz, D₂O): δ 1.0-1.4 (m, 5H), 1.45-2.2 (m, 9H), 2.25-2.45 (m, 1H), 3.53-3.84 (m, 2H), 3.84-4.22 (AB-system centered at δ 4.03, 4 H), 4.26 (d, 1H), 4.35-4.6 (m, 3H), 7.53(d, 2H), 7.77 (d, 2H)

25 ¹³C-NMR (75 MHz, D₂O): amidine and carbonyl carbons: δ 167.1, 167.3, 170.6 and 174.5

Example 6

30 H-(R)Cgl-Pic-Pab × 2 HCl

(i) Boc-(R)Cgl-Pic-Pab(Z)

35 0.478 g (2.49 mmol) EDC was added at -18°C to a stirred solution of 0.875 g (2.37 mmol) Boc-(R)Cgl-Pic-OH (See preparation of starting materials), 1.22 g (9.97 mmol) DMAP, and 0.706 g (2.49 mmol) H-Pab(Z) (See preparation

Example 4

5 (i) $\text{BnOOC-CH}_2\text{-CH}_2\text{-(R)Cgl-Pro-Pab(Z)}$

0.406 g (0.782 mmole) of $\text{H-(R)Cgl-Pro-Pab(Z)}$ (See Example 3) was dissolved in 3 ml ethanol and 132 μl (0.861 mmole) of bensylacrylate was added. The reaction mixture was 10 stirred for three days at room temperature. The mixture was evaporated and the crude product purified by flash chromatography using a stepwise gradient of $\text{CH}_2\text{Cl}_2:\text{MeOH}$ 95/5 and 90/10 as eluent to yield 0.399 g (75%) of the product.

15

$^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.8-1.0 (m, 1H), 1.0-1.3 (m, 4H), 1.35-2.2 (m, 9H), 2.3-2.6 (m, 4H), 2.65-2.78 (m, 1H), 3.05 (d, 1H), 3.4-3.6 (m, 2H), 4.25-4.52 (ABX-system central at d 4.40, 2 H), 4.64 (dd, 1H), 5.05 (s, 2H), 20 5.20 (s, 2H), 7.2-7.38 (m, 10H), 7.43 (d, 2H), 7.78 (d, 2H)

$^{13}\text{C-NMR}$ (75 MHz, CDCl_3): amidine and carbonyl carbons: δ 164.7, 167.9, 171.3, 172.7 and 175.4.

25

(ii) $\text{HOOC-CH}_2\text{-CH}_2\text{-(R)Cgl-Pro-Pab x 2 HCl}$

0.261 g (0.383 mmole) of $\text{BnOOC-CH}_2\text{-CH}_2\text{-(R)Cgl-Pro-Pab(Z)}$ was mixed with 0.075 g 5 % Pd/C, 1ml 1M HCl-solution and 30 10 ml ethanol. The mixture was hydrogenated at atmospheric pressure for two hours. After filtration through hyflo and evaporation of the solvent the product 0.196 g (96%) was obtained by freeze drying twice from water

35

$^1\text{H-NMR}$ (300 MHz, D_2O): δ 1.17-1.40 (m, 5H), 1.60-1.92 (m, 5H), 1.92-2.2 (m, 4H), 2.32-2.48 (m, 1H), 2.81 (t, 2H),

2H), 7.76 (d, 2H)

¹³C-NMR (75 MHz, D₂O): amidine and carbonyl carbons: δ 167.2, 170.5 and 173.4.

5

Example 7



10 (i) BnOOC-CH₂-(R,S)CH(COOBn)-(R)Cgl-Pic-Pab(Z)

A mixture of 350 mg (0.66 mmol) H-(R)Cgl-Pic-Pab(Z) (See Example 6) and 233 mg dibenzyl maleate in 2.5 ml ethanol was kept at room temperature for 4 days. The ethanol was removed in vacuo and the residue was subjected to flash chromatography using ethyl acetate/heptane 9:1 as eluent to give 0.108 mg of the product.



20

105 mg (0.13 mmol) BnOOC-CH₂-(R,S)CH(COOBn)-(R)Cgl-Pic-Pab(Z) dissolved in 5 ml 95% ethanol and 1 ml water was hydrogenated for 5 hours in the presence of 5 % Pd/C. 0.3 ml 1 M hydrochloric acid was added and the mixture was filtered and the solvent was removed in vacuo. The residue was dissolved in water and freeze dried to yield 54 mg (73%) of the desired substance.

¹H-NMR (300 MHz, CD₃OD, mixture of two diastereomers 5/4):

30 δ 1.10-1.60 (m, 7H), 1.60-2.04 (m, 9H), 2.23-2.42 (m, 1H), 2.93-3.15 (m 2H), 3.30-3.42 (m, 1H, partially hidden by the MeOD-peak), 3.71-3.95 (m, 1H), 3.98-4.10 (m, 1H), 4.40-4.60 (m, 3H), 5.10-5.20 (m, 1H), 7.49-7.60 (m, 2H), 7.70-7.81 (m, 2H)

35

¹³C-NMR (75 MHz D₂O): amidine and carbonyl carbons: δ 167.1, 168.95, 169.6 and 173.1.

of starting materials) in a mixture of 30 ml acetonitrile and 1 ml DMF. The reaction mixture was allowed to reach room temperature during a couple of hours and stirring was continued for 48 h. The solvent was removed in vacuo and the residue was dissolved in 50 ml ethyl acetate. The solution was washed with 15 ml water, 3x15 ml 0.3 M KHSO_4 , 2x15 ml Na_2CO_3 solution and water. Removal of the solvent gave a residue which was subjected to flash chromatography using ethyl acetate/heptane 9:1 as eluent.

5 The yield was 0.96 g (64%).

10

(ii) $\text{H}-(\text{R})\text{Cgl-Pic-Pab(Z)}$

Hydrogen chloride was bubbled through a solution of 0.56 g (0.88 mmol) $\text{Boc}-(\text{R})\text{Cgl-Pic-Pab(Z)}$ in 25 ml ethyl acetate. After a couple of minutes crystals precipitated from the solution. The solvent was removed in vacuo and 50 ml ethyl acetate was added. Washing with 2x15 ml 2 M sodium hydroxide solution and extraction of the aqueous phase with 25 ml ethyl acetate was followed by drying (sodium sulphate) of the combined extracts and removal of the solvent in vacuo to give 0.448 g (95%) of the desired product.

15

20

25 (iii) $\text{H}-(\text{R})\text{Cgl-Pic-Pab} \times 2 \text{ HCl}$

A solution of 98 mg (0.18 mmol) H-Cgl-Pic-Pab(Z) in 5 ml 95% ethanol and 1 ml water was stirred in an atmosphere of hydrogen for 4 hours in the presence of 5 % Pd/C. The mixture was filtered and 0.3 ml 1 M hydrochloric acid was added. The ethanol was removed in vacuo and the residue was freeze dried to give 70 mg (81%) of the desired compound.

30

35 $^1\text{H-NMR}$ (300 MHz, CD_3OD): δ 1.00-1.56 (m, 7H), 1.56-1.94 (m, 9H), 2.32 (bd, 1H), 3.32-3.45 (m, 1H), 3.90 (bd, 1H), 4.35 (d, 1H), 4.50 (s, 2H), 5.10-5.20 (m, 1H), 7.55 (d,

(iii) H-(R)Cha-Aze-Pab x 2 HCl

76 mg (0.15 mmol) H-(R)Cha-Aze-Pab(Z) dissolved in 5 ml 95% ethanol and 1 ml water was hydrogenated at atmospheric pressure in the presence of 5% Pd/C for 4 h. Removal of the catalyst by filtration, addition of 0.4 ml 1M hydrochloric acid and evaporation of the solvent in vacuo gave a residue which was dissolved in 2 ml water. Freeze drying gave 57 mg (85%) of the product.

10

¹H-NMR (500 MHz, D₂O, 2 rotamers, 3:1 mixture): δ 1.02-1.20 (m, 2H), 1.22-1.92 (m, 11H), 2.40-2.50 (m, 1H), 2.80-2.90 (m, 1H), 4.25 (bt, 1H), 4.40 (dq, 1H), 4.53 (dq, 1H), 4.65 (s, 2H), 5.05-5.10 (m, 1H), 7.65 (d, 2H), 7.88 (d, 2H).

15

Chemical shifts of resolved signals of the minor rotamer:

δ 0.57 (m), 0.85 (m), 2.95 (m), 4.06 (dq), 4.17 (dq), 4.63 (s), 5.33(m), 7.70(d), 7.93 (d).

20

¹³C-NMR (125 MHz D₂O): amidine and carbonyl carbons: δ 167.2, 170.4 and 172.8.

Example 9

25

HOOC-CH₂-(R)Cha-Aze-Pab x 2 HCl(i) BnOOOC-CH₂-(R)Cha-Aze-Pab(Z)

30 0.119 g (0.52 mmol) benzyl bromoacetate was added to a mixture of 0.27 g (0.52 mmol) H-(R)Cha-Aze-Pab(Z) (See Example 8) and 0.158 g (1.14 mmol) K₂CO₃ in 5.2 ml acetonitrile and heated to 60°C in an oilbath for 1 h. The solvent was removed and ethyl acetate and water was added. The phases were separated and the organic phase was washed with brine and dried (Na₂SO₄). Evaporation in vacuo gave 0.344 g of a residue which was subjected to

35

MS m/z 516 ($M^+ +1$)

Example 8


5 H-(R)Cha-Aze-Pab x 2 HCl

(i) Boc-(R) Cha-Aze-Pab(Z)

409 mg (2.13 mmol) EDC was added at -18°C to a stirred mixture of 0.72 g (2.03 mmol) Boc-(R) Cha-Aze-OH (See preparation of starting materials), 1.04 g (8.53 mmol) DMAP, and 604 mg (2.13 mmol) H-Pab(Z) (See preparation of starting materials) in 20 ml acetonitrile. The reaction mixture was allowed to reach room temperature over night and the solvent was subsequently removed in vacuo. The residue was dissolved in 40 ml ethyl acetate and the organic phase was washed successively with 10 ml water, 3x10 ml 0.3M KHSO₄, 2x10 ml Na₂CO₃-NaCl (aq), and finally 10 ml Brine. Drying (Na₂SO₄) and removal of the solvent in vacuo gave a residue which was subjected to flash chromatography using ethyl acetate/methanol 9:1 as eluent to yield 645 mg (51%) of the title compound.

(ii) H-(R) Cha-Aze-Pab(Z)

Hydrogen chloride was bubbled through a solution of 640 mg (1.03 mmol) Boc-(R) Cha-Aze-Pab(Z) in 25 ml of ethyl acetate. After a couple of minutes, TLC analysis indicated the completion of the reaction. Vacuum was applied to remove excess hydrogen chloride and the mixture was then diluted to 50 ml with ethyl acetate. Washing with 2x15 ml Na₂CO₃ (aq) was followed by extraction of the aqueous phase with 15 ml ethyl acetate. The combined organic extracts were washed with water and dried (Na₂CO₃) and the solvent was removed in vacuo to give 513 mg (96%) of H-(R) Cha-Aze-Pab(Z).

Example 10

5 (i) $\text{BnOOC-CH}_2\text{-(R,S)CH(COOBn)-(R)Cha-Aze-Pab(Z)}$

A mixture of 230 mg (0.443 mmol) H-(R)Cha-Aze-Pab(Z) (See Example 8) and 144 mg (0.487 mmol) dibenzyl maleate in 1.5 ml 95% ethanol was stirred at ambient temperature for 10 5 days. After removal of the ethanol in vacuo, the residue was subjected to flash chromatography using ethyl acetate/methanol 95/5 as eluent to give 54 mg (15%) of the product.

15 (ii) $\text{HOOC-CH}_2\text{-(R,S)CH(COOH)-(R)Cha-Aze-Pab}$

49 mg (0.06 mmol) $\text{BnOOC-CH}_2\text{-(R,S)CH(COOBn)-(R)Cha-Aze-Pab(Z)}$ dissolved in 5 ml 95% ethanol and 1 ml water was hydrogenated in the presence of 5% Pd/C for 4.5 h. 20 Removal of the catalyst by filtration and evaporation of the solvent in vacuo gave a residue which was dissolved in 2 ml water and 0.2 ml 1M hydrochloric acid. Freeze drying gave 32 mg (93%) of the product.

25 The $^1\text{H-NMR}$ spectrum of the title compound in D_2O exhibits two sets of strongly overlapping signals arising from the two diastereomers. Additionally resolved resonances of a minor rotamer, integrating to approximatly 15% also appears in the spectrum.

30 $^1\text{H-NMR}$ (300 MHz, D_2O): δ 1.03-2.00 (m, 13H), 2.32-2.53 (m, 1H), 2.72-2.96 (m, 1H), 3.06-3.28 (m, 2H), 4.10-4.55 (m, 4H), 4.62 (bs, 2H), 5.00-5.10 (m, 1H), 7.55-7.68 (m, 2H), 7.80-7.94 (m, 2H)

35 Resolved signals from the minor rotamer appears at δ 0.65 (m), 0.80 (m), 4.00 (m), 5.24 (m), 5.35 (m).

flash chromatography using ethyl acetate as eluent, and then another time using ethylacetate:tetrahydrofuran: NH₃-saturated methanol (60:5:2) to give 0.163 g of the desired product.

5

¹H-NMR (300 MHz, CDCl₃): δ 0.7-1.0 (m, 2H), 1.05-2.05 (m, 11H), 2.35-2.55 (m, 1H), 2.55-2.75 (m, 1H), 3.15-3.32 (m, 3H), 3.95-4.05 (t, 2H), 4.4 and 4.5 (ABX-system, 2H), 4.8-4.95 (m, 1H), 5.05 (s, 2H), 5.2 (s, 2H), 7.2-7.5 (m, 12H), 7.7-7.85 (d, 2H), 8.3-8.45 (t, 1H).

10

¹³C-NMR (75 MHz, CDCl₃): amidine and carbonyl carbons: δ 164.5, 167.8, 170.7, 171.9 and 175.9.

15

(ii) HOOC-CH₂-(R)Cha-Aze-Pab × 2 HCl

20

0.163 g (0.243 mmol) BnOOC-CH₂-(R)Cha-Aze-Pab(Z) dissolved in 5.5 ml ethanol (99.5 %) and 0.7 ml hydrogen chloride (1 N) was hydrogenated in the presence of 0.17 g 5 % Pd/C for 4 h. Removal of the catalyst by filtration and evaporation of the solvent followed by dissolving in water and freeze drying gave 107 mg (85 %) of the title compound.

30

¹H-NMR (500 MHz, CD₃OD, mixture of two rotamers): major rotamer: δ 0.95-1.95 (m, 13H), 2.3-2.4 (m, 1H), 2.6-2.75 (m, 1H), 3.5-3.75 (m, 2H), 4.05-4.15 (m, 1H), 4.15-4.23 (m, 1H), 4.36-4.43 (m, 1H), 4.43-4.5 (m, 1H), 4.58-4.65 (m, 1H), 4.83-4.88 (m, 1H), 7.5-7.6 (m, 2H), 7.73-7.82 (m, 2H).

Resolved signals from the minor rotamer appears at δ 2.2-2.3 (m), 3.95-4.05 (m), 5.1-5.17 (m), 7.6-7.67 (m).

35


¹³C-NMR (75 MHz, CD₃OD): amidine and carbonyl carbons; δ 168.2, 169.8, 168.9 and 172.3.

5 ¹H-NMR (300 MHz, MeOD, mixture of two rotamers): δ 0.85-1.93 (m, 13H), 2.25-2.38 (m, 1H), 2.60-2.75 (m, 1H), 2.88 (dd, 2H), 3.92 (t, 1H), 4.15-4.25 (m, 2H), 4.30-4.43 (m, 1H), 4.56 (AB-system, 2H), 4.76-4.86 (m, 1H, partially obscured by the solvent signal), 7.59 (d, 2H), 7.78 (d, 2H).


10 Resolved signals arising from the minor rotamer appears at δ 0.70, 2.95, 3.82, 4.00, 5.08 and 7.83

15 ¹³C-NMR (75 MHz D₂O): amidine and carbonyl carbons: δ 166.9, 168.8, 171.7, 172.3 and 173.8.

20 Example 12



30 The title compound was obtained by using the same procedure as described in Example 11 above on BnOOC-CH₂-(R,S)CH(COOBn)-(R)Cha-Aze-Pab(Z). This diastereomer came out after the first one from the column. Yield 0.537 g.




530 mg (0.65 mmol) BnOOC-CH₂-(RorS)CH(COOBn)-(R)Cha-Aze-Pab(Z)/b dissolved in 15 ml 95% ethanol and 3 ml water was hydrogenated in the presence of 5% Pd/C for 5 h. Removal of the catalyst by filtration and evaporation of the solvent in vacuo gave a residue which was dissolved in 6 ml water and 1.0 ml 1M hydrochloric acid. Freeze drying gave 290 mg (78%) of the product.

35 ¹H-NMR (300 MHz, MeOD, mixture of two rotamers): δ 0.86-1.90 (m, 13H), 2.30-2.42 (m, 1H), 2.60-2.75 (m, 1H), 2.75-

^{13}C -NMR (75 MHz D_2O): amidine and carbonyl carbons:
 δ 167.2, 169.0, 171.0, 172.3 and 174.1.

Example 11

5



10 A mixture of 2.0 g (3.8491 mmol) H-(R)Cha-Aze-Pab(Z) (See Example 8) and 1.37 g dibenzyl maleate in 10 ml 95% ethanol was stirred at ambient temperature for 4 days. After removal of the ethanol in vacuo, the residue was subjected to flash chromatography using ethyl acetate/methanol 98/2 as eluent to give 1.024 g (32%) of
15 $\text{BnOOC-CH}_2-(\text{R},\text{S})\text{CH}(\text{COOBn})-(\text{R})\text{Cha-Aze-Pab(Z)}$. The two diastereomers were separated by RPLC using ($\text{CH}_3\text{CN}/0.1 \text{ M NH}_4\text{OAc } 65/35$) as eluent. This diastereomer eluted first from the column. After removal of the acetonitrile in
20 vacuo the water phase was extracted three times with ethyl acetate. The organic phase was washed once with water dried (Na_2SO_4), filtered and evaporated to yield 0.352 g of the title compound as a pure stereoisomer.

25



30 350 mg (0.43 mmol) $\text{BnOOC-CH}_2-(\text{R},\text{S})\text{CH}(\text{COOBn})-(\text{R})\text{Cha-Aze-Pab(Z)/a}$ (The diastereomer from (i) above) dissolved in 15 ml 95% ethanol and 3 ml water was hydrogenated in the presence of 5% Pd/C for 4.5 h. Removal of the catalyst by filtration and evaporation of the solvent in vacuo gave a residue which was dissolved in 5 ml water and 1.0 ml 1M hydrochloric acid. Freeze drying gave 214 mg (87%) of the
35 product as a pure stereoisomer.

2H), 3.32 (t, 2H), 4.10 (t, 1H), 4.17-4.25 (m, 1H), 4.40-4.49 (m, 1H), 4.55 (AB, 2H), 4.83-4.90 (m, 1H), 7.58 (d, 2H), 7.77 (d, 2H).

5 ^{13}C -NMR (125 MHz D₂O): amidine and carbonyl carbons: δ 167.0, 168.9, 172.4 and 174.6.

Example 14

10 HOOC-CH₂-NH-CO-CH₂-(R)Cha-Aze-Pab x 2 HCl

(i) BnOOC-CH₂-NH-CO-CH₂-(R)Cha-Aze-Pab(Z)

A mixture of 0.212 g (0.408 mmole) H-(R)Cha-Aze-Pab(Z) (See Example 8), 0.124 g (0.89 mmole) K₂CO₃ and 0.128 g (0.449 mmole) BnOOC-CH₂-NH-CO-CH₂-Br (See preparation of starting materials) in 6 ml acetonitrile was stirred at 50°C for two hours. After evaporation of the solvent the residue was dissolved in water and ethyl acetate. The water layer was extracted twice with ethyl acetate and the combined organic layer was dried (Na₂SO₄), filtered and evaporated. The product was purified by flash chromatography using a stepwise gradient of ethyl acetate/tetrahydrofuran (85/15, 4/1, 7/3) to yield 25 0.190 g (64%) of the title compound.

30 ^1H -NMR (300 MHz, CDCl₃): δ 0.75-2.1 (m, 13H), 2.43 (m, 1H), 2.56 (d, 1H), 2.79 (m, 1H), 3.0-3.15 (m, 2H; thereof 3.05 (d, 1H)), 3.89-4.18 (m, 5H), 4.8-4.98 (m, 2H), 5.15 (s, 2H), 5.18 (s, 2H), 7.2-7.47 (m, 12H), 7.72 (t, NH), 7.86 (d, 2H), 8.14 (bs, NH), 8.31 (dd, NH), 9.42 (bs, NH)

35 ^{13}C -NMR (75 MHz, CDCl₃): amidine and carbonyl carbons: δ 164.5, 168.7, 169.22, 169.83, 171.7, 175.5

(ii) HOOC-CH₂-NH-CO-CH₂-(R)Cha-Aze-Pab x 2 HCl

2.85 (m, 1H), 2.95-3.05 (m, 1H), 3.65-3.71 (m, 1H), 4.00-
4.10 (m, 1H), 4.14-4.24 (m, 1H), 4.36-4.62 (m, 3H), 4.78-
4.86 (m, 1H partially obscured by the solvent signal),
7.57 (d, 2H), 7.75 (d, 2H).

5

Resolved signals arising from a minor rotamer appears at
 δ 0.78, 2.92, 3.82, 5.36 and 7.80

10 ^{13}C -NMR (75 MHz D₂O): amidine and carbonyl carbons: δ
166.8, 169.0, 172.0, 172.4 and 175.2.

Example 13



15

(i) BnOOC-CH₂-CH₂-(R)Cha-Aze-Pab(Z)

A mixture of 182 mg (0.35 mmol) H-(R)Cha-Aze-Pab(Z) (See Example 8) and 62.5 mg (0.385 mmol) benzyl acrylate in 20 1.5 ml 95% ethanol was stirred at room temperature for 4 days. The solvent was removed in vacuo and the residue was subjected to flash chromatography using ethyl acetate/methanol 9:1 as eluent to give 200 mg (84%) of the title compound.

25

(ii) HOOC-CH₂-CH₂-(R)Cha-Aze-Pab x 2 HCl

195 mg (0.29 mmol) BnOOC-CH₂-CH₂-(R)Cha-Aze-Pab(Z) dissolved in 10 ml 95% ethanol and 2 ml water was 30 hydrogenated in the presence of 5% Pd/C for 4 h. Removal of the catalyst by filtration and evaporation of the solvent in vacuo gave a residue which was dissolved in 2 ml water and 0.4 ml 1M hydrochloric acid. Freeze drying gave 130 mg (86%) of the product.

35

^1H -NMR (500 MHz, CD₃OD): δ 0.98-1.27 (m, 2H), 1.30-1.90 (m, 11H), 2.27-2.35 (m, 1H), 2.65-2.74 (m, 1H), 2.77 (t,

acetate/toluene 1:1. The organic phase was dried ($MgSO_4$) and the solvent was removed in vacuo to give a residue which was subjected to flash chromatography using ethyl acetate as eluent. The yield was 309 mg (49%).

5

(ii) H-(R)Cha-Pro-Pab(Z)

Hydrogen chloride was bubbled through a solution, until saturation, of 1.246 g (2 mmol) Boc-(R)Cha-Pro-Pab(Z) in 10 20 ml ethyl acetate at room temperature. After 30 minutes sodium carbonate solution (10%) was added and the organic phase which separated was dried (K_2CO_3). The drying agent was washed with methylene chloride and the solvent was evaporated from the combined organic phases to give 1.11 15 g (100%) of the title compound.

(iii) H-(R)Cha-Pro-Pab x 2 HCl

100 mg (0.19 mmol) H-(R)Cha-Pro-Pab(Z) dissolved in 15 ml 20 ethanol was hydrogenated in the presence of 38 mg 10% Pd/C for 1.5 h. Dilution of the reaction mixture with distilled water and removal of the catalyst by filtration followed by removal of the ethanol in vacuo and freeze drying gave the title compound as a colorless powder. The 25 peptide was finally converted to the dihydrochloride by dissolution in hydrochloric acid followed by freeze drying to give 90 mg (100%) of the title compound.

30 1H -NMR (300 MHz, D₂O); δ 1.0-2.0 (m, 13H), 2.0-2.3 (m, 3H), 2.3-2.5 (m, 1H), 3.6-3.7 (m, 1H), 3.8-3.9 (m, 1H), 4.3-4.5 (t, 1H), 4.5-4.6 (m, 3H), 7.4-7.6 (m, 3H), 7.6-7.9 (m, 2H).

35 ^{13}C -NMR (75 MHz, D₂O): amidine and carbonyl carbons: δ 167.2, 170.0, 174.9.

0.19 g (0.26 mmole) of BnOOC-CH₂-NH-CO-CH₂-(R)Cha-Aze-Pab(Z) was mixed with 0.075 g 5 % Pd/C, 1.5 ml 1N HCl-solution, 3 ml water and 17 ml ethanol and the mixture was hydrogenated at atmospheric pressure for one hour.

5 Filtration of the catalyst, evaporation of the solvent followed by freeze drying from water gave 144 mg (97 %) of the title compound.

10 ¹H-NMR (D₂O, 300 MHz, two rotamers 4:1): δ 0.88-1.88 (m, 13H), 2.25-2.42 (m, 1H), 2.63-2.89 (m, 1H), 3.94 (s, 2H), 3.99 (apparent doublet, 2H), 4.16 (t, 1H), 4.28 (q, 1H), 4.41 (q, 1H), 4.56 (s, 2H), 4.98 (dd, 1H), 7.53 (d, 2H), 7.77 (d, 2H),

15 Resolved signals from the minor rotamer appears at δ 0.50 (bq), 0.77 (bq), 5.21 (dd), 7.56 (d) and 7.81 (d).

13C-NMR (D₂O, 75 MHz): The carbonyls and amidinecarbon at δ 166.8, 166.9, 168.6, 172.3 and 173.4.

20 Resolved signals from the minor rotamer appears at δ: 166.6, 169.6 and 172.0

Example 15

25 H-(R)Cha-Pro-Pab x 2 HCl

(i) Boc-(R)Cha-Pro-Pab(Z)

30 0.135 ml (1.1 mmol) pivaloyl chloride was added at room temperature to a stirred mixture of 0.155 ml (1.1 mmol) triethyl amine and 405 mg (1.1 mmol) Boc-(R)Cha-Pro-OH (See preparation of starting materials) in 5 ml DMF. After 3 h 340 mg (1.1 mmol) H-Pab(Z) (See preparation of starting materials) in 5 ml DMF was added and stirring was continued over night. The reaction mixture was diluted with water and extracted with ethyl

(i) Boc-(Me)(R)Cha-Pro-Pab(Z)

To a solution of 0.8 g (1.67 mmol) of Boc-(Me)(R)Cha-Pro-OSu (See preparation of starting materials) in 3 ml DMF was added a solution of 0.562 g (1.85 mmol) of H-Pab(Z) (See preparation of starting materials) in 3 ml of DMF, and the pH of the resulting solution was adjusted to 8-9 with N-methylmorpholine, whereafter the solution was stirred at room temperature for 2 days.

The solution was poured onto water, and the resulting mixture was extracted with 3x25 ml of ethyl acetate. The organic solution was washed with 1M KHSO₄ solution, 10% NaHCO₃ solution, water and brine, and dried (Na₂SO₄). Evaporation of the solvent gave 0.65 g (60%) of the title compound as a yellowish white powder.

(ii) Me-(R)Cha-Pro-Pab(Z)

A solution of 0.60 g (0.92 mmol) of Boc-(Me)(R)Cha-Pro-Pab(Z) in 50 ml of EtOH was saturated with HCl at 0°C, and the solution was stored in refrigerator overnight. The resulting solution was evaporated to dryness, and the residue was dissolved in a Na₂CO₃ solution, extracted with 3x25 ml ethyl acetate. The extract was washed with brine and evaporated to give 0.4 g (79%) of the compound as a white fluffy powder.

¹H-NMR (CDCl₃, 300 MHz): δ 0.8-1.0 (m, 2H), 1.1-1.4 (m, 5H), 1.4-1.55 (m, 1H), 1.6-1.9 (m, 10H), 1.9-2.05 (m, 2H), 2.05-2.2 (m, 2H), 2.19 (s, 3H), 2.4-2.5 (m, 1H), 3.28 (dd, 1H), 3.41 (q, 1H), 3.62 (m, 1H), 4.42 (m, 2H), 4.61 (d, 1H), 5.2 (s, 2H), 7.2-7.45 (m, 7H), 7.72 (t, 1H), 7.79 (d, 2H).


35 (iii) BnOOC-CH₂-(Me)(R)Cha-Pro-Pab(Z).

A mixture of 0.40 g (0.73 mmol) of Me-(R)Cha-Pro-Pab(Z),

Example 165 (i) $\text{BnOOC-CH}_2\text{-(R)Cha-Pro-Pab(Z)}$

A mixture of 268 mg (0.5 mmol) H-(R)Cha-Pro-Pab(Z) (See Example 15), 90 μl (0.55 mmol) benzyl bromoacetate and 181 mg (1.3 mmol) K_2CO_3 in 2 ml acetonitrile was sonicated at 40°C for 2.5 h. The mixture was filtered through hyflo and the solvent was removed in vacuo to give a residue which was subjected to flash chromatography using ethyl acetate as eluent to give 194 mg (57%) of the title compound.


15



194 mg (0.28 mmol) $\text{BnOOC-CH}_2\text{-(R)Cha-Pro-Pab(Z)}$ dissolved in 10 ml ethanol was hydrogenated in the presence of 77 mg 10% Pd on charcoal for 3 h. The reaction mixture was diluted with water and the catalyst was removed by filtration. Evaporation of the ethanol in vacuo followed by freeze drying gave a white residue. Hydrochloric acid was added and the resulting solution was finally freeze dried to give 115 (68%) of the desired product.

30 $^1\text{H-NMR}$ (300 MHz, D_2O): δ 1.0-1.2 (m, 2H), 1.2-1.5 (m, 3H), 1.5-2.0 (m, 8H), 2.0-2.3 (m, 3H), 2.3-2.5 (m, 1H), 3.6-3.8 (m, 1H), 3.8-4.0 (m, 3H), 4.4-4.7 (m, 4H), 7.5-7.7 (d, 2H), 7.7-7.9 (d, 2H).

35 $^{13}\text{C-NMR}$ (75 MHz, D_2O): amidine and carbonyl carbons: δ 167.1, 168.2, 169.3, 174.6.

35 Example 17

solvent was removed in vacuo and the residue was subjected to flash chromatography using ethyl acetate as eluent to give 124 mg (64%) of the desired product.

5 (ii) HOOC-CH₂-CH₂-(R)Cha-Pro-Pab x 2 HCl

124 mg (0.18 mmol) BnOOC-CH₂-CH₂-(R)Cha-Pro-Pab(Z) dissolved in 10 ml ethanol was hydrogenated for 1 h in the presence of 55 mg 10% Pd/C. The catalyst was removed 10 by filtration and the solvent was removed in vacuo. The residue was dissolved in hydrochloric acid and the resulting solution was freeze dried to give 87 mg (79%) of the title compound.

15 ¹H-NMR (300 MHz, D₂O): δ 1.0-2.0 (m, 13H), 2.0-2.2 (m, 3H), 2.2-2.4 (m, 1H), 2.7-2.8 (t, 2H), 3.2-3.3 (m, 1H), 3.3-3.4 (m, 1H), 3.5-3.7 (m, 1H), 3.7-3.9 (m, 1H), 4.3-4.6 (m, 4H), 7.4-7.6 (m, 2H), 7.7.6-7.8 (m, 2H).

20 ¹³C-NMR (75 MHz, D₂O): amidine and carbonyl carbons: δ 167.0, 168.3 and 174.6 (Two carbons are overlapping).

Example 19

25 HOOC-CH₂-CH₂-(Me)(R)Cha-Pro-Pab x 2 HCl

(i) BnOOC-CH₂-CH₂-(Me)(R)Cha-Pro-Pab(Z)

30 To a solution of 274 mg (0.5 mmol) of Me-(R)Cha-Pro-Pab(Z) (See Example 17) in 5 ml of ETOH (99%) was added 97.3 mg (0.6 mmol) of benzyl acrylate and the reaction was stirred at room temperature. After 72 h an additional amount of 16.2 mg (0.1 mmol) of benzyl acrylate was added and the stirring continued for 24 h. The solvent was 35 evaporated and the residue was subjected to flash chromatography (CH₂Cl₂/MeOH(NH₃-saturated), 95/5) to give 198 mg (56%) of the title compound.

0.17 g BnOOC-CH₂Br and 0.20 g (2 equiv.) of K₂CO₃ (mortared) in 15 ml of CH₃CN was stirred at room temperature overnight. The resulting mixture was evaporated, ethyl acetate was added, and the mixture was washed with water and brine, dried (Na₂SO₄), and evaporated. The crude product (0.69 g) was subjected to flash chromatography (CH₂Cl₂/MeOH 10/1) yielding 0.39 g (77%) of a light yellow very viscous oil.

10 HOOC-CH₂-(Me)(R)Cha-Pro-Pab

To a solution of 0.39 g (0.56 mmol) of BnOOC-CH₂-(Me)(R)Cha-Pro-Pab(Z) in 30 ml of EtOH was added 0.1 g of Pd/C (10%), and the substance was hydrogenated at atmospheric pressure. The solution was filtered and evaporated, whereafter the remaining syrupy material was freeze dried to yield 0.25 g (95%) of the compound as a white crystalline powder.

20 ¹H-NMR (300 MHz, CD₃OD): δ 0.85-1.1 (m, 2H), 1.1-1.4 (m, 6H), 1.5-1.85 (m, 9H), 1.9-2.05 (m, 3H), 2.05-2.15 (m, 1H), 2.15-2.3 (m, 1H), 2.57 (s, 3H), 3.32 (d, 1H), 3.55-3.75 (m, 2H), 3.95-4.1 (m, 2H), 4.35-4.5 (m, 3H), 7.55 (d, 2H), 7.72 (d, 2H).

25 ¹³C-NMR (75 MHz, CD₃OD): amidine and carbonyl carbons: δ 168.4, 171.5, 174.7, 175.1.

Example 18

30 HOOC-CH₂-CH₂-(R)Cha-Pro-Pab × 2 HCl

(i) BnOOC-CH₂-CH₂-(R)Cha-Pro-Pab(Z)

35 A mixture of 149 mg (0.28 mmol) H-(R)Cha-Pro-Pab(Z) (See Example 15) and 66 mg (0.4 mmol) benzyl acrylate in 1.5 ml ethanol was kept at room temperature for 36 h. The

A mixture of 0.50 g (0.94 mmol) of H-(R)Cha-Pro-Pab(Z) (See Example 15) and 0.28 g (0.94 mmol) of dibenzyl maleate in 20 ml of EtOH was kept at room temperature for 5 days. Evaporation of the solvent followed by flash chromatography using CH₂Cl₂/MeOH as eluent gave 0.15 g (19 %) of the diastereomeric mixture.

¹H NMR (500 MHz, CDCl₃) δ 0.7-2.1 (m, 17 H), 2.3-2.4 (m, 1 H), 2.5-2.8 (m, 2 H), 3.2-3.7 (m, 4 H), 4.46 (d, 1 H), 4.65 (bd, 1 H), 4.81 (d, 1 H), 4.9-5.1 (m, 3 H), 5.20 (s, 2 H), 7.1-7.4 (m, 15 H), 7.4-7.5 (m, 2 H), 7.6-7.8 (m, 3 H).

(ii) HOOC-CH₂-(R or S)CH(COOH)-(R)Cha-Pro-Pab/a × 2 HCl

15

A mixture of 0.15 g (0.18 mmol) of BnOOC-CH₂-(R,S)CH(COOBn)-(R)Cha-Pro-Pab(Z) was dissolved in 5 ml of ethanol and was hydrogenated over 5% Pd/C at atmospheric pressure for 1 h. to give HOOC-CH₂-(R,S)CH(COOH)-(R)Cha-Pro-Pab. The two diastereomers were separated by RPLC using (CH₃CN/0.1 M NH₄OAc 15/85) as eluent followed by freeze drying from HCl. This diastereomer eluted first from the column. Yield 19 mg (18 %).

25

¹H-NMR (500 MHz, D₂O, mixture of two rotamers) major rotamer: δ 1.0-2.0 (m, 15H), 2.15 (m, 2H), 2.44 (m, 1H), 3.00 (bd, 1H), 3.05 (bd, 1 H), 3.69 (m, 1H), 3.84 (m, 1H), 3.97 (bs, 1H), 4.5-4.7 (m, 3H), 7.62 (d, 2H), 7.87 (d, 2H).

30

¹³C-NMR (75 MHz, D₂O): amidine and carbonyl carbons: δ 167.2, 168.3, 173.8, 174.6 and 178.2.

Example 21

35

HOOC-CH₂-(R or S)CH(COOH)-(R)Cha-Pro-Pab/b × 2 HCl

5 $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 0.8-2.0 (several m, 16 H), 2.14 (s, 3H), 2.24-2.33 (m, 2H), 2.38-2.46 (m, 1H), 2.67 (t, 2H), 3.32-3.40 (m, 2H), 3.71 (m, 1H), 4.36-4.44 (m, 2H), 4.58 (m, 1H), 5.03 (apparent s, 2H), 5.20 (s, 2H), 7.25-7.37 (m, 10H), 7.43 (d, 2H), 7.64 (t, 1H (NH)), 7.81 (d, 2H).

10 $^{13}\text{C-NMR}$ (125 MHz, CDCl_3): amidine and carbonyl carbons: δ 164.7, 167.9, 171.7, 172.3 and 172.6.

15 (ii) $\text{HOOC-CH}_2-\text{CH}_2-(\text{Me})(\text{R})\text{Cha-Pro-Pab} \times 2 \text{ HCl}$

20 To a solution of 198 mg (0.27 mmol) $\text{BnOOC-CH}_2-\text{CH}_2-(\text{Me})(\text{R})\text{Cha-Pro-Pab(Z)}$ in 10 ml ETOH and 1 ml 1M HCl was added 60 mg of 5 % Pd/C (containing 50 % H_2O by weight) and the mixture was hydrogenated at atmospheric pressure for 4 h. The catalyst was filtered off and the solvent was evaporated. The remaining oil was dissolved in water and freeze dried to give the title compound in a quantitative yield.

25 $^1\text{H-NMR}$ (500 MHz, D_2O): δ 1.08-1.2 (m, 2H), 1.2-1.42 (m, 4H), 1.68-1.91 (m, 5H), 1.93-2.08 (m, 2H), 2.09-2.26 (m, 3H), 2.49 (m, 1H), 2.95 (m, 2H), 3.03 (s, 3H), 3.60 (apparent bs, 2H), 3.82 (m, 1H), 3.98 (m, 1H), 4.53 (m, 1H), 4.61 (bs, 2H), 4.64 (m, 1H), 7.63 (d, 2H), 7.97 (d, 2H).

30 $^{13}\text{C-NMR}$ (75 MHz, D_2O): amidine and carbonyl carbons: δ 167.2, 167.8 and 174.5. Two peaks are probably overlapping.

Example 20

35 $\text{HOOC-CH}_2-(\text{R},\text{S})\text{CH}(\text{COOH})-(\text{R})\text{Cha-Pro-Pab/a} \times 2 \text{ HCl}$

(i) $\text{BnOOC-CH}_2-(\text{R},\text{S})\text{CH}(\text{COOBn})-(\text{R})\text{Cha-Pro-Pab(Z)}$

5 ^{13}C -NMR (75 MHz, CDCl_3): δ 25.0, 26.0, 26.2, 26.4, 26.7,
32.4, 34.2, 34.4, 40.8, 40.9, 42.9, 46.7, 50.5, 58.4,
60.2, 67.0, 67.2, 127.5, 127.8, 128.2, 128.3, 128.4,
128.5, 128.6, 128.6, 134.1, 135.2, 137.0, 142.6, 164.7,
168.9, 169.3, 170.4, 172.2, 175.0

(ii) $\text{HOOC-CH}_2\text{-NH-CO-CH}_2\text{-(R)Cha-Pro-Pab} \times 2 \text{ HCl}$

10 0.089 g (0.12 mmole) $\text{BnOOCC-CH}_2\text{-NH-CO-CH}_2\text{-(R)Cha-Pro-Pab(Z)}$ was mixed with 30 mg 5 % Pd/C and dissolved in 10 ml acetic acid. The mixture was hydrogenated at atmospheric pressure for one and a half hour. Filtration of the catalyst through hyflo and freeze drying with 1ml 1N hydrochloric acid gave 0.058 g (82%) of the desired product.

15 $^1\text{H-NMR}$ (300 MHz, D_2O): δ 0.9-2.2 (m, 16H), 2.25-2.47 (m, 1H), 3.55-3.7 (m, 1H), 3.7-4.1 (m, 5H), 4.42 (t, 1H),
20 4.48-4.6 (m, 3H), 7.51 (d, 2H), 7.77 (d, 2H)

25 $^{13}\text{C-NMR}$ (75 MHz, D_2O): amidine and carbonyl carbons: δ 166.8, 167.1, 168.2, 173.6 and 174.6

25

Example 23

$\text{EtOOC-CH}_2\text{-CH}_2\text{-CH}_2\text{-(R)Cha-Pro-Pab} \times \text{HOAc}$

30 (i) $\text{EtOOC-CH=CH-CH}_2\text{-(R)Cha-Pro-Pab(Z)}$

35 $\text{H-(R)Cha-Pro-Pab(Z)}$ (See Example 15) (275 mg, 0.51 mmol) was treated with K_2CO_3 (141 mg, 1.02 mmol) and $\text{BrCH}_2\text{CH=CHCOOEt}$ (108 mg, 0.56 mmol) in CH_3CN (10 ml) at 20°C for 20 h. The solvent was evaporated and the residue was dissolved in EtOAc (5 ml)/ H_2O (2 ml). The organic layer was separated, dried (Na_2SO_4), and

The title compound was obtained by using the same procedure as described in Example 20 on HOOC-CH₂-(R,S)CH(COOH)-(R)Cha-Pro-Pab. This diastereomer came out after the first one from the column. Yield 19 mg (18%).

5

¹H-NMR (500 MHz, D₂O, mixture of two rotamers) major rotamer: δ 1.0-2.0 (m, 14H), 2.15-2.25 (m, 3H), 2.44 (m, 1H), 3.11 (bd, 1H), 3.19 (bd, 1H), 3.71 (m, 1H), 3.92 (m, 1H), 4.03 (bs, 1H), 4.5-4.7 (m, 3H), 7.58 (d, 2H), 7.84 (d, 2H).

10

Resolved signals arising from the minor rotamer appears at: δ 7.66 (d) and 7.91 (d).

15

¹³C-NMR (75 MHz, D₂O): amidine and carbonyl carbons: δ 167.3, 168.5 and 174.7. Two carbons are probably overlapping.

Example 22

20



(i) BnOOC-CH₂-NH-CO-CH₂-(R)Cha-Pro-Pab(Z)

25

0.246 g (0.460 mmole) of H-(R)Cha-Pro-Pab(Z) (See Example 15), 0.140 g (1.01 mmole) K₂CO₃ and 0.145 g (0.506 mmole) BnOOC-CH₂-NH-CO-CH₂-Br (See preparation of starting materials) was mixed in 6 ml acetonitrile. The mixture was stirred at 50°C for 2 h 30 minutes, the solvent was evaporated and the residue was partitioned between water and ethyl acetate. The layers were separated and the water layer was extracted one more time with ethyl acetate. The combined organic layer was dried (Na₂SO₄), filtered and evaporated to yield 0.350 g of an oil. The crude product was purified by flash chromatography using a stepwise gradient of CH₂Cl₂/MeOH 97/3, 95/5, 92.5/7.5 to yield 0.227 g (67%) of the title compound.

30

35

Example 24**Ph(4-COOH)-SO₂-(R)Cha-Pro-Pab x HCl**5 (i) **Ph(4-COOH)-SO₂-(R)Cha-Pro-Pab(Z)**

64 mg (0.32 mmol) 4-chlorosulfonyl-benzoic acid was added at ice bath temperature to a solution of 156 mg (0.29 mmol) H-(R)Cha-Pro-Pab(Z) (See Example 15) and 59 mg (0.58 mmol) triethyl amine in 4 ml methylene chloride. The mixture was slowly allowed to reach room temperature and after 24 hours it was washed with water and dried (Na₂SO₄). Removal of the solvent in vacuo and purification of the residue by flash chromatography using ethyl acetate/methanol 9:1 followed by methylene chloride/methanol 3:1 as eluents gave 82 mg (39%) of the product.

20 (ii) **Ph(4-COOH)-SO₂-(R)Cha-Pro-Pab x HCl**

80 mg (0.11 mmol) Ph(4-COOH)-SO₂-(R)Cha-Pro-Pab(Z) was hydrogenated over 5 % Pd/C in ETOH. The catalyst was filtered off, the solvent evaporated and the crude product was purified by RPLC using (CH₃CN/0.1 M NH₄OAC 1/4) as eluent and finally converted to the hydrochloride salt by freeze drying from HCl which gave 21 mg (29%) of the product.

30 ¹H-NMR (300 MHz, CD₃OD, mixture of two rotamers): δ 0.45-1.82 (m, 13H), 1.90-2.30 (m, 4H), 2.95-4.16 (several m, total 3H), 4.35-4.68 (m, 3H), 7.54 (d, 2H), 7.74 (d, 1H), 7.80 (d, 1H), 7.90-8.00 (m, 2H), 8.05-8.22 (m, 2H)

35 ¹³C-NMR (75 MHz, CD₃OD): amidine and carbonyl carbons: δ 168.4, 173.4, 173.9 and 174.2

concentrated yielding 397 mg of an oil which was purified by flash chromatography using EtOAc/Heptane, 1/4 as eluent to give 252 mg (77%) of the title compound.

5

¹H-NMR (500 MHz, CDCl₃): δ 0.8-1.05 (m, 2H), 1.1-1.45 (m, 3H), 1.3 (t, 3H), 1.5-1.9 (m, 8H), 1.95-2.05 (m, 1H), 2.1-2.15 (m, 1H), 2.45-2.55 (m, 1H), 3.0 and 3.15 (two d, 2H), 3.35-3.45 (m, 2H), 3.55-3.65 (m, 1H), 4.15 (q, 2H), 4.3 (d, 1H), 4.6-4.7 (m, 2H), 5.2 (s, 2H), 5.85 (d, 1H), 6.75 (dt, 1H), 5.3-5.4 (m, 4H), 7.45 (d, 2H), 7.85 (d, 2H).

10

¹³C-NMR (75.0 MHz, CDCl₃): amidine and carbonyl carbons: δ 165.7, 171.2 and 175.7 (two peaks are probably overlapping).

15

(ii) EtOOCC-CH₂-CH₂-CH₂-(R)Cha-Pro-Pab × HOAc

20

EtOOCCCH=CHCH₂-(R)Cha-Pro-Pab(Z) (250 mg, 0.38 mmol) was dissolved in ethanol and hydrogenated in the presence of 5 % Pd/C during approximately 2 h. Removal of the catalyst by filtration and evaporation of the solvent in vacuo gave after purification by RPLC using (CH₃CN/0.1 M NH₄OAc) as eluent 70 mg (36%) of the desired product.

25

¹H NMR (500 MHz, CD₃OD): δ 0.9-1.05 (m, 2H), 1.15-1.55 (m, 5H), 1.25 (t, 3H), 1.6-1.85 (m, 7H), 1.95-2.6 (m, 8H), 3.55-3.65 (m, 2H), 3.8 (m, 1H), 4.1 (q, 2H), 4.45 (m and d, 2H), 4.55 (d, 1H), 7.55 and 7.75 (two d, 4H).

30

¹³C-NMR (75.0 MHz, CD₃OD): amidine and carbonyl carbons: δ 168.3, 173.2, 174.6 and 174.9.

35

was removed in vacuo to give the title compound in quantitative yield.

5 ¹H-NMR (500 MHz, CD₃OD): δ 0.85-1.05 (m, 2H), 1.15-1.90
 (m, 16H), 2.25-2.35 (m, 1H), 3.20-3.30 (m, 1H), 3.80-3.90
 (d, 1H), 3.90-4.0 (m, 1H), 4.4-4.5 (two d, 2H), 4.7 (br
 s, 5H) 5.15 (s, 2H), 5.20 (m, 1H), 7.25-7.45 (m, 7H),
 7.85 (d, 2H).

10 (iii) H-(R)Cha-Pic-Pab × 2 HCl

55 mg (0.1 mmol) H-(R)Cha-Pic-Pab(Z) dissolved in a mixture of 5 ml ethanol and 0.45 ml 1M hydrochloric acid was hydrogenated in the presence of 33 mg 10% Pd/C for 1.5 h. Removal of the catalyst by filtration and evaporation of the solvent in vacuo gave a residue which was subjected to RPLC using 0.1 M NH₄OAc/CH₃CN as eluent. The purified peptide was finally converted to the dihydrochloride salt by dissolution in hydrochloric acid followed by freeze drying. The yield was 17 mg (35%) of the title compound

25 ¹H-NMR (300 MHz, D₂O, 2 rotamers, 3:1 mixture): δ 1.0-2.0
 (m, 18H), 2.33 (d, 1H), 3.4-3.5 (m, 1H), 3.8-3.9 (m, 1H),
 4.4-4.8 (m, 3H), 5.15.5.25 (m, 1H), 7.5-7.7 (m, 2H),
 7.8-8.0 (m, 2H).

30 Resolved signals from the minor rotamer appears at δ:
 0.5-0.7 (m) and 3.0-3.1 (m)

35 ¹³C-NMR (75 MHz, D₂O): amidine and carbonyl carbons: δ
 167.3, 171.6 and 173.6.

Resolved signals for the minor rotamer appears at δ 170.6
and 172.4.

MS m/z 584 (M⁺ +1)

Example 25

H-(R)Cha-Pab x 2 HCl

(i) Boc-(R)Cha-Pab(Z)

3.57 g (18.6 mmol) EDC was added at -15°C to a mixture of
10 7.11 g (18.6 mmol) Boc-(R)Cha-Pic-OH (See preparation of
starting materials), 9.07 g (74.2 mmol) DMAP and 5.26 g
(18.6 mmol) H-Pab(Z) (See preparation of starting
materials) in 200 ml DMF. The temperature was allowed to
rise to 20°C over night. The solvent was removed in vacuo
15 and toluene and water was added. The organic phase was
washed with water, 1M KHSO₄, 10% Na₂CO₃ and brine. Drying
(MgSO₄) and evaporation of the solvent in vacuo gave 13.63
g of a residue which was subjected to flash chromato-
graphy on silica gel using ethyl acetate/toluene 2:1 as
20 eluent to give 9.5 g (79%) of the title compound.

¹H-NMR (300 MHz, CDCl₃): δ 0.7-1.0 (m, 2H), 1.0-2.2 (m,
25H), 2.3-2.5 (m, 1H), 2.9-3.1 (m, 1H), 3.8 (d, 1H), 4.3
(dd, 1H), 4.4-4.6 (m, 2H), 5.1 (s, 2H), 5.1-5.3 (m, 2H),
25 7.2-7.3 (m, 5H), 7.35 (d, 2H), 7.4-7.5 (m, 1H), 7.75 (d,
2H).

¹³C-NMR (75 MHz, CDCl₃): amidine and carbonyl carbons: δ
156.8, 164.6, 168.2, 170.0 and 173.4.

30 (ii) H-(R)Cha-Pab(Z)

Hydrogen chloride was bubbled through a solution of 9.5
g (14.7 mmol) Boc-(R)Cha-Pab(Z) in 100 ml ethyl
35 acetate at room temperature until saturation. After 10
minutes Na₂CO₃ solution (10%) was added and the organic
phase which separated was dried (K₂CO₃) and the solvent

was removed in vacuo to give the title compound in quantitative yield.

5 ¹H-NMR (500 MHz, CD₃OD): δ 0.85-1.05 (m, 2H), 1.15-1.90
 (m, 16H), 2.25-2.35 (m, 1H), 3.20-3.30 (m, 1H), 3.80-3.90
 (d, 1H), 3.90-4.0 (m, 1H), 4.4-4.5 (two d, 2H), 4.7 (br
 s, 5H) 5.15 (s, 2H), 5.20 (m, 1H), 7.25-7.45 (m, 7H),
 7.85 (d, 2H).

10 (iii) H-(R)Cha-Pic-Pab × 2 HCl

15 55 mg (0.1 mmol) H-(R)Cha-Pic-Pab(Z) dissolved in a mixture of 5 ml ethanol and 0.45 ml 1M hydrochloric acid was hydrogenated in the presence of 33 mg 10% Pd/C for 1.5 h. Removal of the catalyst by filtration and evaporation of the solvent in vacuo gave a residue which was subjected to RPLC using 0.1 M NH₄OAc/CH₃CN as eluent. The purified peptide was finally converted to the dihydrochloride salt by dissolution in hydrochloric acid followed by freeze drying. The yield was 17 mg (35%) of the title compound

20 ¹H-NMR (300 MHz, D₂O, 2 rotamers, 3:1 mixture): δ 1.0-2.0
 (m, 18H), 2.33 (d, 1H), 3.4-3.5 (m, 1H), 3.8-3.9 (m, 1H),
 4.4-4.8 (m, 3H), 5.15.5.25 (m, 1H), 7.5-7.7 (m, 2H),
 7.8-8.0 (m, 2H).

25 Resolved signals from the minor rotamer appears at δ:
 0.5-0.7 (m) and 3.0-3.1 (m)

30 ¹³C-NMR (75 MHz, D₂O): amidine and carbonyl carbons: δ
 167.3, 171.6 and 173.6.

35 Resolved signals for the minor rotamer appears at δ 170.6
 and 172.4.

Example 265 (i) $\text{BnOOC-CH}_2\text{-(R)Cha-Pic-Pab(Z)}$

A mixture of 742 mg (1.35 mmol) H-(R)Cha-Pic-Pab(Z) (See Example 25), 230 ml (1.45 mmol) benzyl bromoacetate and 558 mg (4 mmol) K_2CO_3 in 4 ml acetonitrile was sonicated 10 at 40°C for 40 minutes. The solvent was removed and the residue was subjected to flash chromatography to give 720 mg (77%) of the desired product.

15 $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 0.8-1.0 (m, 2H), 1.1-1.9 (m, 16H), 2.1-2.4 (br s, 1 or 2H), 2.4 (d, 1H), 3.0 (m, 1H), 3.25 (d, 1H), 3.45 (d, 1H), 3.55-3.65 (m, 1H), 3.7 (m, 1H), 4.35 (dd, 1H), 4.55 (dd, 1H), 4.80 (two d, 2H), 5.2 (s, 2H), 5.3 (m, 1H), 7.2-7.4 (m, 12H), 7.8 (d, 2H).

20 $^{13}\text{C-NMR}$ (125 MHz, CDCl_3): amidine and carbonyl carbons: δ 164.5, 167.9, 170.5, 173.4 and 175.5.

(ii) $\text{HOOC-CH}_2\text{-(R)Cha-Pic-Pab} \times 2 \text{ HCl}$

25 509 mg (0.73 mmol) $\text{BnOOC-CH}_2\text{-(R)Cha-Pic-Pab(Z)}$ dissolved in 25 ml ethanol was hydrogenated in the presence of 259 mg 10% Pd/C for 4 h. Removal of the catalyst by filtration and evaporation of the solvent in vacuo gave a residue which was dissolved in distilled water. 30 Hydrochloric acid was added and the solution was finally freeze dried to give 281 mg (79%) of the title compound.

35 $^1\text{H-NMR}$ (500 MHz, D_2O , mixture of rotamers 4:1): major rotamer: δ 1.0-2.0 (m, 18H), 2.25-2.40 (m, 1H), 3.4-3.5 (m, 1H), 3.8-3.95 (m, 3H), 4.55-4.65 (two d, 2H), 5.15 (m, 1H), 7.55-7.75 (m, 2H), 7.8-8.0 (m, 2H).

^{13}C -NMR (125 MHz, D_2O): amidine and carbonyl carbons: δ 167.3, 169.9, 170.3 and 173.5.

Resolved signal for the minor rotamer appears at δ 166.9, 169.2 and 172.0

5

Example 27



10 (i) $\text{BnOOC-CH}_2\text{-(R, S)CH(COOBn)-(R)Cha-Pic-Pab(Z)}$

A mixture of 592 mg (1.1 mmol) H-(R)Cha-Pic-Pab(Z) (See Example 25) and 332 mg (1.1 mmol) dibenzyl maleate in 1 ml ethanol was kept at room temperature for 1 week. The 15 solvent was removed in vacuo and the residue was subjected to flash chromatography using methanol/methylene chloride as eluent to give 275 mg (30%) the diastereomeric mixture.

20

(ii) $\text{HOOC-CH}_2\text{-(R or S)CH(COOH)-(R)Cha-Pic-Pab/a x 2 HCl}$

25 275 mg $\text{BnOOC-CH}_2\text{-(R, S)CH(COOBn)-(R)Cha-Pic-Pab(Z)}$ dissolved in 20 ml 95% ethanol was hydrogenated for 18 hours in the presence of 75 mg 10% Pd/C. The mixture was filtered through hyflo and the solvent was removed in vacuo. Addition of water followed by freeze drying gave 166 mg of $\text{HOOC-CH}_2\text{-(R, S)CH(COOH)-(R)Cha-Pic-Pab}$. The two 30 diastereomers were separated by RPLC using ($\text{CH}_3\text{CN}/0.1 \text{ M NH}_4\text{OAc } 1/4$) as eluent followed by freeze drying from HCl. This diastereomer eluted first from the column. Yield 9 mg.

35 $^1\text{H-NMR}$ (300 MHz, D_2O , mixture of rotamers): δ 1.0-2.0 (m, 18H), 2.25-2.4 (m, 1H), 3.0-3.2 (m, 2H), 3.4 (t, 1H), 3.8 (d, 1H), 4.05 (t, 1H), 4.5-4.7 (m, 3H), 5.2 (s, 1H), 7.55 (d, 2H), 7.9 (d, 2H).

Resolved signals from the minor rotamer appears at δ 4.0(t) and 7.7(d).

Example 28

5



The title compound was obtained by using the same procedure as described in Example 27 on HOOC-CH₂-(R,S)CH(COOH)-(R)Cha-Pic-Pab. This diastereomer came out 10 after the first one from the column.

1H-NMR (500 MHz, D₂O, mixture of rotamers; δ 1.0-2.0 (m, 18H), 2.25-2.4 (m, 1H), 3.0-3.2 (m, 2H), 3.5 (t, 1H), 15 3.85 (d, 1H), 4.15 (s, 1H), 4.5-4.7 (m, 3H), 5.15 (s, 1H), 7.55 (d, 2H), 7.8 (d, 2H).

Resolved signals from the minor rotamer appear at δ 4.35(s), 7.65(d) and 7.9(d).

20

Example 29



25 (i) BnOOC-CH₂-CH₂-(R)Cha-Pic-Pab(Z)

A mixture of 851 mg (1.55 mmol) H-(R)Cha-Pic-Pab(Z) (See Example 25) and 269 mg (1.71 mmol) benzyl acrylate in 5 ml ethanol was kept at room temperature for 40 h. The 30 solvent was removed in vacuo and the residue was subjected to flash chromatography using methylene chloride/methanol as eluent to give 812 mg (74%) of the product.

35 ¹H-NMR (500 MHz, CDCl₃): δ 0.8-1.0 (m, 2H), 1.1-1.9 (m, 16H), 2.3-2.5 (m, 3H), 2.6-2.8 (m, 2H), 3.0 (m, 1H), 3.5 (m, 1H), 3.6-3.7 (m, 1H), 4.3 (dd, 1H), 4.6 (dd, 1H),

4.95-5.05 (tw d, 2H), 5.2 (s, 2H), 5.3 (m, 1H), 6.5-6.9 (br s, 1H), 7.0-7.1 (m, 1H), 7.2-7.5 (m, 12H), 7.75-7.85 (d, 2H), 9.3-9.7 (br s, 1H).

5 (ii) HOOC-CH₂-CH₂-(R)Cha-Pic-Pab x 2 HCl

780 mg (1.1 mmol) BnOOCC-CH₂-CH₂-(R)Cha-Pic-Pab(Z) dissolved in 25 ml ethanol was hydrogenated for 4 h in the presence of 306 mg 15% Pd/C. The catalyst was removed 10 by filtration and the solvent was removed in vacuo. The residue was dissolved in hydrochloric acid and the resulting solution was freeze dried to give 481 mg (78%) of the title compound.

15 ¹H-NMR (500 MHz, D₂O): δ 0.95-1.1 (m, 2H), 1.15-1.9 (m, 16H), 2.2-2.3 (m, 1H), 2.7-2.8 (t, 2H), 3.2-3.3 (m, 3H), 3.4-3.5 (m, 1H), 3.75-3.85 (m, 1H), 4.4-4.6 (m, 3H), 5.15 (m, 1H), 7.5-7.6 (m, 2H), 7.8-7.9 (m, 2H), 8.6-8.7 (m, 1H).

20 ¹³C-NMR (125 MHz, CD₃OD): amidine and carbonyl carbons: δ 170.6, 175.9, 179.5 and 183.5.

Example 30

25 HOOC-CO-(R)Cha-Pic-Pab x HOAc

(i) EtOOCC-CO-(R)Cha-Pic-Pab(Z)

30 0.12 g ethyloxalyl chloride was added to a mixture of 0.42 g (0.77 mmol) H-(R)Cha-Pic-Pab(Z) (See Example 25) and 0.21 g (1.5 mmol) K₂CO₃ in 10 ml CH₃CN at room temperature. After 2 hours an additional amount of 0.07 g (0.5 mmol) ethyloxalyl chloride was added. The mixture 35 was stirred at room temperature over night. The solvent was removed in vacuo. and the residue was dissolved in CH₂Cl₂ and washed with water. Evaporation and flash

chromatography (toluene: ethyl acetate 1: 2 followed by CH₂Cl₂: methanol) gave 0.21 g (42%) of the product.

(ii) HOOC-CO-(R)Cha-Pic-Pab(Z)

5

0.21 g (0.32 mmol) EtoOC-CO-(R)Cha-Pic-Pab(Z) was dissolved in 3 ml THF and 0.17 g (4.2 mmol) LiOH dissolved in 3 ml water was added. The mixture was stirred at room temperature over night and then poured onto ethyl acetate/water. The phases were separated and the organic phase was extracted with a KHCO₃-solution. The aqueous phase was acidified with 0.5M HCl (pH 1) and extracted with CH₂Cl₂, dried over Na₂SO₄ and evaporated to give 80 mg of the product.

10

15

(iii) HOOC-CO-(R)Cha-Pic-Pab x HOAc

20

HOOC-CO-(R)Cha-Pic-Pab(Z) was hydrogenated over 5 % Pd/C in EtOH. The catalyst was filtered off and the solvent evaporated. The residue was subjected to purification by RPLC to give the title compound.

25

¹H NMR (500 MHz, DMSO-d₆): δ 0.8-1.0 (m, 2H), 1.1-1.75 (m, 15H), 1.86-1.94 (m, 1H), 2.13-2.2 (m, 1H), 3.75-3.81 (m, 1H), 4.32, 4.44 (AB, 2H), 4.71-4.77 (m, 1H), 4.98-5.02 (m, 1H), 7.41 (d, 2H), 7.75 (d, 2H), 8.1-8.15 (m, 1H), 8.22-8.27 (m, 1H), 9.32 (broad s), 9.90 (broad s). The signal of one of the protons (3.25) is partially obscured by the solvent signal.

30

MS m/z 486 (M⁺ + 1)

Example 31

35

HOOC-CH₂-CO-(R)Cha-Pic-Pab

(i) MeOOC-CH₂-CO-(R)Cha-Pic-Pab(Z)

0.39 g (0.72 mmol) H-(R)Cha-Pic-Pab(Z) (See Example 25) and 0.9 g (0.8 mmol) monomethylmalonate was dissolved in 40 ml CH₂Cl₂ and 0.16 g (0.8 mmol) DCC was added. The solution was stirred in room temperature over night. The precipitated DCU was removed by filtration and the filtrate was washed with 0.3M KHSO₄ and KHCO₃-solution and dried (NaSO₄). Evaporation of the solvent followed by flash chromatography using toluen/ethyl acetate (1/3) as eluent gave 0.27 g (58%) of the desired product.

10

(ii) MeOOC-CH₂-CO-(R)Cha-Pic-Pab

90 mg (0.14 mmol) MeOOC-CH₂-CO-(R)Cha-Pic-Pab(Z) was dissolved in 10 ml ethanol and was hydrogenated in presence of 5% Pd/C for 5 hours. Removal of the catalyst by filtration and evaporation of the solvent gave 50 mg (70%) of the title product.

20 ¹H NMR (300 MHz, CD₃OD): δ 0.85-1.1 (m, 2H), 1.1-1.9 (m, 16H), 2.35-2.45 (m, 1H), 3.2-3.4 (m, 3H), 3.7 (s, 3H), 3.95-4.05 (m, 1H), 4.4-4.55 (m, 3H), 5.15-5.25 (m, 1H), 7.4-7.55 (m, 2H), 7.7-7.85 (m, 2H).

25 ¹³C NMR (75 MHz, CD₃OD): amidine and carbonyl carbons: δ 168.2, 168.7, 170.0, 172.4 and 174.6.

MS m/z 514 (M⁺ + 1)30 (iii) HOOC-CH₂-CO-(R)Cha-Pic-Pab

To a solution of 0.14 g (0.27 mmol) of MeOOC-CH₂-CO-(R)Cha-Pic-Pab in 5 ml methanol was added 2 ml of 0.5 M NaOH at room temperature. After stirring for 5 hours water was added and the methanol was removed in vacuo. The aqueous phase was freeze dried. The soluble material was extracted out from the insoluble inorganic salts with

absolute ethanol. The remaining solid after evaporation of the ethanol was suspended in water and 70 mg (52%) of the title compound was isolated by filtration.

5 ^1H NMR (300 MHz, DMSO-d₆): δ 0.8-1.0 (m, 2H), 1.0-1.9 (m, 16H), 2.15-2.30 (m, 1H), 2.58, 2.86 (AB, 2H), 3.8-3.95 (m, 1H), 4.2-4.5 (m, 2H), 4.7-4.85 (m, 1H), 4.95-5.05 (m, 1H), 7.40 (d, 2H), 7.77 (d, 2H), 8.2-8.3 (m, 1H), 9.3-9.4 (m, 1H), 9.90 (broad s, 3H). The signal of one of the
10 protons (3.21) is partially obscured by the solvent-signal.

15 ^{13}C NMR (75 MHz, DMSO-d₆): amidine and carbonyl carbons:
 δ 165.8, 168.8, 169.9, 172.2 and 172.4.

15 MS m/z 500 ($M^+ + 1$)

Example 32

20 MeOOC-CH₂-CO-(R)Cha-Pic-Pab

See Example 31 (ii) above.

Example 33

25

H₂N-CO-CH₂-(R)Cha-Pic-Pab

(i) H₂N-CO-CH₂-(R)Cha-Pic-Pab(Z)

30 Attempted alkylation of 455 mg (0.83 mmol) H-(R)Cha-Pic-Pab(Z) (See Example 25) with 80 mg (0.86 mmol) chloroacetamide in 3 ml acetonitrile in the presence of 395 mg (2.86 mmol) potassium carbonate by sonication at 40°C turned out to be an extremely sluggish reaction. Even
35 the addition of 230 mg (2.6 mmol) lithium bromide did not seem to improve the reaction rate. However, addition of lithium iodide and heating/sonication gave small amounts

f product, according t TLC. Workup by addition of water, extraction with ethyl acetate/t luene, drying f the organic phase ($MgSO_4$) and removal of the solvent in vacuo gave a residue which was subjected to flash chromatography using $MeOH/CH_2Cl_2$ as eluent to give 118 mg (24%) of the desired product.

(ii) $H_2N-CO-CH_2-(R)Cha-Pic-Pab \times 2 HCl$

10 118 mg (0.2 mmol) $H_2N-CO-CH_2-(R)Cha-Pic-Pab(Z)$ dissolved in 10 ml 95% ethanol was hydrogenated in the presence of 143 mg 10% Pd/C for 2 h. The mixture was diluted with distilled water and hydrochloric acid and filtered through hyflo. Freeze drying gave 26 mg (24%) of the
15 desired product.

20 ^1H-NMR (300 MHz, CD_3OD): δ 0.9-1.1 (m, 2H), 1.1-1.9 (m, 16H), 2.3 (d, 1H), 3.4 (t, 1H), 3.6 (AB-system, 2H), 3.8 (d, 2H), 4.35 (t, 1H), 4.5 (s, 2H), 5.2 (s, 1H), 7.55 (d, 2H), 7.8 (d, 2H).

Example 34

Boc-(R)Cha-Pic-Pab

25 10 mg (0.015 mmol) Boc-(R)Cha-Pic-Pab(Z) (See Example 25) dissolved in 5 ml ethanol was hydrogenated in the presence of 38 mg 10% Pd/C for 4 h. Removal of the catalyst by filtration and evaporation of the solvent in vacuo followed by dissolution of the residue in water and freeze drying yielded 7.6 mg (95%) of the product.

30 ^1H-NMR (300 MHz, CD_3OD): δ 0.9-1.1 (m, 2H), 1.1-1.9 (m, 16H), 2.4 (d, 1H), 3.25 (t, 1H), 4.0 (d, 1H), 4.5 (AB-system, 2H), 4.5-4.6 (m, 1H), 5.25 (s, 1H), 7.45 (d, 2H), 7.75 (d, 2H).

Example 35**Ac-(R)Cha-Pic-Pab x HCl**5 (i) **Ac-(R)Cha-Pic-Pab(Z)**

Acetyl chloride 0.06 g (0.8 mmol) was added to a mixture of 0.37 g (0.68 mmol) H-(R)Cha-Pic-Pab(Z) (See Example 25) and 0.19 g (1.35 mmol) K_2CO_3 in 10 ml CH_3CN at room 10 temperature. After stirring for an additional 30 minutes at room temperature the solvent was removed in vacuo. The residue was dissolved in CH_2Cl_2 and washed with water. Evaporation and flash chromatography using a stepwise gradient of $CH_2Cl_2/ MeOH$ (99.9/0.1, 99.8/0.2, 99.6/0.4, 15 99.2/0.8 and 98.4/1.6) gave 0.24 g (60%) of the product.

(ii) **Ac-(R)Cha-Pic-Pab x HCl**

Ac-(R)Cha-Pic-Pab(Z) was hydrogenated over 5 % Pd/C at 20 atmospheric pressure. After filtration of the catalyst and evaporation of the solvent the crude material was subjected to purification by RPLC using $CH_3CN/0.1\text{ M }NH_4OAc$ (35/65) as eluent. Removal of the solvent and excess NH_4OAc followed by freeze drying from 1M HCl gave the 25 title compound.

1H -NMR (300 MHz, CD_3OD): δ 0.85-1.1 (m, 2H), 1.15-2.0 (m, 19H), 2.35-2.47 (m, 1H), 3.2-3.33 (m, 1H), 3.95-4.05 (m, 1H), 4.46, 4.57 (ABX, 2H), 5.16-5.22 (m, 1H), 7.51 (d, 2H), 7.76 (d, 2H), 8.23 (m, 1H). The signal of one of the protons is totally obscured by the solvent-signal.

^{13}C -NMR (75 MHz, CD_3OD): amidine and carbonyl carbons: δ 168.3, 172.5, 173.8, 175.1

35

MS m/z 456 ($M^+ + 1$)

Example 36

Me-SO₂-(R)Cha-Pic-Pab x HCl

5 (i) Me-SO₂-(R)Cha-Pic-Pab(Z)

A solution of 48 mg (0.42 mmol) methanesulfonyl chloride in 0.5 ml methylene chloride was added at 0°C to a stirred solution of 209 mg (0.382 mmol) H-(R)Cha-Pic-10 Pab(Z) (See Example 25) and 0.11 ml (0.763 mmol) triethyl amine in 5 ml of methylene chloride. The reaction mixture was allowed to reach room temperature over night. Washing with water followed by drying (Na₂SO₄) and evaporation of the solvent in vacuo gave a residue which was subjected 15 to flash chromatography using ethyl acetate/methanol (95/5) as eluent to give 159 mg (67%) of the product.

(ii) Me-SO₂-(R)Cha-Pic-Pab x HCl

20 150 mg (0.24 mmol) Me-SO₂-(R)Cha-Pic-Pab(z) dissolved in 5 ml 95% ethanol and 1 ml water was hydrogenated in the presence of 5% Pd/C for 4 h. Removal of the catalyst by filtration, addition of 0.2 ml 1M hydrochloric acid and evaporation of the solvent in vacuo gave a residue which 25 was dissolved in 2 ml water and freeze dried to give 116 mg (86%) of the product.

30 ¹H-NMR (500 MHz, CD₃OD): δ 0.90-1.10 (m, 2H), 1.15-1.85 (m, 15H), 1.90 (bd, 1H), 2.30 (bd, 1H), 2.85 (s, 3H), 3.35 (dt, 1H), 3.90 (bd, 1H), 4.45 (AB-system, 2H) 4.50-4.55 (m, 1H), 5.13 (dd, 1H), 7.50 (d, 2H), 7.75 (d, 2H).

¹³C-NMR (125 MHz D₂O): amidine and carbonyl carbons: δ 166.8, 173.0 and 174.6.

Example 37

H-(R)Cha-(R,S)betaPic-Pab x 2 HCl

5 (i) Boc-(R)Cha-(R,S)betaPic-Pab(Z)

EDC was added at -18°C to a stirred solution of 1.0 g (2.6 mmol) Boc-(R)Cha-(R,S)betaPic-OH (See preparation of starting materials), 1.28 g (10.5 mmol) DMAP, 0.74 g (2.6 mmol) H-Pab-(Z) (See preparation of starting materials) in 35 ml DMF. The reaction mixture was allowed to reach room temperature over night and the solvent was subsequently removed in vacuo. The residue was dissolved in CH₂Cl₂ and the organic layer was washed successively with 0.3M KHSO₄, 10 KHCO₃-solution and brine. Drying (Na₂SO₄) and removal of the solvent gave a residue which was subjected to flash chromatography using heptane:ethyl acetate with 4% 15 methanol as eluent to yield 0.74 g (44%) of the desired product.

20 (ii) H-(R)Cha-(R,S)betaPic-Pab(Z)

0.68 g (1.05 mmol) Boc-(R)Cha-(R,S)betaPic-Pab(Z) was dissolved in ethyl acetate saturated with HCl(g). The 25 solution was stirred for 1 h at room temperature. Water was added and the mixture was made alkaline with K₂CO₃. The water phase was extracted with ethyl acetate. The organic phase was then washed with water and dried (Na₂SO₄). Evaporation gave 0.5 g (87%) of the desired 30 product.

(iii) H-(R)Cha-(R,S)betaPic-Pab x 2 HCl

65 mg (0.19 mmol) H-(R)Cha-betaPic(R,S)-Pab(Z) was 35 dissolved in 7 ml ethanol and hydrogenated in presence of 5% Pd/C for 4 hours. Removal of the catalyst by filtration, evaporation of the solvent and freeze drying

from 1M HCl and water gave 41 mg (71%) of the product.

5 ^1H NMR (300 MHz, D_2O , 2 diastereomers 4/5, and rotamers);
δ 0.8-2.16 (m,), 2.5-2.77 (m, 3H), 3.13-3.43 (m, 3H),
3.68-3.94 (m, 1H), 4.18-4.41 (m, 1H), 4.41-4.52 (m, 3H),
7.46-7.57 (m, 2H), 7.72-7.83 (m, 2H).

Example 38

10 HOOC-CH₂-CH₂-(R)Cha-(R,S)betaPic-Pab × 2 HCl

(i) BnOOC-CH₂-CH₂-(R)Cha-(R,S)betaPic-Pab(Z)

15 0.21 g (0.38 mmol) H-(R)Cha-(R,S)betaPic-Pab(Z) (See Example 37) was dissolved in 2 ml ethanol. 0.68 g (0.42 mmol) benzyl acrylate was added and the solution was stirred for 5 days. Evaporation and flash chromatography with CH_2Cl_2 /MeOH (95/5) as eluent gave 0.19 g (70%) of the desired product.

20

(ii) HOOC-CH₂-CH₂-(R)Cha-(R,S)betaPic-Pab × 2 HCl

25 170 mg (0.24 mmol) BnOOC-CH₂-CH₂-(R)Cha-(R,S)betaPic-Pab(Z) was dissolved in 10 ml ethanol and hydrogenated in presence of 5% Pd/C for 4 hours. Removal of the catalyst by filtration, evaporation of the solvent and freeze drying from 1M HCl and water gave 103 mg (77%) of the product.

30 ^1H NMR (300 MHz, D_2O , mixture of 2 diastereomers 4/5 and rotamers); δ 0.92-2.03 (m, H), 2.51-2.78 (m, 1H), 3.21-3.52 (m, 1H), 3.88-4.01 (m, 1H), 4.07-4.3 (m, 2H), 4.4-4.71 (m, 2H), 7.59 (d, 2H), 7.86 (d, 2H)

35 ^{13}C NMR (300.13 MHz, D_2O , mixture of 2 diastereomers 4/5 and rotamers): amidine and carbonyl carbons: δ 167.0, 168.0, 168.1, 175.9, 176.0, 176.3, 176.4 and 178.2.

Example 39

HOOC-CH₂- (R) Cha-Val-Pab x 2 HCl

5 (i) Boc-(R) Cha-Val-Pab(Z)

1.77 g (9.2 mmol) EDC was added at -12°C to a mixture of 3.41 g (9.2 mmol) Boc-(R) Cha-Val-OH (See preparation of starting materials), 2.61 g (9.2 mmol) H-Pab(Z) (See 10 preparation of starting materials), and 4.5 g (36.8 mmol) DMAP in 50 ml DMF. The reaction mixture was allowed to reach room temperature over night and workup by dilution with water was followed by extraction with toluene, ether and ethyl acetate. Subsequent drying ($MgSO_4$) of the 15 combined organic extracts, removal of the solvent in vacuo and flash chromatography using $CH_2Cl_2/MeOH$ as eluent gave 2.77 g (47%) of the desired product.

(ii) H-(R) Cha-Val-Pab(Z)

20 Hydrogen chloride was bubbled through a solution of 2.77 g (4.4 mmol) Boc-(R) Cha-Val-Pab(Z) in 75 ml ethyl acetate. After 15 minutes sodium carbonate solution was added to pH 10 and the aqueous phase was extracted with 25 ethyl acetate. Drying (potassium carbonate) and removal of the solvent in vacuo gave 1.8 g (77%) of H-(R) Cha-Val-Pab(Z).

(iii) BnOOC-CH₂- (R) Cha-Val-Pab(Z)

30 A mixture of 326 mg (0.61 mmol) H-(R) Cha-Val-Pab(Z), 105 ml (0.67 mmol) benzyl bromoacetate, and 252 mg (1.83 mmol) potassium carbonate in 2 ml acetonitrile was sonicated for 2.5 h at 40°C. More acetonitrile was added, 35 in order to dissolve the product, and the mixture was filtered and the solvent was removed in vacuo. The residue was purified by flash chromatography using

methanol/methylene chloride as eluent. The product was finally crystallised from ethyl acetate to give 124 mg (30%) of colourless crystals.

5 (iv) HOOC-CH₂-(R)Cha-Val-Pab x 2 HCl

124 mg (0.18 mmol) BnOOC-CH₂-(R)Cha-Val-Pab(Z) in 20 ml ethanol was hydrogenated for 2 hours in the presence of 25 mg 10% Pd/C. 10 ml of THF was added and the hydrogenation was continued for another 2 hours at 50°C. The mixture was filtered through hyflo and the filtercake was washed with dilute hydrochloric acid. The organic solvents were removed from the combined filtrates in vacuo. Freeze drying of the remaining solution yielded 55 mg (50%) of the desired compound.

20 ¹H-NMR (500 MHz, D₂O); δ 0.75-1.4 (m, 12H), 1.5-1.9 (m, 7H), 2.0-2.15 (bs, 1H), 3.45 (AB-system, 2H), 4.1 (m, 2H), 4.5 (m, 2H), 7.5 (s, 2H), 7.7 (s, 2H), 8.9 (s, 1H).

Example 40

HOOC-CH₂-CH₂-(R)Cha-Val-Pab x 2 HCl

25 (i) H-(R)Cha-(R,S)Val-Pab(Z)

The title compound was prepared by coupling Boc-(R)Cha-Val-OH with H-Pab(Z), using the pivaloyl coupling as described for Boc-(R)Cha-Pic-OMe (See preparation of starting materials). A total epimerization of the valine occurred to give Boc-(R)Cha-(R,S)Val-Pab(Z). The Boc protecting group was removed in the same way as described for Boc-(R)Cha-Val-Pab(Z) (See Example 39) to give the title compound.

35

(ii) BnOOC-CH₂-CH₂-(R)Cha-(R,S)Val-Pab(Z)

A solution of 1.007 g (1.9 mmol) H-(R)Cha-(R,S)Val-Pab(Z) and 308 mg (1.9 mmol) benzyl acrylate in 3 ml of ethanol was kept at 40°C over night. The solvent was removed in vacuo and the residue was purified by flash chromatography using methanol/methylene chloride (10/90) as eluent to give 1.086 g (82%) of the title compound.

(iii) HOOC-CH₂-CH₂-(R)Cha-Val-Pab x 2 HCl

10 1.086 g (1.6 mmol) BnOOC-CH₂-CH₂-(R)Cha-(R,S)Val-Pab(Z) was hydrogenated in 25 ml THF and 14 ml 0.5 M hydrochloric acid in the presence of 223 mg 10% Pd/C for 2 hours. Removal of the catalyst by filtration through celite and removal of the THF in vacuo followed by freeze drying of the remaining aqueous solution gave a residue of which approximately 300 mg was subjected to HPLC using 25% acetonitrile in 0.1 M Ammonium acetate buffer as eluent. Two main fractions were isolated, of which the second fraction contained the title compound. 67 mg of 15 title compound, as the dihydrochloride, was isolated.

20 ¹H-NMR (500 MHz, D₂O); δ 1.0-1.15 (m, 12H), 1.2-1.4 (m, 7H), 1.65-1.9 (m, 7H), 2.15-2.25 (m, 1H), 2.85 (t, 2H), 3.15-3.2 (m, 1H), 3.3-3.35 (m, 1H), 4.15-4.2 (m, 1H), 25 4.25 (d, 1H), 4.55-4.65 (AB-system, 2H), 7.65 (d, 2H), 7.85 (d, 2H).

30 ¹³C-NMR (75 MHz, D₂O): amidine and carbonyl carbons: δ 167.0, 169.8, 173.96 and 174.04.

Example 41

H-(R)Hoc-Aze-Pab x 2 HCl

35 (i) Boc-(R)Hoc-Aze-Pab(Z)

Prepared in the same way as described for Boc-(R)Cha-Pic-

Pab(Z) (See Example 25) by replacing Boc-(R)Cha-Pic-OH with Boc-(R)Hoc-Aze-OH (See preparation of starting materials). The crude product was subjected to flash chromatography (Toluene/EtOAc 1/6) to give 0.32 g (37%) of the desired product.

5
5 (ii) H-(R)Hoc-Aze-Pab(Z)

10 Boc-(R)Hoc-Aze-Pab(Z) was treated in the same way as described for Boc-(R)Cha-Pic-Pab(Z) in Example 25 to give 0.23 g (88%) of the title compound.

15 (iii) H-(R)Hoc-Aze-Pab x 2 HCl

20 20 mg (0.037 mmol) of H-(R)Hoc-Aze-Pab(Z) was dissolved in 3 ml ethanol and hydrogenated in presence of 5% Pd/C for 4 hours at atmospheric pressure. Removal of the catalyst by filtration, evaporation of the solvent and freeze drying from 1M HCl gave 11 mg (63%) of the product.

25 ¹H NMR (300.13 MHz, D₂O, mixture of two rotamers 3:1): major rotamer: δ 0.9-2.1 (m, 15H), 2.4-2.6 (m, 1H), 2.7-3.0 (m, 1H), 4.1-4.3 (m, 1H), 4.35-4.56 (m, 1H), 4.65 (s, 2H), 5.0-5.11 (m, 1H), 7.62 (d, 2H), 7.9 (d, 2H). The signal of one of the protons is totally obscured by the H-O-D-signal.

30 Example 42

HOOC-CH₂-CH₂-(R)Hoc-Aze-Pab x 2 TFA

35 (i) BnOOC-CH₂-CH₂-(R)Hoc-Aze-Pab(Z)

0.067 g (0.41 mmol) benzylacrylate was added to a solution of 0.2 g (0.37 mmol) H-(R)Hoc-Aze-Pab(Z) (See Example 41) in 2 ml ethanol (95%) at room temperature.

The reaction was left at room temperature for 5 days. The solvent was removed in vacuo and the residue was purified with flash chromatography (CH_2Cl_2 : MeOH, 96/4) to give 0.16 g (62%) of the desired product.

5

(ii) $\text{HOOC}-\text{CH}_2-\text{CH}_2-(\text{R})\text{Hoc-Aze-Pab} \times 2 \text{TFA}$

160 mg (0.23 mmol) $\text{BnOOC}-\text{CH}_2-\text{CH}_2-(\text{R})\text{Hoc-Aze-Pab}(Z)$ was dissolved in 10 ml ethanol and subjected to 10 hydrogenation at atmospheric pressure in presence of 5% Pd on charcoal for 3 hours. Removal of the catalyst by filtration evaporation of the solvent and freeze drying from water and TFA gave 120 mg (87%) of the product.


15 ^1H NMR (300.13 MHz, D_2O 2 rotamers 3:1); major rotamer: δ 0.9-1.9 (m, 13H), 1.94-2.16 (m, 2H), 2.38-2.55 (m, 1H), 2.7-2.97 (m, 3H), 3.2-3.44 (m, 2H), 4.16 (m, 1H), 4.35-4.58 (m, 2H), 4.65 (s, 2H), 5.0-5.12 (m, 1H), 7.63 (d, 2H), 7.87 (d, 2H)

20

^{13}C NMR (300.13 MHz, D_2O): amidine and carbonyl carbons: δ 167.3, 168.7, 172.5 and 176.6.

Example 43

25

(i) $\text{Boc}-(\text{R})\text{Hoc-Pro-Pab}(Z)$

30 Prepared from $\text{Boc}-(\text{R})\text{Hoc-Pro-OH}$ (See preparation of starting materials) in the same way as described for $\text{Boc}-(\text{R})\text{Cha-Pic-Pab}(Z)$ in Example 25. Flash chromatography using ethyl acetate as eluent gave 0.886 g (58 %) of the title compound.

35

$^1\text{H-NMR}$. (300 MHz, CDCl_3); δ 0.7-0.95 (m, 2H), 0.95-2.1 (m, 27H (thereof 1.2 (s, 9H)), 2.1-2.4 (m, 1H), 3.3-3.5 (m,

1H), 3.65-3.95 (m, 1H), 4.0-4.2 (m, 1H), 4.2-4.45 (m, 2H), 4.45-4.6 (d, 1H), 5.15 (apparent bs, 2H), 5.2-5.3 (d, 1H), 7.1-7.4 (m, 7H), 7.65 (m, 1H), 7.7-7.8 (d, 2H), 9.4 (bs, 1H).

5

¹³C-NMR (75 MHz, CDCl₃): amidine and carbonyl carbons: δ 156.3, 164.6, 168.1, 171.4 and 172.4.

10 (ii) H-(R)Hoc-Pro-Pab(Z)

40 ml ethyl acetate saturated with hydrogen chloride was added to 0.82 g (1.266 mmol) Boc-(R)Hoc-Pro-Pab(Z) at 0°C. The temperature was allowed to rise to room-
15 temperature. The reaction was not completed after 1.5 h and therefore hydrogen chloride was bubbled through the reaction mixture during 5 minutes. The solvent was evaporated and ethyl acetate and saturated sodium carbonate was added and the phases were separated. The
20 organic phase was washed with brine and dried (Na₂SO₄) and the solvent evaporated in vacuo to give the title compound in almost quantitative yield.

25 ¹H-NMR (300 MHz, CDCl₃): δ 0.75-0.95 (m, 2H), 0.95-2.4 (m, 17H), 3.3-3.55 (m, 2H), 3.55-3.7 (m, 1H), 4.25-4.45 (m, 2H), 4.5-4.6 (m, 1H), 5.15 (s, 2H), 7.15-7.35 (m, 5H), 7.35-7.45 (m, 2H), 7.6-7.7 (m, 1H), 7.7-7.85 (d, 2H).

30 ¹³C-NMR (75 MHz, CDCl₃): amidine and carbonyl carbons: δ 164.5, 167.8, 171.4 and 175.3.

(iii) BnOOC-CH₂-(R,S)CH(COOBn)-(R)Hoc-Pro-Pab(Z)

35 To 0.15 g (0.5 mmol) benzyl acrylate in 1.5 ml EtoH (99%) was added 0.273 g (0.498 mmol) H-(R)Hoc-Pro-Pab(Z) and the mixture was stirred at room temperature for 10 days.

The solvent was removed in vacuo and the residue was subjected to flash chr matography, using ethyl acetate as eluent to give 0.103 g (25 %) of BnOOC-CH₂-(R,S)CH(COOBn)-(R)Hoc-Pro-Pab(Z).

5

¹H-NMR (300 MHz, CDCl₃): δ 0.75-2.05 (m, 18H), 2.3-2.45 (m, 1H), 2.45-2.8 (m, 3H), 3.15-3.45 (m, 3H), 3.5-3.65 (m, 1H), 4.3-4.5 (m, 2H), 4.55-4.7 (m, 1H), 4.8 (s, 1H), 4.9-5.1 (m, 3H), 5.2 (s, 2H), 7.1-7.2 (m, 1H), 7.2-7.4 (m, 13H), 7.4-7.45 (d, 2H), 7.6-7.8 (m, 3H).

10

(iv) HOOC-CH₂-(R,S)CH(COOH)-(R)Hoc-Pro-Pab × 2 HCl

15

103 mg (0.122 mmol) BnOOC-CH₂-(R,S)CH(COOBn)-(R)Hoc-Pro-Pab(Z) dissolved in 4 ml ethanol (99.5 %) and 0.3 ml chloroform was hydrogenated in the presence of 111 mg 5 % Pd/C for 2 h. Removal of the catalyst by filtration and evaporation of the solvent followed by dissolving in water and freeze drying showed incomplete hydrogenation. The hydrogenation was continued in the presence of ethanol, 1 N HCl and 5 % Pd/C for 5 hours.

20

Removal of the catalyst by filtration and evaporation of the solvent followed by dissolving in water and freeze drying gave the title compound.

25

¹H-NMR (500 MHz, CD₃OD, mixture of two diastereomers); δ 0.8-1.0 (m, 2H), 1.1-1.4 (m, 6H), 1.6-1.8 (m, 5H), 1.9-2.15 (m, 5H) 2.25-2.35 (m, 1H), 2.9-3.2 (m, 2H), 3.5-3.65 (m, 1H), 3.7-3.9 (2m, total 1H), 4.15-4.4 (2m, total 1H), 4.4-4.6 (m, 4H), 7.5-7.6 (m, 2H), 7.7-7.85 (m, 2H).

30

¹³C-NMR (75 MHz, CDCl₃): amidine and carbonyl carbons: δ 167.9, 168.2, 168.3, 172.8, 173.6, 174.3 and 174.4. The signals from the two diastereomers are partly overlapping.

Example 44

5 (i) Boc-(R)Hoc-Pic-Pab(Z)

Prepared from Boc-(R)Hoc-Pic-OH (See preparation of starting materials) and H-Pab(Z) (See preparation of starting materials) in the same way as described for Boc-(R)Cha-Pic-Pab(Z) (See Example 25). Flash chromatography using ethyl acetate as eluent gave 1.3 g (78 %) of the title compound.

15 $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.75-0.95 (m, 2H), 0.95-2.0 (m, 31H (thereof 1.3 (s, 9H)), 2.4-2.5 (m, 1H), 3.0-3.1 (m, 1H), 3.8 (m, 1H), 4.2-4.45 (m, 2H), 4.45-4.55 (m, 2H), 5.15 (apparent bs, 3H), 5.25-5.3 (m, 1H), 7.0 (bs, 1H), 7.15-7.5 (m, 7H), 7.7-7.85 (d, 2H), 9.45 (bs, 1H).

20 $^{13}\text{C-NMR}$ (75 MHz, CDCl_3): amidine and carbonyl carbons: δ 156.6, 164.7, 168.1, 170.0 and 173.0.

(ii) H-(R)Hoc-Pic-Pab(Z)

25 100 ml ethyl acetate saturated with hydrogen chloride was added to 1.3 g (1.96 mmol) Boc-(R)Hoc-Pic-Pab(Z) at 0°C. The temperature was allowed to rise to room-temperature. The solvent was evaporated after 40 minutes and ethyl acetate and saturated sodium carbonate was added and the 30 phases were separated. The organic phase was washed with brine and dried (Na_2SO_4) and the solvent evaporated in vacuo to give 0.85 g (77.5 %) of the product.

35 $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.75-0.95 (m, 2H), 1.05-2.3 (m, 25H), 3.0-3.15 (m, 1H), 3.6-3.75 (m, 2H), 4.25-4.4 (m, 2H), 5.15 (apparent bs, 3H), 7.05-7.2 (d, 2H), 7.2-7.35 (m, 4H), 7.35-7.4 (d, 1H), 7.6-7.8 (d, 2H).

^{13}C -NMR (75 MHz, CDCl_3): amidine and carbonyl carbons: δ 164.5, 167.9, 170.8 and 175.7.

5 (iii) $\text{BnOOC-CH}_2\text{-(R)Hoc-Pic-Pab(Z)}$

0.171 g (0.748 mmol) benzyl bromoacetate was added to a mixture of 0.4 g (0.712 mmol) H-(R)Hoc-Pic-Pab(Z) and 0.217 g (1.57 mmol) K_2CO_3 in 7 ml acetonitrile. The 10 mixture was heated to 60°C in oilbath for 1 h. The solvent was removed and ethyl acetate and water was added. The phases were separated and the organic phase was washed with brine and dried (Na_2SO_4). Evaporation in vacuo gave 0.626 g of a residue which was subjected to 15 flash chromatography using ethyl acetate as eluent, to give 2 products. The first compound eluated from the column was $(\text{BnOOC-CH}_2)_2\text{(R)Hoc-Pic-Pab(Z)}$ (0.28 g) and the second compound eluated was the title compund (0.27 g).

20 $\text{BnOOC-CH}_2\text{-(R)Hoc-Pic-Pab(Z)}:$

$^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.7-0.95 (m, 2H), 1.0-1.75 (m, 18H), 2.3-2.5 (m, 1 or 2H), 2.9-3.05 (m, 1H), 3.2-3.3 (m, 1H), 3.35-3.5 (m, 2H), 3.6-3.7 (m, 1H), 4.35, 4.55 (ABX-system, 2H), 4.75 (s, 2H), 5.15 (apparent s, 3H), 5.25-5.3 (m, 1H), 7.1-7.45 (m, 12H), 7.7-7.8 (d, 2H).

$^{13}\text{C-NMR}$ (75 MHz, CDCl_3): amidine and carbonyl carbons: δ 164.6, 167.9, 170.5, 173.4 and 175.0.

30

(iv) $\text{HOOC-CH}_2\text{-(R)Hoc-Pic-Pab} \times 2 \text{ HCl}$

259 mg (0.365 mmol) $\text{BnOOC-CH}_2\text{-(R)Hoc-Pic-Pab(Z)}$ dissolved in 7.8 ml ethanol (99.5 %) and 1.2 ml hydrogen chloride (1 N) was hydrogenated in the presence of 280 mg 5 % Pd/C for 4 h. Removal of the catalyst by filtration and evaporation of the solvent followed by dissolving in

water and freeze drying gave 170 mg (83 %) of the title compound.

5 ¹H-NMR (300 MHz, CDCl₃): δ 0.4-1.85 (m, 20H), 1.85-2.2 (m, 1H), 2.9-3.2 (m, 1H), 3.4-3.9 (m, 3H), 4.05-4.3 (m, 2H), 4.3-5.05 (m, 2H), 7.1-7.4 (m, 2H), 7.4-7.7 (m, 2H).

10 ¹³C-NMR (75 MHz, CDCl₃): amidine and carbonyl carbons: δ 167.8, 168.6, 169.6 and 172.3.

10

Example 45



15 (i) (BnOOC-CH₂)₂(R)Hoc-Pic-Pab(Z)

The title compound was obtained in the alkylation of H-(R)Hoc-Pic-Pab(Z) as described in Example 44 above.

20 ¹H-NMR (300 MHz, CDCl₃): δ 0.7-0.95 (m, 2H), 0.95-1.95 (m, 18H), 2.35-2.5 (m, 1H), 2.9-3.05 (m, 1H), 3.5-3.85 (m, 6H), 4.35-4.55 (m, 2H), 4.9 (2s, 4H), 5.2 (s, 2H), 5.25-5.35 (m, 1H), 7.1-7.45 (m, 16H), 7.5-7.65 (m, 1H), 7.7-7.85 (d, 2H).

25

13C-NMR (75 MHz, CDCl₃): amidine and carbonyl carbons: δ 164.7, 167.9, 170.5, 172.0 and 172.4.

(ii) (HOOC-CH₂)₂-(R)Hoc-Pic-Pab × 2 HCl

30

153 mg (0.178 mmol) (BnOOC-CH₂)₂-(R)Hoc-Pic-Pab(Z) dissolved in 4.5 ml ethanol (99.5 %) and 0.5 ml hydrogen chloride (1 N) was hydrogenated in the presence of 150 mg 5 % Pd/C for 3.5 h. Removal of the catalyst by filtration and evaporation of the solvent followed by dissolving in water and freeze drying gave 109 mg (99 %) of (HOOC-CH₂)₂-(R)Hoc-Pic-Pab dihydrochloride. This crude material

(80 % purity) was subjected to purification by RPLC using CH₃CN/0.1 M NH₄OAc, 1:4 as eluent. Removal of the solvent and excess NH₄OAc followed by freeze drying from 1 M HCl gave the title compound.

5

¹H-NMR (500 MHz, D₂O, mixture of two rotamers): major rotamer: δ 0.95-2.15 (m, 20H), 2.25-2.35 (m, 1H), 3.45-3.55 (m, 1H), 3.95-4.25 (m, 5H), 4.6-4.65 (m, 2H), 4.92-5.01 (m, 1H) 5.15-5.20 (m, 1H), 7.58-7.63 (d, 2H), 7.84-10 7.89 (d, 2H).

10

Resolved signals arising from the minor rotamer appears at: δ 0.7-0.85 (m), 2.35-3.45 (m), 3.05-3.15 (m), 4.47-4.55 (m), 4.55-4.6 (m), 4.65-4.7 (m), 7.63-7.67 (d), 15 7.89-7.95 (d).

¹³C-NMR (75 MHz, D₂O): amidine and carbonyl carbons: δ 168.20, 169.70, 170.20 and 172.71.

20

Example 46



(i) Boc-(R)Pro(3-(S)Ph)-Pro-Pab(Z)

25

To a solution of 570 mg (1.5 mmol) Boc-(R)Pro(3-(S)Ph)-Pro-OH (See preparation of starting materials), 425 mg (1.5 mmol) H-Pab(Z) (See preparation of starting materials) and 733 mg (6 mmol) DMAP in 25 ml CH₃CN/DMF (1.5/1) was added 310 mg (1.62 mmol) EDC and the mixture was stirred for 23 h at room temperature. Most of the solvent was evaporated and 50 ml water was added to the residue. The water phase was extracted with 1 x 75 and 2 x 50 ml EtOAc. The combined organic phase was washed with 30 1 x 20 + 1 x 10 ml 1M KHSO₄, 1 x 15 ml NaHCO₃ (aq), 3 x 15 ml water, 1 x 15 ml brine and dried (MgSO₄). Filtration and evaporation of the solvent gave 670 mg of an oil

35

which was purified by flash chromatography using EtOAc as eluent which gave 529 mg (55 %) of the title compound.

5 $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 1.26 (s, 9H), 1.53-1.88 (m, 3H), 2.1-2.31 (m, 3H), 2.52 (q, 1H), 3.58-3.77 (m, 4H), 4.31 (d, 1H), 4.35 and 4.47 (ABX-system, 2H), 4.65 (dd, 1H), 5.19 (s, 2H), 7.1-7.37 (m, 10H), 7.42 (d, 2H), 7.81 (d, 2H), 8.0 (t, 1H (NH)).

10 $^{13}\text{C-NMR}$ (75 MHz, CDCl_3): amidine and carbonyl carbons: δ 154.6, 164.6, 168.1, 171.1 and 171.3.

(ii) $\text{H-(R)Pro(3-(S)Ph)-Pro-Pab(Z)}$

15 529 mg (0.81 mmol) of Boc-(R)Pro(3-(S)Ph)-Pro-Pab(Z) was dissolved in 15 ml EtOAc/HCl(g,saturated) at room temperature and stirred for 3 h. The solvent was evaporated and the residue was dissolved in 70 ml CH_2Cl_2 . the organic phase was washed with 1 x 10 ml 2 M NaOH, 1
20 x 10 ml water, 1 x 10 ml brine and dried (MgSO_4). Filtration and evaporation of the solvent gave 403 mg (90 %) of the title compound as a white powder.

25 $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 1.44-1.57 (m, 1H), 1.62-1.86 (m, 2H), 1.96-2.35 (m, 3H), 2.45 (q, 1H), 3.05-3.35 (m, 4H), 3.83 (bd, 1H), 4.25-4.45 (m, 2H), 4.53 (m, 1H), 5.19 (s, 2H), 7.16-7.37 (m, 10H), 7.42 (d, 2H), 7.66 (t, 1H, (NH)), 7.77 (d, 2H).

30 $^{13}\text{C-NMR}$ (75 MHz, CDCl_3): amidine and carbonyl carbons: δ 164.4, 167.9, 171.1 and 173.0.

(iii) $\text{BnOOCH}_2-(\text{R})\text{Pro(3-(S)Ph)-Pro-Pab(Z)}$

35 A mixture of 200 mg (0.36 mmol) $\text{H-(R)Pro(3-(S)Ph)-Pro-Pab(Z)}$, 105 mg (0.46 mmol) $\text{Br-CH}_2\text{-COOBn}$ and 125 mg (0.90 mmol) K_2CO_3 in 10 ml CH_3CN was heated to 50°C for 1 h and

30 minutes. The solvent was evaporated and the residue was dissolved in 70 ml EtOAc. The organic phase was washed with 10 ml water and dried ($MgSO_4$). Filtration and evaporation of the solvent gave 260 mg of an oil. The crude material was purified by flash chromatography using a stepwise gradient of $CH_2Cl_2/MeOH(NH_3\text{-saturated})$ (95/5 followed by 9/1) to give 182 mg (72 %) of the title compound as a white solid.

10 1H -NMR (300 MHz, $CDCl_3$): δ 1.43-1.82 (m, 3H), 1.96-2.13 (m, 1H), 2.14-2.22 (m, 1H), 2.26-2.43 (m, 2H), 3.02-3.14 (m, 2H), 3.24-3.51 (m, 4H), 3.83 (d, 1H), 4.29-4.46 (ABX-system centered at 4.37, 2H), 4.58 (dd, 1H), 4.97-5.1 (AB-system centered at 5.03, 2H), 5.19 (s, 2H), 7.16-7.38 (m, 15H), 7.43 (d, 2H), 7.5-7.8 (m, 3H, one NH).

15 ^{13}C -NMR (75 MHz, $CDCl_3$): amidine and carbonyl carbons: δ 164.5, 167.9, 171.15, 171.2 and 172.7.

20 (iv) $HOOC-CH_2-(R)Pro(3-(S)Ph)-Pro-Pab \times 2 HCl$

25 0.18 g (0.26 mmole) of $BnOOC-CH_2-(R)Pro(3-(S)Ph)-Pro-Pab(2)$ was mixed with 0.075 g 5 % Pd/C, 1.0 ml 1N HCl-solution, 1 ml water and 10 ml ethanol and the mixture was hydrogenated at atmospheric pressure for one hour. Filtration of the catalyst through hyflo, evaporation of the solvent followed by freeze drying twice from water gave 129 mg of a crude product . The crude product was purified by RPLC using a stepwise gradient of 0.1 M NH_4OAc/CH_3CN 4/1 followed by 3/1. Evaporation followed by freeze drying from water and 1N HCl-solution gave 70 mg (50%) of the pure product.

30 1H -NMR (300 MHz, D_2O): δ 1.42-1.60 (m, 1H), 1.65-1.83 (m, 1H), 1.83-1.98 (m, 1H), 2.03-2.20 (m, 2H), 2.63 (t, 2H), 3.28-3.40 (m, 1H), 3.55-3.78 (m, 2H), 3.81-3.96 (AB-system central at δ 3.88, 2 H), 4.06-4.19 (m, 1H), 4.37-

4.61 (AB-system central at δ 4.49, 2 H), 4.48 (dd, 1H),
 4.70 (d, 1H), 7.35-7.58 (m, 7H), 7.74 (d, 2H)

¹³C-NMR (75 MHz, CDCl₃): amidine and carbonyl carbons: δ
 5 167.02, 167.2, 169.3 and 174.4.

Example 47

HOOC-CH₂-CH₂-(R)Pro(3-(S)Ph)-Pro-Pab x 2 HCl
 10

(i) BnOOC-CH₂-CH₂-(R)Pro(3-(S)Ph)-Pro-Pab(Z)

To a solution of 190 mg (0.34 mmol) H-(R)Pro(3-(S)Ph)-
 15 Pro-Pab(Z) (See Example 46) in 7 ml EtOH (99%) was added
 114 mg (0.70 mmol) of benzyl acrylate and the reaction
 mixture was stirred at room temperature for 24 h.
 Evaporation of the solvent followed by flash
 chromatography using a stepwise gradient of
 20 CH₂Cl₂/MeOH(NH₃-saturated) (95/5 followed by 9/1) gave 202
 mg (83 %) of the title compound.

¹H-NMR (300 MHz, CDCl₃): δ 1.5-1.71 (m, 2H), 1.74-1.9 (m,
 1H), 1.9-2.05 (m, 1H), 2.2-2.64 (m, 5H), 2.69-2.82 (m,
 2H), 2.84-2.96 (m, 1H), 3.18-3.48 (m, 4H), 4.28-4.44 (m,
 25 2H), 4.61 (m, 1H), 4.48-5.08 (AB-system centered at 5.03,
 2H), 5.19 (s, 2H), 7.15-7.37 (m, 15H), 7.44 (d, 2H),
 7.75-7.85 (m, 3H, one NH).

¹³C-NMR (75 MHz, CDCl₃): amidine and carbonyl carbons: δ
 30 164.6, 168.0, 171.2, 172.5 and 172.9.

(ii) HOOC-CH₂-CH₂-(R)Pro(3-(S)Ph)-Pro-Pab x 2 HCl

35 0.20 g (0.28 mmole) of BnOOC-CH₂-CH₂-(R)Pro(3-(S)Ph)-
 Pro-Pab(Z) was mixed with 0.075 g 5 % Pd/C, 1.0 ml 1N
 HCl-solution, 1 ml water and 10 ml ethanol and the

mixture was hydrogenated at atmospheric pressure for one hour. Filtration of the catalyst through hyflo, evaporation of the solvent followed by freeze drying twice from water gave 125 mg 79 % of the title compound.

5


¹H-NMR (300 MHz, D₂O): δ 1.44 (m, 1H), 1.65-1.9 (m, 2H), 2.0-2.2 (m, 2H), 2.62 (q, 2H), 2.83 (t, 2H), 3.27-3.4 (m, 1H), 3.4-3.8 (m, 4H), 4.0-4.15 (m, 1H), 4.35-4.6 (m, 3H), 4.68 (d, 1H), 7.35-7.6 (m, 7H), 7.77 (d, 2H)

10

¹³C-NMR (75 MHz, CDCl₃): amidine and carbonyl carbons: δ 166.2, 167.1, 174.1 and 174.2.

Example 48

15



(i) Boc-(R)Tic-Pro-Pab(Z)

20

Prepared in the same way as described for Boc-(R)Cha-Pic-Pab(Z) (See Example 25) using Boc-(R)Tic-Pro-OH (See preparation of starting materials) instead of Boc-(R)Cha-Pic-OH. Flash chromatography using heptane/EtOAc (4/1) followed by EtOAc as eluents gave 425 mg (37%) of the title compound.

25

¹H NMR (500 MHz, CDCl₃): δ 1.35 (s, 9H), 1.95-2.15 (m, 3H), 2.4 (m, 1H), 2.8 (m, 1H), 3.3 (m, 1H), 3.55 (m, 2H), 4.25-4.4 (two m, 2H), 4.55-4.7 (two m, 2H), 7.15-7.5 (m, 10H), 7.85 (d, 2H).

30

¹³C-NMR (75.0 MHz, CDCl₃): amidine and carbonyl carbons: δ 164.6, 171.5 and 171.6. (two peaks are probably overlapping)

35

(ii) H-(R)Tic-Pro-Pab(Z)

Boc-(R)Tic-Pro-Pab(Z) (379 mg, 0.59 mmol) was dissolved in EtOAc saturated with HCl(g) and stirred at room temperature. Evaporation of the solvent gave 251 mg (79%) of the title compound as a white powder.

5

¹H NMR (500 MHz, CDCl₃): δ 1.65-2.15 (two m, 7H), 2.45 (m, 1H), 2.75 (m, 1H), 2.9 (m, 1H), 3.0 (m, 1H), 3.25 (m, 1H), 3.55 (m, 1H), 3.85 (m, 1H), 4.35-4.55 (m, 2H), 4.75 (d, 1H), 4.9 (s, 1H), 5.25 (s, 2H), 6.8-7.45 (several m, 10 8H), 7.5 and 7.85 (two d, 4H).

¹³C-NMR (75.0 MHz, CDCl₃): amidine and carbonyl carbons: δ 164.5, 171.3 and 172.7 (two peaks are probably overlapping).

15

(iii) BnO₂C-CH₂-CH₂-(R)Tic-Pro-Pab(Z)

H-(R)Tic-Pro-Pab(Z) (140 mg, 0.26 mmol) was treated with 20 benzyl acrylat (63 mg, 0.39 mmol) in EtOH (1.3 ml) at 20°C during 48 h. Evaporation of the solvent and flash chromatography using (50% EtOAc/Heptan then 10% MeOH/EtOAc) as eluent afforded 133 mg (73%) of the desired product as a white solid material.

25

¹H NMR (500 MHz, CDCl₃): δ 1.75-2.0 (two m, 4H), 2.25 (m, 1H), 1.4-1.65 (m, 3H), 2.7-2.95 (two m, 4H), 3.05-3.2 (m, 2H), 3.9 (m, 1H), 4.45 (m, 2H), 4.65 (m, 1H), 5.1 (two d, 2H), 5.25 (s, 2H), 6.85-7.45 (several m, 12H), 7.5 and 30 7.9 (two d, 4H).

¹³C-NMR (75.0 MHz, CDCl₃): amidine and carbonyl carbons: δ 171.5, 171.9 and 172.1 (two peaks are probably overlapping).

35

(iv) HOOC-CH₂-CH₂-(R)Tic-Pro-Pab x 2 HCl

BnO₂C-CH₂-CH₂-(R)Tic-Pr -Pab(Z) (125 mg, 0.17 mmol) was hyr genated over 5 % Pd/C using EtOH/HCl as solvent. Filtration of the catalyst and freeze drying gave 73 mg (77%) of the title compound as a white powder.

5

¹H NMR (500 MHz, D₂O): δ 2.1-2.35 (two m, 3H), 2.6 (m, 1H), 2.95-3.1 (m, 2H), 3.25-3.5 (two m, 2H), 3.65 (m, 3H), 4.65 (s, 2H), 4.75 (m, 1H), 5.85 (s, 1H), 7.15-7.6 (three m, 4H), 7.6 and 7.85 (two d, 4H).

10

¹³C-NMR (75.0 MHz, D₂O): amidine and carbonyl carbons: δ 166.9, 167.1 and 174.3 (two peaks are probably overlapping).

15

Example 49



(i) Boc-(R)Cgl-Aze-Pig(Z)₂

20

To a mixture of 0.623 g (1.83 mmole) Boc-(R)Cgl-Aze-OH (See preparation of starting materials), 0.816 g (1.92 mmole) H-Pig(Z)₂ (See preparation of starting materials) and 0.89 g (7.3 mmole) DMAP in 10 ml dichloromethane was added 0.368 g (1.92 mmole) of EDC and the mixture was stirred over night. The mixture was diluted and washed with 0.3 M KHSO₄ and once with brine. The organic layer was dried (Na₂SO₄), filtered and evaporated to yield 1.4 g of a crude product. Purification by flash chromatography using ethyl acetate as eluent gave 0.3 g (22%) of the pure product.

(ii) H-(R)Cgl-Aze-Pig(Z)₂

35

0.3 g (0.4 mmole) Boc-(R)Cgl-Aze-Pig(Z)₂ was mixed with 10 ml dichloromethane and 2.5 ml trifluoroacetic acid. The mixture was stirred for one and a half hour. After

evaporation of the solvent the residue was dissolved in dichloromethane and washed twice with 0.2 M NaOH-solution. The combined water layer was extracted one more time with dichloromethane. The combined organic layer was 5 dried (Na_2SO_4), filtered and evaporated to yield 0.24 g (93%) of the product.

10 $^1\text{H-NMR}$ (300 MHz, CDCl_3 , 339K): δ 0.9-1.9 (m, 15H), 1.94 (bd, 1H), 2.37-2.52 (m, 1H), 2.65-2.8 (m, 1H), 2.9-3.08 (m, 3H), 3.20 (t, 2H), 4.05-4.28 (m, 4H), 4.86 (dd, 1H), 5.16 (s, 4H), 7.2-7.42 (m, 10H), 7.98 (bs, NH).

(iii) $\text{BnOOC-CH}_2\text{-CH}_2\text{-(R)Cgl-Aze-Pig(Z)}_2$

15 0.231 g (0.36 mmole) was dissolved in 2 ml ethanol and 61 μl (0.40 mmole) bensylacrylate was added. The reaction mixture was stirred for five days at room temperature. The mixture was evaporated and the crude product purified by flash chromatography using a stepwise gradient of 20 $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (95/5, 90/10) as eluent to yield 0.218 g (75%) of the pure product.

25 $^1\text{H-NMR}$ (300 MHz, CDCl_3 , 335K): δ 0.93 (bq, 1H), 1.02-1.85 (m, 14H), 1.94 (bd, 1H), 2.33-2.5 (m, 3H), 2.58-2.77 (m, 2H), 2.79-3.02 (m, 4H), 3.17 (t, 2H), 4.0-4.25 (m, 4H), 4.86 (dd, 1H), 5.11 (s, 2H), 5.12 (s, 4H), 7.2-7.4 (m, 15H), 8.03 (bs, NH), 10.35 (bs, NH)

30 (iv) $\text{HOOC-CH}_2\text{-CH}_2\text{-(R)Cgl-Aze-Pig} \times 2 \text{ HCl}$

0.218 g (0.27 mmole) of $\text{BnOOC-CH}_2\text{-CH}_2\text{-(R)Cgl-Aze-Pig(Z)}_2$ was mixed with 0.10 g 5 % Pd/C, 1 ml 1M HCl-solution, 1 ml water and 10 ml ethanol and the mixture was 35 hydrogenated at atmospheric pressure for one hour. Filtration of the catalyst through hyflo, evaporation of the solvent followed by freeze drying twice from water


gave 134 mg (95%) of the title compound.

5 $^1\text{H-NMR}$ (300 MHz, D_2O): δ 1.0-1.4 (m, 7H), 1.55-2.05 (m, 9H), 2.22-2.34 (m, 1H), 2.61-2.76 (m, 1H), 2.88 (t, 2H), 3.08 (bt, 2H), 3.19 (d, 2H), 3.34 (m, 2H), 3.83 (bd, 2H), 3.95 (d, 1H), 4.29-4.49 (m, 2H), 4.90 (dd, 1H)

10 $^{13}\text{C-NMR}$ (75 MHz, D_2O): amidine and carbonyl carbons: δ 156.4, 167.6, 172.1 and 174.7

10

Example 50



15

(i) $\text{Boc-(R)Cgl-Pro-Pig(Z)}_2$

20

0.568 g (2.96 mmol) EDC was added at -15°C to a mixture of 1 g (2.82 mmol) Boc-(R)Cgl-Pro-OH (See preparation of starting materials), 1.197 g (2.82 mmol) H-Pig(Z)_2 (See preparation of starting materials) and 1.38 g (11.28 mmol) DMAP in acetonitrile. The temperature was allowed to rise to roomtemperature over night. The solvent was evaporated in vacuo and methylenchloride and 1 M KHSO_4 was added. The phases were separated and the organic phase was washed with saturated NaHCO_3 , water and brine, drying (Na_2SO_4) and evaporation of the solvents gave 2.033 g of a residue which was subjected to flash chromatography using ethylacetate as eluent. This gave two products; 720 mg (34 %) of the title compound which eluted first from the column followed by 775 mg (44 %) of $\text{Boc-(R)Cgl-Pro-Pig(Z)}$ formed by loss of one of the Z-protecting groups.

25

30 $^1\text{H-NMR}$ (300 MHz, CDCl_3); Some signals, especially in the piperidin ring, are selectively broader due to an intramolecular exchange process. This is especially pronounced for the 2- and 6- CH_2 groups of the piperidin ring, which exhibit a broad peak ranging from 3.5 to 4.5

35

ppm.

5 δ 0.85-2.1 (m, 19H), 2.3-2.45 (m, 1H), 2.8-3.2 (m, 4H),
3.45-3.55 (m, 1H), 3.55-3.65 (m, minor rotamer), 3.8-3.93
(m, 1H), 3.97-4.1 (m, 1H), 4.52-4.62 (d, 1H), 5.1
(apparent bs, 5H), 7.12-7.41 (m, 10H).

10 ^{13}C -NMR (75 MHz, CDCl_3): amidine and carbonyl carbons: δ
155.2, 156.3, 171.0 and 172.1.

10

(ii) $\text{H}-(\text{R})\text{Cgl-Pro-Pig(Z)}_2$

15 720 mg (0.946 mmol) of $\text{Boc}-(\text{R})\text{Cgl-Pro-Pig(Z)}_2$ was
dissolved in 35 ml of TFA/ CH_2Cl_2 , 1/4 and stirred for 30
minutes. The solvent was removed in vacuo and
ethylacetate and 2M NaOH was added. The organic layer was
washed with water and brine, dried (Na_2SO_4) and the
solvent was evaporated in vacuo to give the title
compound in quantitative yield.

20

25 ^1H -NMR (300 MHz, CDCl_3): Some signals, especially in the
piperidin ring, are selectively broader due to an
intramolecular exchange process. This is especially
pronounced for the 2- and 6- CH_2 groups of the piperidin
ring, which exhibit a broad peak ranging from 3.5 to 4.5
ppm.

30

6 0.8-2.15 (m, 19H), 2.22-2.4 (m, 1H), 2.75-2.98 (m, 2H),
2.98-3.18 (m, 2H), 3.18-3.35 (m, 1H), 3.35-3.5 (qvart.,
1H), 3.5-3.7 (m, 1H), 4.42-4.58 (d, 1H), 5.1 (s, 4H),
7.1-7.5 (m, 10H).

35 ^{13}C -NMR (75 MHz, CDCl_3): amidine and carbonyl carbons; δ
154.96, 171.31, 174.82.

35

(iii) $\text{BnOOC-CH}_2-(\text{R})\text{Cgl-Pro-Pig(Z)}_2$

0.298 g (0.999 mmol) BnOOC-CH₂-OTf (see preparation of starting materials was added to a mixture of 0.64 g (0.999 mmol) H-(R)Cgl-Pr-Pig(Z)₂ and 0.531 g (2.996 mmol) K₂CO₃ in 6.4 ml acetonitrile and heated to reflux. After 1 h 20 min the mixture was washed with water, dried (Na₂SO₄) and the solvent evaporated in vacuo to give 729 mg of a residue which was subjected to flash chromatography using ethylacetate as eluent. This gave two products: 120 mg of (BnOOC-CH₂)₂-(R)Cgl-Pro-Pig(Z)₂ which eluted first from the column and 142 mg (18 %) of the title compound.

15 ¹H-NMR (300 MHz, CDCl₃); Some signals, especially in the piperidin ring, are selectively broader due to an intramolecular exchange process. This is especially pronounced for the 2- and 6-CH₂ groups of the piperidin ring, which exhibit a broad peak ranging from 3.5 to 4.6 ppm.

20 δ 0.94-2.27 (m, 19H), 2.28-2.43 (m, 1H), 2.8-2.98 (m, 2H), 2.98-3.06 (m, 1H), 3.06-3.15 (d, 1H), 3.15-3.25 (m, 1H), 3.3-3.5 (m, 4H), 4.5-4.61 (d, 1H), 5.1 (s, 6H), 7.1-7.6 (m, 15H), 10.52 (bs, 1H).

25 (iv) HOOC-CH₂-(R)Cgl-Pro-Pig × 2 HCl
142 mg (0.176 mmol) BnOOC-CH₂-(R)Cgl-Pro-Pig(Z)₂ was hydrogenated in the presence of 0.88 ml 1 M hydrochloric acid, 10 ml ethanol (99.5 %) and 180 mg 5 % Pd/C for 2 h. Removal of the catalyst by filtration on hyflo and millipore filter followed by evaporation of the solvent in vacuo and freeze drying gave 95 mg of HOOC-CH₂-(R)Cgl-Pro-Pig × 2 HCl. This crude material (79 % purity) was purified on RPLC using CH₃CN/0.1 M NH₄OAc 15/85 as eluent.

30 Removal of the solvent and excess NH₄OAc by freeze drying, conversion to hydrochloric acid salt by dissolving in 1 M hydrochloric acid followed by freeze drying gave the title compound.

¹H-NMR (500 MHz, D₂O); δ 1.1-1.35 (m, 6H), 1.63-2.14 (m, 13H), 2.26-2.36 (m, 1H), 3.01-3.23 (m, 4H), 3.49-3.62 (qvart., 2H), 3.62-3.77 (m, 2H), 3.77-3.88 (apparent d, 2H), 4.18-4.32 (d, 1H), 4.37-4.5 (m, 1H).

5

Example 51

H-(R)Cha-Aze-Pig × 2 HCl

10 (i) Boc-(R)Cha-Aze-Pig(Z)₂

To a well stirred mixture of 86 mg (0.243 mmol) Boc-(R)Cha-Aze-OH (See preparation of starting materials), 100 mg (0.236 mmol) H-Pig(Z)₂ (See preparation of starting 15 materials) and 115 mg (0.944 mmol) DMAP in 5 ml CH₃CN was added 50 mg (0.260 mmol) EDC and the reaction was stirred for 20 h at room temperature. The solvent was evaporated and the residue was dissolved in 70 ml EtOAc and the organic phase was washed with 3 x 5 ml 1 M KHSO₄, 1 x 5 ml NaHCO₃, 3 x 5 ml H₂O, 1 x 5 ml brine and dried (MgSO₄). Filtration and evaporation of the solvent gave 141 mg of 20 an oil. The crude product was purified by flash chromatography (36 g SiO₂) using a stepwise gradient of CH₂Cl₂/MeOH (97/3 followed by 95/5) to yield 43 mg (24 %) 25 of the title compound.

(ii) H-(R)Cha-Aze-Pig(Z)₂

Hydrogen chloride was bubbled through a mixture of 43 mg 30 (0.0565 mmol) Boc-(R)Cha-Aze-Pig(Z)₂ in 10 ml of ethylacetate during 5 minutes. The solvent was evaporated in vacuo and ethyl acetate and 0.1 M NaOH-solution was added. The phases were separated and the organic phase was washed with water and brine and dried (Na₂SO₄). The 35 solvent was evaporated to give 38 mg, which was subjected to flash chromatography using 10 % NH₃-saturated methanol in ethyl acetate as eluent to give 28 mg of the desired

pr duct.

5 ¹H-NMR (300 MHz, CDCl₃); Some signals, especially in the piperidin ring, are selectively broader due to an intramolecular exchange process. This is especially pronounced for the 2- and 6-CH₂ groups of the piperidin ring, which exhibit a broad peak ranging from 3.7 to 4.5 ppm.

10 δ 0.75-1.85 (m, 18H), 2.35-2.53 (m, 1H), 2.62-2.78 (m, 1H), 2.8-3.0 (m, 2H), 3.0-3.28 (m, 2H), 3.28-3.37 (m, 1H), 3.97-4.18 (m, 2H), 4.8-4.9 (m, 1H), 5.1 (s, 4H), 7.2-7.45 (m, 9H), 8.05-8.15 (m, 1H).


15 (iii) H-(R)Cha-Aze-Pig × 2 HCl

20 28 mg (0.042 mmol) H-(R)Cha-Aze-Pig(Z)₂ dissolved in 2 ml ethanol (99.5 %) and 0.13 ml hydrogen chloride (1 N) was hydrogenated in the presence of 35 mg 5 % Pd/C for 4 h. Removal of the catalyst by filtration and evaporation in vacuo of the solvent followed by dissolving in water and freeze drying gave 12 mg (60 %) of H-(R)Cha-Aze-Pig dihydrochloride.

25 1H-NMR (500 MHz, 300 K, CD₃OD); Some signals, especially in the piperidin ring, are selectively broader due to an intramolecular exchange process. This is especially pronounced for the 2- and 6-CH₂ groups of the piperidin ring, which exhibit a broad peak ranging from 3.7 to 4.5 ppm.

30 δ 0.75-2.1 (m, 18H), 2.2-2.35 (m, 1H), 2.62-2.75 (m, 1H), 3.0-3.12 (t, 2H), 3.12-3.23 (d, 2H), 3.85-3.95 (d, 2H), 3.95-4.0 (dd, 1H), 4.15-4.23 (m, 1H), 4.35-4.42 (m, 1H), 4.72-4.78 (m, 1H).

35 ¹³C-NMR (75 MHz, CD₃OD): guanidine: δ 157.6; carbonyl carbons: δ 170.0 and 172.6.

Example 525 (i) $\text{Boc-(R)Cgl-Aze-Pac(Z)}$

To a solution of 0.47 g (1.4 mmol) of Boc-(R)Cgl-Aze-OH (See preparation of starting materials), 0.40 g (1.4 mmol) of H-Pac(Z) (See preparation of starting materials) 10 and 0.67 g (5.5 mmol) of DMAP in 5 ml of acetonitril was added 0.27 g of EDC at 0°C. The mixture was stirred at room temperature over night and subsequently diluted with ethyl acetate. The solution was washed with KHSO_4 (aq) and NaHCO_3 (aq), dried (Na_2SO_4), filtered and 15 evaporated. Flash chromatography using ethyl acetate followed by ethyl acetate/methanol 98/2 as eluents gave 0.25 g (30%) of the title compound as a mixture of 1,4-cis- and trans-products with respect to the Pac part of the molecule.

20

$^1\text{H-NMR}$ (500 MHz, CDCl_3) : δ 0.8-2.0 (m, 29 H; thereof 1.45 (s, 9 H)), 2.15 and 2.34 (m, 1 H, isomers), 2.45-2.7 (m, 2 H), 3.0-3.4 (m, 2 H), 3.85 (m, 1 H), 4.14 (m, 1 H), 4.33 (m, 1 H), 4.85 (m, 1 H), 4.98 (m, 1 H), 5.04 (s, 2 H), 25 7.25-7.45 (m, 5 H), 7.8-7.9 (m, 1 H), 9.2-9.5 (m, 1 H).

(ii) $\text{H-(R)Cgl-Aze-Pac(Z)} \times \text{HCl}$

$\text{Boc-(R)Cgl-Aze-Pac(Z)}$, 0.25 g (0.41 mmol), was dissolved 30 in 100 ml of ethyl acetate and cooled in an ice bath. HCl (g) was bubbled through for 5 min and the solvent was evaporated.

$^1\text{H-NMR}$ (300 MHz, MeOD) : δ 0.8-2.0 (m, 22 H), 2.05-2.35 (m, 1 H), 2.4-2.55 (m, 1 H), 2.6-2.75 (M, 1 H), 3.00 (d, 1 H), 3.05 and 3.37 (multiplets, 0.6 H and 0.4 H respectively, isomers), 3.15-3.3 (m, 1 H), 4.05-4.2 (m,

2 H), 4.88 (dd, 1 H), 5.11 (s, 2 H), 7.2-7.45 (m, 5 H), 8.0-8.15 (m, 1 H).

5 (iii) $\text{BnO}_2\text{C}-\text{CH}_2-(\text{R})\text{Cgl-Aze-Pac(Z)}$

A mixture of 0.17 g (0.33 mmol) of $\text{H}-(\text{R})\text{Cgl-Aze-Pac(Z)}$ x HCl, 0.11 g (0.37 mmol) of benzyl triflyloxyacetate and 0.14 g (1.0 mmol) of K_2CO_3 in 5 ml of acetonitrile was stirred at room temperature for 3 days. The crude

10 material was flash chromatographed with $\text{EtOAc}/\text{CH}_2\text{Cl}_2/\text{MeOH}$ 95/20/5. Yield: 70 mg (32%).

15 $^1\text{H-NMR}$ (500 MHz, CDCl_3) : δ 0.85-2.3 (m, 20 H), 2.48 (m, 1 H), 2.63 (m, 1 H), 2.87 (m, 1 H), 3.05-3.25 (m, 1 H), 3.25-3.35 (m, 2 H), 3.38 (dd, 1 H), 3.95 (m, 1 H), 4.08 (m, 1 H), 4.88 (m, 1 H), 5.1-5.2 (m, 4 H), 5.9-6.3 (m, 1 H), 7.25-7.5 (m, 10 H), 8.00 and 8.08 (broad triplets, 1 H, isomers).

20 (iv) $\text{HO}_2\text{C}-\text{CH}_2-(\text{R})\text{Cgl-Aze-Pac} \times 2 \text{ HCl}$

BnO₂C-CH₂-(R)Cgl-Aze-Pac(Z), 70 mg (0.11 mmol), was dissolved in 5 ml of ethanol, and 5% Pd/C and 0.1 ml of conc. HCl were added. The mixture was hydrogenated at atmospheric pressure for 1 h. After filtration and evaporation the product was purified through preparative RPLC using 0.1 M $\text{NH}_4\text{OAc}/\text{CH}_3\text{CN}$ 4/1 as eluent. After change of salt to the hydrochloride and freeze drying the title compound was obtained as a 45/55 mixture of 1,4-cis- and trans-isomers with respect to the Pac part of the molecule. Yield: 40 mg (74%).

35 $^1\text{H-NMR}$ (500 MHz, D_2O) δ 1.1-2.1 (m, 20 H), 2.32 (m, 1 H), 2.52 (m, 1 H), 2.63 (m, 1 H), 2.72 (m, 1 H), 3.1-3.3 (m, 1 H), 3.40 (m, 1 H), 3.8-3.95 (m, 2 H), 4.04 (d, 1 H), 4.39 (m, 1 H), 4.93 (m, 1 H).

¹³C-NMR (125 MHz, D₂O) amidine and carbonyl carbons: δ 167.7, 172.0, 174.9 and 175.2.

Example 53

5

H-(R)Cha-Pro-Pac x 2 HCl

(i) Boc-(R)Cha-Pro-Pac(Z)

10 211 mg (1.1 mmol) EDC was added at 0°C to a stirred solution of 0.4 g (1.1 mmol) H-Pac(Z) x 2 HCl (See preparation of starting materials), 0.4 g (1.1 mmol) Boc-(R)Cha-Pro-OH (See preparation of starting materials), and 0.55 g DMAP in 7 ml acetonitrile. The reaction mixture was stirred at 0°C for 1 h and at room temperature for 2 h. The solvent was removed in vacuo and the residue was diluted with ethyl acetate and water. The organic phase was washed with acetic acid, water, and sodium hydrogen carbonate solution and dried (MgSO₄). Removal of the solvent in vacuo gave a residue which was purified by flash chromatography using ethyl acetate as eluent to give 196 mg (27%) of the title compound.

25 (ii) H-(R)Cha-Pro-Pac(Z)

Hydrogen chloride was bubbled through a solution of 196 mg Boc-(R)Cha-Pro-Pac(Z) in 25 ml ethyl acetate. After 10 minutes the reaction mixture was diluted with methylene chloride and sodium hydroxide solution was added. The aqueous phase was extracted several times with methylene chloride and the combined organic phases were dried (K₂CO₃) and the solvent was removed in vacuo to give 86 mg (52%) of the title compound.

35

(iii) H-(R)Cha-Pro-Pac x 2 HCl

The title compound was prepared by hydrogenation of H-(R)Cha-Pr-Pac(Z) in ethanol in the presence of 10% Pd/C.

5 H-NMR (300 MHz, D₂O; A ca: 1:1 mixture of 1,4-cis- and 1,4-trans isomers in the Pac part of the molecule); δ 1.15-1.3 (q), 1.6-1.85 (m), 1.9-2.0 (m), 2.0-2.1 (d), 2.1-2.15 (m), 2.15-2.2 (m), 2.65-2.7 (m), 2.7-2.8 (m), 2.95-3.0 (d), 3.15-3.2 (d), 5.4 (s), 7.45-7.55 (m).

10

Example 54

H-(R)Cgl-Ile-Pab × 2 HCl

15 (i) Boc-(R)Cgl-Ile-Pab(Z)

To a stirred mixture of 1.33 g (3.6 mmol) Boc-(R)Cgl-Ile-OH (See Preparation of starting materials), 1.12 g (3.9 mmol) H-Pab(Z) (See Preparation of starting materials) and 1.76 g (14.4 mmol) DMAP in 50 ml CH₃CN/DMF (1/1) was added 0.75 g (3.9 mmol) EDC at + 5°C. The reaction mixture was allowed to reach room temperature and left for 60 h. The CH₃CN was removed by evaporation and the residue was poured out in 100 ml water (a yellow precipitate was formed). The mixture was extracted with 2 × 50 ml EtOAc and the combined organic phase was washed with 2 × 30 ml NaHCO₃ (saturated), 2 × 50 ml 0.2 M HCl, 1 × 50 ml Brine and dried (MgSO₄). Evaporation followed by flash chromatography using CH₂Cl₂/THF (85/15) as eluent gave 510 mg (24 %) of the title compound.

(ii) H-(R)Cgl-Ile-Pab(Z)

35 530 mg Boc-(R)Cgl-Ile-Pab(Z) was dissolved in 14 ml CH₂Cl₂/TFA (2.5/1) and stirred for 2 h at room temperature. Evaporation of the solvent followed by

flash chromatography using $\text{CH}_2\text{Cl}_2/\text{MeOH}(\text{NH}_3\text{-saturated})$ (95/5) as eluent gave the title compound.

(iii) H-(R)Cgl-Ile-Pab x 2 HCl

5

75 mg (0.14 mmol) H-(R)Cgl-Ile-Pab(Z) was hydrogenated over 10 % Pd/C in 5 ml EtOH, which contained an excess HCl(g) to give the dihydrochloride, at atmospheric pressure for 6 h. Addition of 2 g activated charcoal and 10 20 ml EtOH followed by filtration through celite, evaporation of the solvent and freeze drying from water gave 50 mg (89%) of the title compound as a white powder.

15 $^1\text{H-NMR}$ (500 MHz, MeOD): δ 0.90 (t, 3H), 0.94 (d, 3H), 1.1-2.0 (m, 14H), 3.83 (bs, 1H), 4.26 (d, 1H), 4.50 (m, 2H), 7.57 (bd, 2H), 7.78 (bd, 2H).

Example 55

20

H-(R)Cgl-Aze-Pab

Hydrogenation of 257 mg (5.08 mmol) H-(R)Cgl-Aze-Pab(Z) (See Example 1 (ii)) over 5 % Pd/C in 6 ml EtOH/ H_2O at 25 atmospheric pressure for 6 h followed by filtration of the catalyst, evaporation of the solvent and freeze drying from water gave 200 mg (89 %) of the title compound.

30 $^1\text{H-NMR}$ (500 MHz, D_2O): δ 1.0-2.0 (m, 11H), 2.25 (m, 1H), 2.70 (m, 1H), 3.30 (m, 1H), 3.75 (m, 1H), 4.30 (m, 1H), 4.45 (m, 1H), 4.55 (m, 2H), 7.60 (m, 2H), 7.77 (m, 2H).

MS m/z 372 ($\text{M}^+ + 1$).

35

Example 565 (i) $\text{BnOOC-(R,S)CH(Me)-(R)Cha-Pro-Pab(Z)}$

0.250 g (0.47 mmol) H-(R)Cha-Pro-Pab(Z) (See Example 15) dissolved in 5 ml CH_2Cl_2 was cooled to -10°C and 150 mg (0.48 mmol) of $\text{TfOCH}_2\text{COOBn}$ (See Preparation of Starting materials) dissolved in 3 ml CH_2Cl_2 was added slowly. 200 mg (1.45 mmol) of potassium carbonate was added and the mixture was stirred at roomtemperature for 20 h. The mixture was diluted with CH_2Cl_2 , extracted with water and dried (MgSO_4). Evaporation of the solvent followed by flash chromatography using $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 9/1 as eluent gave 150 mg (46%) of the title compound.

(ii) $\text{HOOC-(R,S)CH(Me)-(R)Cha-Pro-Pab} \times \text{HOAc}$

20 150 mg (0.2 mmol) $\text{BnOOC-(R,S)CH(Me)-(R)Cha-Pro-Pab(Z)}$ was hydrogenated over 50 mg 5 % Pd/C in 20 ml EtOH at atmospheric pressure for 4 h. Filtration of the catalyst, evaporation of the solvent followed by purification by RPLC, using $\text{CH}_3\text{CN}/0.1 \text{ M NH}_4\text{OAc}$ 1/4 as eluent, gave 35 mg (37%) of the title compound.

30 $^1\text{H-NMR}$ (500 MHz, MeOD): δ 1.00 (m, 1H), 1.20-1.45 (m, 5H), 1.5 (m, 1H), 1.6-1.8 (m, 6H), 1.9-2.1 (m, 6H), 2.25 (m, 1H), 3.25 (m, 1H), 3.5 (m, 1H), 3.85 (m, 1H), 4.15 (m, 1H), 4.35-4.6 (m, 3H), 4.9 (m, partially hidden by the HOD line, 6H), 7.55 (d, 2H), 7.75 (d, 2H).

Example 5735 $\text{MeOOC-CH}_2\text{-(R)Cgl-Aze-Pab} \times 2 \text{ HCl}$ (i) $\text{MeOOC-CH}_2\text{-(R)Cgl-Aze-Pab(Z)}$

0.186 g (0.841 mmol) TfO-CH₂-COOMe (See preparation of starting materials) was dissolved in CH₂Cl₂ and slowly added to a mixture of 0.425g (0.841 mmol) H-(R)Cgl-Aze-Pab(Z) (See Example 1), 0.894 g (5.04 mmol) K₂CO₃ in 5 CH₂Cl₂ (totally 4.3 ml) at roomtemperatur, and stirred over night. More CH₂Cl₂ was added and the mixture was washed with water and brine, dried, filtered and the solvent was evaporated in vacuo to give 0.51 g of a residue that was three times subjected to flash 10 chromatography on silica gel using, first CH₂Cl₂/THF/MeOH (16/4/1), then CH₂Cl₂/THF(2%NH₃) (8/2) and the last time diethylether/MeOH(NH₃-saturated) (95/5) as eluent. This gave 0.324 g (67 %) of the title compound.

15

(ii) MeOOC-CH₂-(R)Cgl-Aze-Pab x 2 HCl

220 mg (0.38 mmol) MeOOC-CH₂-(R)Cgl-Aze-Pab(Z) was 20 hydrogenated in the presence of 1.14 ml 1 N HCl, 6.5 ml MeOH and 300 mg Pd/C for 2 h. Removal of the catalyst by filtration on cellite and millipore filter followed by evaporation of the solvent in vacuo and freeze drying twice gave 178 mg (91 %) of the title compound.

25

¹H-NMR (500 MHz, D₂O); δ 1.12-1.4 (m, 5H), 1.68-1.81 (m, 2H), 1.81-1.9 (m, 3H), 1.97-2.1 (m, 1H), 2.29-2.4 (m, 1H), 2.68-2.8 (m, 1H), 3.86 (s, 3H), 4.1 (s, 2H), 4.1-4.5 (d, 1H), 4.36-4.42 (t, 2H), 4.59 (s, 2H), 4.99-5.04 (m, 1H), 7.65-7.7 (d, 2H), 7.8-7.85 (d, 2H).

30

¹³C-NMR (75 MHz, MeOD): amidine and carbonyl carbons; δ 146.78, 167.68, 168.15, 172.29.

Example 58

35

EtoOC-CH₂-(R)Cgl-Aze-Pab x 2 HCl

(i) EtoOC-CH₂-(R)Cgl-Aze-Pab(Z)

0.208 g (0.876 mm l) TfO-CH₂-COOEt (See preparation of starting materials) was dissolved in CH₂Cl₂ and sl wly added to a mixture of 0.443 g (0.876 mmol) H-(R)Cgl-Aze-Pab(Z) (See Example 1) and 0.931 g (5.26 mmol) K₂CO₃ in CH₂Cl₂ (totally 4 ml) cooled on an ice-bath. After 2 h the ice-bath was removed and stirring was continued at roomtemperature for 2 hours. More CH₂Cl₂ was added and the mixture was washed with water and brine, dried, filtered and the solvent was evaporated in vacuo to give 0.51 g of a residue that was subjected to flash chromatography using diethylether/MeOH(NH₃-saturated) (95/5) as eluent. This gave 0.387 g (75 %) of the title compound.

(ii) EtoOC-CH₂-(R)Cgl-Aze-Pab x 2 HCl

395 mg (0.668 mmol) EtoOC-CH₂-(R)Cgl-Aze-Pab(Z) was hydrogenated in the presence of 12 ml EtOH (99.5 %) and 390 mg Pd/C for 5 h. Removal of the catalyst by filtration on cellulose and millipore filter, followed by evaporation of the solvent in vacuo and freeze drying twice, gave 281 mg (88 %) of EtoOC-CH₂-(R)Cgl-Aze-Pab. 2 equivalents of 1 N HCl was added, and freeze drying three times gave 288 mg (81 %) of the title compound.

¹H-NMR (500 MHz, D₂O); δ 1.05-1.48 (m, 8H), 1.6-2.05 (m, 6H), 2.15-2.33 (m, 1H), 2.58-2.79 (m, 1H), 3.89-4.0 (m, 3H), 4.2-4.33 (m, 3H), 4.33-4.44 (m, 1H), 4.44-4.66 (m, 2H), 4.91 (m, 1H (partially hidden by the H-O-D signal)), 7.54-7.63 (d, 2H), 7.72-7.84 (d, 2H).

Example 59

35

nBuO C-CH₂-(R)Cgl-Aze-Pab x HOAc

(i) $^n\text{BuOOC-CH}_2-(\text{R})\text{Cgl-Aze-Pab(Z)}$

Prepared in the same way as described for $^n\text{HexOOC-CH}_2-(\text{R})\text{Cgl-Aze-Pab(Z)}$ (See Example 60 (i)) using $\text{TfO-CH}_2-\text{COO}^n\text{Bu}$ as alkylating agent. The crude product was purified by flash chromatography twice, first using $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (95/1) as eluent and then $\text{CH}_2\text{Cl}_2/\text{i-propylalcohol}$ (90/7) to give 324 mg (47 %) of the title compound.

10

(ii) $^n\text{BuOOC-CH}_2-(\text{R})\text{Cgl-Aze-Pab x HOAc}$

The deprotection was done according to the procedure described in Example 57 (ii). The crude material was purified on RPLC using CH_3CN (30 %) in 0.05 M NH_4OAc and 0.05 M HOAc as eluent to give 100 mg (53 %) of the title compound.

20 $^1\text{H-NMR}$ (300 MHz, MeOD); δ 0.85-2.1 (m, 18H), 2.15-2.37 (m, 1H), 2.58-2.8 (m, 1H), 3.7-5.0 (m, 10H), 4.88-5.0 (partially hidden by the H-O-D signal)), 7.46-7.65 (d, 2H), 7.71-7.88 (d, 2H).

25 $^{13}\text{C-NMR}$ (75 MHz, MeOD): amidine and carbonyl carbons; δ 146.8, 168.12, 168.2, 172.2.

Example 6030 $^n\text{HexOOC-CH}_2-(\text{R})\text{Cgl-Aze-Pab x 2 HCl}$ (i) $^n\text{HexOOC-CH}_2-(\text{R})\text{Cgl-Aze-Pab(Z)}$

35 0.402 g (1.375 mmol) $\text{TfO-CH}_2-\text{COO}^n\text{Hex}$ (See Preparation of starting materials) was dissolved in CH_2Cl_2 and slowly added to a mixture of 0.695 g (1.375 mmol) $\text{H-(R)Cgl-Aze-Pab(Z)}$ (See Example 1), 1.463 g (8.25 mmol) K_2CO_3 in

CH₂Cl₂ (totally 4 ml) at <-10°C. After 1 h the CO₂-ice-bath was removed and stirring was continued at room temperature for 45 minutes. More CH₂Cl₂ was added and the mixture was washed with water and brine, dried, filtered and the solvent was evaporated in vacuo to give 0.828 g of a residue, which was twice subjected to flash chromatography, first using diethylether/MeOH(NH₃-saturated) (95/5), and then CH₂Cl₂/MeOH(NH₃-saturated) (95/5) as eluent. This gave 0.42 g (47 %) of the title compound.

(ii) ⁿHexOOC-CH₂-(R)Cgl-Aze-Pab x 2 HCl

Hydrogenation of 400 mg (0.617 mmol) ⁿHexOOC-CH₂-(R)Cgl-Aze-Pab(Z) in the presence of 12 ml THF and 400 mg Pd/C for 1.5 h did not give complete de-protection. The hydrogenation was completed in 4 h in the presence of 1.7 ml 1 N HCl, 12 ml MeOH and 340 mg Pd/C. Removal of the catalyst by filtration on cellulose and millipore filter, followed by evaporation of the solvent in vacuo and freeze drying twice, gave 287 mg (79 %) of the title compound.

¹H-NMR (300 MHz, MeOD); δ 0.8-2.13 (m, 22H), 2.13-2.31 (m, 1H), 2.61-2.81 (m, 1H), 3.93-4.15 (m, 3H), 4.15-4.37 (m, 3H), 4.37-4.7 (m, 3H), 4.88-5.0 (m, 1H (partially hidden by the H-O-D signal)), 7.52-7.69 (d, 2H), 7.75-7.9 (d, 2H).

¹³C-NMR (75 MHz, MeOD): amidine and carbonyl carbons; δ 146.84, 167.67, 167.84, 172.17.

Example 61

35

H-(R)Cgl-Pro-Pac x 2 HCl

(i) Boc-(R)Cgl-Pro-Pac(Z)

377 mg (1.97 mmol) EDC was added at 0°C to a stirred solution of 708 mg (1.95 mmol) of Boc-(R)Cgl-Pro-OH (See Preparation of startingmaterial), 714 mg (2.0 mmol) H-Pac(Z) x 2 HCl (See Preparation of startingmaterial) and 1.078 g (8.8 mmol) DMAP in 12.5 ml acetonitrile. The reaction mixture was allowed to reach room temperature over night. The solvent was removed in vacuo and the residue was first purified by flash chromatography, using 10 % methanol in methylene chloride as eluent, and subsequently by RPLC. Two fractions (51 mg and 150 mg) giving MS m/z = 626 (M + 1) were isolated.

15 (ii) H-(R)Cgl-Pro-Pac(Z)

Hydrogen chloride was bubbled into a solution of 141 mg (0.22 mmol) Boc-(R)Cgl-Pro-Pac(Z) in 50 ml ethyl acetate. After 15 minutes 10 % sodium carbonate solution was added and the organic phase was separated and dried (K_2CO_3). Evaporation of the solvent gave 71 mg (61 %) of the product.

25 (iii) H-(R)Cgl-Pro-Pac x 2 HCl

A mixture of 71 mg (0.14 mmol) H-(R)Cgl-Pro-Pac(Z) and a small spatula of 10 % Pd/C in 10 ml of ethanol was hydrogenated at room temperature and atmospheric pressure for 2 h. The catalyst was removed by filtration and the solvent was removed in vacuo. The residue was dissolved in 50 ml water and 0.6 g 1M hydrochloric acid. Freeze drying yielded 38 mg (58 %) of the title compound

MS m/z 392 (M + 1)

Example 62

HOOC-CH₂-(R)Cha-Pro-Pac x HOAc

5 (i) BnOOC-CH₂-(R)Cha-Pro-Pac(Z)

A mixture of 84 mg (0.15 mmol) H-(R)Cha-Pro-Pac(Z) (See Example 53 (ii)), one spatula of potassium carbonate, and 47 mg of TfOCH₂-COOBn (See Preparation of starting materials) in 3 ml of methylene chloride was stirred at room temperature over night. The reaction mixture was filtered and the solvent was removed in vacuo to give a residue which was subjected to flash chromatography using ethyl acetate/methylene chloride/methanol 95:20:5 15 as eluent. 29 mg of the desired product was isolated.

(ii) HOOC-CH₂-(R)Cha-Pro-Pac x HOAc

A mixture of 29 mg BnOOC-CH₂-(R)Cha-Pro-Pac(Z) and 37 mg 20 of 10 % Pd-C in 5 ml etanol was stirred for 4 h at room temperature and atmospheric pressure. Filtration of the catalyst followed by removal of the solvent and purification by RPLC gave the desired compound.

25 MS m/z = 464 (M + 1).

Example 63

HOOC-CH₂-CH₂-(R)Cgl-Pro-Pac

30

(i) BnOOC-CH₂-CH₂-(R)Cgl-Pro-Pac(Z)

A solution of 0.35 g (0.64 mmol) H-(R)Cgl-Pro-Pac(Z) 35 (See Example 61 (ii)), 124 mg (0.76 mmol) benzyl acrylate, and 280 μ l (2 mmol) triethyl amine in 1 ml ethanol was kept at room temperature for 3 days. Removal of the solvent followed by purification by HPLC gave 18

mg (4 %) of the title compound.

(ii) HOOC-CH₂-CH₂-(R)Cgl-Pro-Pac

5 A mixture of 18 mg BnOOC-CH₂-CH₂-(R)Cgl-Pro-Pac(Z) and a small spatula of 10 % Pd/C was hydrogenated for 2 h at room temperature and atmospheric pressure in ETOH. Filtration followed by removal of the solvent in vacuo and dissolution in water and freeze drying gave 7 mg (78 %) of the title compound. MS m/z = 464 (M + 1).

Example 64

HOOC-CH₂-CH₂-(R)Cha-Aze-Pac

15

(i) Boc-(R)Cha-Aze-Pac(Z)

A solution of 0.4 g (1.38 mmol) H-Pac(Z) (See Preparation of startingmaterial of H-Pac(Z) x 2 HCl), 20 0.5 g (1.41 mmol) Boc-(R)Cha-Aze-OH (See Preparation of startingmaterial), and 0.67 g (5.5 mmol) DMAP in 20 ml acetonitrile was mixed at 0°C with a solution of 0.26 g (1.4 mmol) EDC in 15 ml acetonitrile. The reaction mixture was kept at room temperature over night and the 25 solvent was subsequently removed in vacuo. The residue was partitioned between ethyl acetate and water. The aqueous phase was extracted once more with ethyl acetate and the combined organic phases were washed with sodium hydrogen sulphate solution, sodium carbonate solution, 30 and brine and then dried (sodium sulphate). Evaporation of the solvent gave 0.54 g (63 %) of the title compound.

(ii) H-(R)Cha-Aze-Pac(Z)

35 Hydrogen chloride was bubbled into a solution of 0.54 g (0.9 mmol) Boc-(R)Cha-Aze-Pac(Z) in ethyl acetate. The solution was kept in the refrigerator over night and

the solvent was then removed in vacuo and the residue was dissolved in ethyl acetate. The solution was washed with aqueous sodium hydrogen carbonate solution, water and brine and dried (sodium sulphate). Removal of the solvent gave 0.35 g (77 %) of the product.

5 (iii) $\text{BnOOC-CH}_2\text{-CH}_2\text{-(R)Cha-Aze-Pac(Z)}$

A solution of 180 mg (0.33 mmol) H-(R)Cha-Aze-Pac(Z) and 10 53 mg (0.33 mmol) benzyl acrylate in ethanol was kept at room temperature for 60 h. The solvent was removed in vacuo and the residue was dissolved in ethyl acetate. The solution was washed with potassium hydrogen sulphate solution and sodium hydrogen carbonate solution and 15 brine. Drying (sodium sulphate) and removal of the solvent in vacuo gave a residue which was purified by flash chromatography, using 10 % methanol in methylene chloride as eluent to yield 150 mg (66 %) of the title compound

20

(iv) $\text{HOOC-CH}_2\text{-CH}_2\text{-(R)Cha-Aze-Pac x 2 HCl}$

A mixture of 115 mg $\text{BnOOC-CH}_2\text{-CH}_2\text{-(R)Cha-Aze-Pac(Z)}$ and 25 67 mg of 10 % Pd-C in 10 ml ethanol was hydrogenated for 1.5 h at room temperature and atmospheric pressure. Filtration followed by removal of the solvent in vacuo and dissolution of the residue in water and 1.5 ml of 1M hydrochloric acid gave a solution which was freeze dried to give 30 mg (33 %) of the title compound.

30

MS m/z 464 (M + 1).

Example 65

35 $\text{HOOC-CH}_2\text{-(R)Cha-Aze-Pig x 2 HCl}$

(i) $\text{Boc-(R)Cha-Aze-Pig(Z)}$

0.249 g (1.298 mmol) EDC was added at <-15°C to a mixture of 0.473 g (1.236 mmol) Boc-(R)Cha-Aze-OH (See Preparation of starting materials), 0.404 g (1.236 mmol) H-Pig(Z) x HCl (See Preparation of starting materials) and 0.604 g (4.94 mmol) DMAP in 13.5 ml DMF. The temperature was allowed to rise to roomtemperature over night. The solvent was evaporated in vacuo and EtOAc and 2 M KHSO₄ was added. The phases were separated and the organic phase was washed with saturated Na₂CO₃ and brine. Repeting the extractive procedure, drying (Na₂SO₄), filtration and evaporation of the solvents gave 0.612 g of a residue which was subjected to flash chromatography using EtOAc/MeOH 9/1 as eluent. This gave 407 mg (53 %) of the title compound.

(ii) H-(R)Cha-Aze-Pig(Z)

0.4 g (0.638 mmol) of Boc-(R)Cha-Aze-Pig(Z) was dissolved in 24.4 ml of TFA/CH₂Cl₂ 1/4, stirred for 30 minutes on an ice-bath, and for 30 minutes at roomtemperature. The solvent was removed in vacuo and EtOAc and saturated Na₂CO₃ was added. The phases were seperated and the organic layer was washed with water and brine, dried (Na₂SO₄), filtered and the solvent was evaporated in vacuo to give 336 mg (100 %) of the title compound.

(iii) BnOOC-CH₂-(R)Cha-Aze-Pig(Z)

89 ml (0.562 mmol) BnOOC-CH₂-Br was slowly added to a mixture of 0.296 g (0.562 mmol) H-(R)Cha-Aze-Pig(Z) and 0.171 g (1.236 mmol) K₂CO₃ in 6 ml CH₃CN heated to 60°C on an oilbath. After 1 h 45 minutes the solvent was evaporated, EtOAc was added, and the mixture was washed with water, dried (Na₂SO₄), filtered and the solvent was evaporated in vacuo to give 346 mg of a

residue which was subjected to flash chromatography using $\text{CH}_2\text{Cl}_2/\text{THF}/\text{MeOH}$ (8/2/1) as eluent. This gave 297 mg (78 %) of the title compound.

5 (iv) $\text{HOOC-CH}_2-(\text{R})\text{Cha-Aze-Pig} \times 2 \text{ HCl}$

243 mg (0.36 mmol) $\text{BnOOC-CH}_2-(\text{R})\text{Cha-Aze-Pig(Z)}$ was hydrogenated in the presence of 1.7 ml 1 N HCl, 10 ml EtOH (99.5 %) and 300 mg Pd/C for 2 h. Removal of the catalyst by filtration on cellulose and millipore filter followed by evaporation of the solvent in vacuo and freeze drying twice gave 166 mg (88 %) of the title compound

15 $^1\text{H-NMR}$ (500 MHz, D_2O); δ 0.6-1.9 (m, 18H), 2.1-2.27 (m, 1H), 2.52-2.76 (m, 1H), 2.82-3.2 (m, 4H), 3.46-3.61 (m, 1H), 3.61-3.81 (m, 2H), 3.81-4.0 (m, 2H), 4.0-4.24 (m, 2H), 4.24-4.4 (m, 1H).

20 Example 66

$\text{HOOC-CH}_2-(\text{R})\text{Cha-Pro-Pig} \times 2 \text{ HCl}$

(i) $\text{Boc-(R)Cha-Pro-Pig(Z)}$

25 To a mixture of 0.3495 g (0.95 mmole) Boc-(R)Cha-Pro-OH (See Preparation of starting materials), 0.464 g (3.8 mmole) DMAP, 0.310 g (0.95 mmole) H-Pig(Z) \times HCl (See Preparation of starting materials) in 5 ml CH_2Cl_2 was added 0.192 g (1 mmole) of EDC and the mixture was stirred over night at room temperature. The mixture was evaporated and the residue was dissolved in ethyl acetate. The organic phase was washed twice with 0.3 M KHSO_4 and once with brine. The organic layer was dried (Na_2SO_4), filtered and evaporated. The crude product was purified by flash chromatography using a stepwise gradient of $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (100/0, 97/3,

95/5, 90/10) as eluent to yield 307 mg of the title compound.

(ii) H-(R)Cha-Pro-Pig(Z)

5

0.306 g (0.48 mmole) Boc-(R)Cha-Pro-Pig(Z) was dissolved in 30 ml HCl saturated ethyl acetate. The mixture was allowed to stand for half an hour. The solvent was evaporated and the residue was dissolved in CH₂Cl₂. The organic layer was washed twice with 0.2 M NaOH. The combined water layer was extracted once with CH₂Cl₂ and the combined organic layer was dried (Na₂SO₄), filtered and evaporated to yield 257 mg (99%) of the title compound.

10

(iii) BnOOC-CH₂-(R)Cha-Pro-Pig(Z)

A mixture of 0.256 g (0.473 mmole) H-(R)Cha-Pro-Pig(Z), 0.144 g (1.04 mmole) K₂CO₃ and 82 μl (0.521 mmole) of bensylbromoacetate in 6 ml acetonitrile was heated to 60°C for two hours under stirring. The solvent was evaporated and the residue was dissolved in CH₂Cl₂, washed once with water and once with brine, dried (Na₂SO₄), filtered and the solvent evaporated.

15

The crude product was purified by flash chromatography using a stepwise gradient of CH₂Cl₂/MeOH (97/3, 95/5, 90/10) as eluent to yield 0.2 g product (90% pure according to RPLC). The final purification was made on a chromatotron (Harrison research, model 7924T) on a 2mm silica plate in CH₂Cl₂/MeOH 95/5 yielding 0.158 g (48%) of the pure product.

(iv) HOOC-CH₂-(R)Cha-Pro-Pig x 2 HCl

20

0.158 g (0.227 mmole) of BnOOC-CH₂-(R)Cha-Pro-Pig(Z) was mixed with 0.075 g Pd/C (5%), 1.0 ml 1N HCl-

solution and 10 ml ethanol. The mixture was hydrogenated at atmospheric for one hour. Filtration through cellite and evaporation of the solvent followed by freeze drying twice from water gave 119
5 mg (97%) of the product

¹H-NMR (D₂O, 300 MHz): δ 0.95-1.44 (m, 7H), 1.52 (m,
1H), 1.60-2.20 (m, 13H), 2.39 (m, 1H), 3.07-3.32 (m,
4H), 3.68 (m, 1H), 3.77-4.02 (m, 5H; thereof 3.98 (s,
10 2H), 4.44-4.58 (m, 2H)

¹³C-NMR (D₂O, 75 MHz): carbonyl- and guanidine carbons: δ 156.5, 168.3, 169.6, 174.5

15 Example 67



(i) BnOOC-CH₂-CH₂-(R)Cha-Pro-Pig(Z)

20 0.297 g (0.55 mmole) H-(R)Cha-Pro-Pig(Z) (See Example 66 (ii)) was dissolved in 2 ml ethanol and 90 μl (0.59 mmole) bensylacrylate was added. The reaction mixture was stirred for four days at room
25 temperature. The solvent was evaporated and the crude product chromatographed on a chromatotron (Harrison research, model 7924T) using a 2mm silica plate with a stepwise gradient of CH₂Cl₂/MeOH (95/5, 90/10) as eluent to yield 0.338 g (87%) of the title compound.

30 (iii) HOOC-CH₂-CH₂-(R)Cha-Pro-Pig × 2 HCl

0.238 g (0.227 mmole) of BnOOC-CH₂-CH₂-(R)Cha-Pro-Pig(Z) was mixed with 0.120 g Pd/C (5%), 1.2 ml 1N
35 HCl-solution and 15 ml ethanol. The mixture was hydrogenated at atmospheric pressure for one hour. Filtration of the catalyst through cellite,

evaporation of the solvent followed by freeze drying twice from water gave 178 mg (95 %) of the title comp und.

5 $^1\text{H-NMR}$ (D_2O , 300 MHz): δ 0.82-1.45 (m, 8H), 1.45-2.15 (m, 13H), 2.29 (m, 1H), 2.83 (t, 2H), 2.9-3.4 (m, 6H), 3.57 (bq, 1H), 3.67-3.87 (m, 3H), 4.25-4.43 (m, 2H)

10 $^{13}\text{C-NMR}$ (D_2O , 75 MHz): carbonyl- and guanidine carbons: δ 156.3, 168.2, 174.3, 174.6

MS m/z 479 (M^++1)

15 Example 68




20 120 mg (0.126) mmol $(\text{BnOOC}-\text{CH}_2)_2-(\text{R})\text{Cgl-Pro-Pig(Z)}_2$ (See Example 50 (iii)) was hydrogenated in the presence of 0.75 ml 1 N HCl, 7 ml EtOH (99.5 %) and 150 mg Pd/C for 4 h. Removal of the catalyst by filtration on cellite and millipore filter and evaporation of the solvent in vacuo followed by 25 freeze drying gave 66 mg (90 %) of the title compound

1 H-NMR (500 MHz, D_2O): δ 1.05-1.38 (m, 7H), 1.53-1.64 (d, 1H), 1.64-2.14 (m, 11H), 2.27-2.39 (m, 1H), 3.03-3.28 (m, 4H), 3.58-3.70 (m, 1H), 3.7-3.8 (m, 1H), 3.8-3.9 (d, 2H), 4.07-4.22 (m, 2H), 4.22-4.35 (m, 1H), 4.38-4.5 (m, 1H).

30 $^{13}\text{C-NMR}$ (75 MHz, D_2O): amidine and carbonyl carbons; δ 156.28, 166.73, 170.14, 174.01.

Example 69



5 To a cold (ice-bath temperature) mixture of 100 mg (0.14 mmol) $\text{BnOOC-CH}_2\text{-CH}_2\text{-(R)Cha-Pro-Pig(Z)}$ (See Example 67 (i)) and 80 mg (0.57 mmol) potassium carbonate in 4 ml of CH_2Cl_2 was carefully added a solution of 64 mg (0.21 mmol) $\text{TfO-CH}_2\text{-COOBn}$ dissolved in 1 ml CH_2Cl_2 . The reaction mixture was left at 0°C for 30 minutes and then allowed to reach room temperature for 2 h after which it was heated to reflux for 30 minutes and finally left over night at room temperature. Evaporation of the solvent followed by flash chromatography using $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (97/3) as eluent afforded 65 mg (54 %) of the title compound.



20 65 mg (0.08 mmol) of $\text{BnOOC-CH}_2\text{-CH}_2\text{-(BnOOC-CH}_2\text{)-(R)Cha-Pro-Pig(Z)}$ was dissolved in 10 ml of EtOH/1M HCl (9/1) and hydrogenated over 10 % Pd/C for 3 h at atmospheric pressure. Filtration of the catalyst evaporation of the solvent followed by freeze drying from water gave 40 mg (97 %) of the title compound as a white powder.

30 $^{13}\text{C-NMR}$ (125 MHz, MeOD): amidine and carbonyl carbons: δ 157.5, 167.2, 169.1, 173.7 and 174.1.

Example 70



35 (i) $\text{BOC-(R)Cgl-Aze-(R,S)Itp(Ts)}$

BOC-(R)Cgl-Aze-OH (See Preparation of starting

materials) (400 mg, 1.17 mmol), H-(R,S)Itp(Ts) (See Preparation of starting materials) (366 mg, 1.23 mmol) and DMAP (286 mg, 2.34 mmol) was dissolved in CH₃CN (6 ml) and cooled to 5°C. EDC (236 mg, 1.23 mmol) was added and the resulting mixture was stirred at room temperature over night. The CH₃CN was removed and the residue was dissolved in MeOH/EtOAc/H₂O. The separated organic layer was washed with K₂CO₃(sat), 2 M KHSO₄, brine and dried(Na₂SO₄). Evaporation of the solvent resulted in a white solid, 688 mg (85%).

MS m/z 620 (M⁺ + 1)

(ii) H-(R)Cgl-Aze-(R,S)Itp(Ts)

Boc-(R)Cgl-Aze-(R,S)Itp(Ts) (500 mg, 0.8 mmol) was dissolved in CH₂Cl₂ (50 ml) and HCl(g) was bubbled through the solution for ca 4 min. After 45 min the solvent was removed by evaporation and the resulting product was dissolved in EtOAc/MeOH/H₂O and the acidic solution was treated with 2 M NaOH(aq) to pH=8-9. The organic layer was separated and dried(Na₂SO₄). Evaporation of the solvent afforded 425 mg (100%) of the title compound as a white solid

MS m/z 520 (M⁺ + 1)

(iii) BnOOC-CH₂-(R)Cgl-Aze-(R,S)Itp(Ts)

H-(R)Cgl-Aze-(R,S)Itp(Ts) (400 mg, 0.77 mmol), Benzyl-2-(para-nitrobenzenesulfonyloxy)acetate (See Preparation of starting materials) (325 mg, 0.92 mmol) and K₂CO₃ (235 mg, 1.7 mmol) was stirred in CH₃CN (5 ml) at 45°C. After a few hours the conversion was only 25% and therefore the temperature was increased to 60°C and an additional amount of Benzyl-2-(para-nitrobenzenesulfonyloxy)acetate was added.

The reaction was stirred for 48 h,
(startingm.:product/25:63), and then worked up. The solvent was evaporated and EtOAc/H₂O was added to the residue. The phases were separated and the water-
5 phase was washed twice with EtOAc and then the combined organic phase was washed with K₂CO₃(sat), 2 M KHSO₄, H₂O and dried Na₂SO₄). This afforded, after back-extraction of the acidic KHSO₄, some 340 mg which was purified by RPLC. This gave 34 mg (7%) of the
10 title compound

MS m/z 668 (M⁺ + 1).

(iv) HOOC-CH₂-(R)Cgl-Aze-(R,S)Itp x 2 HCl

15 BnOOC-CH₂-(R)Cgl-Aze-(R,S)Itp(Ts) (34 mg, 0.05 mmol) was dissolved in THF (5 ml) and NH₃(g) was destilled (40 ml) into the reaction flask with a dry-ice cooler. Na(s) was added and a deep blue color
20 appeared. The reaction was stirred for 5 min before it was quenched with HOAc (50 µl). The dry-ice cooler was removed and the NH₃(l) was allowed to evaporate. To the residue H₂O and HOAc was added to pH=7. Freeze-drying and preparative RPLC gave several fractions
25 which were analyzed with FAB-MS. Two fractions contained the desired compound, 3 mg (10%) after freeze-drying with 2.2 eq of 1 M HCl:

MS m/z 424 (M⁺ +1).

30

Example 71

HOOC-CH₂-(R)Cha-Aze-(R,S)Itp

35 (i) Boc-(R)Cha-Aze-(R,S)Itp(Ts)

Boc-(R)Cha-Aze-OH (See Preparation of starting

materials) (169 mg, 0.5 mmol), H-(R,S)It_p(Ts) (See Preparation of starting materials) (155 mg, 0.52 mmol), DMAP (122 mg, 1 mmol) was dissolved in CH₃CN (2.5 ml) and cooled to 5°C. EDC × HCl (115 mg, 0.6 mmol) was added and the resulting mixture was stirred at room temperature over night. Extra (0.5 eq) H-(R,S)It_p(Ts) and EDC was added after stirring over night. The reaction mixture was stirred an additional night and worked up as described in the Boc-(R)Cgl-Aze-(R,S)It_p(Ts) (See Example 70) case above. This gave 260 mg of crude product. Purification by RPLC gave 180 mg (57%) of the title compound

MS m/z 634 (M⁺ +1).

15

(ii) H-(R)Cha-Aze-(R,S)It_p(Ts)

Boc-(R)Cha-Aze-(R,S)It_p(Ts) (180 mg, 0.28 mmol) was dissolved in CH₂Cl₂ (20 ml) and HCl(g) was bubbled through the solution for ca 4 min. After 45 min the solvent was removed by evaporation and the resulting product was dissolved in CH₂Cl₂ and washed with 2 M NaOH to pH=8-9. The phases were separated and the organic phase was dried(Na₂SO₄) and evaporated to yield 163 mg (ca 100%):

MS m/z 534 (M⁺ +1).

(iii) BnOOC-CH₂-(R)Cha-Aze-(R,S)It_p(Ts)

30

H-(R)Cha-Aze-(R,S)It_p(Ts) (80 mg, 0.15 mmol), K₂CO₃ (45 mg, 0.33 mmol) and Br-CH₂COOBn (39 mg, 0.17 mmol) was stirred in CH₃CN (1.5 ml) at 60°C for 2.5 h. The solvent was evaporated and the residue was dissolved in EtOAc/H₂O. The phases were separated and organic phase was washed with 10% citric acid and dried (Na₂SO₄). Evaporation of the solvent gave a 171 mg of

crude product, which was purified by RPLC yielding 53 mg (52%) of the title compound.

MS m/z 681 (M⁺ +1).

5

(iv) HOOC-CH₂-(R)Cha-Aze-(R,S)Itp

BnOOC-CH₂-(R)Cha-Aze-(R,S)Itp(Ts) (50 mg, 0.07 mmol) was treated as described for BnOOC-CH₂-(R)Cgl-Aze-(R,S)Itp(Ts) (See Example 70 (iv)). This gave a product mixture which was purified on a RPLC yielding 12 mg of a 1:1 mixture of the title compound together with a reduced form which appear at mass 439 (m/z).

15 MS m/z 438 (M⁺ +1)

Example 72

H-(R)Cha-Pic-(R,S)Itp x 2 HCl

20

(i) Boc-(R)Cha-Pic-(R,S)Itp(Ts)

At roomtemperature 2.1 g (5.5 mmol) Boc-(R)Cha-Pic-OH (See Preparation of starting materials), 1.0 g (8.2 mmol) DMAP and 1.7 g (5.8 mmol) H-(R,S)Itp(Ts) (See Preparation of starting materials) was dissolved in 40 mL acetonitrile. After a few minutes of stirring 1.1 g (5.8 mmol) EDC was added and the stirring was continued for 60 hours. The solvent was removed in vacuo and the residue was dissolved in CH₂Cl₂, washed with water, 0.3M KHSO₄ and KHCO₃ (aq) and dried(Na₂SO₄). Evaporation of the solvent and filtration through Silica gel gave 2.43 g (67%) of the product.

35

MS m/z 661 (M⁺ +1)

(ii) B c-(R)Cha-Pic-(R,S)Itp

2.4 g (3.6 mm l) Boc-(R)Cha-Pic-(R,S)Itp(Ts) was dissolved in 15 mL THF and NH₃ (g) was condensed into the flask followed by addition of Na. The reaction was quenched after 5 min with acetic acid and the NH₃ and the THF was evaporated. The residue was freezedried from water and purified by RPLC (CH₃CN/0.1M NH₄OAc, 6/4) to give 0.93 g (51%) of the desired product.

MS m/z 507 (M⁺ +1)

(iii) H-(R)Cha-Pic-(R,S)Itp x 2 HCl

At roomtemperature 50 mg (0.099 mmol) Boc-(R)Cha-Pic-(R,S)Itp was dissolved in ethylacetate saturated with HCl (g). After stirring 2 h the solvent was removed in vacuo. The residue was freezedried from water three times to give 35 mg (74%) of the desired product.

MS m/z 407 (M⁺ +1)

25 Example 73HOOC-CH₂-(R)Cha-Pic-(R,S)Itp x 2 HCl

(i) Boc-(R)Cha-Pic-(R,S)Itp(Z)

At roomtemperature 0.84 g (1.66 mmol) Boc-(R)Cha-Pic-(R,S)Itp (See Example 72) was dissolved in 10 mL CH₂Cl₂ and 10 mL 0.5M NaOH. 0.29 mL (1.82 mmol) Z-Cl was added dropwise. After stirring for 3 h the phases was separated and the organic phase was washed with water and dried over Na₂SO₄. Evaporation and flash chromatography (ethylacetate/heptane 9/1) gave 0.5 g

(47%) of the desired product.

MS m/z 641 ($M^+ +1$)

5 (ii) H-(R)Cha-Pic-(R,S)Itp(Z)

At roomtemperature 0.5 g (0.78 mmol) Boc-(R)Cha-Pic-(R,S)Itp(Z) was dissolved in ethylacetate saturated with HCl. Water was added and the mixture was made basic with K_2CO_3 . The phasees was separated. The waterphase was extracted with CH_2Cl_2 and the organic phase was washed with water. The combined organic phase was then dried(Na_2SO_4). Evaporation of the solvent gave 0.3 g (71%) of the desired product.

15

MS m/z 541 ($M^+ +1$)

(iii) BnOOC- CH_2 -(R)Cha-Pic-(R,S)Itp(Z)

20 0.29 g (0.5 mmol) H-(R)Cha-Pic-(R,S)Itp(Z), 0.15 g (1 mmol) K_2CO_3 was taken up in 25 mL acetonitrile. 154 mg (0.6 mmol) benzylbromoacetate was added and the mixture was stirred at 50°C for 4 h. evaporation and purification by RPLC
25 (acetonitrile:0.1M NH_4OAc 70:30) gave about 200 mg of the desired product.

(iv) HOOC- CH_2 -(R)Cha-Pic-(R,S)Itp x 2 HCl

30 200 mg BnOOC- CH_2 -(R)Cha-Pic-(R,S)Itp(Z) was dissolved in ethanol. A small spoon of 10% Pd on charcoal was added and the mixture was hydrogenated for 4 h. Filtration through hyflo, evaporation of the solvent followed by freezedrying from water gave 53 mg of the desired product.

1H NMR (300.13 MHz, D_2O); δ 1.0-2.35 (overlapping m,

22H), 3.28-3.51 (m, 5H), 3.51-3.64 (m, 1H), 3.75-4.03 (m, 3H), 5.03-5.14 (s broad, 1H). The signal of one of the protons is partially obscured by the H-O-D-signal.

5

MS m/z 465 ($M^+ +1$)

Example 74

10 H-(R)Cgl-Pro-(R,S)Hig x 2 HCl

(i) Boc-(R)Cgl-Pro-(R,S)Hig(Z)

To a mixture of 1.0 g (2.95 mmole) Boc-(R)Cgl-Pro-OH (See Preparation of startingmaterials), 1.44 g (11.8 mmole) DMAP, 1.12 g (3.25 mmole) H-(R,S)Hig(Z) (See Preparation of startingmaterials) in 15 ml CH_2Cl_2 was added 0.62 g (3.2 mmole) of EDC and the mixture was stirred at room temperature over night. The solvent was evaporated and the residue was dissolved in ethyl acetate. When the organic layer was washed twice with a 0.3 M KHSO_4 -solution an oil separated from the organic layer. The ethyl acetate layer was dried (Na_2SO_4) and filtered. The oil and the water layer was then extracted with CH_2Cl_2 . The organic layer was dried (Na_2SO_4), filtered and combined with the EtOAc phase from above. Evaporation and purification of the crude product on a chromatotron (Harrison research, model 7924T) using a 2mm silica plate with a stepwise gradient of $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (97/3, 95/5, 90/10) as eluent to yielded 1.1 g (59%) of the title compound.

(ii) H-(R)Cgl-Pro-(R,S)Hig x 2 HCl

35

81 mg (0.13 mmole) of Boc-(R)Cgl-Pro-(R,S)Hig(Z) was dissolved in 50 ml ethyl acetate saturated with HCl.

The mixture was allowed to stand for one hour, evaporated and the residue was dissolved in 10 ml ethanol. 40 mg Pd/C (5%), 1 ml water and 0.5 ml 1 M HCl-solution was added and the mixture was
5 hydrogenated at atmospheric pressure over night. Filtration of the catalyst through cellulose and evaporation of the solvent followed by freeze drying 3 times from water gave the title compound in 75% yield.

10

¹H-NMR (D₂O, 300 MHz): δ 0.95-1.35 (m, 5H), 1.50-2.45 (m, 15H), 3.02 (bt, 1H), 3.1-3.8 (m, 7H), 4.13 (d, 1H), 4.38 (bd, 1H)

¹³C-NMR (D₂O, 75 MHz): carbonyl and guanidine carbons:
15 δ 154.8, 168.9, 174.4

MS m/z 393 (M⁺+1)

Example 75

20



(i) H-(R)Cgl-Pro-(R,S)Hig(Z)

25 1 g (1.6 mmole) Boc-(R)Cgl-Pro-(R,S)Hig(Z) (See Example 74 (i)) was dissolved in 100 ml ethyl acetate saturated with HCl, and the mixture was allowed to stand for one hour. The mixture was evaporated and the residue was dissolved in CH₂Cl₂. The organic layer
30 was washed twice with 0.2 M NaOH-solution, dried (Na₂SO₄), filtered and evaporated to yield 0.825 g (98%) of title compound.

(ii) BnOOC-CH₂-(R)Cgl-Pro-(R,S)Hig(Z)

35

0.442 g (0.839 mmole) H-(R)Cgl-Pro-(R,S)Hig(Z), 0.256 g (1.85 mmole) K₂CO₃ and 145 μl (0.521 mmole) of

bensylbromoacetate was mixed in 12 ml THF. The mixture was stirred at 40°C for one hour and at room temperature over night. After evaporation of the solvent the residue was dissolved in CH₂Cl₂ and washed once with water and once with brine. The organic layer was dried (Na₂SO₄), filtered and evaporated and the crude product was purified on a chromatotron (Harrison research, model 7924T) using a 2mm silica plate with a stepwise gradient of CH₂Cl₂/MeOH (97/3, 95/5, 90/10) as eluent to yield 0.165 g (29%) of the title compound.

(iii) HOOC-CH₂-(R)Cgl-Pro-(R,S)Hig x 2 HCl

0.165 g (0.25 mmole) of BnOOC-CH₂-(R)Cgl-Pro-(R,S)Hig(Z) was mixed with 0.050 g Pd/C (5%), 0.7 ml 1 M HCl-solution and 10 ml ethanol. The mixture was hydrogenated at atmospheric pressure for four hours. Filtration of the catalyst through cellite and evaporation of the solvent followed by freeze drying twice from water gave 0.1 g (75%) of the product.

¹H-NMR (D₂O, 300 MHz): δ 1.05-1.45 (m, 5H), 1.55-2.5 (m, 15H), 3.08 (bt, 1H), 3.2-4.05 (m, 9H), 4.30 (d, 1H), 4.44 (m, 1H)

¹³C-NMR (D₂O, 75 MHz): carbonyl and guanidinecarbons: δ 154.9, 167.2, 169.4, 174.1

Example 76

H-(R)Cha-Pro-(R,S)Hig x 2 HCl

(i) Boc-(R)Cha-Pro-(R,S)Hig(Z)

0.72 g (1.95 mmole) Boc-(R)Cha-Pro-OH (See Preparation of starting materials), 0.95 g (7.8

mmole) DMAP, 0.74 g (2.14 mmole) 82% pure H-(R,S)Hig(Z) (See Preparation f starting materials) in 10 ml CH₂Cl₂ was added 0.486 g (2.54 mmole) of EDC and the mixture was stirred at room temperature for 3 days. The mixture was diluted with CH₂Cl₂ and washed with water, twice with 0.3M KHSO₄-solution and once with brine. The organic layer was dried (Na₂SO₄), filtered and evaporated and the crude product was purified by flash chromatography using CH₂Cl₂/MeOH 95/5 as eluent to yield 0.450 g (33%) of the product.

(ii) H-(R)Cha-Pro-(R,S)Hig x 2 HCl

50 mg (0.078 mmole) of Boc-(R)Cha-Pro-(R,S)Hig(Z) was dissolved in 20 ml ethyl acetate saturated with HCl. The mixture was allowed to stand for one hour, evaporated and the residue was dissolved in 10 ml ethanol. 20 mg Pd/C (5%) and 0.3 ml 1 M HCl-solution was added and the mixture was hydrogenated at atmospheric pressure for two hours. Filtration of the catalyst through through cellite and evaporation of the solvent followed by freeze drying twice from water gave 28 mg (76%) of the title compound.

25 ¹H-NMR (D₂O, 300 MHz): δ 0.9-1.6 (m, 6H), 1.6-2.5 (m, 16H), 3.09 (t, 1H), 3.31 (t, 1H), 3.37-3.74 (m, 4H), 3.81 (m, 1H), 4.35-4.47 (m, 2H)

30 ¹³C-NMR (D₂O, 75 MHz): carbonyl and guanidinecarbons: δ 154.9, 169.8, 174.5

Example 77

H-(R)Cgl-Aze-Rig x 2 HCl

35

(i) Boc-(R)Cgl-Aze-Rig(Z)

To a solution of 0.50 g (1.6 mmol) of H-Rig(Z) (See Preparation of starting materials), 0.59 g (1.6 mmol) of Boc-(R)Cha-Aze-OH(See preparation of starting materials), 0.84 g (6.9 mmol) of 5 dimethylaminopyridine in 30 ml of acetonitrile and 5 ml of dimethylformamide was added 0.33 g (1.7 mmol) of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride. The reaction was allowed to stir for 3 days then evaporated and partitioned between aqueous 10 potassium hydrogen sulfate and methylene chloride. The methylene chloride layer was washed with aqueous sodium bicarbonate and water, dried (Na_2SO_4) and evaporated. The crude material was suction filtered through a pad of silica gel with methylene 15 chloride/methanol 9/1 to give 0.78 g (76%) of the desired compound after evaporation.

^1H NMR (300 MHz, CDCl_3): δ 0.8-1.9 (m, 27 H), 2.4-2.6 (m, 2 H), 2.78 (bt, 2 H), 3.15-3.4 (m, 2 H), 3.80 20 (bt, 1 H), 4.0-4.4 (m, 4 H), 4.75 (bt, 1 H), 4.97 (bd, 1 H), 5.08 (s, 2 H), 7.1-7.4 (m, 7 H), 7.74 (b, 1 H).

(ii) H-(R)Cgl-Aze-Rig(Z) x 2 HCl

A flask containing Boc-(R)Cgl-Aze-Rig(Z), 0.76 g (1.2 mmol), in 50 ml of ethyl acetate was cooled in an ice bath. Dry HCl was bubbled through for 5 min and the 25 solution was evaporated to give 0.74 g (100%) of the dihydrochloride as a white powder.

$^1\text{H-NMR}$ (300 MHz, MeOD): δ 1.1-2.0 (m, 18 H), 2.23 (m, 1 H), 2.68 (m, 1 H), 3.15-3.45 (m, 4 H), 3.72 (bd, 1 H), 3.9-4.0 (bd, 2 H), 4.27 (m, 1 H), 4.39 (m, 1 H), 35 4.78 (m, 1 H), 5.30 (s, 2 H), 7.3-7.5 (m, 5 H).

(iii) H-(R)Cgl-Aze-Rig x 2 HCl


A flask containing a solution of 20 mg of H-(R)Cgl-Aze-Rig(Z) and a small amount of 5% Pd/C was hydrogenated at atmospheric pressure for 1 h. The mixture was filtered through celite and evaporated.

5 The residue was lyophilized with a few drops of conc. HCl added to give the product. Yield: 8 mg (52%).

10 $^1\text{H-NMR}$ (300 MHz, D_2O): δ 1.1-2.0 (m, 18 H), 2.37 (m, 1 H), 2.75 (m, 1 H), 3.08 (bt, 2 H), 3.39 (bt, 2 H), 3.8-4.0 (m, 3 H), 4.35-4.5 (m, 2 H), 4.90 (m, 1 H).

15 $^{13}\text{C-NMR}$ (75.5 MHz, D_2O): guanidine and carbonyl carbons: δ 172.2, 169.4, 156.4.

15 Example 78



(i) $\text{BnOOC-CH}_2\text{-(R)Cgl-Aze-Rig(Z)}$

20 A mixture of 0.20 g (0.33 mmol) of H-(R)Cgl-Aze-Rig(Z) (See Example 77), 0.13 g of potassium carbonate, 80 mg of sodium iodide, 10 ml of tetrahydro-furane and 10 ml of acetonitrile was heated at 60°C for 10 h. The solvents were evaporated and the crude material was flash chromatographed on silica gel using methylene chloride/methanol 92/8 as eluent. Yield: 0.13 g (58%).

30 $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ 0.9-2.1 (m, 18 H), 2.45 (m, 1 H), 2.61 (m, 1 H), 2.81 (m, 2 H), 2.88 (d, 1 H), 3.2-3.5 (m, 4 H), 3.94 (m, 1 H), 4.0-4.25 (m, 3 H), 4.85 (m, 1 H), 5.12 (s, 2 H), 5.14 (s, 2 H), 6.9-7.2 (b, 2 H), 7.2-7.5 (m, 10 H), 7.95 (m, 1 H).

35 (ii) $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Rig x 2 HCl}$

A mixture of 0.12 g (0.18 mm l) of $\text{BnOOC-CH}_2\text{-(R)Cgl-Aze-Rig(Z)}$, 5 ml of ethanol, 3 drops of conc. HCl and a small amount of 5% Pd/C was hydronated at atmospheric pressure for 1 h. The mixture was 5 filtered through celite and evaporated. The residue was lyophilized in water to give 91 mg (98%) of the product.

10 $^1\text{H-NMR}$ (500 MHz, D_2O): δ 1.1-1.9 (m, 17 H), 2.00 (m, 1 H), 2.29 (m, 1 H), 2.70 (m, 1 H), 3.10 (m, 2 H), 3.34 (t, 2 H), 3.83 (bd, 2 H), 3.89 (dd, 2 H), 4.00 (d, 1 H), 4.35 (m, 2 H), 4.87 (m, 1 H).

15 $^{13}\text{C NMR}$ (125.8 MHz, D_2O): guanidine and carbonyl carbons: δ 171.8, 169.6, 167.7, 156.3.

Example 79

$\text{HOOC-CH}_2\text{-(R)Cha-Pro-Rig x 2 HCl}$

20

(i) $\text{Boc-(R)Cha-Pro-Rig(Z)}$

To a solution of 0.25 g (0.82 mmol) of 4-aminoethyl-1-benzyloxycarbonylamidino piperidine(H-Rig(Z)), (See 25 preparation of starting materials), 0.32 g (0.82 mmol) of Boc-(R)Cha-Pro-OH (See Preparation of starting materials), 0.40 g (3.3 mmol) of dimethylaminopyridine in 10 ml of acetonitrile and 2 ml of dimethylformamide was added 0.165 g (0.86 mmol) 30 of $\text{N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride}$. The reaction was allowed to stir for 3 days then evaporated and partitioned between aqueous potassium hydrogen sulfate and methylene chloride. The methylene chloride layer was washed with aqueous sodium bicarbonate and water, dried (Na_2SO_4) and 35 evaporated. The NMR spectrum of the crude product was satisfactory and the product which contained some

dimethylformamide was used in the next step without further purification.

5 ¹H-NMR (500 MHz, CDCl₃) δ 0.8-2.2 (m, 32 H; thereof
1.41 (s, 9 H)), 2.34 (m, 1 H), 2.77 (bt, 2 H), 3.10
(m, 1 H), 3.29 (m, 1 H), 3.40 (m, 1 H), 3.83 (m, 1
H), 4.17 (m, 2 H), 4.30 (m, 1 H), 4.54 (m, 1 H), 5.07
(m, 1 H), 5.08 (s, 2 H), 7.03 (m, 1 H), 7.05-7.4 (m,
7 H).

10

(ii) H-(R)Cha-Pro-Rig(Z)

15 A flask containing the crude product of Boc-(R)Cha-Pro-Rig(Z) in 100 ml of ethyl acetate was cooled in an ice bath. Dry HCl was bubbled through for 5 min and the solution was evaporated to get rid of the excess of HCl. The product was dissolved in water and the extracted twice with ethyl acetate to remove the dimethylform-amide from the previous step. The
20 aqueous phase was made alkaline with NaHCO₃ (aq) and extracted twice with methylene chloride. The combined organic phase was washed with water, dried (Na₂SO₄) and evaporated. Yield: 0.37 g (81%) over two steps.

25 ¹H-NMR (300 MHz, CDCl₃) δ 0.8-2.4 (m, 24 H), 2.82 (bt,
2 H), 3.26 (m, 2 H), 3.42 (bq, 1 H), 3.70 (m, 2 H),
4.19 (m, 2 H), 4.49 (bd, 1 H), 5.11 (s, 2 H), 6.9-7.5
(m, 8 H).

30 (iii) BnOOC-CH₂-(R)Cha-Pro-Rig(Z)

35 A mixture of 0.18 g (0.32 mmol) of H-(R)Cha-Pro-Rig(Z), an excess of potassium carbonate and 10 ml of acetonitrile was heated at 60°C for 2 h. The solvents were evaporated and the crude material was flash chromatographed on silica gel using methylene chloride/methanol 95/5 as eluent. Yield: 0.20 g

(88%).

5 $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ 0.8-2.1 (m, 23 H), 2.37 (m, 1 H), 3.1-3.5 (m, 7 H), 4.0-4.2 (m, 2 H), 4.54 (m, 1 H), 5.1 (m, 4 H), 6.9-7.5 (m, 13 H).

(iv) $\text{HOOC-CH}_2\text{-(R)Cha-Pro-Rig} \times 2 \text{ HCl}$

10 A mixture of 0.15 g (0.21 mmol) of $\text{BnOOC-CH}_2\text{-(R)Cha-Pro-Rig(Z)}$, 10 ml of ethanol, 4 drops of conc. HCl and a small amount of 5% Pd/C was hydrogenated at atmospheric pressure for 1 h. The mixture was filtered through celite and evaporated. The residue was lyophilized in water to give 95 mg (64%) of the product.

15 $^1\text{H-NMR}$ (500 MHz, MeOD) δ 0.85- 2.1 (m, 23 H), 2.30 (m, 1 H), 3.10 (m, 2 H), 3.25 (m, 1 H), 3.35 (m, 1 H), 3.54 (m, 1 H), 3.85-4.0 (m, 3 H), 4.03 (d, 1 H), 4.41 (m, 1 H), 4.50 (m, 1 H).

20 $^{13}\text{C-NMR}$ (125.8 MHz, D_2O): guanidine and carbonyl carbons: δ 174.0, 168.9, 168.1, 157.5.

25 Example 80

$\text{HOOC-CH}_2\text{-CH}_2\text{-(R)Cha-Aze-Rig} \times 2 \text{ HCl}$

(i) $\text{Boc-}(R)\text{Cha-Aze-Rig}(Z)$

30 To a solution of 0.25 g (0.82 mmol) of 4-aminoethyl-1-benzyloxy-carbonylamidino piperidine (H-Rig(Z)), (See preparation of starting materials), 0.31 g (0.86 mmol) of $\text{Boc-}(R)\text{Cha-Aze-OH}$ (See preparation of starting materials), 0.40 g (3.3 mmol) of dimethylaminopyridine in 10 ml of acetonitrile and 2 ml of dimethylformamide was added 0.17 g (0.86 mmol)

of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydr chloride. The reaction was allowed to stir for 3 days then evaporated and partitioned between aqueous potassium hydrogen sulfate and methylene chloride.

5 The methylene chloride layer was washed with aqueous sodium bicarbonate and water, dried (Na_2SO_4) and evaporated. The crude product which contained some dimethylformamide was used in the next step without further purification.

10 $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ 0.85 (m, 1 H), 0.97 (m, 1 H), 1.1-1.75 (m, 26 H; thereof 1.41 (s, 9 H)), 1.82 (bd, 1 H), 2.53 (m, 2 H), 2.77 (bt, 2 H), 3.25 (m, 2 H), 4.03 (q, 1 H), 4.08 (m, 1 H), 4.18 (m, 2 H), 4.29 (m, 1 H), 4.78 (m, 1 H), 4.97 (m, 1 H), 5.09 (s, 2 H), 7.1-7.4 (m, 7 H), 7.65 (m, 1 H).

(ii) H-(R)Cha-Aze-Rig(Z)

20 A flask containing the crude product of Boc-(R)Cha-Aze-Rig(Z) in 100 ml of ethyl acetate was cooled in an ice bath. Dry HCl was bubbled through for 5 min and the solution was evaporated to get rid of the excess of HCl. The product was dissolved in water and the extracted twice with ethyl acetate to remove the dimethylformamide from the previous step. The aqueous phase was made alkaline with NaHCO_3 (aq) and extracted twice with methylene chloride. The combined organic phase was washed with water, dried (Na_2SO_4) and evaporated. Yield: 0.31 g (70%) over two steps.

30 $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ 0.8-1.9 (m, 20 H), 2.48 (m, 1 H), 2.73 (m, 1 H), 2.85 (bt, 2 H), 3.25 (m, 1 H), 3.35 (m, 2 H), 4.05 (q, 1 H), 4.1-4.25 (m, 3 H), 4.86 (m, 1 H), 5.12 (s, 2 H), 6.9-7.2 (m, 2 H), 7.2-7.45 (m, 5 H), 7.93 (m, 1 H).

(iii) BnOOC-CH₂-CH₂-(R)Cha-Aze-Rig(Z)

A solution of 0.31 g (0.57 mmol) of H-(R)Cha-Aze-Rig(Z) and 93 mg (0.57 mmol) of benzyl acrylate in 5 ml of ethanol was allowed to stand at room temperature for one week. It was evaporated and flash chromatographed on silica gel using methylene chloride/methanol 94/6 as eluent. Yield: 0.20 g (49%).

10

¹H NMR (500 MHz, CDCl₃) δ 0.8-1.0 (m, 2 H), 1.1-1.8 (m, 18 H), 2.48 (m, 1 H), 2.54 (bt, 2 H), 2.68 (m, 2 H), 2.81 (bt, 2 H), 2.87 (m, 1 H), 3.20 (m, 1 H), 3.25 (m, 1 H), 3.31 (m, 1 H), 4.04 (q, 1 H), 4.1-4.2 (m, 3 H), 4.84 (dd, 1 H), 5.05-5.15 (m, 4 H), 7.0-7.5 (m, 12 H), 8.03 (m, 1 H).

15

(iv) HOOC-CH₂-CH₂-(R)Cha-Aze-Rig x 2 HCl

The title compound was made and purified in the same way as described in Example 80 from 0.20 g (0.28 mmol) of BnOOC-CH₂-CH₂-(R)Cha-Aze-Rig-(Z). Yield: 30 mg (19%) of the dihydrochloride salt.

25

¹H-NMR (500 MHz, CDCl₃) δ 1.0-1.9 (m, 20 H), 2.33 (m, 1 H), 2.70 (m, 1 H), 2.83 (m, 2 H), 3.10 (m, 2 H), 3.3-3.4 (m, 4 H), 3.85 (bd, 2 H), 3.92 (m, rotamer), 4.14 (t, 1 H), 4.17 (m, rotamer), 4.31 (m, 1 H), 4.46 (m, 1 H), 4.89 (m, 1 H), 5.18 (m, rotamer).

30

¹³C NMR (125.8 MHz, D₂O) guanidine and carbonyl carbons: δ 175.4, 171.8, 168.8, 156.3.

Example 81

35

HOOC-CH₂-(R)Cha-Pro-(S)Itp x 2 HCl

(i) Boc-(R)Cha-Pro-(S)Itp(Ts)

At roomtemperature 0.87 g (2.36 mmol) Boc-(R)Cha-Pro-OH (See preparation of startingmaterials), 0.78 g (4.72 mmol) DMAP and 0.70 g (2.36 mmol) H-(S)Itp(Ts) (See preparation of starting materials) was dissolved in 12 mL acetonitrile. After stirring 20 minutes 0.59 g (3.07 mmol) EDC was added. After 18 hours the solvent was removed in vacuo and the residue was dissolved in CH_2Cl_2 , washed with water, citric acid (10%), KHCO_3 (aq), water and dried with Na_2SO_4 . Evaporation gave 1.74 g (> 100% yiled (purity of about 60%)) of the desired product. Which was used in the next step without further purification.

15

FAB-MS: m/z = 647 ($\text{M}^+ + 1$)

(ii) H-(R)Cha-Pro-(S)Itp(Ts)

20 The Boc-protecting group was removed in the same way as described for Boc-(R)Cha-Pic-(R,S)Itp(Z) (See Example 72 (ii)) to give 0.75 g (81%) of the title compound.

25 FAB-MS: m/z = 547 ($\text{M}^+ + 1$)(iii) BnOOC- CH_2 -(R)Cha-Pro-(S)Itp(Ts)

30 0.75 g (1.37 mmol) H-(R)Cha-Pro-(S)Itp(Ts), 0.38 g (2.74 mmol) K_2CO_3 was taken up in 15 mL acetonitrile. 0.39 g (1.65 mmol) benzylbromoacetate was added and the mixture was stirred at 50°C for 2 h. Evaporation of the solvent followed by flash chromatography using ethylacetate/methanol 95/5 as eluent gave about 530 mg of the desired product.

35 FAB-MS: m/z = 695 ($\text{M}^+ + 1$)

(iv) HOOC-CH₂-(R)Cha-Pro-(S)Itp x 2 HCl

0.53 g (0.76 mmol) BnOOC-CH₂-(R)Cha-Pro-(S)Itp(Ts) was dissolved in 15 mL THF. NH₃ (g) was condensed into the flask and Na (m) was added. The reaction was quenched after 30 min with acetic acid and the NH₃ and the THF was evaporated. The residue was freeze dried from water and the crude product was purified by RPLC (acetonitrile/0.1M HOAc 15/85) gave 0.25 g (61%) of the desired product after freeze-drying from aqueous HCl.

¹H-NMR (500.13 MHz, D₂O); δ 0.9-2.09 (overlapping m, 20H), 2.22-2.35 (m, 1H), 3.2-3.36 (m, 4H), 3.44-3.62 (overlapping m, 2H), 3.7-3.8 (m, 1H), 3.87-3.99 (m, 2H), 4.33-4.48 (overlapping m, 2H).

¹³C-NMR (500.13 MHz, D₂O); carbonyl- and guanidinecarbons: δ 154.3, 168.1, 169.0 and 174.2

20

Example 82

H-(R)Cha-Pro-(R,S)Nig x 2 HCl

25 (i) Boc-(R)Cha-Pro-(R,S)Nig(Z)

174 mg (0.471 mmole) Boc-(R)Cha-Pro-OH (See preparation of starting materials), 229 mg (1.87 mmole) DMAP, 130 mg (0.471 mmole) H-(R,S)Nig(Z) (See Preparation of starting materials) was mixed in 2 ml CH₂Cl₂ and 117 mg (0.61 mmole) of EDC was added and the mixture was stirred for four days. The mixture was diluted with CH₂Cl₂ and washed with water, twice with 0.3 M KHSO₄-solution and once with brine. The organic layer was dried (Na₂SO₄), filtered and evaporated and the crude product was purified twice by flash chromatography using CH₂Cl₂/MeOH 95/5 as

eluent the first time and CH₂Cl₂/MeOH 97/3 as eluent the second time to yield 0.104 g (35%) of the title compound.

5 MS m/z 627 (M⁺+1)

(ii) H-(R)Cha-Pro-(R,S)Nig x 2 HCl

10 10 mg (0.016 mmole) of Boc-(R)Cha-Pro-(R,S)Nig(Z) was dissolved in 15 ml ethyl acetate saturated with HCl. The mixture was allowed to stand for half an hour. The mixture was evaporated and the residue was dissolved in 6 ml ethanol and 8 mg 5% Pd/C (5%) and 0.1 ml 1 M HCl-solution was added and the mixture was 15 hydrogenated at atmospheric pressure for one and a half hour. After filtration through hyflo and evaporation of the solvent gave 4 mg of the title compound the product

20 ¹H-NMR (300 MHz, D₂O): δ 0.9-1.58 (m, 6H), 1.58-2.45 (m, 13H), 2.65 (m, 1H), 3.19 (m, 1H), 3.34 (d, 2H), 3.4-3.73 (m, 4H), 3.82 (m, 1H), 4.34-4.49 (m, 2H).

25 ¹³C-NMR(75 MHz, D₂O): carbonyl and guanidinecarbons: δ 155.1, 169.9 and 174.8.

Example 83

H-(R)Pro-Phe-Pab x 2 HCl

30 (i) Boc-(R)Pro-Phe-Pab(Z)

To a mixture of 1.2 g (3.31 mmol) Boc-(R)Pro-Phe-OH (See preparation of starting materials) and 1.70 g (13.91 mmol) DMAP in 40 ml CH₃CN at room temperature 35 was added 0.98 g (3.35 mmol) H-Pab(Z) (See preparation of starting materials) dissolved in 1 ml

DMF. After stirring for 2 h the reaction mixture was cooled to - 18°C and 0.66 g (3.48 mmol) EDC was added portion wise and the reaction was left at room temperature over night. The solvent was evaporated
5 and the residue was dissolved in 100 ml EtOAc and washed with 1 x 30 ml water, 3 x 30 ml 0.3 M KHSO₄, 1 x 30 ml Na₂CO₃, 1 x 30 ml water and dried. Evaporation of the solvent followed by flash chromatography using CH₂Cl₂/MeOH (95/5) as eluent gave 0.691 g (38%) of
10 the title compound.

(ii) H-(R)Pro-Phe-Pab(Z)

0.673 g Boc-(R)Pro-Phe-Pab(Z) was dissolved in 30 ml EtOAc and the solution was saturated with HCl(g) for a few minutes (a white solid precipitated out from the solution). The solvent and excess HCl was evaporated and 60 ml EtOAc was added to the residue and the organic phase was washed with 2 x 20 ml 2 M
20 NaOH. The washing water was extracted with 1 x 25 ml EtOAc which was combined with the other EtOAc-phase and the combined organic phase was washed with water, dried and evaporated to give 560 mg (98%) of the desired product.

25 ¹H-NMR (500 MHz, CDCl₃): δ 1.5-1.74 (m, 3H), 1.98-2.05 (m, 1H), 2.78-2.85 (m, 1H), 2.90-2.96 (m, 1H), 3.0-3.2 (ABX-system centered at 3.1, 2H), 3.62 (dd, 1H), 4.3-4.45 (ABX-system centered at 4.37, 2H), 4.58 (q, 1H), 5.22 (s, 2H), 6.96 (bt, 1H), 7.1-7.4 (m, 10H), 7.46 (d, 2H), 7.76 (d, 2H), 8.12 (d, 1H).

(iii) H-(R)Pro-Phe-Pab x 2 HCl

35 200 mg H-(R)Pro-Phe-Pab(Z) was dissolved in 10 ml 95 % EtOH and 2 ml of water and the mixture was hydrogenated over 5 % Pd/C at atmospheric pressure

for 5 h. Filtration of the catalyst and addition of 1 ml 1 M HCl followed by evaporation and freeze drying from water gave the title compound in 88 % yield.

5 ¹H-NMR (500 MHz, CD₃OD): δ 1.51-1.59 (m, 1H), 1.69-1.80 (m, 1H), 1.87-1.97 (m, 1H), 2.19-2.29 (m, 1H), 2.90 (dd, 1H), 3.20-3.33 (m, 3H, partially hidden by the solvent peak), 4.27 (m, 1H), 4.43-4.54 (AB-system centered at 4.48, 2H), 4.75-4.81 (m, 1H), 4.87 (s, 2H), 7.2-7.3 (m, 5H), 7.45 (d, 2H), 7.75 (d, 2H).

10 ¹³C-NMR (125 MHz, D₂O): amidine and carbonyl carbons: δ 166.7, 170.1 and 173.4.

15 Example 84



(i) BnOOC-CH₂- (R)Pro-Phe-Pab(Z)

20 To a slurry of 244 mg (0.463 mmol) H-(R)Pro-Phe-Pab(Z) (See Example 83) and 159.9 mg (1.157 mmol) K₂CO₃ in 8 ml DMF/CH₃CN (5/3) was added 127.2 mg (0.555 mmol) benzylbromo acetate dissolved in 2 ml DMF and the mixture was stirred at 60°C for 1.5 h and at room temperature over night. The solvent was evaporated and the residue was dissolved in 50 ml EtoAc, washed with 2 x 20 ml water and dried (Na₂SO₄). Evaporation of the solvent followed by flash chromatography using CH₂Cl₂/MeOH (9/1) as eluent gave 176 mg (56 %) of the title compound as a white solid.

30 ¹H-NMR (300 MHz), CDCl₃): δ 1.45-1.80 (m, 3H), 2.06 (m, 1H), 2.54 (m, 1H), 2.92-3.28 (m, 6H), 4.3-4.5 (ABX-system centered at δ = 4.4, 2H), 4.60 (dd, 1H), 5.10 (apparent s, 2H), 5.2 (apparent s, 2H), 7.1-7.4 (m, 15H), 7.43 (d, 2H), 7.75 (d, 2H), 7.932 (d, 1H).

(ii) HOOC-CH₂-(R)Pro-Phe-Pab x 2HCl

170 mg (0.252 mmol) of BnOOC-CH₂-(R)Pro-Phe-Pab(Z) was dissolved in 12 ml EtOH/water (5/1) and 5 hydrogenerated over 5 % Pd/C at atmospheric for 4.5 h. The catalyst was filtered off, the solvent evaporated and the residue freeze dried from HCl(aq) to give the title compound.

10 ¹H-NMR (500 MHz, CD₃OD): δ 1.62 (m, 1H), 1.82 (m, 1H), 2.08 (m, 1H), 2.38 (m, 1H), 2.90 (dd, 1H), 3.25-3.35 (m, 2H), partially hidden by the solvent peak), 3.80 (m, 1H), 4.08-4.19 (AB-system centered at δ=4.19, 2H), 4.39 (m, 1H), 4.45-4.58 (AB-system centered at 15 δ= 4.50, 2H), 4.80 (m, 1H), 7.20-7.35 (m, 5H), 7.45 (d, 2H), 7.75 (D, 2H).

13C-NMR (125 MHz, D₂O): amidine and carbonyl carbons: δ 166.8, 169.1, 169.5 and 173.2.

20

Example 85**H-(R)Phe-Phe-Pab**

25 (i) Boc-(R)Phe-Phe-Pab(Z)

Boc-(R)Phe-Phe-OH (16.4 mmol) (see preparation of starting materials), Pab(Z)-HCl (18.0 mmol) and 4-dimethylaminopyridine (24.6 mmol) were dissolved in 30 50 mL of acetonitrile. The solution was cooled to ice-water temperature and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (21.3 mmol) was added. The cooling bath was removed and the reaction mixture was stirred over night. The solvent was then 35 evaporated under reduced pressure, the residue dissolved in 50 mL of ethylacetate and the resulting solution extracted with 50 mL of water. Boc-(R)Phe-

Phe-Pab(Z) precipitating from the two-phase mixture was filtered and washed with water yielding 8.7 g (78%) after drying under vacuum at 45°C for 24 h. ^1H NMR (200 MHz, d₆-CHCl₃ and d₄-CH₃OH); δ 8.35-7.00 (m, 19H), 4.63 (t, 1H), 4.3-4.1 (m, 1H), 3.40-2.70 (m, 6H), 1.30 (s, 9H).

5 (ii) H-(R)Phe-Phe-Pab(Z)

10 Boc-(R)Phe-Phe-Pab(Z) (10.3 mmol) was slurried in 70 mL of ethylacetate and 31 mL of 3.3 M ethylacetate/HCl was added. The slurry was stirred for 4 h after which the hydrochloride salt of H-(R)Phe-Phe-Pab(Z) was filtered off and washed with several portions of ethylacetate. The salt was dissolved in a mixture of 50 mL of methylenechloride, 50 mL of 1 M potassiumcarbonate and ca 5 mL of ethanol. The organic layer was collected and the solvent was removed under reduced pressure yielding 5.0 g of H-(R)Phe-Phe-Pab(Z) (84%). ^1H NMR (200 MHz, d₆-DMSO); δ 9.1 (s, 2H), 8.59 (m, 1H), 8.1 (m, 1H), 7.90 (d, 2H), 7.4-7.0 (m, 17H), 5.09 (s, 2H), 4.58 (m, 1H), 4.31 (m, 2H), 3.1-2.7 (m, 4H).

15 25 (iii) H-(R)Phe-Phe-Pab(Z) (0.42 mmol) was dissolved in 10 mL of tetrahydrofuran and 1 mL of water. Palladium on charcoal (42 mg) was charged to the solution and the mixture was hydrogenated at 45 psi hydrogen pressure in a Parr shaking apparatus for 2 days. After complete hydrogenolysis the mixture was diluted with methanol and the catalyst was filtered off. Evaporation of the solvents gave crude H-(R)Phe-Pab which was purified by chromatography on neutral alumina (70-230 Mesh) eluting with 30 methylenechloride-methanol--ammoniumhydroxide (80:20:2). Yield 76 mg of the title compound (41%). ^1H NMR (200 MHz, d₆-DMSO); δ 7.61 (d, 2H), 7.4-7.0 (m,

12H), 4.64 (m, 1H), 4.44 (m, 2H), 4.13 (t, 1H), 3.1-
2.8 (m, 4H).

Example 86

5

HOOC-CO-(R)Phe-Phe-Pab

(i) MeOOC-CO-(R)Phe-Phe-Pab(Z)

10 H-(R)Phe-Phe-Pab(Z) (0.87 mmol) (see Example 85 (ii)) was dissolved in 10 mL of tetrahydrofuran. The solution was cooled on an icewater bath and triethylamine (1.73 mmol) followed by methyloxalylchloride (0.95 mmol) were added. The 15 cooling bath was removed and the reaction mixture stirred for 18 h at ambient temperature. The reaction mixture was diluted with ethylacetate and extracted with water. The organic phase was collected and the solvent was removed under reduced pressure yielding 20 0.45 g of MeOOC-CO-(R)Phe-Phe-Pab(Z) (78%) which was used in the next step without further purification. TSP-MS found m/z 664 (calculated for MH^+ ($C_{37}H_{38}N_5O_7$) 664).

25 (ii) HOOC-CO-(R)Phe-Phe-Pab(Z)

MeOOC-CO-(R)Phe-Phe-Pab(Z) (0.68 mmol) was dissolved in 4 mL of tetrahydrofuran and 2 mL of water. Lithiumhydroxide (2.6 mmol) was added and the 30 reaction mixture was stirred at room temperature for 1.5 h. After complete hydrolysis the reaction mixture was diluted with 25 mL of water and acidified by addition of 0.5 mL of acetic acid. The precipitate was filtered and washed with several portions of 35 water yielding 0.40 g of crude HOOC-CO-(R)Phe-Phe-Pab(Z) after drying under vacuum at 45°C for 24 h. The crude product was slurried in 10 mL of ethanol

and 1 mL of water. The solution was brought to reflux and the insoluble title comp und was filtered off, yielding 0.23 g of HOOC-CO-(R)Phe-Phe-Pab(Z) (41% over two steps). ^1H NMR (200 MHz, d_6 -DMSO); δ 8.62 (m, 2H), 8.41 (d, 1H), 7.89 (d, 2H), 7.4-6.9 (m, 17H), 5.10 (s, 2H), 4.54 (m, 2H), 4.34 (m, 2H), 3.2-2.6 (m, 4H).

10 (iii) HOOC-CO-(R)Phe-Phe-Pab

HOOC-CO-(R)Phe-Phe-Pab(Z) (0.20 mmol) was slurried in 20 mL of tetrahydrofuran and 5 mL of water. Palladium on charcoal (52 mg) was charged to the solution and the mixture was hydrogenated at 45 psi hydrogen pressure in a Parr shaking apparatus for 2 days. After complete hydrogenolysis the mixture was diluted with 40 mL of methanol and the catalyst was filtered off. Evaporation of the solvents yielded 50 mg of the title compound (49%). ^1H NMR (200 MHz, d_6 -DMSO); δ 9.2(s), 8.78(d), 8.60(m), 7.91(m), 7.79(d, 2H), 7.35-6.8(m, 12H), 4.6-4.0(m, 4H), 3.0-2.6(m, 4H).

Example 87

25 HOOC-CH₂-(R)Phe-Phe-Pab

(i) BnOOCC-CH₂-(R)Phe-Phe-Pab(Z)

H-(R)Phe-Phe-Pab(Z) (0.87 mmol) (see Example 85 (ii)) and potassium carbonate (2.6 mmol) were slurried in 10 mL of acetonitrile. Iodobenzylacetate (0.95 mmol) was added to the mixture and the solution was heated to 30°C and stirred at that temperature for 2 days. After complete alkylation the solvent was removed and the residue dissolved in 10 mL of ethylacetate. The solution was rapidly extracted with 10 mL of water and from the collected organic phase the title

compound precipitates. BnOOC-CH₂(R)Phe-Phe-Pab(Z) was filtered off and dried under vacuum at 45°C for 24 h yielding 177 mg BnOOC-CH₂-(R)Phe-Phe-Pab(Z) (28%). ¹H NMR (200 MHz, CDCl₃); δ 7.79(d, 2H), 7.5-7.1(m, 22H), 5 6.55(t, 1H), 5.21(s, 2H), 5.03(s, 2H), 4.64(m, 1H), 4.41(m 2H), 3.3-2.6(m, 7H).

(ii) BnOOC-CH₂-(R)Phe-Phe-Pab(Z)

10 BnOOC-CH₂-(R)Phe-Phe-Pab(Z) (0.32 mmol) was slurried in 30 mL of tetrahydrofuran and 3 mL of water. Palladium on charcoal (41 mg) was charged to the solution and the mixture was hydrogenated at 45 psi hydrogen pressure in a Parr shaking apparatus for 2 days. After complete hydrogenolysis the mixture was 15 diluted with 40 mL of water and the catalyst was filtered off. Evaporation of the solvents yielded 95 mg of the title compound (59%). TSP-MS found m/z 502 (calculated for MH⁺ (C₂₈H₃₂N₅O₄)502).
20

Example 88

H-(R)Cha-Pro-Mig

25 (i) Boc-(R)Cha-Pro-Mig(Z)

To a stirred mixture of 0.344 g (0.93 mmol) Boc-(R)Cha-Pro-OH (see preparation of starting materials), 0.245 g (0.93 mmol) of H-Mig(Z) (see 30 preparation of starting materials) and 0.227 g (1.86 mmol) of DMAP in 10 mL CH₃CN was added 0.232 g (1.21 mmol) of EDC at -10°C. The reaction mixture was allowed to reach roomtemperature and left for 5 days. The CH₃CN was evaporated and the residue was dissolved 35 in EtOAc and washed with H₂O, NaHCO₃ (aq) and brine. The organic layer was dried with Na₂SO₄ and evaporated. The crude product was purified by flash

chromatography using a gradient of EtOAc/MeOH, 95/5 to 90/10, as eluent to yield 0.340 g (60 %) of the title compound.

5 (ii) H-(R) Cha-Pro-Mig(Z)

0.34 g (0.55 mmol) Boc-(R) Cha-Pro-Mig(Z) was dissolved in 8 mL of EtOAc saturated with HCl(g) and stirred for 10 min. at roomtemperature. 10 mL of a 10 saturated solution of KOH(aq) was added dropwise. The layers were separated and the aqueous phase was extracted with 3x8 mL EtOAc. The organic layers were combined, washed with brine, dried with Na₂SO₄ and evaporated to yield 0.286 g (100 %) of the title 15 compound.

(iii) H-(R) Cha-Pro-Mig

0.050 g (0.132 mmol) of H-(R) Cha-Pro-Mig(Z) was 20 dissolved in 3 mL MeOH and hydrogenated over 10 % Pd/C at atmospheric pressure over night. The solution was filtered through celite and the solvent evaporated to yield 0.040 g (80 %) of the title 25 compound.

1^H-NMR (500 MHz, MeOD): δ 0.92-1.02 (m, 2H), 1.18-1.47 (m, 6H), 1.66-1.73 (m, 4H), 1.85-2.04 (m, 4H), 2.17-2.22 (m, 1H), 2.95-2.98 (m, 1H), 3.12-3.16 (m, 1H), 3.47-3.55 (m, 2H), 3.62-3.66 (m, 1H), 3.75-3.78 (m, 1H), 3.85-3.89 (m, 1H), 4.05-4.12 (m, 3H), 4.34-4.37 (m, 1H).

Signals from a minor rotamer appear at: δ 3.4, 3.7, 4.13-4.16, 4.3.

35

MS m/z 379 (M⁺ + 1)

Example 89**H-(R)Cha-Pro-Dig****5 (i) Boc-(R)Cha-Pro-Dig(Z)**

To a stirred mixture of 0.280 g (0.76 mmol) Boc-(R)Cha-Pro-OH (see preparation of starting materials), 0.210 g (0.76 mmol) of H-Dig(Z) (see preparation of starting materials) and 0.186 g (1.52 mmol) of DMAP in 8 mL CH₃CN was added 0.189 g (0.99 mmol) of EDC at -10°C. The reaction mixture was allowed to reach roomtemperature and left for 4 days. The CH₃CN was evaporated and the residue was dissolved in EtOAc and washed with H₂O, NaHCO₃ (aq) and brine. The organic layer was dried with Na₂SO₄ and evaporated. The crude product was purified by flash chromatography using a gradient of EtOAc/MeOH, 95/5 to 90/10, as eluent to yield 0.210 g (44 %) of the title compound.

(ii) H-(R)Cha-Pro-Dig(Z)

0.210 g (0.33 mmol) Boc-(R)Cha-Pro-Dig(Z) was dissolved in 8 mL of EtOAc saturated with HCl(g) and stirred for 10 min. at roomtemperature. 8 mL of a saturated solution of KOH(aq) was added dropwise. The layers were separated and the aqueous phase was extracted with 3x8 mL EtOAc. The organic layers were combined, washed with brine, dried with Na₂SO₄ and evaporated to yield 0.146 g (83 %) of the title compound.

(iii) H-(R)Cha-Pro-Dig

35 0.046 g (0.087 mmol) of H-(R)Cha-Pro-Dig(Z) was dissolved in 3 mL MeOH and hydrogenated over 10 %

Pd/C at atmospheric pressure over night. The solution was filtered through celite and the solvent evaporated to yield 0.040 g (100 %) of the title compound.

5

¹H-NMR (500 MHz, MeOD): δ 0.90-1.04 (m, 2H), 1.10-1.47 (m, 6H), 1.66-1.74 (m, 4H), 1.78-2.05 (m, 4H), 2.13-2.21 (m, 1H), 2.74-2.83 (m, 1H), 2.94-2.99 (m, 1H), 3.15-3.29 (m, 1H), 3.44-3.57 (m, 2H), 3.65-3.87 (m, 3H), 4.07-4.25 (m, 3H), 4.35-4.39 (m, 2H).

10

Signals from a minor rotamer appear at: δ 4.29-4.32.

MS m/z 393 ($M^+ + 1$)

15

Example 90

H-(R) Cha-Aze-Dig

20

(i) **Boc-(R) Cha-Aze-Dig(Z)**

25

The title compound was prepared from Boc-(R) Cha-Aze-OH and H-Dig(Z) (see preparation of starting material) according to the procedure for Boc-(R) Cha-Pro-Dig(Z) in a yield of 0.253 g (54 %).

(ii) **H-(R) Cha-Aze-Dig(Z)**

30

The title compound was prepared from Boc-(R) Cha-Aze-Dig(Z) according the procedure for Boc-(R) Cha-Pro-Dig(Z) in a yield of 0.210 g (100 %).

(iii) **H-(R) Cha-Aze-Dig**

35

0.060 g (0.117 mmol) of H-(R) Cha-Aze-Dig(Z) was dissolved in 3 mL MeOH and hydrogenated over 10 % Pd/C at atmospheric pressure over night. The solution

was filtered through celite and the solvent evaporated to yield 0.042 g (95 %) of the title compound.

5 ¹H-NMR (500 MHz, MeOD): δ 0.91-1.02 (m, 2H), 1.18-1.48 (m, 6H), 1.66-1.90 (m, 8H), 2.15-2.17 (m, 1H), 2.66-2.68 (m, 1H), 2.80-2.83 (m, 1H), 3.14-3.29 (m, 1H), 3.39-3.44 (m, 1H), 3.72-3.80 (m, 2H), 4.01-4.04 (m, 1H), 4.14-4.23 (m, 2H), 4.48-4.49 (m, 1H), 4.60-4.64 (m, 1H).

10 Signals from a minor rotamer appear at: δ 2.25, 2.6, 4.3, 4.67.

15 MS m/z 379 ($M^+ + 1$).

Examples of pharmaceutical preparations

20 The compound according to the invention can be formulated in solid dosage forms for oral administration such as plain tablets, coated tablets or modified release tablets. Liquid or solid-semisolid dosage forms for rectal administration. Lyophilized substance or liquids as emulsion or 25 suspension for parenteral use. Liquid solid or semisolid dosage forms for topical administration.

In pressurized aerosols or in dry powder inhalers for oral or nasal inhalation.

30

Example P1

Tablets for oral administration

35

1000 tablets are prepared from the following ingredients:

| | | |
|---|----------------------------|-------|
| | Active compound | 100 g |
| | Lactose | 200 g |
| | Polyvinyl pyrrolidone | 30 g |
| | Microcrystalline cellulose | 30 g |
| 5 | Magnesium stearate | 6 g |

The active constituent and lactose are mixed with an aqueous solution of polyvinyl pyrrolidone. The mixture is dried and milled to form granules. The microcrystalline cellulose and then the magnesium stearate are then admixed. The mixture is then compressed in a tablet machine giving 1000 tablets, each containing 100 mg of active constituent.

15

Example P2solution for parenteral administration

20 A solution is prepared from the following ingredients:

| | |
|-------------------------------|-----|
| Active compound | 5 g |
| Sodium chloride for injection | 6 g |

25 Sodium hydroxide for pH adjustment ad pH 5-7
Water for inj. up to 1000 ml

30 The active constituent and the sodium chloride are dissolved in the water. The pH is adjusted with 2 M NaOH to pH 3-9 and the solution is filled into sterile ampoules.

Example P3

35 Tablets for oral administration

| | | |
|----|-----------------------------|-------|
| 1. | Active compound | 150 g |
| 2. | Sodium aluminium silicate | 20 g |
| 3. | Paraffin | 120 g |
| 4. | Microcrystalline cellulose | 20 g |
| 5 | 5. Hydroxy propyl cellulose | 5 g |
| 6 | 6. Sodium stearyl fumarate | 3 g |

1-4 are mixed and an aqueous solution of 5 is added.
The mixture is dried and milled and 6 is admixed. The
10 mix is then compressed in a tablet machine.

Example B6

Inhaler powder

15 The active compound is micronized in a jet mill to a particle size suitable for inhalation (mass diameter < 4 μ m).

20 100 mg of the micronized powder is filled into a powder multidose inhaler (Turbohaler®). The inhaler is equipped with a dosing unit which delivers a dose of 1 mg.

25 Biology

Determination of Thrombin clotting Time (TT):

Human thrombin (T 6769, Sigma Chem Co) in buffer 30 solution, pH 7.4, 100 μ l, and inhibitor solution, 100 μ l, were incubated for one min. Pooled normal citrated human plasma, 100 μ l, was then added and the clotting time measured in an automatic device (KC 10, Amelung).

35 The clotting time in seconds was plotted against the inhibitor concentration, and the IC₅₀TT was determined

by interpolation.

IC₅₀TT is the concentration of inhibitor that doubles the thrombin clotting time for human plasma.

5

Determination of Activated Partial Thromboplastin Time (APTT)

APTT was determined in pooled normal human citrated plasma with the reagent PTT Automated 5 manufactured by Stago. The inhibitors were added to the plasma (10 µl inhibitor solution to 90 µl plasma) and APTT was determined in the mixture by use of the coagulation analyser KC10 (Amelung) according to the instructions of the reagent producer. The clotting time in seconds was plotted against the inhibitor concentration in plasma and the IC₅₀APTT was determined by interpolation.

IC₅₀APTT is defined as the concentration of inhibitor in plasma that doubled the Activated Partial Thromboplastin Time.

Determination of thrombin time ex vivo

25

The inhibition of thrombin after oral administration of the compounds were examined in conscious rats that two days prior to the experiment were equipped with a catheter for blood sampling from the carotid artery.

30

On the experimental day blood samples were withdrawn at fixed times after the administration of the compound into plastic tubes containing 1 part sodium citrate solution (0.13 mol per L.) and 9 parts of blood. The tubes were centrifuged to obtain platelet poor plasma. The plasma was used for determination of thrombin time as described below.

35

The citrated rat plasma, 100 μ l, was diluted with a saline solution, 0.9%, 100 μ l, and plasma coagulation was started by the addition of human thrombin (T 6769, Sigma Chem Co, USA) in a buffer solution, pH 7.4, 100 μ l. The clotting time was measured in an automatic device (KC 10, Amelung, Germany).

Determination of the inhibition constant K_i for plasma kallikrein

10

K_i determinations were made with a chromogenic substrate method, and performed on a Cobas Bio centrifugal analyzer manufactured by Roche (Basel, Switzerland). Residual enzyme activity after incubation of human plasma kallikrein with various concentrations of test compound was determined at three different substrate concentrations, and measured as change in optical absorbance at 405 nm and 37°C.

20

Human plasma kallikrein (E.C.3.4.21.34, Chromogenix AB, Mölndal, Sweden), 250 μ l of 0.4 nkat/ml in buffer (0.05 mol/l Tris-HCl, pH 7.4, 1 0.15 adjusted with NaCl) with bovine albumin 5 g/l (cat no 810033, ICI Biochemicals Ltd, High Wycombe, Bucks, GB), was incubated for 300 s with 80 μ l of test compound solution in 0.15 mol/l NaCl containing albumin 10 g/l. An additional 10 μ l of water was supplied in this step. Then 40 μ l of kallikrein substrate (S-2302, Chromogenix AB, 1.25, 2.0 or 4.0 mmol/l in water) was added together with another 20 μ l of water, and the absorbance change monitored.

K_i was evaluated from Dixon plots, i.e. diagrams of inhibitor concentration versus $1/(ΔA/\text{min})$, where the data for the different substrate concentrations form straight lines which intercept at $x = -K_i$.

ABBREVIATIONS


| | | |
|----|---------------------------|---|
| | Ac = | acetyl |
| | aq = | aqueous |
| 5 | Aze = | Azetidine-2-carboxylic acid |
| | betaPic = | Piperidine-3-carboxylic acid |
| | Boc = | tert-butyloxycarbonyl |
| | Boc-Dig(Z) = | 3-(N-tert-butyloxycarbonyl-aminoethyl)-1-(N-benzyloxy-carbonylamidino) azetidine |
| 10 | | 3-(N-tert-butyloxycarbonyl-aminomethyl)-1-(N-benzyloxy-carbonylamidino) azetidine |
| | Boc-Mig(Z) = | 4-(N-tert-butyloxycarbonyl-aminomethyl)-1-(N-benzyloxy-carbonylamidino) piperidine |
| 15 | | 4-(N-tert-butyloxycarbonyl-aminomethyl)-1-(N,N'-dibenzyloxy-carbonylamidino) piperidine |
| | Boc-Pig(Z) = | saturated water/NaCl solution |
| | Boc-Pig(Z) ₂ = | benzyl |
| 20 | Brine = | butyl |
| | Bn = | Cyclohexyl glycine |
| | Bu = | β -cyclohexyl alanine |
| | Cgl = | 1-Cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-p-toluenesulfonate |
| 25 | Cha = | 1,8-diazabicyclo[5.4.0]undec-7-ene |
| | CME-CDI = | dicyclohexyl carbodiimide |
| | DBU = | dicyclohexyl urea |
| | DCC = | N,N-dimethyl amino pyridine |
| | DCU = | dimethyl formamide |
| 30 | DMAP= | dimethyl sulphoxide |
| | DMF = | 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride |
| | DMSO = | ethyl |
| | EDC = | ethyl acetate |
| 35 | Et = | ethanol |
| | EtOAc = | |
| | EtOH = | |

| | | |
|----|-----------------|--|
| | Gly = | glycine |
| | h = | hours |
| | HCl = | hydrochloric acid |
| | Hex = | hexyl |
| 5 | HOAc = | acetic acid |
| | HOBt = | N-hydroxy benzotriazole |
| | Hoc = | Homocyclohexyl alanine |
| | Hop = | Homophenyl alanine |
| | HOSu = | N-hydroxysuccinimide |
| 10 | H-Dig(Z) = | 3-aminoethyl-1-(N-benzyloxycarbonyl-amidino) azetidine |
| | H-Dig = | 3-aminoethyl-1-amidino azetidine |
| | H-(R,S)Hig(Z)= | (3RS)-1-(N-benzyloxycarbonylamidino)-3-aminoethyl pyrrolidine |
| 15 | H-(R,S)Hig = | (3RS)-1-amidino-3-aminoethyl pyrrolidine |
| | H-Hig = | 1-amidino-3-aminoethyl pyrrolidine |
| | H-(R,S)Itp(Ts)= | (4RS)-1,3-diaza-2-tosylimino-4-aminoethylcyclohexane |
| 20 | H-(R,S)Itp = | (4RS)-1,3-diaza-2-imino-4-aminoethylcyclohexane |
| | H-(S)Itp(Ts)= | (4S)-1,3-diaza-2-tosylimino-4-aminoethylcyclohexane |
| | H-(S)Itp = | (4S)-1,3-diaza-2-imino-4-aminoethylcyclohexane |
| 25 | H-Itp = | 1,3-diaza-2-imino-4-aminoethylcyclohexane |
| | H-Mig(Z) = | 3-aminomethyl-1-(N-benzyloxycarbonylamidino) azetidine |
| 30 | H-Mig = | 3-aminomethyl-1-amidino azetidine |
| | H-(R,S)Nig(Z)= | (3RS)-1-(N-benzyloxycarbonylamidino)-3-aminomethyl pyrrolidine |
| | H-(R,S)Nig = | (3RS)-1-amidino-3-aminomethyl pyrrolidine |
| 35 | H-Nig = | 1-amidino-3-aminomethyl pyrrolidine |
| | H-Pab = | 1-amidino-4-aminomethyl benzene |



| | |
|-------------------------|---|
| H-Pab(Z) = | 4-aminomethyl-1-(N-benzyloxy carbonylamidino) benzene |
| H-Pac = | 1-amidino-4-aminomethyl cyclohexane |
| H-Pac(Z) = | 4-aminomethyl-1-(N-benzyloxy carbonylamidino) cyclohexane |
| 5 H-Pig = | 4-aminomethyl-1-amidino piperidine |
| H-Pig(Z) = | 4-aminomethyl-1-(N-benzyloxycarbonyl-amidino)-piperidine |
| H-Pig(Z) ₂ = | 4-aminomethyl-1-(N,N'-dibenzyloxy carbonylamidino) piperidine |
| 10 H-Rig(Z) = | 4-aminoethyl-1-(N-benzyloxy-carbonylamidino)piperidine |
| H-Rig = | 4-aminoethyl-1-N-amidino piperidine |
| 15 Me = | methyl |
| MeOH = | methanol |
| Mpa = | mega pascal |
| Ms = | mesyl |
| NMM = | N-methyl morpholine |
| Pd/C = | palladium on charcoal |
| 20 Pgl = | phenyl glycine |
| Phe = | phenyl alanine |
| Pic = | pipecolinic acid |
| Pro = | proline |
| RPLC = | Reverse phase high performance liquid chromatography |
| 25 Tf = | trifluoromethylsulfonyl |
| TFA = | trifluoroacetic acid |
| THF = | tetrahydrofuran |
| Tic = | 1-carboxy-1,2,3,4-tetrahydro-isoquinoline |
| 30 Ts = | tosyl |
| Val = | valine |
| Z = | benzyloxy carbonyl |

35 Prefixes n, s, i and t have their usual meanings: normal, iso, sec and tertiary. The stereochemistry for the amino acids is by default (S) if not otherwise stated.


ABBREVIATIONS (continued, the wavy lines on the nitrogen atoms in the structural formulas below signify the bond position of the fragment.)





Pab (n=1)

Pig (n=1)
Rig (n=2)

Pac (n=1)




Itcp (n=2)

Nig (n=1)
Hig (n=2)Mig (n=1)
Dig (n=2)

CLAIMS

1. A compound of the general formula

5




**Formula I**

10

wherein:



15 A^1 represents a structural fragment of Formula
 IIa, IIb, IIc, IID or IIe;

20



25

30



35

wherein:

k is an integer 0, 1, 2, 3 or 4;

m is an integer 1, 2, 3 or 4;

5 q is an integer 0, 1, 2, or 3;

R¹ represents H, an alkyl group having 1 to 4 carbon atoms, or R¹¹OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted in the position which is alpha to the carbonyl group, and the alpha substituent is a group R¹⁷-(CH₂)_p-, wherein p is 10 0, 1 or 2 and R¹⁷ is methyl, phenyl, OH, COOR¹², CONHR¹², where R¹² is H or an alkyl group having 1 to 4 carbon atoms, and R¹¹ is H or an alkyl group having 1 to 15 6 carbon atoms, or

R¹ represents Ph(4-COOR¹²)-CH₂-, where R¹² is as defined above, or

20 R¹ represents R¹³-NH-CO-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R¹³ is H or an alkyl group having 1 to 4 carbon atoms or -CH₂COOR¹², where R¹² is as 25 defined above, or

R¹ represents R¹²OOC-CH₂-OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R¹² is as defined 30 above, or

35 R¹ represents R¹⁴SO₂-, Ph(4-COOR¹²)-SO₂-, Ph(3-COOR¹²)-SO₂-, Ph(2-COOR¹²)-SO₂- where R¹² is as defined above and R¹⁴ is an alkyl group having 1-4 carbon atoms, or

R¹ represents -CO-R¹⁵, wherein R¹⁵ is an alkyl group

having 1-4 carbon atoms, or

R¹ represents -CO-OR¹⁵, where R¹⁵ is as defined above,
or

5

R¹ represent -CO-(CH₂)_p-COOR¹², where R¹² is as defined
above and p is an interger 0, 1 or 2, or

10 R¹ represents -CH₂PO(OR¹⁶)₂, -CH₂SO₃H or
-CH₂-(5-(1H)-tetrazolyl) where R¹⁶ is, individually at
each occurrence, H, methyl or ethyl;

15 R² represents H or an alkyl group having 1 to 4 carbon
atoms or R²¹OOC-alkyl-, where the alkyl group has 1 to 4
carbon atoms and where R²¹ is H or an alkyl group
having 1 to 4 carbon atoms;

20 R³ represents an alkyl group having 1-4 carbon atoms,
and the alkyl group may or may not carry one or more
fluorine atoms, or

25 R³ represents a cyclopentyl, cyclohexyl- or a phenyl
group which may or may not be substituted with an alkyl
group having 1 to 4 carbon atoms, or

25

R³ represents a phenyl group substituted with a OR³¹
group, where R³¹ is H or an alkyl group having 1 to 4
carbon atoms and k is 0, 1, or

30

R³ represents a 1-naphthyl or 2-naphthyl group and k is
0, 1, or

35 R³ represent a cis- or trans-decalin group and k is 0,
1, or

35

R³ represents 4-pyridyl, 3-pyrrolidyl or 3-indolyl
which may or may not be substituted with a OR³¹ group,

where R^{31} is as defined above and k is 0, 1, or


R^3 represents $Si(Me)_3$ or $CH(R^{32})_2$, wherein R^{32} is a cyclohexyl- or a phenyl group;

5

R^4 represents H, an alkyl group having 1 to 4 carbon atoms, a cyclohexyl or a phenyl group;


A^2 represents a structural fragment of Formula IIIa,
10 IIIb or IIIc

15




20

IIIa



IIIb



IIIc

wherein:

25 p is an integer 0, 1 or 2;

m is an integer 1, 2, 3 or 4;

30 Y represents a methylene group, or

Y represents an ethylene group and the resulting 5-membered ring may or may not carry one or two fluorine atoms, a hydroxy group or an oxo group in position 4, or may or may not be unsaturated, or

35

Y represents $-CH_2-O-$, $-CH_2-S-$, $-CH_2-SO-$, with the heteroatom functionality in position 4, or

Y represents a n-propylene group and the resulting 6-membered ring may or may not carry in position 5 one fluorine atom, a hydroxy group or an oxo group, carry two fluorine atoms in one of positions 4 or 5, or be unsaturated in position 4 and 5, or carry in position 4 an alkyl group with 1 to 4 carbon atoms, or

Y represents $-\text{CH}_2-\text{O}-\text{CH}_2-$, $-\text{CH}_2-\text{S}-\text{CH}_2-$, $-\text{CH}_2-\text{SO}-\text{CH}_2-$, or

Y represent $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$;

R^3 is as defined above;





R^5 represents H or an alkyl group having 1 to 4 carbon atoms, or

R^5 represents $-(\text{CH}_2)_p-\text{COOR}^{51}$, where p is 0, 1 or 2 and R^{51} is H or an alkyl group having 1 to 4 carbon atoms;

n is an integer 0, 1, 2, 3 or 4;

B represents a structural fragment of Formula IVa, IVb, IVc or IVd

IVa



IVb

IVc

IVd

35

wherein:

r is an integer 0 or 1;

5. x^1 represent CH_2 or NH or is absent;

x^2 represents CH_2 , NH or C=NH;

10 x^3 represents NH, C=NH, N-C(NH)-NH₂, CH-C(NH)-NH₂, CH-NH-C(NH)-NH₂ or CH-CH₂-C(NH)-NH₂;

x^4 represents CH_2 or NH;

15 x^5 represents C(NH)-NH₂ or NH-C(NH)-NH₂;


x^6 represents CH or N;

R⁶ is H or an alkyl group having 1-4 carbon atoms;

20 either the compound as such or stereoisomers thereof or in the form of a physiologically acceptable salt.

2. A compound of the general formula

25




Formula V

30

wherein:

35 A^1 represents a structural fragment of Formula IIa, IIb, IIc, IID or IIe;



wherein:

20 k is an integer 0, 1, 2, 3 or 4;

 m is an integer 1, 2, 3 or 4;

25 q is an integer 0, 1, 2, or 3;

30 R¹ represents R¹¹OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted in the position which is alpha to the carbonyl group, and the alpha substituent is a group R¹⁷-(CH₂)_p-, wherein p is 0, 1 or 2 and R¹⁷ is, COOR¹², CONHR¹², where R¹² is H, an alkyl group having 1 to 4 carbon atoms or a benzyl group, and R¹¹ is H or an alkyl group having 1 to 6 carbon atoms, or a benzyl group, or

35 R¹ represents Ph(4-COOR¹²)-CH₂-, where R¹² is as defined above, or

5 R¹ represents R¹³-NH-CO-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R¹³ is H or an alkyl group having 1 to 4 carbon atoms or -CH₂COOR¹², where R¹² is as defined above, or

10 R¹ represents R¹²OOC-CH₂-OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and where R¹² is as defined above, or

15 R¹ represents R¹⁴SO₂-, Ph(4-COOR¹²)-SO₂-, Ph(3-COOR¹²)-SO₂-, Ph(2-COOR¹²)-SO₂- where R¹² is as defined above and R¹⁴ is an alkyl group having 1-4 carbon atoms, or

20 R¹ represents -CO-R¹⁵, wherein R¹⁵ is an alkyl group having 1-4 carbon atoms, or

R¹ represents -CO-OR¹⁵, where R¹⁵ is as defined above, or

25 R¹ represent -CO-(CH₂)_p-COOR¹², where R¹² is as defined above and p is an interger 0, 1 or 2, or

30 R² represents H or an alkyl group having 1 to 4 carbon atoms or R²¹OOC-alkyl-, where the alkyl group has 1 to 4 carbon atoms and where R²¹ is H or an alkyl group having 1 to 4 carbon atoms or a benzyl group;

35 R³ represents an alkyl group having 1-4 carbon atoms, and the alkyl group may or may not carry one or more fluorine atoms, or

R³ represents a cyclopentyl, cyclohexyl- or a phenyl group which may or may not be substituted with an alkyl

gr up having 1 to 4 carbon atoms, or

5 R³ represents a phenyl group substituted with a OR³¹ group, where R³¹ is H or an alkyl group having 1 to 4 carbon atoms and k is 0, 1, or

R³ represents a 1-naphthyl or 2-naphthyl group and k is 0, 1, or

10 R³ represent a cis- or trans-decalin group and k is 0, 1, or


15 R³ represents 4-pyridyl, 3-pyrrolidyl or 3-indolyl which may or may not be substituted with a OR³¹ group, where R³¹ is as defined above and k is 0, 1, or

R³ represents Si(Me)₃ or CH(R³²)₂, wherein R³² is a cyclohexyl- or a phenyl group;


20 R⁴ represents H, an alkyl group having 1 to 4 carbon atoms, a cyclohexyl or a phenyl group;

A² represents a structural fragment of Formula IIIa, IIIb or IIIc


25



IIIa



IIIb



IIIc

35

wherein:

p is an integer 0, 1 or 2;

5 m is an integer 1, 2, 3 or 4;

Y represents a methylene group, or

10 Y represents an ethylene group and the resulting 5-membered ring may or may not carry one or two fluorine atoms, a hydroxy group or an oxo group in position 4, or may or may not be unsaturated, or

15 Y represents -CH₂-O-, -CH₂-S-, -CH₂-SO-, with the heteroatom functionality in position 4, or

20 Y represents a n-propylene group and the resulting 6-membered ring may or may not carry in position 5 one fluorine atom, a hydroxy group or an oxo group, carry two fluorine atoms in one of positions 4 or 5 or be unsaturated in position 4 and 5, or carry in position 4 an alkyl group with 1 to 4 carbon atoms, or

25 Y represents -CH₂-O-CH₂-, -CH₂-S-CH₂-, -CH₂-SO-CH₂-, or

Y represent -CH₂-CH₂-CH₂-CH₂-;

R³ is as defined above;

30 R⁵ represents H or an alkyl group having 1 to 4 carbon atoms, or





35 R⁵ represents -(CH₂)_p-COOR⁵¹, where p is 0, 1 or 2 and R⁵¹ is H or an alkyl group having 1 to 4 carbon atoms;

n is an integer 0, 1, 2, 3 or 4;

B represents a structural fragment of Formula IVa, IVb,
IVc or IVd

5

10



15

wherein:

r is an integer 0 or 1;

x¹ represents CH₂ or NH or is absent;

20

x² represents CH₂, NH or C=NH;

25

x⁴ represents CH₂ or NH;

x⁵ represents C(NH)-NH₂ or NH-C(NH)-NH₂;

30

x⁶ represents CH or N;

R⁶ is H or an alkyl group having 1-4 carbon atoms;

D is Z or (Z)₂;

35

Z is a benzyloxy carbonyl group;

either the compound as such or stereoisomers thereof or in the form of a physi logically acceptable salt.

3. A compound according to claims 1 or 2 wherein A¹ is
5 a structural fragment of formula IIIa or IIb.

4. A compound according to one or more of the precedings claims 1-3 wherein R¹ represents R¹¹OOC-alkyl-, where the alkyl group has 1 to 4 carbon
10 atoms and R¹¹ is H.

5. A compound according to one or more of the precedings claims 1-4 wherein A² is a structural fragment of formula IIIa.

15 6. A compound according to one or more of the preceding claims 1-4 wherein A² is a structural fragment of formula IIIb.

20 7. A compound according to one or more of the preceding claims 1-6 wherein B is a structural fragment of formula IVa, wherein X¹, X² and X⁴ are CH₂, X³ is CH-C(NH)-NH₂, r is 1 and n is 1.

25 8. A compound according to one or more of the preceding claims 1-6 wherein B is a structural fragment of formula IVa, wherein X¹, X² and X⁴ are CH₂, X³ is N-C(NH)-NH₂, r is 0 or 1 and n is 1 or 2.

30 9. A compound according to one or more of the preceding claims 1-6 wherein B is a structural fragment of formula IVb, wherein X⁵ is C(NH)-NH₂ and R⁶ is H and n is 1.

35 10. A compound according to one or more of the preceding claims 1-6 wherein B is a structural element of formula IVa, wherein X¹ and X³ are NH, X² is C=NH, X⁴

is CH_2 , r is 1 and n is 2.

11. A compound according to one or more of the preceding claims 1-6 wherein B is a structural element of formula IVa, wherein X^1 is absent, X^2 and X^4 are CH_2 , X^3 is $\text{N}-\text{C}(\text{NH})-\text{NH}_2$, r is 0 and n is 1 or 2.

12. A compound according to claims 1 or 2 in which n is 1 or 2, A^1 is a structural fragment of formula IIa wherein k is 0 or 1, R^1 represents $R^{11}\text{OOC-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms, R^2 represents H, R^3 represents a cyclohexyl group, A^2 represents a structural fragment of Formula IIIa wherein Y represents a methylene group, an ethylene group, or a n-propylene group and the resulting 6-membered ring may or may not carry in position 4 an alkyl group with 1 to 4 carbon atoms, R^5 represents H, B represents a structural fragment of formula IVa wherein X^1 , X^2 and X^4 are CH_2 and X^3 is $\text{CH}-\text{C}(\text{NH})-\text{NH}_2$ or $\text{N}-\text{C}(\text{NH})-\text{NH}_2$, r is 0 or 1, or X^1 and X^3 is NH, X^2 is $\text{C}=\text{NH}$, X^4 is CH_2 , r is 1, or X^1 is absent, X^2 and X^4 are CH_2 , X^3 is $\text{N}-\text{C}(\text{NH})-\text{NH}_2$, r is 0.

13. A compound according to claims 1 or 2 in which n is 1, A^1 is a structural fragment of formula IIa wherein k is 0 or 1, R^1 represents $R^{11}\text{OOC-alkyl-}$, where the alkyl group has 1 to 4 carbon atoms, R^2 represents H, R^3 represents a cyclohexyl group, A^2 represents a structural fragment of Formula IIIa wherein Y represents a methylene group, an ethylene group, or a n-propylene group and the resulting 6-membered ring may or may not carry in position 4 an alkyl group with 1 to 4 carbon atoms, R^5 represents H, B represents a structural fragment of formula IVb wherein X^5 represents $\text{C}(\text{NH})-\text{NH}_2$ and R^6 is H.

14. A comp und selected from

HOOC-CH₂-(R)Cgl-Aze-Pab
 HOOC-CH₂-CH₂-(R)Cgl-Aze-Pab
 5 HOOC-CH₂-(R)Cgl-Pro-Pab
 HOOC-CH₂-CH₂-(R)Cgl-Pro-Pab
 (HOOC-CH₂)₂-(R)Cgl-Pro-Pab
 H-(R)Cgl-Pic-Pab
 HOOC-CH₂-(R,S)CH(COOH)-(R)Cgl-Pic-Pab
 10 H-(R)Cha-Aze-Pab
 HOOC-CH₂-(R)Cha-Aze-Pab
 HOOC-CH₂-(R,S)CH(COOH)-(R)Cha-Aze-Pab
 HOOC-CH₂-(RorS)CH(COOH)-(R)Cha-Aze-Pab/a
 HOOC-CH₂-(RorS)CH(COOH)-(R)Cha-Aze-Pab/b
 15 HOOC-CH₂-CH₂-(R)Cha-Aze-Pab
 HOOC-CH₂-NH-CO-CH₂-(R)Cha-Aze-Pab
 H-(R)Cha-Pro-Pab
 HOOC-CH₂-(R)Cha-Pro-Pab
 HOOC-CH₂-(Me)(R)Cha-Pro-Pab
 20 HOOC-CH₂-CH₂-(R)Cha-Pro-Pab
 HOOC-CH₂-CH₂-(Me)(R)Cha-Pro-Pab
 HOOC-CH₂-(RorS)CH(COOH)-(R)Cha-Pro-Pab/a
 HOOC-CH₂-(RorS)CH(COOH)-(R)Cha-Pro-Pab/b
 HOOC-CH₂-NH-CO-CH₂-(R)Cha-Pro-Pab
 25 EtoOC-CH₂-CH₂-CH₂-(R)Cha-Pro-Pab
 Ph(4-COOH)-SO₂-(R)Cha-Pro-Pab
 H-(R)Cha-Pic-Pab
 HOOC-CH₂-(R)Cha-Pic-Pab
 HOOC-CH₂-(RorS)CH(COOH)-(R)Cha-Pic-Pab/a
 30 HOOC-CH₂-(RorS)CH(COOH)-(R)Cha-Pic-Pab/b
 HOOC-CH₂-CH₂-(R)Cha-Pic-Pab
 HOOC-CO-(R)Cha-Pic-Pab
 HOOC-CH₂-CO-(R)Cha-Pic-Pab
 Me-OOC-CH₂-CO-(R)Cha-Pic-Pab
 35 H₂N-CO-CH₂-(R)Cha-Pic-Pab
 Boc-(R)Cha-Pic-Pab
 Ac-(R)Cha-Pic-Pab

Me-SO₂-(R) Cha-Pic-Pab
H-(R) Cha-(R,S) betaPic-Pab
HOOC-CH₂-CH₂-(R) Cha-(R,S) betaPic-Pab
HOOC-CH₂-(R) Cha-Val-Pab
5 HOOC-CH₂-CH₂-(R) Cha-Val-Pab
H-(R) Hoc-Aze-Pab
HOOC-CH₂-CH₂-(R) Hoc-Aze-Pab
HOOC-CH₂-(R,S) CH(COOH)-(R) Hoc-Pro-Pab
HOOC-CH₂-(R) Hoc-Pic-Pab
10 (HOOC-CH₂)₂-(R) Hoc-Pic-Pab
HOOC-CH₂-(R) Pro(3-(S)Ph)-Pro-Pab
HOOC-CH₂-CH₂-(R) Pro(3-(S)Ph)-Pro-Pab
HOOC-CH₂-CH₂-(R) Tic-Pro-Pab
HOOC-CH₂-CH₂-(R) Cgl-Aze-Pig
15 HOOC-CH₂-(R) Cgl-Pro-Pig
H-(R) Cha-Aze-Pig
HOOC-CH₂-(R) Cgl-Aze-Pac
H-(R) Cha-Pro-Pac
H-(R) Cgl-Ile-Pab
20 H-(R) Cgl-Aze-Pab
HOOC-(R,S) CH(Me)-(R) Cha-Pro-Pab
MeOOC-CH₂-(R) Cgl-Aze-Pab
ETOOC-CH₂-(R) Cgl-Aze-Pab
ⁿBuOOC-CH₂-(R) Cgl-Aze-Pab
25 ⁿHexOOC-CH₂-(R) Cgl-Aze-Pab
H-(R) Cgl-Pro-Pac
HOOC-CH₂-(R) Cha-Pro-Pac
HOOC-CH₂-CH₂-(R) Cgl-Pro-Pac
HOOC-CH₂-CH₂-(R) Cha-Aze-Pac
30 HOOC-CH₂-(R) Cha-Aze-Pig
HOOC-CH₂-(R) Cha-Pro-Pig
HOOC-CH₂-CH₂-(R) Cha-Pro-Pig
(HOOC-CH₂)₂-(R) Cgl-Pro-Pig
HOOC-CH₂-CH₂(HOOC-CH₂)-(R) Cha-Pro-Pig
35 HOOC-CH₂-CH₂-(R) Cgl-Aze-(R,S) Itp
HOOC-CH₂-(R) Cha-Aze-(R,S) Itp
H-(R) Cha-Pic-(R,S) Itp

HOOC-CH₂-(R)Cha-Pic-(R,S)Itp

H-(R)Cgl-Pro-(R,S)Hig

HOOC-CH₂-(R)Cgl-Pro-(R,S)Hig

H-(R)Cha-Pro-(R,S)Hig

5 H-(R)Cgl-Aze-Rig

HOOC-CH₂-(R)Cgl-Aze-Rig

HOOC-CH₂-(R)Cha-Pro-Rig

HOOC-CH₂-CH₂-(R)Cha-Aze-Rig

HOOC-CH₂-(R)Cha-Pro-(S)Itp

10 H-(R)Cha-Pro-(R,S)Nig

H-(R)Cha-Pro-Mig

H-(R)Cha-Pro-Dig

H-(R)Cha-Aze-Dig

15 either as such or stereoisomer thereof or in the form
of a physiologically acceptable salt.

15. A compound selected from

20 HOOC-CH₂-(R)Cgl-Aze-Pab

HOOC-CH₂-CH₂-(R)Cha-Aze-Pab

HOOC-CH₂-(R)Cha-Pro-Pab

HOOC-CH₂-CH₂-(R)Cha-Pro-Pab

HOOC-CH₂-(R)Cha-Pic-Pab

25 HOOC-CH₂-(R)Cgl-Pro-Pig

EtOOC-CH₂-(R)Cgl-Aze-Pab

HOOC-CH₂-(R)Cha-Pro-Pac

HOOC-CH₂-(R)Cha-Pro-Pig

30 either as such or stereoisomer thereof or in the form
of a physiologically acceptable salt.

16. A compound selected from

35 BnOOOC-CH₂-(R)Cgl-Aze-Pab(Z)

BnOOOC-CH₂-CH₂-(R)Cgl-Aze-Pab(Z)

BnOOOC-CH₂-(R)Cgl-Pro-Pab(Z)

BnOOC-CH₂-CH₂-(R)Cgl-Pro-Pab(Z)
(BnOOC-CH₂)₂-(R)Cgl-Pro-Pab(Z)
BnOOC-CH₂-(R,S)CH(COOBn)-(R)Cgl-Pic-Pab(Z)
BnOOC-CH₂-(R)Cha-Aze-Pab(Z)
5 BnOOC-CH₂-(R,S)CH(COOBn)-(R)Cha-Aze-Pab(Z)
BnOOC-CH₂-(RorS)CH(COOBn)-(R)Cha-Aze-Pab(Z)/a
BnOOC-CH₂-(RorS)CH(COOBn)-(R)Cha-Aze-Pab(Z)/b
BnOOC-CH₂-CH₂-(R)Cha-Aze-Pab(Z)
BnOOC-CH₂-NH-CO-CH₂-(R)Cha-Aze-Pab(Z)
10 BnOOC-CH₂-(R)Cha-Pro-Pab(Z)
BnOOC-CH₂-(Me)(R)Cha-Pro-Pab(Z)
BnOOC-CH₂-CH₂-(R)Cha-Pro-Pab(Z)
BnOOC-CH₂-CH₂-(Me)(R)Cha-Pro-Pab(Z)
BnOOC-CH₂-(R,S)CH(COOBn)-(R)Cha-Pro-Pab(Z)
15 BnOOC-CH₂-NH-CO-CH₂-(R)Cha-Pro-Pab(Z)
Ph(4-COOH)-SO₂-(R)Cha-Pro-Pab(Z)
Boc-(R)Cha-Pic-Pab(Z)
BnOOC-CH₂-(R)Cha-Pic-Pab(Z)
BnOOC-CH₂-(R,S)CH(COOBn)-(R)Cha-Pic-Pab(Z)
20 BnOOC-CH₂-CH₂-(R)Cha-Pic-Pab(Z)
EtOOC-CO-(R)Cha-Pic-Pab(Z)
MeOOC-CH₂-CO-(R)Cha-Pic-Pab(Z)
H₂N-CO-CH₂-(R)Cha-Pic-Pab(Z)
Ac-(R)Cha-Pic-Pab(Z)
25 Me-SO₂-(R)Cha-Pic-Pab(Z)
BnOOC-CH₂-(R)Cha-Val-Pab(Z)
BnOOC-CH₂-CH₂-(R)Cha-(R,S)Val-Pab(Z)
BnOOC-CH₂-CH₂-(R)Hoc-Aze-Pab(Z)
BnOOC-CH₂-(R,S)CH(COOBn)-(R)Hoc-Pro-Pab(Z)
30 BnOOC-CH₂-(R)Hoc-Pic-Pab(Z)
(BnOOC-CH₂)₂-(R)Hoc-Pic-Pab(Z)
BnOOC-CH₂-(R)Pro(3-(S)Ph)-Pro-Pab(Z)
BnOOC-CH₂-CH₂-(R)Pro(3-(S)Ph)-Pro-Pab(Z)
BnOOC-CH₂-CH₂-(R)Tic-Pro-Pab(Z)
35 BnOOC-CH₂-CH₂-(R)Cgl-Aze-Pig(Z)₂
BnOOC-CH₂-(R)Cgl-Pro-Pig(Z)₂
BnOOC-CH₂-(R)Cgl-Aze-Pac(Z)

BnOOC-(R,S)CH(Me)-(R)Cha-Pro-Pab(Z)

MeOOC-CH₂-(R)Cgl-Aze-Pab(Z)

EtoOC-CH₂-(R)Cgl-Aze-Pab(Z)

ⁿBuOOC-CH₂-(R)Cgl-Aze-Pab(Z)

5 ⁿHexOOC-CH₂-(R)Cgl-Aze-Pab(Z)

BnOOC-CH₂-(R)Cha-Pro-Pac(Z)

BnOOC-CH₂-CH₂-(R)Cgl-Pro-Pac(Z)

BnOOC-CH₂-CH₂-(R)Cha-Aze-Pac(Z)

BnOOC-CH₂-(R)Cha-Aze-Pig(Z)

10 BnOOC-CH₂-(R)Cha-Pro-Pig(Z)

BnOOC-CH₂-CH₂-(R)Cha-Pro-Pig(Z)

(BnOOC-CH₂)₂-(R)Cgl-Pro-Pig(Z)

BnOOC-CH₂-CH₂(BnOOC-CH₂)-(R)Cha-Pro-Pig(Z)

BnOOC-CH₂-(R)Cha-Pic-(R,S)Itp(Z)

15 BnOOC-CH₂-(R)Cgl-Pro-(R,S)Hig(Z)

BnOOC-CH₂-(R)Cgl-Aze-Rig(Z)

BnOOC-CH₂-(R)Cha-Pro-Rig(Z)

BnOOC-CH₂-CH₂-(R)Cha-Aze-Rig(Z)

20 either as such or stereoisomer thereof or in the form
of a physiologically acceptable salt.

17. A compound selected from

25

BnOOC-CH₂-(R)Cgl-Aze-Pab(Z)

BnOOC-CH₂-(R)Cha-Pro-Pab(Z)

BnOOC-CH₂-(R)Cha-Pic-Pab(Z)

BnOOC-CH₂-(R)Cgl-Pro-Pig(Z)₂

30

EtoOC-CH₂-(R)Cgl-Aze-Pab(Z)

BnOOC-CH₂-(R)Cha-Pro-Pac(Z)

BnOOC-CH₂-(R)Cha-Pro-Pig(Z)

35 either as such or stereoisomer thereof or in the form
of a physiologically acceptable salt.

18. A compound selected from

H-(R)Pro-Phe-Pab
HOOC-CH₂-(R)Pro-Phe-Pab
5 H-(R)Phe-Phe-Pab
HOOC-CH₂-(R)Phe-Phe-Pab
HOOC-CO-(R)Phe-Phe-Pab

either as such or stereoisomer thereof or in the form
10 of a physiologically acceptable salt.

19. A compound selected from

Boc-(R)Pro-Phe-Pab(Z)
15 BnOOC-CH₂-(R)Pro-Phe-Pab(Z)
Boc-(R)Phe-Phe-Pab(Z)
MeOOC-CO-(R)Phe-Phe-Pab(Z)
BnOOC-CH₂-(R)Phe-Phe-Pab(Z)

20 either as such or stereoisomer thereof or in the forms
of a physiologically acceptable salt.

25 20. A process for preparing a compound according to any
of claims 1-19, which process comprises coupling of an
N-terminally protected amino acid or dipeptide or amino
acid, when an N-terminally amino acid is used a second
aminoacid is added afterwards using standard methods
to a compound

30



wherein n is an integer 0, 1, 2, 3 or 4, X is B or B-D,
35 where B is as defined in formula I and D is as defined
in formula V as such or having the guanidino or amidino
nitrogens either mono or diprotected with an amine


protecting group such as a benzyl xy carbonyl- or tertbutyloxy carbonyl- or p-toluenesulphonyl group or X is a group transferable into B followed by removal of the protecting group(s) or deprotection of the N-terminal nitrogen followed by alkylation of the N-terminal nitrogen and if desired deprotection by known methods and if desired forming a physiologically acceptable salt, and in those cases where the reaction results in a mixture of stereoisomers, these are optionally separated by standard chromatographic or re-crystallisation techniques, and if desired a single stereoisomer is isolated.

21. A process according to claim 20 for preparing a compound according to any of claims 1-19, which process comprises:


a) (Method Ia) Coupling of an N-terminally protected dipeptide, selected from A¹ and A² in Formulas I or V by using standard peptide coupling, shown in the formula



25



30




wherein n is as defined in Formula I, W¹ is an N-terminal amino protecting group such as tert-butyloxy carbonyl and benzyloxy carbonyl and Q¹ is -C(NH)-

NH₂, -C(NW²)—NH—W², -C(NH)—NH—W², -NH—C(NH)—NH₂, -NH—C(NH)—NH—W², -N(W²)—C(NH)—NH—W² or -NH—C(NW²)—NH—W², where W² is an amine protecting group such as 5 tert-butyloxyl carbonyl or benzyloxyl carbonyl, or Q¹ is -CN, -CO-NH₂ or -CS-NH₂, where the group is subsequently transferred into a amidino group or Q¹ is NH₂ or NH-W², where W² is as defined above, where the amino group is subsequently transferred into a 10 guanidino group (giving Q¹= -NH-C(NH)-NH₂), after deprotection of the W²-group when Q¹ is -NH-W² (W² in this case must be orthogonal to W¹), by methods known 15 in the art.


b) (Method Ib) Coupling of an N-terminally protected 20 amino acid, selected from A² in Formulas I or V and prepared by using standard peptide coupling, shown in the formula



25



30



35


wherein n, W¹, and Q¹ are as defined above followed by deprotection of the W¹-group and coupling with the N-terminal amino acid, in a protected form, leading to the protected peptide described in Method Ia above,

c) (Meth d IIa) Coupling of an N-terminally protected dipeptide, selected fr m A¹ and A² in Formulas I or V by using standard peptide coupling, shown in the formula


5



10



15



20


wherein n is as defined in Formula I, W¹ is an N-terminal amino protecting group such as tert. butyloxy carbonyl and benzyloxy carbonyl and and Q¹ is -C(NH)-NH₂, -C(NW²)-NH-W², -C(NH)-NH-W², -NH-C(NH)-NH₂, -NH-C(NH)-NH-W², -N(W²)-C(NH)-NH-W² or -NH-C(NW²)-NH-W², where W² is an amine protecting group such as tert. butyloxy carbonyl or benzyloxy carbonyl, or Q¹ is -CN, -CO-NH₂ or CS-NH₂, where the group is subsequently transferred into a amidino group or Q¹ is NH₂ or NH-W², where W² is as defined above, where the amino group is subsequently transferred into a guanidino group (giving Q¹= -NH-C(NH)-NH₂), after deprotection of the W²-group when Q¹ is -NH-W² (W² in this case must be orthogonal to W¹), by methods known in the art.

d) (Method IIb) Coupling of an N-terminally protected amino acid, selected from A² in Formulas I or V by using standard peptide coupling, shown in the formula


5



10



15




20

wherein n, w¹ and Q¹ are as defined above followed by deprotection of the w¹-group and coupling with the N-terminal amino acid, in a protected form, leading to the protected peptide described in Method IIIa above,


25

e) (Metod IIIa) Coupling of an N-terminally protected dipeptide, selected from A¹ and A² in Formulas I or V by using standard peptide coupling, shown in the formula

30





35





wherein n is as defined in Formula I and r is 0 or 1 when X^1 , X^2 and X^4 are CH_2 , or r is 0 when X^2 and X^4 are CH_2 and X^1 is absent, W^1 is an N-terminal amino protecting group such as tert-butyloxycarbonyl and 5 benzyloxycarbonyl and Q² is $-\text{C}(\text{NH})-\text{NH}_2$, $-\text{C}(\text{NW}^2)-\text{NH}-W^2$, or $-\text{C}(\text{NH})-\text{NH}-W^2$, where W^2 is an amine protecting group such as tert-butyloxycarbonyl or benzyloxycarbonyl, or Q² is equal to W² where the amino group, after deprotection of the W² group (W² in this case must 10 be orthogonal to W¹), is subsequently transferred into a guanidino group using an unprotected, N-protected or N,N'-diprotected guanidation reagent by methods known in the art,

15 f) (Method IIIb) Coupling of an N-terminally protected amino acid, selected from A² in Formulas I or V by using standard peptide coupling, shown in the formula





wherein n, r, X¹, X² and X⁴, W¹, and Q² are as defined above followed by deprotection of the W¹-group and coupling with the N-terminal amino acid, in a protected form, leading to the protected peptide described in Method IIIa above,

g) (Method IVa) Coupling of an N-terminally protected dipeptide, selected from A¹ and A² in Formulas I or V by using standard peptide coupling, shown in the formula



wherein n is as defined in Formula I, w¹ is an N-terminal amino protecting group such as tert-butyloxycarbonyl or benzyloxycarbonyl and w³ is H or an amino protecting group such as aryl sulfonyl, benzyloxycarbonyl or tert-butyloxycarbonyl.

25 h) (Method IVb) Coupling of an N-terminally protected amino acid, selected from A² in Formulas I or V by using standard peptide coupling, shown in the formula



wherein n, W¹, and W³ are as defined above followed by deprotection of the W¹-group and coupling with the N-terminal amino acid, in a protected form, leading to the protected peptide described in Method IVa,

5

the final compounds can be made in any of the following ways, depending on the nature of the Q¹- or Q²-groups used: Removal of the protecting group(s) (when Q¹= -C(NH)-NH₂, -C(NW²)-NH-W², -C(NH)-NH-W², -NH-C(NH)-NH₂, -NH-C(NH)-NH-W², -N(W²)-C(NH)-NH-W² or -NH-C(NW²)-NH-W²), or a selective deprotection of the W¹- group (e.g when Q¹ or Q²= -C(NW²)-NH-W², -C(NH)-NH-W², -NH-C(NH)-NH-W², -N(W²)-C(NH)-NH-W² or -NH-C(NW²)-NH-W² (W² in this case must be orthogonal to W¹) followed by alkylation of the N-terminal nitrogen and if desired deprotection.

10

15

20

22. A compound according to any of claims 1-19 for use in therapy.

25

23. A compound according to any of claims 1-5 or 7-17 for use as an anticoagulant or antithrombotic agent.

30

24. A compound according to any of claims 1-4, 6-10 or 18-19 for use as an antiinflammatory agent.

25. A pharmaceutical preparation comprising an effective amount of a compound as outlined in claims 1-19 in conjunction with one or more pharmaceutical carriers.

35

26. A pharmaceutical preparation comprising an effective amount of a compound as outlined in any of claims 1-5 or 7-17 in conjunction with one or more pharmaceutical carriers for use as an anticoagulant or antithrombotic agent.

27. A pharmaceutical preparation comprising an effective amount of a compound as outlined in any of claims 1-4, 6-10 or 18-19 in conjunction with one or more pharmaceutical carriers for use as an antiinflammatory agent.


28. Use of compound according to any of claims 1-5 or 7-17 as an active ingredient for manufacture of a pharmaceutical preparation for inhibition of thrombin in a human or animal organism.

29. Use of compound according to any of claims 1-4, 6-10 or 18-19 as an active ingredient for manufacture of a pharmaceutical preparation for inhibition of kininogenases in a human or animal organism.

30. A method for obtaining inhibition of thrombin in a human or animal organism in need of such inhibition, comprising administering to said organism an inhibitory effective amount of a compound claimed in any of claims 1-5 or 7-17.

31. A method for obtaining inhibition of kininogenases in a human or animal organism in need of such inhibition, comprising administering to said organism an inhibitory effective amount of a compound claimed in any of claims 1-4, 6-10 or 18-19.


32. Use of a compound of the formula:



either as such or having the amidino group either mono- or diprotected at the nitrogens with a protective group, or in the form of a salt, as a starting material in synthesis of a peptidic serine protease inhibitor, and in particular in synthesis of a peptidic thrombin inhibitor or a peptidic kininogenases inhibitor.

33. A structural fragment of the formula

10



15

as a structural element in a pharmaceutically active compound, especially a peptidic compound.


20

34. A compound 4-aminomethyl-1-(N-benzyloxycarbonylamidino) benzene either as such, in the form of a salt or having a protection with a benzyloxycarbonyl group at the other nitrogen.

25

35. Use of a compound of the formula:

30




35

either as such or having the amidino group either mono- or diprotected at the nitrogens with a protective group, or in the form of a salt, as a starting material in synthesis of a thrombin inhibitor, and in particular in synthesis of a peptidic thrombin inhibitor.

36. A structural fragment of the formula

5



as a structural element in a thrombin inhibitor,
especially a peptidic thrombin inhibitor.


10

37. A compound 4-aminomethyl-1-(N-benzyloxycarbonylamidino) cyclohexane either as such, in the form of a salt or having a protection with a benzyloxycarbonyl group at the other nitrogen.

15

38. A compound of the formula:

20




25

either as such or having the amidino group either mono- or diprotected at the nitrogens with a protective group, or in the form of a salt, .

30

39. Use of a compound as described in claim 38, as a starting material in the synthesis of a serine protease inhibitor.

40. A structural fragment of the formula




as a structural element in a thrombin inhibitor,
especially a peptidic thrombin inhibitor.

41. A compound of the formula:

5

10



either as such or having the amidino group either mono-
or diprotected at the nitrogens with a protective
group, or in the form of a salt.


15

42. Use of a compound as described in claim 41, as a
starting material in the synthesis of a serine protease
inhibitor.

20

43. A structural fragment of the formula:

25



30


as a structural element in a thrombin inhibitor,
especially a peptidic thrombin inhibitor.

35

44. A compound 4-aminoethyl-1-benzyloxy-carbonylamidino
piperidine either as such, in the form of a salt or
having a protection with a benzyloxycarbonyl group at
the other nitrogen.

45. A compound of the formula:

5



10

15

where n is 1 or 2 and s is 0 or 1,
either as such or having the amidino group either mono-
or diprotected at the nitrogens with a protective
group, or in the form of a salt.


20

46. Use of a compound as described in claim 45, as a
starting material in the synthesis of a serine protease
inhibitor.

25

30

47. A structural fragment of the formula



35

where n is 1 or 2 and s is 0 or 1,
as a structural element in a thrombin inhibitor,
especially a peptidic thrombin inhibitor.

48. A compound which is (3RS)-1-(N-benzyloxycarbonyl-amidino)-3-aminomethyl pyrrolidine, (3RS)-1-(N-benzyl-oxy carbonylamidino)-3-aminoethyl pyrrolidine, 3-amino-methyl-1-(N-benzyloxycarbonyl-amidino) azetidine,
5 3-aminoethyl-1-(N-benzyloxycarbonyl-amidino) azetidine or either as such, in the form of a salt or having a protection with a benzyloxycarbonyl group at the other nitrogen.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00535

A. CLASSIFICATION OF SUBJECT MATTER

IPC & C07K 5/06, C07K 5/02, A61K 38/55, C07C 257/18, C07C 257/16, C07D 239/14,
 C07D 211/26, C07D 205/04, C07D 207/09
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS, MEDLINE, EMBASE, CA, WPI, CLAIMS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| A | EP, A1, 0530167 (AKTIEBOLAGET ASTRA), 3 March 1993 (03.03.93) -- | 1-29 |
| A | EP, A1, 0513543 (BEHRINGWERKE AKTIENGESELLSCHAFT), 19 November 1992 (19.11.92) -- | 1-29 |
| A | EP, A1, 0236163 (SANOFI), 9 Sept 1987 (09.09.87) -- | 1-29 |
| A | EP, A2, 0542525 (ELI LILLY AND COMPANY), 19 May 1993 (19.05.93) -- | 1-29 |

 Further documents are listed in the continuation of Box C. See patent family annex.

- * Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same parent family

Date of the actual completion of the international search

27 October 1994

Date of mailing of the international search report

31 -10- 1994

Name and mailing address of the ISA/
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. + 46 8 666 02 86

Authorized officer
 Elisabeth Carlborg
 Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00535

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| X | THROMBOSIS ET DIATHESIS HAEMORRHAGICA, Volume 23, No 3, 1970, J.D. Geratz, "Inhibition of Thrombin, Plasmin and Plasminogen Activation by Amidino Compounds" page 486 - page 499 -- | 32,34 |
| X | THROMBOSIS ET DIATHESIS HAEMORRHAGICA, Volume 31, 1974, Erika Glusa et al, "The Influence of Benzamidine Derivatives on Human Platelet Function" page 172 - page 178 -- | 32,34 |
| X | BIOCHEMICAL PHARMACOLOGY, Volume 23, 1974, Fritz Markwardt et al, "Synthetic Low Molecular Weight Inhibitors of Serum Kallikrein" page 2247 - page 2256 -- | 32,34 |
| X | PHARMAZIE, Volume 34, No 10, 1979, D. Labes et al, "Hansch-Analyse der Hemmwirkung von 3- und 4- substituierten Benzamidinen gegenüber Thrombin, Plasmin und Trypsin" page 649 - page 653 -- | 132,34 |
| X | EP, A1, 0001774 (BAYER AKTIENGESELLSCHAFT ZENTRALBEREICH PATENTE), 16 May 1979 (16.05.79), page 32, line 16 - page 33, line 14; page 51, line 1 - line 9 ----- | 35,37 |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00535

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 30 and 31
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1 (iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. Claims Nos.: 33, 36, 40, 43 and 47
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

** see extra sheet
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- a) claims 1-29, 33, 36, 40, 43 and 47,
- b) claims 32, 34, 35 and 37,
- c) claims 38 and 39,
- d) claims 41, 42, 44-46 and 48

* see extra sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

* The subjects of invention as listed below are so different from each other, that no technical relationship can be appreciated to be present so as to form a single general inventive concept.

Claims 1-29, 33, 36, 40, 43 and 47 relate to compounds, to processes for preparing them, to pharmaceutical preparations containing the compounds, to the use of the compounds for manufacture of pharmaceutical preparations and to structural fragments, which have been regarded as being part of the compounds disclosed in claim 1.

Claims 32, 34, 35 and 37 relate to structurally similar compounds (intermediates) and to the use of such compounds as starting material in synthesis of enzyme inhibitors.

Claims 38 and 39 relate to a compound (intermediate) and to its use as starting material in the synthesis of a serine protease inhibitor.

Claims 41, 42, 44-46 and 48 relate to compounds (intermediates) and to their use as starting material in the synthesis of a serine protease inhibitor.

** The wording of claims 33, 36, 40, 43 and 47, which indicates several possible end compounds with a structural fragment, does not define one solution of one technical problem. Therefore, the claims are not searchable.

INTERNATIONAL SEARCH REPORT
Information on patent family members

01/10/94

International application No.
PCT/SE 94/00535

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|---|--|
| EP-A1- 0530167 | 03/03/93 | AP-A- 313 AU-A- 2499092 CA-A- 2116527 EP-A- 0605462 FI-A,D- 940945 HU-D- 9400589 NZ-A- 243675 WO-A- 9305069 | 10/02/94 05/04/93 18/03/93 13/07/94 28/02/94 00/00/00 27/06/94 18/03/93 |
| EP-A1- 0513543 | 19/11/92 | AU-B- 651196 AU-A- 1608692 CN-A- 1067249 DE-A- 4115468 JP-A- 5155898 NZ-A- 242668 | 14/07/94 12/11/92 23/12/92 12/11/92 22/06/93 27/06/94 |
| EP-A1- 0236163 | 09/09/87 | FR-A,B- 2593812 JP-A- 62228050 US-A- 4977168 EP-A,B- 0236164 FR-A,B- 2593814 US-A- 4791102 | 07/08/87 06/10/87 11/12/90 09/09/87 07/08/87 13/12/88 |
| EP-A2- 0542525 | 19/05/93 | AU-B- 646767 AU-A- 2829892 AU-A- 2831292 CA-A- 2082748 CN-A- 1074438 FI-A- 925124 HU-A- 65858 JP-A- 5221964 US-A- 5252566 | 03/03/94 13/05/93 13/05/93 13/05/93 21/07/93 13/05/93 28/07/94 31/08/93 12/10/93 |
| EP-A1- 0001774 | 16/05/79 | DE-A- 2748295 JP-A- 54073702 | 03/05/79 13/06/79 |

THIS PAGE BLANK (USPTO)